
<html lang="en"     class="pb-page"  data-request-id="da02c352-8e86-4397-b28a-1726c5a981ea"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;issue:issue:10.1021/jmcmar.2018.61.issue-6;wgroup:string:ACHS website Group;article:article:10.1021/acs.jmedchem.7b01854;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="Discovery of Novel 1-Cyclopentenyl-3-phenylureas as Selective, Brain Penetrant, and Orally Bioavailable CXCR2 Antagonists" /></meta><meta name="dc.Creator" content="Hongfu  Lu" /></meta><meta name="dc.Creator" content="Ting  Yang" /></meta><meta name="dc.Creator" content="Zhongmiao  Xu" /></meta><meta name="dc.Creator" content="Xichen  Lin" /></meta><meta name="dc.Creator" content="Qian  Ding" /></meta><meta name="dc.Creator" content="Yueting  Zhang" /></meta><meta name="dc.Creator" content="Xin  Cai" /></meta><meta name="dc.Creator" content="Kelly  Dong" /></meta><meta name="dc.Creator" content="Sophie  Gong" /></meta><meta name="dc.Creator" content="Wei  Zhang" /></meta><meta name="dc.Creator" content="Metul  Patel" /></meta><meta name="dc.Creator" content="Royston C. B.  Copley" /></meta><meta name="dc.Creator" content="Jianing  Xiang" /></meta><meta name="dc.Creator" content="Xiaoming  Guan" /></meta><meta name="dc.Creator" content="Paul  Wren" /></meta><meta name="dc.Creator" content="Feng  Ren" /></meta><meta name="dc.Description" content="CXCR2 has emerged as a therapeutic target for not only peripheral inflammatory diseases but also neurological abnormalities in the central nervous system (CNS). Herein, we describe the discovery of..." /></meta><meta name="Description" content="CXCR2 has emerged as a therapeutic target for not only peripheral inflammatory diseases but also neurological abnormalities in the central nervous system (CNS). Herein, we describe the discovery of..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="February 6, 2018" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.7b01854" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="Copyright © 2018 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.7b01854" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.7b01854" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.7b01854" /></link>
        
    
    

<title>Discovery of Novel 1-Cyclopentenyl-3-phenylureas as Selective, Brain Penetrant, and Orally Bioavailable CXCR2 Antagonists | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.7b01854" /></meta><meta property="og:title" content="Discovery of Novel 1-Cyclopentenyl-3-phenylureas as Selective, Brain Penetrant, and Orally Bioavailable CXCR2 Antagonists" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.7b01854/20180315/images/large/jm-2017-01854x_0015.jpeg" /></meta><meta property="og:description" content="CXCR2 has emerged as a therapeutic target for not only peripheral inflammatory diseases but also neurological abnormalities in the central nervous system (CNS). Herein, we describe the discovery of a novel 1-cyclopentenyl-3-phenylurea series as potent and CNS penetrant CXCR2 antagonists. Extensive SAR studies, wherein molecules’ property forecast index (PFI) was carefully optimized for overall balanced developability profiles, led to the discovery of the advanced lead compound 68 with a desirable PFI. Compound 68 demonstrated good in vitro pharmacology with excellent selectivity over CXCR1 and other chemokine receptors. Rat and dog pharmacokinetics (PK) revealed good oral bioavailability, high oral exposure, and desirable elimination half-life of the compound in both species. In addition, the compound demonstrated dose-dependent efficacy in the in vivo pharmacology neutrophil infiltration “air pouch” model in rodents after oral administration. Further, compound 68 is a CNS penetrant molecule with high unbound fraction in brain tissue." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.7b01854"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.7b01854">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.7b01854&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.7b01854&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.7b01854&amp;href=/doi/10.1021/acs.jmedchem.7b01854" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2018</span><span class="cit-fg-volume">, 61</span><span class="cit-fg-issue">, 6</span><span class="cit-fg-pageRange">, 2518-2532</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/61/6" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.7b01781" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/acs.jmedchem.7b01884" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Discovery of Novel 1-Cyclopentenyl-3-phenylureas as Selective, Brain Penetrant, and Orally Bioavailable CXCR2 Antagonists</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Hongfu Lu</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Hongfu Lu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Neurosciences Therapeutic Area Unit, GSK Pharmaceuticals R&D, 898 Halei Road, Zhangjiang Hi-Tech Park, Pudong, Shanghai 201203, P. R. China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Hongfu++Lu">Hongfu Lu</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Ting Yang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Ting Yang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Neurosciences Therapeutic Area Unit, GSK Pharmaceuticals R&D, 898 Halei Road, Zhangjiang Hi-Tech Park, Pudong, Shanghai 201203, P. R. China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Ting++Yang">Ting Yang</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Zhongmiao Xu</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Zhongmiao Xu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Neurosciences Therapeutic Area Unit, GSK Pharmaceuticals R&D, 898 Halei Road, Zhangjiang Hi-Tech Park, Pudong, Shanghai 201203, P. R. China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Zhongmiao++Xu">Zhongmiao Xu</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Xichen Lin</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Xichen Lin</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Neurosciences Therapeutic Area Unit, GSK Pharmaceuticals R&D, 898 Halei Road, Zhangjiang Hi-Tech Park, Pudong, Shanghai 201203, P. R. China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Xichen++Lin">Xichen Lin</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Qian Ding</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Qian Ding</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Neurosciences Therapeutic Area Unit, GSK Pharmaceuticals R&D, 898 Halei Road, Zhangjiang Hi-Tech Park, Pudong, Shanghai 201203, P. R. China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Qian++Ding">Qian Ding</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Yueting Zhang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Yueting Zhang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">R&D Projects Clinical Platforms and Sciences, GSK Pharmaceuticals R&D, 898 Halei Road, Zhangjiang Hi-Tech Park, Pudong, Shanghai 201203, P. R. China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Yueting++Zhang">Yueting Zhang</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Xin Cai</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Xin Cai</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Platform Technology Sciences, GSK Pharmaceuticals R&D, 898 Halei Road, Zhangjiang Hi-Tech Park, Pudong, Shanghai 201203, P. R. China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Xin++Cai">Xin Cai</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Kelly Dong</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Kelly Dong</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Platform Technology Sciences, GSK Pharmaceuticals R&D, 898 Halei Road, Zhangjiang Hi-Tech Park, Pudong, Shanghai 201203, P. R. China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Kelly++Dong">Kelly Dong</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Sophie Gong</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Sophie Gong</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Platform Technology Sciences, GSK Pharmaceuticals R&D, 898 Halei Road, Zhangjiang Hi-Tech Park, Pudong, Shanghai 201203, P. R. China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Sophie++Gong">Sophie Gong</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Wei Zhang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Wei Zhang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Platform Technology Sciences, GSK Pharmaceuticals R&D, 898 Halei Road, Zhangjiang Hi-Tech Park, Pudong, Shanghai 201203, P. R. China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Wei++Zhang">Wei Zhang</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Metul Patel</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Metul Patel</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Platform Technology Sciences, GSK Pharmaceuticals R&D, Stevenage, Hertfordshire SG1 2NY, U.K.</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Metul++Patel">Metul Patel</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Royston C. B. Copley</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Royston C. B. Copley</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Platform Technology & Science, GSK Medicines Research Centre, Gunnels Wood Road, Stevenage, Hertfordshire SG1 2NY, U.K.</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Royston+C.+B.++Copley">Royston C. B. Copley</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Jianing Xiang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Jianing Xiang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Neurosciences Therapeutic Area Unit, GSK Pharmaceuticals R&D, 898 Halei Road, Zhangjiang Hi-Tech Park, Pudong, Shanghai 201203, P. R. China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Jianing++Xiang">Jianing Xiang</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Xiaoming Guan</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Xiaoming Guan</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Neurosciences Therapeutic Area Unit, GSK Pharmaceuticals R&D, 898 Halei Road, Zhangjiang Hi-Tech Park, Pudong, Shanghai 201203, P. R. China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Xiaoming++Guan">Xiaoming Guan</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Paul Wren</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Paul Wren</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Neurosciences Therapeutic Area Unit, GSK Pharmaceuticals R&D, 1250 South Collegeville Road, Collegeville, Pennsylvania 19426, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Paul++Wren">Paul Wren</a></span></div></div></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor">Feng Ren</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Feng Ren</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Neurosciences Therapeutic Area Unit, GSK Pharmaceuticals R&D, 898 Halei Road, Zhangjiang Hi-Tech Park, Pudong, Shanghai 201203, P. R. China</div></div><span class="conrtib-corresp"><strong>*</strong>Phone: +86-21-61590721. Fax: +86-21-61590730. Email: <a href="/cdn-cgi/l/email-protection#93f5f6fdf4bde2bde1f6fdd3f4e0f8bdf0fcfe"><span class="__cf_email__" data-cfemail="fa9c9f949dd48bd4889f94ba9d8991d4999597">[email protected]</span></a>, <a href="/cdn-cgi/l/email-protection#61535755595757575857592110104f020e0c"><span class="__cf_email__" data-cfemail="774541434f4141414e414f3706065914181a">[email protected]</span></a></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Feng++Ren">Feng Ren</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-9157-9182" title="Orcid link">http://orcid.org/0000-0001-9157-9182</a></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.7b01854&amp;href=/doi/10.1021%2Facs.jmedchem.7b01854" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2018</span></span><span class="cit-volume">, 61</span><span class="cit-issue">, 6</span><span class="cit-pageRange">, 2518–2532</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">February 6, 2018</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>19 December 2017</li><li><span class="item_label"><b>Published</b> online</span>6 February 2018</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 22 March 2018</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.7b01854" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.7b01854</a></div><div class="article_header-article-copyright"><strong>Copyright © 2018 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D2518%26pageCount%3D15%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DHongfu%2BLu%252C%2BTing%2BYang%252C%2BZhongmiao%2BXu%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D61%26issueNum%3D6%26contentID%3Dacs.jmedchem.7b01854%26title%3DDiscovery%2Bof%2BNovel%2B1-Cyclopentenyl-3-phenylureas%2Bas%2BSelective%252C%2BBrain%2BPenetrant%252C%2Band%2BOrally%2BBioavailable%2BCXCR2%2BAntagonists%26numPages%3D15%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D2532%26publicationDate%3DMarch%2B2018">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.7b01854"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">2626</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">9</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.7b01854" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Discovery of Novel 1-Cyclopentenyl-3-phenylureas as Selective, Brain Penetrant, and Orally Bioavailable CXCR2 Antagonists&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Hongfu&quot;,&quot;last_name&quot;:&quot;Lu&quot;},{&quot;first_name&quot;:&quot;Ting&quot;,&quot;last_name&quot;:&quot;Yang&quot;},{&quot;first_name&quot;:&quot;Zhongmiao&quot;,&quot;last_name&quot;:&quot;Xu&quot;},{&quot;first_name&quot;:&quot;Xichen&quot;,&quot;last_name&quot;:&quot;Lin&quot;},{&quot;first_name&quot;:&quot;Qian&quot;,&quot;last_name&quot;:&quot;Ding&quot;},{&quot;first_name&quot;:&quot;Yueting&quot;,&quot;last_name&quot;:&quot;Zhang&quot;},{&quot;first_name&quot;:&quot;Xin&quot;,&quot;last_name&quot;:&quot;Cai&quot;},{&quot;first_name&quot;:&quot;Kelly&quot;,&quot;last_name&quot;:&quot;Dong&quot;},{&quot;first_name&quot;:&quot;Sophie&quot;,&quot;last_name&quot;:&quot;Gong&quot;},{&quot;first_name&quot;:&quot;Wei&quot;,&quot;last_name&quot;:&quot;Zhang&quot;},{&quot;first_name&quot;:&quot;Metul&quot;,&quot;last_name&quot;:&quot;Patel&quot;},{&quot;first_name&quot;:&quot;Royston&quot;,&quot;last_name&quot;:&quot;C. B. Copley&quot;},{&quot;first_name&quot;:&quot;Jianing&quot;,&quot;last_name&quot;:&quot;Xiang&quot;},{&quot;first_name&quot;:&quot;Xiaoming&quot;,&quot;last_name&quot;:&quot;Guan&quot;},{&quot;first_name&quot;:&quot;Paul&quot;,&quot;last_name&quot;:&quot;Wren&quot;},{&quot;first_name&quot;:&quot;Feng&quot;,&quot;last_name&quot;:&quot;Ren&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2018&quot;,&quot;month&quot;:&quot;02&quot;,&quot;day&quot;:&quot;06&quot;,&quot;issue&quot;:&quot;6&quot;,&quot;volume&quot;:&quot;61&quot;,&quot;pages&quot;:&quot;2518-2532&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.7b01854&quot;},&quot;abstract&quot;:&quot;CXCR2 has emerged as a therapeutic target for not only peripheral inflammatory diseases but also neurological abnormalities in the central nervous system (CNS). Herein, we describe the discovery of a novel 1-cyclopentenyl-3-phenylurea series as potent and CNS penetrant CXCR2 antagonists. Extensive SAR studies, wherein molecules’ property forecast index (PFI) was carefully optimized for overall balanced developability profiles, led to the discovery of the advanced lead compound 68 with a desirable PFI. Compound 68 demonstrated good in vitro pharmacology with excellent selectivity over CXCR1 and other chemokine receptors. Rat and dog pharmacokinetics (PK) revealed good oral bioavailability, high oral exposure, and desirable elimination half-life of the compound in both species. In addition, the compound demonstrated dose-dependent efficacy in the in vivo pharmacology neutrophil infiltration “air pouch” model in rodents after oral administration. Further, compound 68 is a CNS penetrant molecule with high unbound&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.7b01854&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.7b01854" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.7b01854&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.7b01854" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.7b01854&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.7b01854" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.7b01854&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.7b01854&amp;href=/doi/10.1021/acs.jmedchem.7b01854" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.7b01854" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.7b01854" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (3 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.7b01854&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.7b01854%26sid%3Dliteratum%253Aachs%26pmid%3D29406702%26genre%3Darticle%26aulast%3DLu%26date%3D2018%26atitle%3DDiscovery%2Bof%2BNovel%2B1-Cyclopentenyl-3-phenylureas%2Bas%2BSelective%252C%2BBrain%2BPenetrant%252C%2Band%2BOrally%2BBioavailable%2BCXCR2%2BAntagonists%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D61%26issue%3D6%26spage%3D2518%26epage%3D2532%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (2)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=291316" title="Mixtures">Mixtures</a>,</li><li><a href="/action/doSearch?ConceptID=290758" title="Anatomy">Anatomy</a>,</li><li><a href="/action/doSearch?ConceptID=291350" title="Assays">Assays</a>,</li><li><a href="/action/doSearch?ConceptID=292464" title="Rodent models">Rodent models</a>,</li><li><a href="/action/doSearch?ConceptID=292462" title="Central nervous system">Central nervous system</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/61/6" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/jmcmar.2018.61.issue-6/20180322/jmcmar.2018.61.issue-6.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.7b01854/20180315/images/medium/jm-2017-01854x_0015.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.7b01854/20180315/images/large/jm-2017-01854x_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01854&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">CXCR2 has emerged as a therapeutic target for not only peripheral inflammatory diseases but also neurological abnormalities in the central nervous system (CNS). Herein, we describe the discovery of a novel 1-cyclopentenyl-3-phenylurea series as potent and CNS penetrant CXCR2 antagonists. Extensive SAR studies, wherein molecules’ property forecast index (PFI) was carefully optimized for overall balanced developability profiles, led to the discovery of the advanced lead compound <b>68</b> with a desirable PFI. Compound <b>68</b> demonstrated good in vitro pharmacology with excellent selectivity over CXCR1 and other chemokine receptors. Rat and dog pharmacokinetics (PK) revealed good oral bioavailability, high oral exposure, and desirable elimination half-life of the compound in both species. In addition, the compound demonstrated dose-dependent efficacy in the in vivo pharmacology neutrophil infiltration “air pouch” model in rodents after oral administration. Further, compound <b>68</b> is a CNS penetrant molecule with high unbound fraction in brain tissue.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_21175" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_21175" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">CXCR2, a CXC chemokine receptor of the G-protein-coupled receptor (GPCR) family, is a seven-transmembrane protein with a 67–70 kDa molecular weight expressed on neutrophils, granulocytes, NK cells, T lymphocytes, mast cells, monocytes, endothelial cells, megakarocytes, neurons, and oligodendrocytes.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> CXCR2 and its main cognate ligands CXCL1 (Gro-α) and CXCL8 (IL-8) have been extensively reported as critical pro-inflammatory components of neutrophil activation and chemotaxis, megakaryocytic proliferation, and angiogenesis.<a onclick="showRef(event, 'ref2 ref3 ref4'); return false;" href="javascript:void(0);" class="ref ref2 ref3 ref4">(2−4)</a> Increasing evidence has emerged to implicate the important role of CXCR2 in numerous inflammatory disorders<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> including chronic obstructive pulmonary disease (COPD),<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> rheumatoid arthritis (RA),<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a> and atherosclerosis.<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> Recently, CXCR2 inhibitor was reported to reduce metastases and augment anti-PD1 immunotherapy in KPC mice to result in prolonged survival.<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a> Likewise, CXCR2 antagonist significantly enhanced the efficacy of immune checkpoint blockage (ICB) treatment in a mouse prostate cancer model.<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> These preclinical data have raised significant interest of CXCR2 as a therapeutic target for cancer immunotherapy. The correlation between CXCR2 expression and human glioma was reported, and CXCR2 inhibition was found to mitigate glioma cell migration.<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> In addition to peripheral immune system, CXCR2 also plays a role in regulating neuronal activity and brain development even though its expression level is low in both human and rodent brains.<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> Increasingly, CXCR2 has been recognized as a potential target for the treatment of CNS diseases such as multiple sclerosis<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> and Alzheimer’s disease (AD)<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> and others.<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> Thus, discovery of small molecule CXCR2 antagonists with brain penetration properties may open new opportunities to explore and tackle abnormalities in the CXCL1 (Gro-α)/CXCL8 (IL-8) signaling pathway in CNS diseases.</div><div class="NLM_p">The first small molecule CXCR2 antagonists were reported in 1998,<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> and since then, a number of chemical series of small molecule CXCR2 antagonists with diverse pharmacophores have been developed (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>). Among them, quite a few compounds have been progressed into clinical trials for the treatment of neutrophil-induced pulmonary diseases. Reparixin (<b>1</b>), an allosteric inhibitor of CXCR1 with several hundred-fold selectivity over CXCR2, was reported to block CXCL8- and CXCL-1 mediated neutrophil (PMN) migration and was advanced into clinical trials via intravenous administration for delayed graft function and transplant rejection.<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> Later, the compound was repositioned for a clinical trial for breast cancer. A pyrimidine-based compound, AZD5069 (<b>2</b>), with reasonable oral bioavailability, was progressed to clinical stage for COPD and asthma, and afterward, a clinic study for cancer treatment was initiated. Compound <b>2</b> proved to be a potent CXCR2 antagonist with around 100-fold selectivity over CXCR1.<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> Later, a bicyclic pyrimidine series was reported as dual CXCR2/CCR2 antagonists and a representative, AZ10397767 (<b>3</b>), demonstrated nanomolar antagonism activity for both CXCR2 and CCR2.<a onclick="showRef(event, 'ref17 ref18'); return false;" href="javascript:void(0);" class="ref ref17 ref18">(17,18)</a> Navarixin (<b>4</b>, also known as SCH527123 or MK-7123), bearing a novel squaramide core structure, was described as a potent and selective antagonist of CXCR2 with 80-fold selectivity over CXCR1.<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> A phase 2 clinical trial of compound <b>4</b> in COPD patients demonstrated clinical benefit of the anti-inflammatory mechanism resulting from CXCR2 antagonism.<a onclick="showRef(event, 'ref20 ref21'); return false;" href="javascript:void(0);" class="ref ref20 ref21">(20,21)</a> Several other novel chemical series were also disclosed as CXCR2 antagonists including the 5-carbonitrile pyrimidines,<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> 2-amino-quinoxalines,<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> and boronic acid derivatives containing aminopyridines/aminopyrimidines.<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> However, none of these structures was able to be progressed to clinic testing. Among all the small molecule CXCR2 antagonists reported to date, the diarylurea series was the first disclosed,<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> and the successful chemical series from which a couple of compounds had been advanced to the clinic. SB-332235 (<b>5</b>), even though not progressed to the clinic, was an important diarylurea early tool compound for mechanistic explorations of CXCR2 antagonism for COPD and AD.<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> The first diarylurea-based CXCR2 antagonist advanced to clinical trial is SB-656933 (<b>6</b>), which has been tested in COPD and cystic fibrosis (CF) patients.<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> Further development of compound <b>6</b> was discontinued due to lack of significant lung function improvement in clinics during the dosing regimen<a onclick="showRef(event, 'cit25b'); return false;" href="javascript:void(0);" class="ref cit25b">(25b)</a> and in favor of a more attractive diarylurea analogue, danirixin (<b>7</b>, also known as GSK1325756).<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> Currently, compound <b>7</b> is in phase II clinical trial for COPD. Extensive literature reports have been focused on the small molecule CXCR2 antagonists for the treatment of peripheral indications.<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> On the other hand, however, little has been disclosed on brain penetration characteristics of compounds. Most recently, a CNS penetrant CXCR2 antagonist based on the diarylurea skeleton (<b>8</b>) was disclosed, and the compound promoted remyelination in mouse brain in the cuprizone-induced demyelination model.<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> The series including compound <b>8</b> was reported to have low unbound fractions in plasma<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> which might be attributed to its high lipophilicity (cLogP) and high property forecast index (PFI). PFI, the sum of hydrophobicity value and number of aromatic rings, has evolved as one of the key “drug-likeness” measurements as supported by its correlations with compound developability properties including solubility, membrane permeability, plasma protein binding, cytochrome P450 inhibition, hERG binding, and promiscuity, etc.<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a></div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.7b01854/20180315/images/medium/jm-2017-01854x_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.7b01854/20180315/images/large/jm-2017-01854x_0001.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Structures of representative small molecule CXCR2 antagonists.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.7b01854/20180315/images/large/jm-2017-01854x_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01854&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">Herein, we report the discovery of a novel 1-cyclopentenyl-3-phenylurea series as brain penetrant and selective CXCR2 antagonists for the potential treatment of CNS diseases. In our work, replacing one aromatic ring of the previously reported diarylureas with the aliphatic cyclopentenyl group provides marked reduction of PFI thus significant improvement of the developability profile (plasma protein binding, solubility, etc.) of the series.</div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_52800" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_52800" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i4" class="anchor-spacer"></div><h3 class="article-section__title" id="_i4"> Structure–Activity Relationships and CNS Penetration</h3><div class="NLM_p">We started our exploration from the known CNS penetrant diarylurea series where compound <b>8</b> was identified as the lead.<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> However, compound <b>8</b> might suffer from an active demethylation metabolite issue wherein the methyl group of the <i>N</i>-methylpiperidine was observed to be metabolized to a significant extent in vitro in human liver microsomes.<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> Therefore, among the diarylurea analogues without the <i>N</i>-methylpiperidine substitution, taken into consideration of compounds’ potency and “drug-likeness” properties such as molecular weight (MW) and PFI, compound <b>9</b> (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>) was selected as the chemistry starting point. Our initial work was focused on replacing the 2-chloro-3-fluorophenyl group (R, <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>) of <b>9</b> with aliphatic rings to reduce PFI. The cyclohexyl analogue (<b>10</b>) demonstrated much reduced PFI (6.7) compared to compound <b>9</b> (8.2) but decreased CXCR2 antagonism activity (pIC<sub>50</sub> = 7.3) by ∼100-fold in the CXCR2 Tango assay, which determined compounds’ functional potency at recombinant CXCR2 receptors. Introduction of methyl (<b>11</b>, pIC<sub>50</sub> = 6.5) or methoxyl (<b>12</b>, pIC<sub>50</sub> = 5.8) substitutions to the cyclohexyl ring resulted in even lower potencies. Six-membered saturated heterocyclic rings including tetrahydropyran (<b>13</b>, <b>14</b>) and piperidine (<b>15</b>, pIC<sub>50</sub> < 5.0) were not tolerated, indicating a hydrophobic pocket occupied by the R group. We then explored the ring size and found that the five-membered cyclopentane ring (<b>16</b>) demonstrated higher potency (pIC<sub>50</sub> = 8.0) and lower PFI (6.0) than its six-membered analogue (<b>10</b>). Efforts to further improve CXCR2 antagonist activity by introducing hydrophobic and/or hydrophilic substitutions (<b>17</b>–<b>21</b>) failed to provide any compound with higher potency. The <i>ortho</i>-substitution (<b>17</b>, pIC<sub>50</sub> = 8.0) demonstrated better potency than the <i>meta</i>-substitution (<b>18</b>, pIC<sub>50</sub> = 6.7). Increasing the size of the <i>ortho</i>-substitution resulted in decreased potency (<b>19</b>, pIC<sub>50</sub> = 7.2), suggesting that small substitutions be preferred. The hydrophilic substitution was poorly tolerated (<b>20</b>, pIC<sub>50</sub> = 6.6), further supporting the existence of a hydrophobic binding pocket. The disubstitution at the <i>ortho</i>-position of the cyclopentanyl group resulted in low activity (<b>21</b>, pIC<sub>50</sub> = 6.8), likely due to the unfavorable steric effect. Sterically less hindered spiro and fused analogues afforded better potencies (<b>22</b>, <b>23</b>). As expected, the hydrophilic pyrrolidine group led to an inactive compound (<b>24</b>, pIC<sub>50</sub> < 5.0). We then started to explore the unsaturated rings to increase planarity which might better mimic aromatic rings. Intriguingly, the cyclopentenyl ring afforded slightly improved potency (<b>25</b>, pIC<sub>50</sub> = 8.2) compared with the cyclopentanyl analogue (<b>16</b>). A breakthrough was achieved when a methyl substitution was introduced to the α-position of the cyclopentenyl group (<b>26</b>, pIC<sub>50</sub> = 9.4). The Cl substitution provided comparable potency (<b>27</b>, pIC<sub>50</sub> = 9.0), whereas sterically more hindered and less hindered substitutions were less potent (<b>28</b>, <b>29</b>). Disubstituted cyclopentenyl groups (<b>30</b>, <b>31</b>) were observed to result in decreased potency. Again, ring size was explored and, similarly, six-membered unsaturated rings (<b>32</b>–<b>34</b>) were less potent than their five-membered counterparts. Thus, the 2-methylcyclopentenyl (<b>26</b>) was identified as the best right-hand-side (RHS) R group for future SAR studies.</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. SAR of the R Group to Replace the 2-Chloro-3-fluorophenyl Aromatic Ring with Aliphatic Rings<a class="ref internalNav" href="#t1fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.7b01854/20180315/images/medium/jm-2017-01854x_0008.gif" alt="" id="fx1" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.7b01854/20180315/images/medium/jm-2017-01854x_0009.gif" alt="" id="fx2" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup><sup>a</sup></sup><p class="last">All compounds except for <b>9</b>, <b>10</b>, <b>14</b>, <b>15</b>, and <b>16</b> were prepared and tested as racemates. Detailed synthetic procedures are described in the <a href="/doi/suppl/10.1021/acs.jmedchem.7b01854/suppl_file/jm7b01854_si_001.pdf" class="ext-link">Supporting Information</a>.</p></div><div class="footnote" id="t1fn2"><sup><sup>b</sup></sup><p class="last">PFI = Chrom log <i>D</i><sub>pH7.4</sub> + # Ar, and Chrom log <i>D</i><sub>pH7.4</sub> was measured.<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a></p></div><div class="footnote" id="t1fn3"><sup><sup>c</sup></sup><p class="last">CXCR2 Tango assay pIC<sub>50</sub> value is the average of at least two measurements.</p></div><div class="footnote" id="t1fn4"><sup><sup>d</sup></sup><p class="last">Using predicted log <i>D</i><sub>pH7.4</sub> value from ACD software, version 11.0.</p></div></div><div></div></div><div class="NLM_p">Compounds in <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a> were synthesized and tested as racemates. To further understand the effect of cyclopentenyl stereochemistry on the CXCR2 antagonism activity, several pairs of the single known (<i>R</i>)- and (<i>S</i>)-enantiomers were designed and synthesized. It was worth mentioning that the 2-chlorocyclopent-2-enamine was synthetically more accessible in both (<i>R</i>)-and (<i>S</i>)-configurations comparing to the 2-methylcyclopent-2-enamine, thus the 2-Cl-cyclopentenyl analogues were used for stereochemistry SAR exploration (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>). Generally, the (<i>R</i>)-isomers (<b>35</b>–<b>37</b>) were observed to be ∼100-fold more potent than the (<i>S</i>)-isomers (<b>35′</b>–<b>37′</b>) as evaluated in the CXCR2 Tango assay. When R was oxetane, the potency difference between the (<i>R</i>)-isomer (<b>38</b>, pIC<sub>50</sub> = 6.5) and the (<i>S</i>)-isomer (<b>38′</b>, pIC<sub>50</sub> = 5.6) was less significant although still ∼10-fold. Having established the SAR that the 2-methylcyclopentene was the best RHS group and the (<i>R</i>)-configuration was more favored than the (<i>S</i>)-configuration, future SAR studies were focused on analogues containing the (<i>R</i>)-2-methylcyclopentenyl ring.</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Comparisons between (<i>R</i>)- and (<i>S</i>)-Isomers<a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.7b01854/20180315/images/medium/jm-2017-01854x_0010.gif" alt="" id="fx3" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup><sup>a</sup></sup><p class="last">All compounds were prepared and tested as known single (<i>R</i>)- or (<i>S</i>)-enantiomers. Detailed synthetic procedures are described in the <a href="/doi/suppl/10.1021/acs.jmedchem.7b01854/suppl_file/jm7b01854_si_001.pdf" class="ext-link">Supporting Information</a>.</p></div><div class="footnote" id="t2fn2"><sup><sup>b</sup></sup><p class="last">CXCR2 Tango assay pIC<sub>50</sub> value is the average of at least two measurements.</p></div></div><div></div></div><div class="NLM_p">SAR studies were then focused on the left-hand-side (LHS), especially on R<sup>1</sup> and R<sup>2</sup> substitutions (<a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>). The aim was to balance the overall profile of the series including potency, solubility, permeability, and P-glycoprotein (P-gp)/breast cancer resistance protein (BCRP) efflux, which are in vitro measurements for CNS penetration property.<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a> Exploration of the R<sup>1</sup> substitution started from the <i>tert</i>-butyl group (<b>39</b>), which demonstrated high CXCR2 antagonist potency (pIC<sub>50</sub> = 9.0) in the Tango assay. It was further evaluated in the human whole blood (HWB) Gro-α induced CD11b expression assay, which measured the functional potency at the native CXCR2 receptor, and was found quite active (pIC<sub>50</sub> = 6.5). In addition, compound <b>39</b> showed high cell permeability (364 nm/s) and proved not to be a P-gp/BCRP efflux substrate, resulting in good CNS penetration. However, the compound demonstrated very low solubility (1.2 μg/mL) in fasted state simulated intestinal fluids (FaSSIF),<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a> likely due to its high PFI (7.4). Incorporating electron withdrawing group (EWG) such as F or CF<sub>3</sub> to the <i>tert</i>-butyl group provided analogues (<b>40</b>, <b>41</b>) with slightly reduced PFI (6.6 and 6.7, respectively), however, not surprisingly, only marginal improvements in FaSSIF solubility were observed. Further reducing PFI by replacing two methyl groups with two F led to compound <b>42</b> (PFI = 4.3) with much improved solubility (50.8 μg/mL). Introduction of a dimethylamino group resulted in a significant drop in CXCR2 antagonist potency (<b>43</b>, pIC<sub>50</sub> = 6.9) even though its solubility was high (395.4 μg/mL). Another dimethylamino derivative (<b>44</b>) demonstrated improved potency (pIC<sub>50</sub> = 8.7), however, it proved to be a strong P-gp/BCRP substrate (ER = 12.6) and thus carried high risk for adequate CNS penetration. Intrigued by the high solubility of <b>43</b> and <b>44</b>, a series of nitrogen-containing derivatives were synthesized and evaluated (<b>45</b>–<b>51</b>). Among them, compounds <b>50</b> and <b>51</b> demonstrated balanced overall profiles for further progression, and the rest of compounds were less attractive due to P-gp/BCRP liabilities (<b>45</b>, <b>46</b>) or low potency (<b>47</b>, <b>49</b>). Substitutions at the R<sup>2</sup> position were also investigated. The acidity of the phenol group was believed to be critical for the potency of the series, and we thus limited our exploration to the EWG only in order to maintain or increase its acidity. Replacing the Cl of <b>39</b> with a stronger electron-withdrawing CN group provided compound <b>52</b> with improved potency (pIC<sub>50</sub> = 9.7), presumably due to the increased acidity of the phenol. In addition, <b>52</b> demonstrated much lower PFI and as a result high solubility (685.6 μg/mL). On the other hand, as the compound got more polar its passive permeability decreased (90 nm/s). A similar profile was also observed with another CN derivative (<b>53</b>) with even lower permeability (30 nm/s).</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. Selected SAR of LHS R<sup>1</sup> and R<sup>2</sup> Exploration<a class="ref internalNav" href="#t3fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.7b01854/20180315/images/medium/jm-2017-01854x_0011.gif" alt="" id="fx5" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.7b01854/20180315/images/medium/jm-2017-01854x_0012.gif" alt="" id="fx6" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup><sup>a</sup></sup><p class="last">All compounds were prepared and tested as known single (<i>R</i>)-isomers for the cyclopentenyl RHS. Detailed synthetic procedures are described in the <a class="ref internalNav" href="#sec4" aria-label="Experimental Section">Experimental Section</a> and <a href="/doi/suppl/10.1021/acs.jmedchem.7b01854/suppl_file/jm7b01854_si_001.pdf" class="ext-link">Supporting Information</a>. N.D.: not determined.</p></div><div class="footnote" id="t3fn2"><sup><sup>b</sup></sup><p class="last">PFI = Chrom log <i>D</i><sub>pH7.4</sub> + # Ar, and Chrom log <i>D</i><sub>pH7.4</sub> was measured.<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a></p></div><div class="footnote" id="t3fn3"><sup><sup>c</sup></sup><p class="last">CXCR2 Tango assay pIC<sub>50</sub> value is the average of at least two measurements.</p></div><div class="footnote" id="t3fn4"><sup><sup>d</sup></sup><p class="last">Solubility was measured after 4 h incubation.</p></div><div class="footnote" id="t3fn5"><sup><sup>e</sup></sup><p class="last">Detailed assay protocol to measure efflux ratio is described in the <a class="ref internalNav" href="#sec4" aria-label="Experimental Section">Experimental Section</a>.</p></div><div class="footnote" id="t3fn6"><sup><sup>f</sup></sup><p class="last">Permeability ratio.</p></div><div class="footnote" id="t3fn7"><sup><sup>g</sup></sup><p class="last">Using predicted log <i>D</i><sub>pH7.4</sub> value from ACD software, version 11.0.</p></div></div><div></div></div><div class="NLM_p">On the basis of the overall properties, especially potencies and P-gp/BCRP profiles, several representative analogues (<b>40</b>–<b>42</b>, <b>50</b>–<b>52</b>) were selected for evaluation for in vivo CNS penetration using a rat short oral absorption (SOA) model (<a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>). The brain-to-blood ratio (<i>K</i><sub>p</sub>) of the area under curve (AUC) of compound <b>40</b> was measured to be 0.16 after oral gavage to rats. Intriguingly, its free unbound fraction in both brain (<i>F</i><sub>u,br</sub> = 3.4%) and blood (<i>F</i><sub>u,bl</sub> = 1.1%) were measured to be significantly higher than the diarylurea exemplars (e.g., compound <b>9</b>)<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> which was likely due to its lower PFI. Increasingly, the brain-to-blood ratio of free unbound drug concentration (<i>K</i><sub>p,uu</sub>) has been described as a critical parameter for CNS penetration.<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a><i>K</i><sub>p,uu</sub> for compound <b>40</b> was determined to be 0.48. The trifluoromethyl analogue <b>41</b> also demonstrated good CNS penetration in terms of both total drug exposure (<i>K</i><sub>p</sub> = 0.20) and free unbound drug exposure (<i>K</i><sub>p,uu</sub> = 0.59). With a slightly higher PFI, its free unbound fractions in both brain (<i>F</i><sub>u,br</sub> = 2.1%) and blood (<i>F</i><sub>u,bl</sub> = 0.70%) were slightly lower than compound <b>40</b>. The nitrogen-containing analogues (<b>50</b> and <b>51</b>) demonstrated high peripheral drug exposure with dose normalized area under curve (DNAUC) of 2580 and 11721 (ng·h/mL)/(mg/kg), respectively. However, their <i>K</i><sub>p</sub> values were measured as very low (0.06 and 0.03, respectively), and as a result, their <i>K</i><sub>p,uu</sub> could not be determined with meaningful values. Both <b>50</b> and <b>51</b> were thus considered peripherally restricted compounds. Compound <b>52</b> with the CN substitution also demonstrated low CNS penetration as evidenced by its low brain-to-blood ratio of AUC (<i>K</i><sub>p</sub> = 0.03). It was noteworthy that all the compounds evaluated with low brain penetration showed PFI values <5 (4.3, 3.7, 3.7, and 4.1 for compound <b>42</b>, <b>50</b>, <b>51</b>, and <b>52</b>, respectively), whereas compounds with high brain penetration showed PFI values >5 (6.6 and 6.7 for compound <b>40</b> and <b>41</b>, respectively). SAR suggested that, for this 1-cyclopentenyl-3-phenylurea series, compounds with PFI > 5 might have better potential to be brain penetrant. On the other hand, high PFI has been shown to be associated with low solubility, high protein binding, and other developability risks.<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a> We thus focused our efforts on the compounds with PFIs between 5 and 7 for the purpose of achieving balanced profiles of CNS penetration and developability (solubility, free unbound fraction, etc.).</div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. CNS Penetration Profile of CXCR2 Antagonists <b>40</b>–<b>42</b> and <b>50</b>–<b>52</b><a class="ref internalNav" href="#t4fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="center" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center" char=".">blood DNAUC<sub>0–7h</sub> (ng·h/mL)/(mg/kg)</th><th class="colsep0 rowsep0" align="center" char=".">brain DNAUC<sub>0–7h</sub> (ng·h/g)/(mg/kg)</th><th class="colsep0 rowsep0" align="center" char="."><i>K</i><sub>p</sub><a class="ref internalNav" href="#t4fn2" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center" char="."><i>F</i><sub>u,br</sub><a class="ref internalNav" href="#t4fn3" aria-label="c">c</a> (%)</th><th class="colsep0 rowsep0" align="center" char="."><i>F</i><sub>u,bl</sub><a class="ref internalNav" href="#t4fn4" aria-label="d">d</a> (%)</th><th class="colsep0 rowsep0" align="center"><i>K</i><sub>p,uu</sub><a class="ref internalNav" href="#t4fn5" aria-label="e">e</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>40</b></td><td class="colsep0 rowsep0" align="char" char=".">614</td><td class="colsep0 rowsep0" align="char" char=".">97</td><td class="colsep0 rowsep0" align="char" char=".">0.16</td><td class="colsep0 rowsep0" align="char" char=".">3.4</td><td class="colsep0 rowsep0" align="char" char=".">1.1</td><td class="colsep0 rowsep0" align="center">0.48</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>41</b></td><td class="colsep0 rowsep0" align="char" char=".">535</td><td class="colsep0 rowsep0" align="char" char=".">107</td><td class="colsep0 rowsep0" align="char" char=".">0.20</td><td class="colsep0 rowsep0" align="char" char=".">2.1</td><td class="colsep0 rowsep0" align="char" char=".">0.70</td><td class="colsep0 rowsep0" align="center">0.59</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>42</b></td><td class="colsep0 rowsep0" align="char" char=".">4331</td><td class="colsep0 rowsep0" align="char" char=".">243</td><td class="colsep0 rowsep0" align="char" char=".">0.06</td><td class="colsep0 rowsep0" align="char" char=".">5.1</td><td class="colsep0 rowsep0" align="char" char=".">0.65</td><td class="colsep0 rowsep0" align="center">ND</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>50</b></td><td class="colsep0 rowsep0" align="char" char=".">2580</td><td class="colsep0 rowsep0" align="char" char=".">161</td><td class="colsep0 rowsep0" align="char" char=".">0.06</td><td class="colsep0 rowsep0" align="char" char=".">13.7</td><td class="colsep0 rowsep0" align="char" char=".">5.0</td><td class="colsep0 rowsep0" align="center">ND</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>51</b></td><td class="colsep0 rowsep0" align="char" char=".">11721</td><td class="colsep0 rowsep0" align="char" char=".">296</td><td class="colsep0 rowsep0" align="char" char=".">0.03</td><td class="colsep0 rowsep0" align="char" char=".">11.4</td><td class="colsep0 rowsep0" align="char" char=".">0.65</td><td class="colsep0 rowsep0" align="center">ND</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>52</b></td><td class="colsep0 rowsep0" align="char" char=".">2575</td><td class="colsep0 rowsep0" align="char" char=".">73</td><td class="colsep0 rowsep0" align="char" char=".">0.03</td><td class="colsep0 rowsep0" align="char" char=".">11.6</td><td class="colsep0 rowsep0" align="char" char=".">3.4</td><td class="colsep0 rowsep0" align="center">ND</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t4fn1"><div class="footnote" id="t4fn1"><sup><sup>a</sup></sup><p class="last">CNS penetration was measured using in vivo rat SOA model. Detailed protocol is described the <a class="ref internalNav" href="#sec4" aria-label="Experimental Section">Experimental Section</a>. ND: not determined.</p></div><div class="footnote" id="t4fn2"><sup><sup>b</sup></sup><p class="last"><i>K</i><sub>p</sub> = brain DNAUC<sub>0–7h</sub>/blood DNAUC<sub>0–7h</sub>.</p></div><div class="footnote" id="t4fn3"><sup><sup>c</sup></sup><p class="last">Free unbound fraction measured in rat brain.</p></div><div class="footnote" id="t4fn4"><sup><sup>d</sup></sup><p class="last">Free unbound fraction measured in rat blood.</p></div><div class="footnote" id="t4fn5"><sup><sup>e</sup></sup><p class="last"><i>K</i><sub>p,uu</sub> = <i>K</i><sub>p</sub> × Fu<sub>br</sub>/Fu<sub>bl</sub>.</p></div></div></div><div class="NLM_p">Because of low solubility for alkyl/haloalkyl groups and high efflux ratios for <i>N</i>-containing groups as R<sup>1</sup> substitutions, <i>O</i>-containing substituents were then investigated to balance solubility and efflux ratio (<a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a></a>). Compound <b>54</b> with a methoxyl substitution demonstrated a balanced profile of FaSSIF solubility (72.0 μg/mL) and P-gp/BCRP efflux ratio (3.2), however its potency, especially when measured in the human whole blood CD11b assay, was not optimal (pIC<sub>50</sub> = 6.4). Addition of a four-membered oxetane ring (<b>55</b>) provided much improved CXCR2 antagonist potency in the Tango assay, whereas the solubility decreased dramatically (7.0 μg/mL). Increasing the ring size (<b>56</b>–<b>58</b>) failed to improve the potency and/or resulted in low solubility (<b>58</b>). The HWB potency was slightly improved (pIC<sub>50</sub> = 6.7) when the tetrahydropyran was directly connected to the sulfonyl group (<b>59</b>) but low solubility was observed. Replacing the methyl group of <b>59</b> with an ethyl group (<b>60</b>) led to higher solubility but lower HWB potency. Introduction of F atom provided compounds (<b>61</b>–<b>63</b>) with increased P-gp/BCRP efflux liability. Changing the position of oxygen atom in tetrahydropyran (<b>64</b>, <b>65</b>) failed to provide compounds with more balanced profile of solubility and P-gp/BCRP efflux. We then switched to a five-membered tetrahydrofuran ring with 5 < PFI < 6 (<b>66</b>–<b>68</b>) and, to our delight, compound <b>68</b> demonstrated a balanced profile of solubility (21.0 μg/mL) and P-gp/BCRP efflux ratio (2.0). In addition, the HWB potency of <b>68</b> (pIC<sub>50</sub> = 7.4) proved to be the highest among all the compounds explored. Introduction of a F atom (<b>69</b>) resulted in an increased efflux ratio, similar to the six-membered tetrahydropyran analogues. The hydroxyl (<b>70</b>) and spiro (<b>71</b>) substitutions led to high efflux ratios (26.8 and 25.5, respectively), likely due to their low PFIs (<5).</div><div class="NLM_table-wrap" id="tbl5"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 5. Selected SAR of Oxygen-Containing R<sup>1</sup> Substituent Exploration<a class="ref internalNav" href="#t5fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.7b01854/20180315/images/medium/jm-2017-01854x_0013.gif" alt="" id="fx7" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.7b01854/20180315/images/medium/jm-2017-01854x_0014.gif" alt="" id="fx8" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t5fn1"><div class="footnote" id="t5fn1"><sup><sup>a</sup></sup><p class="last">All compounds were prepared and tested as known single (<i>R</i>)-isomers for the cyclopentenyl RHS. Detailed synthetic procedures are described in the <a class="ref internalNav" href="#sec4" aria-label="Experimental Section">Experimental Section</a> and <a href="/doi/suppl/10.1021/acs.jmedchem.7b01854/suppl_file/jm7b01854_si_001.pdf" class="ext-link">Supporting Information</a>. ND: not determined.</p></div><div class="footnote" id="t5fn2"><sup><sup>b</sup></sup><p class="last">PFI = Chrom log <i>D</i><sub>pH7.4</sub> + # Ar, and Chrom log <i>D</i><sub>pH7.4</sub> was measured.<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a></p></div><div class="footnote" id="t5fn3"><sup><sup>c</sup></sup><p class="last">CXCR2 Tango assay pIC<sub>50</sub> value is the average of at least two measurements.</p></div><div class="footnote" id="t5fn4"><sup><sup>d</sup></sup><p class="last">Solubility was measured after 4 h incubation.</p></div><div class="footnote" id="t5fn5"><sup><sup>e</sup></sup><p class="last">Detailed assay protocol to measure efflux ratio (ER) is described in the <a class="ref internalNav" href="#sec4" aria-label="Experimental Section">Experimental Section</a>.</p></div><div class="footnote" id="t5fn6"><sup><sup>f</sup></sup><p class="last">Permeability ratio.</p></div><div class="footnote" id="t5fn7"><sup><sup>g</sup></sup><p class="last">Using predicted log <i>D</i><sub>pH7.4</sub> value from ACD software, version 11.0.</p></div></div><div></div></div><div class="NLM_p">On the basis of their overall profiles including potency, solubility, and P-gp/BCRP efflux, compounds <b>56</b>, <b>67</b>, and <b>68</b> were selected for rat SOA studies for in vivo CNS penetration evaluation (<a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">Table <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">6</a></a>). Among them, compound <b>68</b> demonstrated the highest <i>K</i><sub>p,uu</sub> (0.63), indicating a good in vivo brain penetration property. It showed a higher brain penetration property compared to the previously reported CNS penetrant compound (<b>8</b>),<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> the <i>K</i><sub>p,uu</sub> of which was determined to be 0.18. In addition, the unbound fractions of compound <b>68</b> were measured to be reasonable in both rat blood (<i>F</i><sub>u,bl</sub> = 2.7%) and human plasma (<i>F</i><sub>u,pl</sub> = 1.9%), which were more than 10-fold higher than the unbound fraction of compound <b>8</b> in human plasma (<i>F</i><sub>u,pl</sub> = 0.13%) described previously.<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> The balanced profile of CNS penetration and free unbound fraction of compound <b>68</b> was likely due to its desirable PFI (5.8), supporting the belief that ideal values of PFIs of the series are between 5 and 7 as discussed previously. It was noteworthy that the free unbound fraction of <b>68</b> in brain (<i>F</i><sub>u,br</sub> = 12.3%) was observed to be much higher than in blood. This phenomenon was consistent throughout the series and likely due to the acidic character of the sulfone substituted phenol group unique within this 1-cyclopentenyl-3-phenylurea series. The diastereoisomer of <b>68</b>, compound <b>67</b>, had the same PFI (5.8), thus its free unbound fractions in both blood (<i>F</i><sub>u,bl</sub> = 3.6%) and brain (<i>F</i><sub>u,br</sub> = 10.6%) were similar to that of <b>68</b>. However, the CNS penetration properties of <b>67</b> measured as both <i>K</i><sub>p</sub> (0.08) and <i>K</i><sub>p,uu</sub> (0.23) were less attractive. Compound <b>56</b> demonstrated a good CNS penetration profile, whereas its low exposure in blood [63.8 (ng·h/mL)/(mg/kg)] was a concern and prohibited further progression.</div><div class="NLM_table-wrap" id="tbl6"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 6. CNS Penetration Profile of CXCR2 Antagonists <b>56</b>, <b>67</b>, and <b>68</b><a class="ref internalNav" href="#t6fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center" char=".">blood DNAUC<sub>0–7h</sub> (ng·h/mL)/(mg/kg)</th><th class="colsep0 rowsep0" align="center" char=".">brain DNAUC<sub>0–7h</sub> (ng·h/g)/(mg/kg)</th><th class="colsep0 rowsep0" align="center" char="."><i>K</i><sub>p</sub><a class="ref internalNav" href="#t6fn2" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center" char="."><i>F</i><sub>u,br</sub><a class="ref internalNav" href="#t6fn3" aria-label="c">c</a> (%)</th><th class="colsep0 rowsep0" align="center" char="."><i>F</i><sub>u,bl</sub><a class="ref internalNav" href="#t6fn4" aria-label="d">d</a> (%)</th><th class="colsep0 rowsep0" align="center" char="."><i>K</i><sub>p,uu</sub><a class="ref internalNav" href="#t6fn5" aria-label="e">e</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>56</b></td><td class="colsep0 rowsep0" align="char" char=".">63.8</td><td class="colsep0 rowsep0" align="char" char=".">13.4</td><td class="colsep0 rowsep0" align="char" char=".">0.21</td><td class="colsep0 rowsep0" align="char" char=".">3.3</td><td class="colsep0 rowsep0" align="char" char=".">1.6</td><td class="colsep0 rowsep0" align="char" char=".">0.42</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>67</b></td><td class="colsep0 rowsep0" align="char" char=".">788</td><td class="colsep0 rowsep0" align="char" char=".">60.5</td><td class="colsep0 rowsep0" align="char" char=".">0.08</td><td class="colsep0 rowsep0" align="char" char=".">10.6</td><td class="colsep0 rowsep0" align="char" char=".">3.6</td><td class="colsep0 rowsep0" align="char" char=".">0.23</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>68</b></td><td class="colsep0 rowsep0" align="char" char=".">651</td><td class="colsep0 rowsep0" align="char" char=".">87.7</td><td class="colsep0 rowsep0" align="char" char=".">0.14</td><td class="colsep0 rowsep0" align="char" char=".">12.3</td><td class="colsep0 rowsep0" align="char" char=".">2.7</td><td class="colsep0 rowsep0" align="char" char=".">0.63</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t6fn1"><div class="footnote" id="t6fn1"><sup><sup>a</sup></sup><p class="last">CNS penetration was measured using in vivo rat SOA model. Detailed protocol is described the <a class="ref internalNav" href="#sec4" aria-label="Experimental Section">Experimental Section</a>.</p></div><div class="footnote" id="t6fn2"><sup><sup>b</sup></sup><p class="last"><i>K</i><sub>p</sub> = brain DNAUC<sub>0–7h</sub>/blood DNAUC<sub>0–7h</sub>.</p></div><div class="footnote" id="t6fn3"><sup><sup>c</sup></sup><p class="last">Free unbound fraction measured in rat brain.</p></div><div class="footnote" id="t6fn4"><sup><sup>d</sup></sup><p class="last">Free unbound fraction measured in rat blood.</p></div><div class="footnote" id="t6fn5"><sup><sup>e</sup></sup><p class="last"><i>K</i><sub>p,uu</sub> = <i>K</i><sub>p</sub> × Fu<sub>br</sub>/Fu<sub>bl</sub>.</p></div></div></div></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i11" class="anchor-spacer"></div><h3 class="article-section__title" id="_i11"> DMPK</h3><div class="NLM_p">Lead compounds <b>40</b> and <b>68</b> were further progressed in an in vivo PK study in rats following 1 mg/kg intravenous (IV) and 2 mg/kg oral administration (<a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">Table <a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">7</a></a>). Both compounds showed low clearance and high exposure in rat, consistent with their profile from the in vivo rat SOA study. The half-life (<i>T</i><sub>1/2</sub>) of compound <b>68</b> (4.3 h) was longer than that of compound <b>40</b> (2.5 h), likely due to its lower clearance (9.1 mL/min/kg) compared to <b>40</b> (15.7 mL/min/kg). The DNAUC values for compounds <b>40</b> and <b>68</b> were determined to be 1071 and 1829 (ng·h/mL)/(mg/kg), respectively. The oral exposure of both compounds was measured high with DNAUC values of 961 (ng·h/mL)/(mg/kg) for <b>40</b> and 860 (ng·h/mL)/(mg/kg) for <b>68</b>, corresponding to 88% and 47% oral bioavailability, respectively. Compound <b>68</b> was selected as the advanced lead compound due to its longer <i>T</i><sub>1/2</sub>, better solubility, and higher free unbound fraction compared to compound <b>40</b>. An in vivo dog PK study was conducted for compound <b>68</b> and low clearance (5.6 mL/min/kg), reasonable <i>T</i><sub>1/2</sub> (3.6 h), high oral exposure [2298 (ng·h/mL)/(mg/kg)], and good oral bioavailability (76%) were observed, which were consistent with the rat profile. In addition, the in vitro metabolic stability of compound <b>68</b> in human, rat, and dog hepatocytes was determined (<a class="ref showTableEvent internalNav" data-ID="tbl8" href="#tbl8">Table <a class="ref showTableEvent internalNav" data-ID="tbl8" href="#tbl8">8</a></a>). The result revealed that the compound was most stable in human hepatocytes [Cl<sub>int</sub> = 0.79 (mL/min/g)] and least stable in rat hepatocytes [Cl<sub>int</sub> = 7.7 (mL/min/g)].</div><div class="NLM_table-wrap" id="tbl7"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 7. DMPK Profile of Lead Compounds <b>40</b> and <b>68</b></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" align="center"><b>40</b></th><th class="rowsep1 colsep0" colspan="2" align="center"><b>68</b></th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center">rat</th><th class="colsep0 rowsep0" align="center">rat</th><th class="colsep0 rowsep0" align="center">dog</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">in vivo PK</td><td class="colsep0 rowsep0" align="center"> </td><td class="colsep0 rowsep0" align="center"> </td><td class="colsep0 rowsep0" align="center"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">IV dose (mg/kg)</td><td class="colsep0 rowsep0" align="center">1.01</td><td class="colsep0 rowsep0" align="center">0.98</td><td class="colsep0 rowsep0" align="center">0.85</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Cl<sub>b</sub> (mL/min/kg)</td><td class="colsep0 rowsep0" align="center">15.7</td><td class="colsep0 rowsep0" align="center">9.1</td><td class="colsep0 rowsep0" align="center">5.6</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>V</i><sub>ss</sub> (L/kg)</td><td class="colsep0 rowsep0" align="center">2.2</td><td class="colsep0 rowsep0" align="center">2.1</td><td class="colsep0 rowsep0" align="center">0.88</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>T</i><sub>1/2</sub> (h)</td><td class="colsep0 rowsep0" align="center">2.5</td><td class="colsep0 rowsep0" align="center">4.3</td><td class="colsep0 rowsep0" align="center">3.6</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">DNAUC<sub>0–∞</sub> (ng·h/mL)/(mg/kg)</td><td class="colsep0 rowsep0" align="center">1071</td><td class="colsep0 rowsep0" align="center">1829</td><td class="colsep0 rowsep0" align="center">2996</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">oral dose (mg/kg)</td><td class="colsep0 rowsep0" align="center">2.38</td><td class="colsep0 rowsep0" align="center">2.41</td><td class="colsep0 rowsep0" align="center">1.29</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>T</i><sub>max</sub> (h)</td><td class="colsep0 rowsep0" align="center">2.5</td><td class="colsep0 rowsep0" align="center">1.0</td><td class="colsep0 rowsep0" align="center">1.1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>C</i><sub>max</sub> (ng/mL)</td><td class="colsep0 rowsep0" align="center">292</td><td class="colsep0 rowsep0" align="center">452</td><td class="colsep0 rowsep0" align="center">728</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">DNAUC<sub>0–∞</sub> (ng·h/mL)/(mg/kg)</td><td class="colsep0 rowsep0" align="center">961</td><td class="colsep0 rowsep0" align="center">860</td><td class="colsep0 rowsep0" align="center">2298</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>F</i> (%)</td><td class="colsep0 rowsep0" align="center">88</td><td class="colsep0 rowsep0" align="center">47</td><td class="colsep0 rowsep0" align="center">76</td></tr></tbody></table></div></div><div class="NLM_table-wrap" id="tbl8"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 8. Metabolic Stability of Lead Compound <b>68</b> in Human, Rat, and Dog Hepatocytes</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="center" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">metabolic stability</th><th class="colsep0 rowsep0" align="center"><b>68</b></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">human Cl<sub>int</sub> (mL/min/g)</td><td class="colsep0 rowsep0" align="center">0.79</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">rat Cl<sub>int</sub> (mL/min/g)</td><td class="colsep0 rowsep0" align="center">7.7</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">dog Cl<sub>int</sub> (mL/min/g)</td><td class="colsep0 rowsep0" align="center">1.8</td></tr></tbody></table></div></div></div><div id="sec2_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i14" class="anchor-spacer"></div><h3 class="article-section__title" id="_i14"> In Vitro Pharmacology in Mouse and Human Whole Blood</h3><div class="NLM_p">The ability of compound <b>68</b> to inhibit CXCR2 receptor activation was assessed in whole blood Gro-α induced CD11b expression assays and quantified by flow cytometry. In the mouse whole blood assay (<a data-tab="pane-pcw-Figures" href="#fig2a" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2a" id="" class=" internalNav">2</a></a>a), compound <b>68</b> inhibited Gro-α induced CD11b expression with a IC<sub>50</sub> value of 5.9 nM (<i>N</i> = 3), comparable to the control compound navarixin<a onclick="showRef(event, 'ref19 ref20'); return false;" href="javascript:void(0);" class="ref ref19 ref20">(19,20)</a> (IC<sub>50</sub> = 8.1 nM). It was worth mentioning that the maximal response of compound <b>68</b> was less than that of navarixin, around two-thirds of CD11b inhibition driven by navarixin at 10 μM, suggesting a partial inhibitory effect of compound <b>68</b> in mouse whole blood. In contrast, in human whole blood CD11b assay (<a data-tab="pane-pcw-Figures" href="#fig2a" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2a" id="" class=" internalNav">2</a></a>b), compound <b>68</b> (similar to navarixin) fully inhibited Gro-α induced CD11b expression with an IC<sub>50</sub> value of 0.04 μM (<i>N</i> = 5), which was 17-fold more potent than that of navarixin (IC<sub>50</sub> = 0.68 μM). In addition, compound <b>68</b> was 12-fold more potent than the reported CNS penetrant compound <b>8</b><a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> (IC<sub>50</sub> = 0.50 μM) in this HWB assay.</div><figure id="fig2a" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.7b01854/20180315/images/medium/jm-2017-01854x_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.7b01854/20180315/images/large/jm-2017-01854x_0002.jpeg" id="GRAPHIC-d128e2287-autogenerated" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. (a) Mouse whole blood CD11b assay of compound <b>68</b>. (b) Human whole blood CD11b assay of compound <b>68</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.7b01854/20180315/images/large/jm-2017-01854x_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01854&amp;id=fig2a"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i15" class="anchor-spacer"></div><h3 class="article-section__title" id="_i15"> In Vitro Chemokine Selectivity</h3><div class="NLM_p">Compound <b>68</b> demonstrated excellent selectivity for CXCR2 antagonist activity over other CXC and CC chemokine receptors (<a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">Table <a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">9</a></a>). A total of 18 CXC and CC chemokine receptors including CXCR2 were evaluated in both agonism and antagonism modes in β-arrestin assays and, among them, compound <b>68</b> was measured to be inactive (IC<sub>50</sub><i>s</i> > 10 μM) in all assays except for CXCR2 and CXCR1. IC<sub>50</sub>s of the compound on CXCR2 and CXCR1 were 5.2 nM and 3.8 μM, respectively. Thus, compound <b>68</b> was determined to be a highly selective CXCR2 antagonist with ∼730-fold selectivity over CXCR1 and >1900-fold selectivity over all other chemokine receptors evaluated.</div><div class="NLM_table-wrap" id="tbl9"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 9. Chemokine Selectivity Profile of Lead Compound <b>68</b><sup>a</sup></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="center" /></col><col align="center" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">assay target</th><th class="colsep0 rowsep0" align="center">agonism EC<sub>50</sub> (μM)</th><th class="colsep0 rowsep0" align="center">antagonism IC<sub>50</sub> (μM)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CCR10</td><td class="colsep0 rowsep0" align="center">>10</td><td class="colsep0 rowsep0" align="center">>10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CCR2</td><td class="colsep0 rowsep0" align="center">>10</td><td class="colsep0 rowsep0" align="center">>10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CCR3</td><td class="colsep0 rowsep0" align="center">>10</td><td class="colsep0 rowsep0" align="center">>10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CCR4</td><td class="colsep0 rowsep0" align="center">>10</td><td class="colsep0 rowsep0" align="center">>10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CCR5</td><td class="colsep0 rowsep0" align="center">>10</td><td class="colsep0 rowsep0" align="center">>10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CCR6</td><td class="colsep0 rowsep0" align="center">>10</td><td class="colsep0 rowsep0" align="center">>10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CCR7</td><td class="colsep0 rowsep0" align="center">>10</td><td class="colsep0 rowsep0" align="center">>10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CCR8</td><td class="colsep0 rowsep0" align="center">>10</td><td class="colsep0 rowsep0" align="center">>10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CCR9</td><td class="colsep0 rowsep0" align="center">>10</td><td class="colsep0 rowsep0" align="center">>10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CMKLR1</td><td class="colsep0 rowsep0" align="center">>10</td><td class="colsep0 rowsep0" align="center">>10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CXC3R1</td><td class="colsep0 rowsep0" align="center">>10</td><td class="colsep0 rowsep0" align="center">>10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CXCR1</td><td class="colsep0 rowsep0" align="center">>10</td><td class="colsep0 rowsep0" align="center">3.8</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CXCR2</td><td class="colsep0 rowsep0" align="center">>10</td><td class="colsep0 rowsep0" align="center">0.0052</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CXCR3</td><td class="colsep0 rowsep0" align="center">>10</td><td class="colsep0 rowsep0" align="center">>10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CXCR4</td><td class="colsep0 rowsep0" align="center">>10</td><td class="colsep0 rowsep0" align="center">>10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CXCR5</td><td class="colsep0 rowsep0" align="center">>10</td><td class="colsep0 rowsep0" align="center">>10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CXCR6</td><td class="colsep0 rowsep0" align="center">>10</td><td class="colsep0 rowsep0" align="center">>10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CXCR7</td><td class="colsep0 rowsep0" align="center">>10</td><td class="colsep0 rowsep0" align="center">>10</td></tr></tbody></table></div></div></div><div id="sec2_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i17" class="anchor-spacer"></div><h3 class="article-section__title" id="_i17"> In Vivo Pharmacology in Mouse and Rat</h3><div class="NLM_p">The effects of compound <b>68</b> on peripheral inflammatory cell infiltration induced by 2% carrageenan was tested using mouse and rat air pouch models.<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a> As shown in <a data-tab="pane-pcw-Figures" href="#fig3a" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3a" id="" class=" internalNav">3</a></a>a, compound <b>68</b> significantly inhibited neutrophil infiltration into mouse air pouch as compared to vehicle (One-Way ANOVA), 4 h after carrageenan induction at 1, 3, and 10 mg/kg oral dosing twice daily (BID). Similar in vivo pharmacology was observed in the rat air pouch model (<a data-tab="pane-pcw-Figures" href="#fig3a" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3a" id="" class=" internalNav">3</a></a>b). In this species, compound <b>68</b> demonstrated a marked dose-dependent inhibition of neutrophil migration from 1 to 3 mg/kg to 10 mg/kg BID oral dosing.</div><figure id="fig3a" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.7b01854/20180315/images/medium/jm-2017-01854x_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.7b01854/20180315/images/large/jm-2017-01854x_0003.jpeg" id="GRAPHIC-d128e2519-autogenerated" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. (a) Compound <b>68</b> inhibited neutrophil migration to the air pouch in mouse. The neutrophil cell number in the lavage were counted after 4 h carageenan induction, and the percentage was calculated compared to vehicle group. * <i>p</i> < 0.05, ** <i>p</i> < 0.01, compared with the vehicle group. One-Way ANOVA, followed by Bonferroni multiple comparison test. (b) Compound <b>68</b> inhibited neutrophil migration to air pouch in rat. The neutrophil cell number in the lavage were counted after 4 h carageenan induction, and the percentage was calculated compared to vehicle group. *** <i>p</i> < 0.001 indicates significantly decreasing compared with the vehicle group. One-way ANOVA, followed by Dunnett’s multiple comparison test.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.7b01854/20180315/images/large/jm-2017-01854x_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01854&amp;id=fig3a"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i18" class="anchor-spacer"></div><h3 class="article-section__title" id="_i18"> Synthetic Chemistry</h3><div class="NLM_p">Convergent synthetic routes for the syntheses of 1-cyclopentenyl-3-phenylureas were developed as illustrated in the syntheses of key compounds <b>40</b> and <b>68</b>. Both compounds were assembled from the common RHS chiral amine intermediate (<b>75</b>) and the corresponding LHS aminophenol intermediates (<b>82</b> for compound <b>40</b> and <b>85</b> for compound <b>68</b>), as shown in <a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>. Synthesis of chiral amine <b>75</b> was initiated from the commercial starting material, ketone <b>72</b>. Enantioselective reduction of the ketone group of <b>72</b> catalyzed by (<i>R</i>)-CBS<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a> provided alcohol <b>73</b> in quantitative yield, and the enantiomeric excess (<i>ee</i>) was determined in the next step. Stereospecific reversion of the chiral alcohol with phthalimide by Mitsunobu reaction afforded chiral phthalimide intermediate <b>74</b> with 74% <i>ee</i> favoring the (<i>R</i>)-isomer. Chiral purification of the mixture by supercritical fluid chromatography (SFC) afforded enantiomerically pure intermediate <b>74</b> as the (<i>R</i>)-isomer with >98% <i>ee</i>. Treatment of <b>74</b> with hydrazine at elevated temperature provided the common RHS intermediate, the chiral amine <b>75</b>.</div><figure id="sch1" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.7b01854/20180315/images/medium/jm-2017-01854x_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.7b01854/20180315/images/large/jm-2017-01854x_0005.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Retrosynthetic Analysis and Synthesis of RHS Intermediate <b>75</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.7b01854/20180315/images/large/jm-2017-01854x_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01854&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) (<i>R</i>)-CBS, BH<sub>3</sub>·THF, THF, −60 °C; (b) phthalimide, PPh<sub>3</sub>, DIAD, THF, 0 °C, 28% over two steps; (c) hydrazine, EtOH, reflux, 100%.</p></p></figure><div class="NLM_p">Synthesis of the lead compound <b>40</b> was initiated from the reported starting material, thiol <b>76</b> (<a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>).<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a><b>76</b> was treated with ethyl 2-bromo-2-methylpropanoate to afford the thiol ether <b>77</b>, which was then oxidized by <i>m</i>-CPBA to afford sulfone <b>78</b> in 64% yield over two steps. Reduction of the ethyl ester of <b>78</b> with DIBAL-H provided the alcohol <b>79</b>. The hydroxyl group of <b>79</b> was converted to trifluoromethanesulfonate (<b>80</b>) and, after treatment with TBAF, the F-containing intermediate <b>81</b> was obtained in good yield (46% over three steps). Hydrolysis of the benzoxazole moiety in strong acidic condition at elevated temperature gave the LHS intermediate, aminophenol <b>82</b>. Coupling of LHS <b>82</b> with the transient isocyanate intermediate derived from RHS <b>75</b> provided the final compound <b>40</b> in good isolated yield (58%).</div><figure id="sch2" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.7b01854/20180315/images/medium/jm-2017-01854x_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.7b01854/20180315/images/large/jm-2017-01854x_0006.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of Lead Compound <b>40</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.7b01854/20180315/images/large/jm-2017-01854x_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01854&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) ethyl 2-bromo-2-methylpropanoate, K<sub>2</sub>CO<sub>3</sub>, DMF, 60 °C; (b) <i>m</i>-CPBA, DCM, rt, 64% over two steps; (c) DIBAL-H, THF, −50 °C → rt; (d) triflic anhydride, pyridine, DCM, rt; (e) TBAF, THF, −15 °C → 30 °C, 46% over three steps;( f) 37% HCl, dioxane, reflux, 98%; (g) (i) <b>75</b>, triphosgene, NaHCO<sub>3</sub>, DCM, 0 °C → rt, (ii) pyridine, rt, 58%.</p></p></figure><div class="NLM_p">For the synthesis of lead compound <b>68</b> (<a class="ref internalNav" href="#sch3" aria-label="Scheme 3">Scheme 3</a>), the starting material <b>83</b> was prepared in large quantities following a published procedure.<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> Compound <b>83</b> was treated with methyl iodide in the presence of LHMDS to afford the intermediate <b>84</b> as an enantiomeric mixture at the tetrahydrofuran moiety. The benzoxazole group of <b>84</b> was hydrolyzed under acidic condition to afford the LHS aminophenol <b>85</b> in good isolated yield over two steps (66%). Similarly, the LHS <b>85</b> was coupled with the isocyanate derived from RHS <b>75</b> to produce the diastereomeric mixture <b>66</b> in high yield (96%). The two diastereomers of <b>66</b> were separated by SFC to afford the desired single diastereomer <b>68</b> in 22% isolated yield (>93% <i>de</i>). The absolute stereochemistry of the 3-methyltetrahydrofuran-3-yl group of compound <b>68</b> was established unambiguously as the (<i>S</i>)-isomer from crystal structure.</div><figure id="sch3" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.7b01854/20180315/images/medium/jm-2017-01854x_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.7b01854/20180315/images/large/jm-2017-01854x_0007.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthesis of Lead Compound <b>68</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.7b01854/20180315/images/large/jm-2017-01854x_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01854&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) LiHMDS, MeI, THF, −70 °C → rt; (b) 37% HCl, dioxane, reflux, 66% over two steps; c) (i) <b>75</b>, triphosgene, NaHCO<sub>3</sub>, DCM, 0 °C → rt, (ii) pyridine, 40 °C, 96%; (d) chiral SFC separation, 22%.</p></p></figure></div><div id="sec2_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i22" class="anchor-spacer"></div><h3 class="article-section__title" id="_i22"> X-ray Crystallography</h3><div class="NLM_p">The absolute configuration of compound <b>68</b> was determined using single crystal X-ray diffraction techniques. The compound crystallizes with two independent molecules in the asymmetric unit. One of these is shown in <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>. For both molecules, the 3-methyltetrahydrofuran-3-yl groups are found to be disordered over two positions but the (<i>S</i>)-configuration for this moiety is maintained within the model throughout (see <a href="/doi/suppl/10.1021/acs.jmedchem.7b01854/suppl_file/jm7b01854_si_001.pdf" class="ext-link">Supporting Information</a> for further information). The chiral center of the 2-methylcyclopent-2-enamine moiety was confirmed to be (<i>R</i>), consistent with the reported stereochemistry assignment generated from (<i>R</i>)-CBS reduction. Intermolecular hydrogen bonds between urea groups alternately link the two independent molecules into chains within the structure. An intramolecular interaction exists in both molecules between the hydroxyl group and a sulfonyl oxygen atom.</div><figure id="fig4" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.7b01854/20180315/images/medium/jm-2017-01854x_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.7b01854/20180315/images/large/jm-2017-01854x_0004.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. A view of one of the independent molecules from the crystal structure of <b>68</b>, showing the numbering scheme employed (the second molecule is numbered in an analogous fashion, from N31 to C57). Anisotropic atomic displacement ellipsoids for the non-hydrogen atoms are shown at the 50% probability level. For clarity, only one of the two disorder components for the 3-methyltetrahydrofuran-3-yl group is shown. Hydrogen atoms are displayed with an arbitrarily small radius.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.7b01854/20180315/images/large/jm-2017-01854x_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01854&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i23">Conclusions</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_85420" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_85420" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">In summary, a series of novel 1-cyclopentenyl-3-phenylureas were discovered as potent, brain penetrant, and orally available CXCR2 antagonists. Extensive SAR studies to improve solubility, protein binding, and in vitro and in vivo CNS penetration properties by carefully optimizing molecules’ PFI led to the discovery of the advanced lead compound <b>68</b>. Compound <b>68</b> demonstrated desirable PFI (5.8), good solubility (21.0 μg/mL), and high free unbound fraction in both blood (<i>F</i><sub>u,bl</sub> = 2.7%) and brain (<i>F</i><sub>u,br</sub> = 12.3%). Rat and dog PK studies revealed moderate to good oral bioavailability (47% and 76%, respectively) with high oral exposure [DNAUC: 860 and 2298 (ng·h/mL)/(mg/kg), respectively] and desirable <i>T</i><sub>1/2</sub> (4.3 and 3.6 h, respectively) in both species. Compound <b>68</b> inhibited human whole blood Gro-α induced CD11b expression with a IC<sub>50</sub> value of 0.04 μM, 17-fold more potent than a reported clinical compound navarixin (IC<sub>50</sub> = 0.68 μM). Screening of <b>68</b> on a panel of 18 chemokine receptors highlighted potent inhibition of CXCR2 (IC<sub>50</sub> = 5.2 nM) with ∼730-fold selectivity over CXCR1 and >1900-fold selectivity over all other chemokine receptors tested (IC<sub>50</sub>s > 10 μM). Compound <b>68</b> dose-dependently reduced neutrophil infiltration in vivo in rat and mouse “air pouch” models upon oral administration (1, 3, and 10 mg/kg BID). In addition, a good CNS penetration profile of compound <b>68</b> was observed in rat in vivo SOA study (<i>K</i><sub>p,uu</sub> = 0.63). Compared to the reported CNS penetrant compound <b>8</b>, compound <b>68</b> demonstrated much better potency (12-fold) in human whole blood assay, significantly higher unbound fraction in human plasma (>10-fold), and improved brain penetration as measured by <i>K</i><sub>p,uu</sub> (>3 fold). The compound might represent a promising candidate for not only peripheral inflammatory diseases but also a range of CNS indications.</div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i24">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_28504" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_28504" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i25" class="anchor-spacer"></div><h3 class="article-section__title" id="_i25"> Chemistry</h3><div class="NLM_p last">The syntheses of the compounds <b>40</b>, <b>66</b>, and <b>68</b> are described below. Detailed experimental procedures for the syntheses of all other compounds, their intermediates, and characterization data are provided in the <a href="/doi/suppl/10.1021/acs.jmedchem.7b01854/suppl_file/jm7b01854_si_001.pdf" class="ext-link">Supporting Information</a>. Liquid chromatography mass spectrometry (LCMS) was used to determine the purity of compounds, and all tested compounds were determined with ≥95% purity.</div></div><div id="sec4_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i26" class="anchor-spacer"></div><h3 class="article-section__title" id="_i26"> Materials and Methods</h3><div class="NLM_p last">Reagents were purchased from commercial suppliers and used directly without further purification. <sup>1</sup>H NMR and <sup>13</sup>C NMR spectra were measured on Bruker 400/600 NMR spectrometer wherein CDCl<sub>3</sub> (deuterochloroform), CD<sub>3</sub>OD (deuterated methanol), or DMSO-<i>d</i><sub>6</sub> (hexadeuterio-dimethyl sulfoxide) were used as the solvents, and TMS (tetramethylsilane) was used as the internal standard. Chemical shifts (δ) were given in parts per million (ppm) downfield from the internal standard TMS signal. In NMR spectra, the following abbreviations were used for multiplicity: s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet, dd = doublet of doublets, dt = doublet of triplets, ddd = doublet of doublet of doublets, br = broad. <i>J</i> was used to indicate the NMR coupling constant measured in hertz. High resolution mass (HRMS) measurement was achieved using an orthogonal acceleration time-of-flight (oa-TOF) SYNAPT G2 HDMS equipped with a positive mode of electrospray ionization (ESI) (Waters, Manchester, UK). LCMS analysis was conducted on Agilent 1200SL-6110 under the acidic condition, water containing 0.05% TFA/acetonitrile as the mobile phase on Agilent SB-C18 column (1.8 μm, 4.6 mm × 30 mm), with MS and photodiode array detector (PDA). The following conditions were used for LCMS: a gradient from 5 to 95% in 5 min (or 6 min) and held at 95% for 1 min; UV detection at 214 and 254 nm; a flow rate of 1.5 mL/min; full scan; mass range from 100 to 1000 amu. Column chromatography purifications were performed on Isco or Biotage with a detector with UV wavelength at 254 and 280 nm, using a prepacked silica gel column.</div></div><div id="sec4_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i27" class="anchor-spacer"></div><h3 class="article-section__title" id="_i27"> Preparation of the Target Compounds <b>40</b>, <b>66</b>, and <b>68</b></h3><div id="sec4_3_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i28" class="anchor-spacer"></div><h4 class="article-section__title" id="_i28"> Synthesis of (<i>R</i>)-1-(4-Chloro-3-((1-fluoro-2-methylpropan-2-yl)sulfonyl)-2-hydroxyphenyl)-3-(2-methylcyclopent-2-en-1-yl)urea (<b>40</b>)</h4><div class="NLM_p last">To a solution of (<i>R</i>)-2-methylcyclopent-2-enamine and hydrochloride salt (<b>75</b>, 560 mg) in toluene (36 mL) was added triphosgene (746 mg). The reaction mixture was refluxed for 6 h and then cooled to room temperature to give the fresh prepared isocyanate solution. To a solution of 6-amino-3-chloro-2-((1-fluoro-2-methylpropan-2-yl)sulfonyl)phenol (<b>82</b>, 100 mg) in pyridine (5 mL) was added the above isocyanate solution in toluene (4 mL). The reaction mixture was stirred at room temperature overnight. The reaction mixture was concentrated, and the resulting residue was purified by prep-HPLC to give (<i>R</i>)-1-(4-chloro-3-((1-fluoro-2-methylpropan-2-yl)sulfonyl)-2-hydroxyphenyl)-3-(2-methylcyclopent-2-en-1-yl)urea (<b>40</b>, 70 mg, 58% yield) as a white solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.31 (s, 1H), 8.38 (d, <i>J</i> = 8.8 Hz, 1H), 8.16 (s, 1H), 7.12 (d, <i>J</i> = 8.8 Hz, 1H), 7.07 (d, <i>J</i> = 8.3 Hz, 1H), 5.51 (br s, 1H), 4.73 (s, 1H), 4.62 (s, 1H), 4.45–4.57 (m, 1H), 2.10–2.37 (m, 3H), 1.66 (s, 3H), 1.45–1.57 (m, 1H), 1.35–1.42 (m, 6H). <sup>13</sup>C NMR (151 MHz, DMSO-<i>d</i><sub>6</sub>) δ 155.1, 148.1, 140.6, 130.8, 127.4, 124.1, 124.0, 123.9, 116.6, 85.2, 84.0, 67.8, 58.0, 32.6, 30.0, 17.5, 14.3. LCMS (ESI) <i>m</i>/<i>z</i> 405 [M + H]<sup>+</sup>. HRMS (EI) <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calcd for C<sub>17</sub>H<sub>23</sub>ClFN<sub>2</sub>O<sub>4</sub>S 405.1051, found 405.1045.</div></div><div id="sec4_3_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i29" class="anchor-spacer"></div><h4 class="article-section__title" id="_i29"> Synthesis of 1-(4-Chloro-2-hydroxy-3-((3-methyltetrahydrofuran-3-yl)sulfonyl)phenyl)-3-((<i>R</i>)-2-methylcyclopent-2-en-1-yl)urea (<b>66</b>)</h4><div class="NLM_p last">To a solution of 6-amino-3-chloro-2-((3-methyltetrahydrofuran-3-yl)sulfonyl)phenol (<b>85</b>, 3.0 g) in pyridine (20 mL) was added the fresh prepared isocyanate solution (as described in the synthesis of <b>40</b>). The mixture was stirred at 40 °C for 12 h. Ice–water (30 mL) was added to the above solution, and the mixture was extracted with DCM (2 × 100 mL). The combined organic layers were dried over sodium sulfate, filtered, and concentrated in vacuo. The resulting residue was purified by silica gel column chromatography eluting with 0–80% ethyl acetate in petroleum ether to give 1-(4-chloro-2-hydroxy-3-((3-methyltetrahydrofuran-3-yl)sulfonyl)phenyl)-3-((<i>R</i>)-2-methylcyclopent-2-en-1-yl)urea (<b>66</b>, 4.1 g, 96% yield) as a white solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.51 (s, 1H), 8.37 (d, <i>J</i> = 9.0 Hz, 1H), 8.20 (s, 1H), 7.15 (d, <i>J</i> = 8.8 Hz, 1H), 7.08 (d, <i>J</i> = 8.6 Hz, 1H), 5.51 (s, 1H), 4.47–4.58 (m, 1H), 4.33 (d, <i>J</i> = 10.0 Hz, 1H), 3.75–3.89 (m, 2H), 3.60 (d, <i>J</i> = 10.0 Hz, 1H), 2.67 (dt, <i>J</i> = 13.3, 7.9 Hz, 1H), 2.09–2.37 (m, 3H), 1.90–2.02 (m, 1H), 1.66 (s, 3H), 1.44–1.60 (m, 4H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 155.1, 148.0, 140.6, 131.0, 127.4, 124.1, 123.5, 117.1, 73.7, 73.3, 67.8, 58.0, 34.3, 32.6, 30.0, 20.3, 14.3. LCMS (ESI) <i>m</i>/<i>z</i> 415 [M + H]<sup>+</sup>. HRMS (EI) <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calcd for C<sub>18</sub>H<sub>24</sub>ClN<sub>2</sub>O<sub>5</sub>S 415.1094, found 415.1085.</div></div><div id="sec4_3_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i30" class="anchor-spacer"></div><h4 class="article-section__title" id="_i30"> Synthesis of 1-(4-Chloro-2-hydroxy-3-(((<i>S</i>)-3-methyltetrahydrofuran-3-yl)sulfonyl)phenyl)-3-((<i>R</i>)-2-methylcyclopent-2-en-1-yl)urea (<b>68</b>)</h4><div class="NLM_p last">The compound 1-(4-chloro-2-hydroxy-3-((3-methyltetrahydrofuran-3-yl)sulfonyl)phenyl)-3-((<i>R</i>)-2-methylcyclopent-2-en-1-yl)urea (<b>66</b>, 3.0 g) was separated by supercritical fluid chromatograpy (SFC) and purified by mass detected auto purification system (MDAP) under acidic condition to afford 1-(4-chloro-2-hydroxy-3-(((<i>S</i>)-3-methyltetrahydrofuran-3-yl)sulfonyl)phenyl)-3-((<i>R</i>)-2-methylcyclopent-2-en-1-yl)urea (<b>68</b>, 666 mg, 22% yield) as a white solid. HPLC: Chiralpak IC column (4.6 mm × 250 mm, 5 μM); 1:1 ACN/IPA (containing 0.5% DEA); CO<sub>2</sub> flow rate, 2.55 mL/min; cosolvent flow rate, 0.45 mL/min; back pressure, 120 bar); <i>t</i><sub>r</sub> = 16.9 min; >93% <i>de</i>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.53 (s, 1H), 8.36 (d, <i>J</i> = 8.8 Hz, 1H), 8.17 (s, 1H), 7.14 (d, <i>J</i> = 8.8 Hz, 1H), 7.05 (d, <i>J</i> = 8.3 Hz, 1H), 5.51 (s, 1H), 4.49–4.63 (m, 1H), 4.33 (d, <i>J</i> = 10.3 Hz, 1H), 3.76–3.89 (m, 2H), 3.61 (d, <i>J</i> = 10.0 Hz, 1H), 2.68 (dt, <i>J</i> = 13.3, 7.9 Hz, 1H), 2.10–2.35 (m, 3H), 1.91–2.02 (m, 1H), 1.67 (s, 3H), 1.44–1.58 (m, 4H). <sup>13</sup>C NMR (151 MHz, DMSO-<i>d</i><sub>6</sub>) δ 155.1, 148.0, 140.6, 131.0, 127.4, 124.1, 124.1, 123.5, 117.1, 73.7, 73.3, 67.8, 58.1, 34.4, 32.6, 30.0, 20.3, 14.3. LCMS (ESI) <i>m</i>/<i>z</i> 415 [M + H]<sup>+</sup>. HRMS (EI) <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calcd for C<sub>18</sub>H<sub>24</sub>ClN<sub>2</sub>O<sub>5</sub>S 415.1094, found 415.1097.</div></div></div><div id="sec4_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i31" class="anchor-spacer"></div><h3 class="article-section__title" id="_i31"> Preparation of the Intermediates <b>73</b>–<b>75</b>, <b>77</b>–<b>82</b>, and <b>84</b>–<b>85</b></h3><div id="sec4_4_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i32" class="anchor-spacer"></div><h4 class="article-section__title" id="_i32"> Synthesis of (<i>S</i>)-2-Methylcyclopent-2-enol (<b>73</b>)</h4><div class="NLM_p last">To a solution of (<i>R</i>)-CBS catalyst (1 M in toluene, 31.8 mL) in anhydrous THF (20 mL) at −60 °C was added 2-methylcyclopent-2-enone (<b>72</b>, 15.3 g) and BH<sub>3</sub>·THF (1 M in THF, 111 mL). The mixture was stirred at this temperature for 1 h. Methanol (150 mL) was added to the reaction, and the resulting mixture was diluted with brine (150 mL). The aqueous layer was extracted with DCM (2 × 200 mL). The combined organic layers were dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated in vacuo to give (<i>S</i>)-2-methylcyclopent-2-enol (<b>73</b>, 16.0 g) as a yellow oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 5.45 (s, 1H), 4.51 (s, 1H), 2.42–1.98 (m, 4H), 1.70 (s, 3H).</div></div><div id="sec4_4_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i33" class="anchor-spacer"></div><h4 class="article-section__title" id="_i33"> Synthesis of (<i>R</i>)-2-(2-Methylcyclopent-2-en-1-yl)isoindoline-1,3-dione (<b>74</b>)</h4><div class="NLM_p last">To a solution of (<i>S</i>)-2-methylcyclopent-2-enol (<b>73</b>, 16.0 g) and phthalimide (36.0 g) in THF (240 mL) was added PPh<sub>3</sub> (77.0 g) under nitrogen, followed by the addition of DIAD (63.4 mL) at 0 °C. The reaction mixture was stirred at 0 °C for overnight. The solvent was removed in vacuo, and the resulting residue was directly purified by column chromatography eluting with petroleum ether/ethyl acetate (10:1) to give a crude product (74% <i>ee</i>), which was further purified by supercritical fluid chromatography (SFC) to afford (<i>R</i>)-2-(2-methylcyclopent-2-en-1-yl)isoindoline-1,3-dione (<b>74</b>, 10.6 g, 28% yield over two steps, >98% <i>ee</i>) as a white solid. Chiral HPLC (column, AD-H, 4.6 mm × 250 mm, 5 μm; MeOH/CO<sub>2</sub> = 10%; column temperature, 40 °C; CO<sub>2</sub> flow rate, 2.7 mL/min); <i>t</i><sub>R</sub> = 2.17 min; >98% <i>ee</i>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.83 (dd, <i>J</i> = 5.4, 3.1 Hz, 2H), 7.76–7.61 (m, 2H), 5.68 (s, 1H), 5.21 (d, <i>J</i> = 7.4 Hz, 1H), 2.69 (dd, <i>J</i> = 5.7, 3.5 Hz, 1H), 2.42–2.30 (m, 2H), 2.22–2.12 (m, 1H), 1.61 (s, 3H). LCMS (ESI) <i>m</i>/<i>z</i> 228 [M + H]<sup>+</sup>.</div></div><div id="sec4_4_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i34" class="anchor-spacer"></div><h4 class="article-section__title" id="_i34"> Synthesis of (<i>R</i>)-2-Methylcyclopent-2-enamine (<b>75</b>)</h4><div class="NLM_p last">To a solution of (<i>R</i>)-2-(2-methylcyclopent-2-en-1-yl)isoindoline-1,3-dione (<b>74</b>, 10.7 g) in ethanol (150 mL) was added hydrazine (85% in water, 3.0 mL). After refluxing for 3 h, the reaction mixture was cooled to room temperature. The precipitate was filtered, and the filter cake was rinsed with EtOH (10 mL). To the filtrate was added HCl in dioxane (4 M, 5 mL), and the mixture was concentrated. The resulting residue was dissolved in water and then freeze-dried to afford (<i>R</i>)-2-methylcyclopent-2-enamine hydrochloride salt (<b>75</b>, 6.3 g, 100% yield) as a brown solid, which was used in the next step without purification. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.27 (3 H, br s), 5.68 (1 H, s), 3.87–4.02 (1 H, m), 2.32–2.48 (1 H, m), 2.15–2.30 (2 H, m), 1.71–1.85 (1 H, m), 1.78 (3 H, s).</div></div><div id="sec4_4_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i35" class="anchor-spacer"></div><h4 class="article-section__title" id="_i35"> Synthesis of Ethyl 2-((2-(<i>tert</i>-Butyl)-6-chlorobenzo[<i>d</i>]oxazol-7-yl)thio)-2-methylpropanoate (<b>77</b>)</h4><div class="NLM_p last">To a solution of 2-(<i>tert</i>-butyl)-6-chlorobenzo[<i>d</i>]oxazole-7-thiol (<b>76</b>, 11.0 g) in DMF (80 mL) at room temperature was added ethyl 2-bromo-2-methylpropanoate (9.0 g) and K<sub>2</sub>CO<sub>3</sub> (2.9 g). After stirring at 60 °C for 3 h, the reaction mixture was diluted with ethyl acetate (200 mL) and washed by brine (3 × 150 mL). The organic layer was dried over sodium sulfate, filtered, and concentrated in vacuo to afford ethyl 2-((2-(<i>tert</i>-butyl)-6-chlorobenzo[<i>d</i>]oxazol-7-yl)thio)-2-methylpropanoate (<b>77</b>, 14.8 g) as a white solid. LCMS (ESI) <i>m</i>/<i>z</i> 356 [M + H]<sup>+</sup>.</div></div><div id="sec4_4_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i36" class="anchor-spacer"></div><h4 class="article-section__title" id="_i36"> Synthesis of Ethyl 2-((2-(<i>tert</i>-Butyl)-6-chlorobenzo[<i>d</i>]oxazol-7-yl)sulfonyl)-2-methylpropanoate (<b>78</b>)</h4><div class="NLM_p last">To a solution of ethyl 2-((2-(<i>tert</i>-butyl)-6-chlorobenzo[<i>d</i>]oxazol-7-yl)thio)-2-methylpropanoate (<b>77</b>, 14.8 g) in dichloromethane (200 mL) at room temperature was added <i>m</i>-CPBA (20.6 g). The mixture was stirred at room temperature overnight. The reaction mixture was added saturated aqueous Na<sub>2</sub>SO<sub>3</sub> solution and was washed with saturated sodium carbonate solution (100 mL) and brine (100 mL). The organic phase was dried over sodium sulfate, filtered, and concentrated in vacuo. The resulting residue was purified by column chromatography eluting with 0–40% ethyl acetate in petroleum ether to give ethyl 2-((2-(<i>tert</i>-butyl)-6-chlorobenzo[<i>d</i>]oxazol-7-yl)sulfonyl)-2-methylpropanoate (<b>78</b>, 10.3 g, 64% yield over two steps) as a white solid. LCMS (ESI) <i>m</i>/<i>z</i> 388 [M + H]<sup>+</sup>.</div></div><div id="sec4_4_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i37" class="anchor-spacer"></div><h4 class="article-section__title" id="_i37"> Synthesis of 2-((2-(<i>tert</i>-Butyl)-6-chlorobenzo[<i>d</i>]oxazol-7-yl)sulfonyl)-2-methylpropan-1-ol (<b>79</b>)</h4><div class="NLM_p last">To a solution of ethyl 2-((2-(<i>tert</i>-butyl)-6-chlorobenzo[<i>d</i>]oxazol-7-yl)sulfonyl)-2-methylpropanoate (<b>78</b>, 5.0 g) in THF (130 mL) under nitrogen at −50 °C was added DIBAL-H (1 M in hexane, 64.5 mL). The reaction mixture was allowed to warm to room temperature and stirred at room temperature for overnight. The reaction mixture was quenched with saturated ammonium chloride (20 mL) and then partitioned between ethyl acetate (150 mL) and sodium hydroxide solution (2 M, 150 mL). The organic phase was washed with saturated brine (150 mL), dried over sodium sulfate, and evaporated in vacuo to give 2-((2-(<i>tert</i>-butyl)-6-chlorobenzo[<i>d</i>]oxazol-7-yl)sulfonyl)-2-methylpropan-1-ol (<b>79</b>, 4.5 g) as a white solid. LCMS (ESI) <i>m</i>/<i>z</i> 346 [M + H]<sup>+</sup>.</div></div><div id="sec4_4_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i38" class="anchor-spacer"></div><h4 class="article-section__title" id="_i38"> Synthesis of 2-((2-(<i>tert</i>-Butyl)-6-chlorobenzo[<i>d</i>]oxazol-7-yl)sulfonyl)-2-methylpropyl trifluoromethanesulfonate (<b>80</b>)</h4><div class="NLM_p last">To a solution of 2-((2-(<i>tert</i>-butyl)-6-chlorobenzo[<i>d</i>]oxazol-7-yl)sulfonyl)-2-methylpropan-1-ol (<b>79</b>, 5.2 g) in dichloromethane (100 mL) under nitrogen at room temperature was added pyridine (2.1 mL) and triflic anhydride (1 M in dichloromethane, 19.4 mL). The mixture was stirred at room temperature for 1 h and then partitioned between dichloromethane (100 mL) and brine (100 mL). The organic phase was dried over anhydrous sodium sulfate and evaporated in vacuo to give 2-((2-(<i>tert</i>-butyl)-6-chlorobenzo[<i>d</i>]oxazol-7-yl)sulfonyl)-2-methylpropyl trifluoromethanesulfonate (<b>80</b>, 6.5 g) as a white solid. LCMS (ESI) <i>m</i>/<i>z</i> 478 [M + H]<sup>+</sup>.</div></div><div id="sec4_4_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i39" class="anchor-spacer"></div><h4 class="article-section__title" id="_i39"> Synthesis of 2-(<i>tert</i>-Butyl)-6-chloro-7-((1-fluoro-2-methylpropan-2-yl)sulfonyl)benzo[<i>d</i>]oxazole (<b>81</b>)</h4><div class="NLM_p last">To a solution of 2-((2-(<i>tert</i>-butyl)-6-chlorobenzo[d]oxazol-7-yl)sulfonyl)-2-methylpropyl trifluoromethanesulfonate (<b>80</b>, 6.5 g) in THF (100 mL) at −15 °C was added TBAF (1 M in THF, 27.2 mL) dropwise. The reaction mixture was allowed to warm to 30 °C gradually and stirred for 2 h. The solvent was evaporated, and the residue was partitioned between ethyl acetate (100 mL) and saturated brine (100 mL). The organic phase was dried over anhydrous sodium sulfate and evaporated in vacuo. The resulting residue was purified by column chromatography by eluting with 0–50% ethyl acetate in petroleum ether to afford 2-(<i>tert</i>-butyl)-6-chloro-7-((1-fluoro-2-methylpropan-2-yl)sulfonyl)benzo[<i>d</i>]oxazole (<b>81</b>, 2.4 g, 46% yield over three steps) as a white solid. LCMS (ESI) <i>m</i>/<i>z</i> 348 [M + H]<sup>+</sup>.</div></div><div id="sec4_4_9" class="NLM_sec NLM_sec_level_3"><div id="ac_i40" class="anchor-spacer"></div><h4 class="article-section__title" id="_i40"> Synthesis of 6-Amino-3-chloro-2-((1-fluoro-2-methylpropan-2-yl)sulfonyl)phenol (<b>82</b>)</h4><div class="NLM_p last">To a solution of 2-(<i>tert</i>-butyl)-6-chloro-7-((1-fluoro-2-methylpropan-2-yl)sulfonyl)benzo[d]oxazole (<b>81</b>, 2.4 g) in 1,4-dioxane (20 mL) was added 37% HCl solution (20 mL). The reaction mixture was refluxed for 4 h and then concentrated in vacuo. The residue was dissolved in ethyl acetate (20 mL), and the pH of the solution was adjusted to 8 with triethylamine. The organic phase was washed with brine (20 mL), dried over sodium sulfate, and concentrated in vacuo. The resulting residue was purified by column chromatography eluting with 0–80% ethyl acetate in petroleum ether to afford 6-amino-3-chloro-2-((1-fluoro-2-methylpropan-2-yl)sulfonyl)phenol (<b>82</b>, 1.9 g, 98% yield) as a white solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 10.18 (1 H, s), 6.89 (1 H, d, <i>J</i> = 8.8 Hz), 6.82 (1 H, d, <i>J</i> = 8.8 Hz), 4.62 (2 H, d, <i>J</i> = 41.6 Hz), 4.02 (2 H, br.s), 1.49 (6 H, s). LCMS (ESI) <i>m</i>/<i>z</i> 282 [M + H]<sup>+</sup>.</div></div><div id="sec4_4_10" class="NLM_sec NLM_sec_level_3"><div id="ac_i41" class="anchor-spacer"></div><h4 class="article-section__title" id="_i41"> Synthesis of 2-(<i>tert</i>-Butyl)-6-chloro-7-((3-methyltetrahydrofuran-3-yl)sulfonyl)benzo[<i>d</i>]oxazole (<b>84</b>)</h4><div class="NLM_p last">To a solution of 2-(<i>tert</i>-butyl)-6-chloro-7-((tetrahydrofuran-3-yl)sulfonyl)benzo[<i>d</i>]oxazole (<b>83</b>, 4.3 g) and methyl iodide (2.0 mL) in THF (100 mL) at −70 °C was added LHMDS (1 M in THF, 31.3 mL). The reaction mixture was gradually warmed to room temperature and stirred at room temperature for 30 min.The reaction mixture was diluted with saturated NH<sub>4</sub>Cl solution (100 mL) and extracted with ethyl acetate (2 × 150 mL). The combined organic layers were dried over sodium sulfate, filtered, and concentrated in vacuo to afford 2-(<i>tert</i>-butyl)-6-chloro-7-((3-methyltetrahydrofuran-3-yl)sulfonyl)benzo[<i>d</i>]oxazole (<b>84</b>, 4.4 g). LCMS (ESI) <i>m</i>/<i>z</i> 358 [M + H]<sup>+</sup>.</div></div><div id="sec4_4_11" class="NLM_sec NLM_sec_level_3"><div id="ac_i42" class="anchor-spacer"></div><h4 class="article-section__title" id="_i42"> Synthesis of 6-Amino-3-chloro-2-((3-methyltetrahydrofuran-3-yl)sulfonyl)phenol (<b>85</b>)</h4><div class="NLM_p last">To a solution of 2-(<i>tert</i>-butyl)-6-chloro-7-((3-methyltetrahydrofuran-3-yl)sulfonyl)benzo[<i>d</i>]oxazole (<b>84</b>, 4.4 g) in 1,4-dioxane (150 mL) was added 37% HCl solution (30.3 mL). The mixture was refluxed overnight and then concentrated in vacuo. The residue was dissolved in ethyl acetate (100 mL). After pH of the solution was adjusted to 8 with saturated NaHCO<sub>3</sub> solution, and the organic layer was washed with saturated brine, dried over sodium sulfate, filtered, and concentrated in vacuo. The resulting residue was purified by column chromatography eluting with 0–80% ethyl acetate in petroleum ether to afford 6-amino-3-chloro-2-((3-methyltetrahydrofuran-3-yl)sulfonyl)phenol (<b>85</b>, 2.4 g, 66% yield over two steps). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 6.89–6.96 (2 H, m), 4.32 (1 H, d, <i>J</i> = 10.0 Hz), 3.76–3.89 (2 H, m), 3.60 (1 H, d, <i>J</i> = 10.0 Hz), 2.67 (1 H, dt, <i>J</i> = 13.3, 7.8 Hz), 1.93 (1 H, ddd, <i>J</i> = 13.1, 7.3, 5.3 Hz), 1.48 (3 H, s). LCMS (ESI) <i>m</i>/<i>z</i> 292 [M + H]<sup>+</sup>.</div></div></div><div id="sec4_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i43" class="anchor-spacer"></div><h3 class="article-section__title" id="_i43"> Biology and DMPK</h3><div class="NLM_p last">All studies were conducted in accordance with the GSK Policy on the Care, Welfare, and Treatment of Laboratory Animals and were reviewed the Institutional Animal Care and Use Committee either at GSK or by the ethical review process at the institution where the work was performed. The human biological samples were sourced ethically, and their research use was in accord with the terms of the informed consents.</div></div><div id="sec4_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i44" class="anchor-spacer"></div><h3 class="article-section__title" id="_i44"> CXCR2 Tango Assay</h3><div class="NLM_p">The assay measures ligand-induced activation of the receptor CXCR2 in a stable cell line containing the recombinant human CXCR2 linked to a TEV protease site and a Gal4-VP16 transcription factor (Invitrogen). Ligand binding to the receptor results in the recruitment of arrestin proteins (tagged with protease) to the receptor and triggers the release of a tethered transcription factor. The transcription factor enters the nucleus and activates the transcription of the reporter gene. The ability of a compound to inhibit CXCR2 activation is indirectly assessed by measuring the reporter gene activity.</div><div class="NLM_p last">Cells were starved for 24 h at 37 °C, 5% CO<sub>2</sub>, harvested, and resuspended in assay medium at a density ∼200000 cells/mL, and 50 nL/well of testing compounds in 100% DMSO solution were dispensed into the assay plate (Greiner 781090) using Echo 555 (Labcyte) with a concentration–response program. The cell-free and unstimulated control wells were loaded with 50 nL/well pure DMSO to ensure that the DMSO concentration was constant across the plate for all assays, and 50 μL of assay medium, cell suspension without hCXCL1 (a CXCR2 ligand), and cell suspension with 80 nM hCXCL1 were added to cell-free control wells, unstimulated control wells, and the rest of wells, respectively. The cells were incubated overnight at 37 °C/5% CO<sub>2</sub>, and then 10 μL of 6× substrate mixture [LiveBLAzer-FRET B/G substrate (CCF4-AM) catalogue no. K1096 from Invitrogen, Inc.] was dispensed into each well using Bravo and the plates were incubated at room temperature for another 2 h in the dark before reading on EnVision using one excitation channel (409 nm) and two emission channels (460 and 530 nm). The blue/green emission ratio (460 nm/530 nm) was calculated for each well by dividing the cell-free background-subtracted Blue emission values by the background-subtracted Green emission values. The concentration response curves were fitted based on sigmoidal concentration–response model to return IC<sub>50</sub> and intrinsic activity (IA, percentage of maximum inhibition).</div></div><div id="sec4_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i45" class="anchor-spacer"></div><h3 class="article-section__title" id="_i45"> P-gp/BCRP Efflux Ratio (ER) and Cell Permeability Assay</h3><div class="NLM_p last">Polarized Madin–Darby canine kidney (MDCKII) cells stably transfected with human P-gp (MDCKII-MDR1 cell line) were obtained from The Netherlands Cancer Institute (Amsterdam, The Netherlands). MDCKII-MDR1 cells transduced with BacMam2-BCRP according to experimental protocols reported previously were used for the in vitro transport studies in the Transwell system.<a onclick="showRef(event, 'cit33b'); return false;" href="javascript:void(0);" class="ref cit33b">(33b)</a> The procedures of cell culture and transport studies were described previously.<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a> The transport of test compounds (3 μM) was measured in duplicates in two directions [apical to basolateral (A → B) and basolateral to apical (B → A)] or one direction [apical to basolateral (A → B)] after 90 min incubation in the absence and presence of GF120918 (5 μM, a dual P-gp and BCRP inhibitor). The passive permeability (<i>P</i><sub>exact</sub>, nm/s) for test compounds across MDCKII monolayers were calculated using the equation reported previously.<a onclick="showRef(event, 'cit33b'); return false;" href="javascript:void(0);" class="ref cit33b">(33b)</a> Efflux ratio (ER) is defined as the ratio of permeability of basolateral-to-apical to apical-to-basolateral direction in the absence of GF120918. The permeability ratio is defined as the ratio of permeability of apical-to-basolateral direction in the presence to absence of GF120918. The functionality of human P-gp and BCRP transporters in this in vitro system was qualified by typical ERs of amprenavir (a P-gp specific substrate) and dantrolene (a BCRP specific substrate) greater than 12 and 5, respectively.</div></div><div id="sec4_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i46" class="anchor-spacer"></div><h3 class="article-section__title" id="_i46"> Human Whole Blood CD11b Assay</h3><div class="NLM_p">The whole blood assay tested the compounds’ ability to inhibit the upregulation of CD11b in GRO-α stimulated neutrophils in human whole blood. Blood was withdrawn by venipuncture from consented adults and poured into a Sterilin tube containing an anticoagulant heparin (10 μL/mL of blood). All the test compounds were screened at a top 10 μM final assay concentration (1 in 3 serial dilution to provide 10-point dose response curves) with a final DMSO concentration to 0.25% after addition of blood.</div><div class="NLM_p">Ten μL of blood was transferred to the compound plate using a multichannel pipet, gently tapped, and incubated for 15 min, at 37 °C. After 15 min, the stimulant GRO-α was diluted to 100 nM in 0.1% BSA (Albumin Bovine Serum)-PBS, and 5 μL was dispensed across the whole plate for a final concentration of 33 nM. The plate was gently tapped and incubated further for 15 min at 37 °C. The plate was placed on ice for 1 min before addition of 10 μL of an antibody cocktail consisting of CD11b-FITC (40 μg/mL) purchased from BioLegend (Cambridge Bioscience, Munro House, Trafalgar Way, Bar Hill, Cambridge, UK) and CD16-PE purchased from BD Pharmingen (The Danby Building, Edmung Halley Road, Oxford Science Park, Oxford, UK) (stock concentration 100 tests, 2 mL stock volume is diluted 1 in 5). The plate was placed on ice for 1 h in the dark. The cells were then fixed using 200 μL/well of 1× FACS (Flow Activated Cell Sorting) Lyse solution (Becton and Dickinson-BD) and on ice for 20 min in the dark. The plate was centrifuged at 1600 rpm for 5 min and resuspended with 200 μL of ice-cold PBS. This step was repeated twice, and on the final step the plate was resuspended with 50 μL of ice-cold PBS for flow cytometric analysis.</div><div class="NLM_p last">Samples were run on a Becton and Dickinson (BD)-Acurri C6 flow cytometer using a HyperCyt sampling apparatus (IntelliCyt) with a flow rate 2 μL/s. CD11b upregulation is monitored in neutrophils and identified using a combination of both side scatter and CD16 expression.</div></div><div id="sec4_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i47" class="anchor-spacer"></div><h3 class="article-section__title" id="_i47"> Mouse Whole Blood CD11b Assay</h3><div class="NLM_p">First, 50 μL of freshly isolated whole blood with anticoagulant heparin (10 μL/mL of blood) from C57 mice was pretreated with CXCR2 compounds at concentrations from 1.5 nM to 10 μM in 96-U-well-plates (Corning, NY, US, catalogue no. 3799). Then samples were gently mixed with multichannel pipet and incubated for 2 h in 37 °C incubator, and 55 μL of blood–compound mixture in each well was transferred into 96-V-well plate (Corning, NY, US, catalogue no. 3897) for the secondary treatment with 100 nM murine CXCL1 (Pepro Tech, NJ, US, catalogue no. 250-11) in DPBS (ThermoFisher, PA, USA, catalogue no. 14190250)/0.1% BSA (Sigma, MO, US, catalogue no. 85040C). Samples were incubated for 10 min in 37 °C water bath with gentle agitation at 5 min. Then samples were placed on ice and fixed with 150 μL of ice-cold CellFix solution (1% formaldehyde/0.1% azide/DPBS further 1:4 diluted in Robosep buffer from Stemcell Technologies, Vancouver, Canada, catalogue no. 20104) for 1 min. Then 50 μL of each sample was transferred to 96 V-well-plate preloaded with 5 μL of anti-CD11b-FITC (ThermoFisher, PA, US,catalogue no. 11-0112-82) or isotype control of FITC-IgG2a (BD Biosciences, NJ, US, catalogue no. 553456). Samples were gently mixed and incubated for 20 min in the dark on ice, and 200 μL offreshly prepared 1× red blood lysis buffer (BD Biosciences, NJ, US, catalogue no. 555899) was added into antibody–blood mixture for red blood cells lysis. This usually took 3–5 min. Samples were centrifuged at 1000 rpm for 5 min, and supernatant was discarded with replacement of 250 μL of ice-cold and sterile 1% FBS (ThermoFisher, PA, USA, catalogue no. 10099141)/DPBS.</div><div class="NLM_p last">Samples were gently mixed for FACS reading within 1 h with BD FACS Canto II flow cytometer and FACsDiva Software. CD11b population was analyzed by first gating on the granulocyte population on the FSC vs SSC plot and then gating on the CD16+ cells of neutrophil within the granulocyte population. As CD16+ cells usually take up 95% of granulocytes, this step is usually omitted. Therefore, mean FITC signal of granulocyte population subtracted by mean fluorescence of isotype control can reflect specific CD11b content.</div></div><div id="sec4_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i48" class="anchor-spacer"></div><h3 class="article-section__title" id="_i48"> Rat SOA for CNS Penetration</h3><div class="NLM_p">The blood–brain barrier (BBB) separates the brain from the peripheral circulation. These barriers have tight junctions and also multiple efflux transporters to prevent CNS exposure of compounds to reach their CNS molecular targets. CNS penetration properties of CXCR2 compounds were evaluated in the male Han–Wistar rats after oral gavage at 2 mg/kg. Test compound was formulated as homogeneous suspension in a dosing vehicle containing DMSO:1% methylcellulose (w/v) = 1:99. At each time point post dose (0.25, 0.5, 1, 2, 4, and 7 h), blood samples (>60 μL/time point/each site) were collected via cardiac puncture into separate EDTA-K<sub>2</sub> (0.5 M) containers following anesthesia with isofluorane. Exactly 50 μL of blood samples were diluted with 150 μL of diH<sub>2</sub>O (1:3), snap frozen on dry ice, and further stored at −80 °C. Immediately after blood collection, the brains from all the animals were excised, transferred to suitable containers, and immediately stored frozen. Brains were homogenized with 3-fold PBS (w/v) and further stored at −80 °C (dilution factor = 3.9).</div><div class="NLM_p">Two separate calibration curves were prepared in blank blood/water mixture and brain homogenate, respectively. Study samples and their corresponding calibration curves were extracted by protein precipitation. Exactly 50 μL of sample was aliquoted into a clean extract plate and then extracted with 150 μL of acetonitrile containing analytical internal standard. After mixing and centrifugation, approximately 100 μL of supernatant was removed into an injection plate and sample was further diluted with same volume of deionized water. Quantitation of test compound was carried out by UPLC/MS/MS using an optimized methodology.</div><div class="NLM_p last">Systemic and brain exposure were estimated by AUC up to the last time point at 7 h. CNS penetration potential (<i>K</i><sub>p</sub>) of test compounds was evaluated from the ratio of AUC<sub>brain</sub>/AUC<sub>blood</sub>. <i>K</i><sub>p,uu</sub> value was calculated using the measured <i>K</i><sub>p</sub>, free unbound compound fractions in blood and brain.</div></div><div id="sec4_11" class="NLM_sec NLM_sec_level_2"><div id="ac_i49" class="anchor-spacer"></div><h3 class="article-section__title" id="_i49"> Air Pouch Model in Mouse and Rat</h3><div class="NLM_p">Air pouch model was induced with carrageenan in mouse and rat as described in previous studies with minor modifications.<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a> In brief, 6–8 week old male C57Bl/6 mice were anesthetized with pentobarbital and 5 mL of sterile air was injected into the shaved back of each mouse on day 0. On day 3, 2.5 mL of sterile air was used to reinflate the pouch. Three days later (day 6), another 2.5 mL of sterile air was reinflated. Similarly, the air pouch model was induced in rats; 8–10 week old male Wistar rats were used and 20 mL of sterile air was injected for the first inflation and 10 mL of sterile air was injected for reinflation on day 3 and day 6. In both mouse and rat air pouch model, 1 mL 2% carrageenan was injected into the pouch after the last air injection to induce inflammatory infiltration. Then 4 h after stimulation, the pouch was flushed with 4 mL of PBS and exudates were collected for further analysis. Exudates were centrifuged, and cell pellets were resuspended and transfer to slides using cytospin. The slides were stained with Giemsa, and total infiltrated cells and neutrophil were counted.</div><div class="NLM_p last">For compound testing, mice or rats were divided into four groups and orally treated with vehicle or 1, 3, and 10 mg/kg compound <b>68</b> orally BID from day 3. On day 6, vehicle and compound dosing were given immediately before air reinflation and carrageenan induction. Whole blood was collected at 0, 1, and 4 h post compound treatment for PK analysis.</div></div><div id="sec4_12" class="NLM_sec NLM_sec_level_2"><div id="ac_i50" class="anchor-spacer"></div><h3 class="article-section__title" id="_i50"> X-ray Diffraction Study</h3><div class="NLM_p last">A solution of <b>68</b> in toluene was evaporated to obtain crystals that were suitable for study. Data were collected with an Oxford Diffraction Gemini A Ultra diffractometer at 175(2) K using Cu Kα X-radiation (λ = 1.54178 Å). Crystal data and refinement summary: C<sub>18</sub>H<sub>23</sub>ClN<sub>2</sub>O<sub>5</sub>S; M = 414.89; colorless rod; 0.24 × 0.11 × 0.06 mm<sup>3</sup>; orthorhombic; space group <i>P</i>2<sub>1</sub>2<sub>1</sub>2<sub>1</sub> (no. 19); <i>a</i> = 11.9118(2) Å, <i>b</i> = 15.4757(4) Å, <i>c</i> = 21.1168(5) Å; <i>V</i> = 3892.74(15) Å<sup>3</sup>; <i>Z</i> = 8; <i>D</i><sub>calc</sub> = 1.416 Mgm<sup>–3</sup>, θ<sub>max</sub> = 66.78°; reflections collected = 13820; independent reflections = 6360; <i>R</i><sub>int</sub> = 0.0460; coverage = 97.7%; restraints = 448; parameters = 621; <i>S</i> = 1.032; <i>R</i><sub>1</sub> [<i>I</i> > 2σ(<i>I</i>)] = 0.0388; <i>wR</i><sub>2</sub> (all data) = 0.0956; absolute structure parameter = 0.007(13); largest difference peak and hole = 0.281 and −0.278 eÅ<sup>–3</sup>. A description of the refinement, a further discussion on the assignment of the absolute configuration, and the full tables associated with the crystal structure are given in the <a href="/doi/suppl/10.1021/acs.jmedchem.7b01854/suppl_file/jm7b01854_si_001.pdf" class="ext-link">Supporting Information</a>. A crystallographic information file has been deposited with the Cambridge Crystallographic Data Centre. CCDC 1810782 contains the supplementary crystallographic data for this paper. The data can be obtained free of charge from The Cambridge Crystallographic Data Centre via <a href="http://www.ccdc.cam.ac.uk/structures" class="extLink">www.ccdc.cam.ac.uk/structures</a>.</div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i51"><a href="/doi/suppl/10.1021/acs.jmedchem.7b01854" class="ext-link">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_02217" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_02217" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a href="/" class="ext-link">ACS Publications website</a> at DOI: <a href="/doi/abs/10.1021/acs.jmedchem.7b01854" class="ext-link">10.1021/acs.jmedchem.7b01854</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">Detailed synthetic procedures for compounds <b>9</b>–<b>39</b>, <b>41</b>–<b>65</b>, <b>67</b>, <b>69</b>–<b>71</b>, and <b>35′</b>–<b>38′</b> and spectral data for the compounds (<a href="/doi/suppl/10.1021/acs.jmedchem.7b01854/suppl_file/jm7b01854_si_001.pdf" class="ext-link">PDF</a>)</p></li><li><p class="inline">Molecular formula strings and some in vitro data (<a href="/doi/suppl/10.1021/acs.jmedchem.7b01854/suppl_file/jm7b01854_si_002.csv" class="ext-link">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.7b01854/suppl_file/jm7b01854_si_001.pdf">jm7b01854_si_001.pdf (4.01 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.7b01854/suppl_file/jm7b01854_si_002.csv">jm7b01854_si_002.csv (4.2 kb)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/acs.jmedchem.7b01854" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_72618" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_72618" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Feng Ren</span> - <span class="hlFld-Affiliation affiliation">Neurosciences Therapeutic
Area Unit, GSK Pharmaceuticals R&D, 898 Halei Road, Zhangjiang Hi-Tech
Park, Pudong, Shanghai 201203, P. R. China</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-9157-9182" title="Orcid link">http://orcid.org/0000-0001-9157-9182</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#eb8d8e858cc59ac5998e85ab8c9880c5888486cbd9dddfd3ddddddd2ddd3ab9a9ac5888486"><span class="__cf_email__" data-cfemail="284e4d464f0659065a4d46684f5b43064b4745">[email protected]</span> <span class="__cf_email__" data-cfemail="073531333f3131313e313f4776762964686a">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Hongfu Lu</span> - <span class="hlFld-Affiliation affiliation">Neurosciences Therapeutic
Area Unit, GSK Pharmaceuticals R&D, 898 Halei Road, Zhangjiang Hi-Tech
Park, Pudong, Shanghai 201203, P. R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ting Yang</span> - <span class="hlFld-Affiliation affiliation">Neurosciences Therapeutic
Area Unit, GSK Pharmaceuticals R&D, 898 Halei Road, Zhangjiang Hi-Tech
Park, Pudong, Shanghai 201203, P. R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Zhongmiao Xu</span> - <span class="hlFld-Affiliation affiliation">Neurosciences Therapeutic
Area Unit, GSK Pharmaceuticals R&D, 898 Halei Road, Zhangjiang Hi-Tech
Park, Pudong, Shanghai 201203, P. R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Xichen Lin</span> - <span class="hlFld-Affiliation affiliation">Neurosciences Therapeutic
Area Unit, GSK Pharmaceuticals R&D, 898 Halei Road, Zhangjiang Hi-Tech
Park, Pudong, Shanghai 201203, P. R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Qian Ding</span> - <span class="hlFld-Affiliation affiliation">Neurosciences Therapeutic
Area Unit, GSK Pharmaceuticals R&D, 898 Halei Road, Zhangjiang Hi-Tech
Park, Pudong, Shanghai 201203, P. R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yueting Zhang</span> - <span class="hlFld-Affiliation affiliation">R&D Projects Clinical Platforms and Sciences, GSK Pharmaceuticals R&D, 898 Halei Road, Zhangjiang Hi-Tech Park, Pudong, Shanghai 201203, P. R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Xin Cai</span> - <span class="hlFld-Affiliation affiliation">Platform Technology Sciences, GSK Pharmaceuticals R&D, 898 Halei Road, Zhangjiang Hi-Tech Park, Pudong, Shanghai 201203, P. R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Kelly Dong</span> - <span class="hlFld-Affiliation affiliation">Platform Technology Sciences, GSK Pharmaceuticals R&D, 898 Halei Road, Zhangjiang Hi-Tech Park, Pudong, Shanghai 201203, P. R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Sophie Gong</span> - <span class="hlFld-Affiliation affiliation">Platform Technology Sciences, GSK Pharmaceuticals R&D, 898 Halei Road, Zhangjiang Hi-Tech Park, Pudong, Shanghai 201203, P. R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Wei Zhang</span> - <span class="hlFld-Affiliation affiliation">Platform Technology Sciences, GSK Pharmaceuticals R&D, 898 Halei Road, Zhangjiang Hi-Tech Park, Pudong, Shanghai 201203, P. R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Metul Patel</span> - <span class="hlFld-Affiliation affiliation">Platform
Technology Sciences, GSK Pharmaceuticals
R&D, Stevenage, Hertfordshire SG1 2NY, U.K.</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Royston C. B. Copley</span> - <span class="hlFld-Affiliation affiliation">Platform Technology & Science, GSK Medicines Research Centre, Gunnels Wood Road, Stevenage, Hertfordshire SG1 2NY, U.K.</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jianing Xiang</span> - <span class="hlFld-Affiliation affiliation">Neurosciences Therapeutic
Area Unit, GSK Pharmaceuticals R&D, 898 Halei Road, Zhangjiang Hi-Tech
Park, Pudong, Shanghai 201203, P. R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Xiaoming Guan</span> - <span class="hlFld-Affiliation affiliation">Neurosciences Therapeutic
Area Unit, GSK Pharmaceuticals R&D, 898 Halei Road, Zhangjiang Hi-Tech
Park, Pudong, Shanghai 201203, P. R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Paul Wren</span> - <span class="hlFld-Affiliation affiliation">Neurosciences Therapeutic Area Unit, GSK Pharmaceuticals R&D, 1250 South Collegeville Road, Collegeville, Pennsylvania 19426, United States</span></div></li></ul></li><li><span class="author-information-subsection-header">Author Contributions</span><p>The manuscript was written through contributions of all authors. All authors have given approval to the final version of the manuscript.</p></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare the following competing financial interest(s): All the authors are/were employees of GlaxoSmithKline, a global healthcare company that may conceivably benefit financially through this publication.<br /></br></div></li></ul></div><div class="ack" id="ACK-d128e4020-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i53">Acknowledgments</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_51487" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_51487" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">We thank Professor W. Clegg and Dr. M. R. Probert for the GSK-funded crystal structure of <b>68</b>.</p></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviations Used</td></tr><tr><td class="NLM_term">AD</td><td class="NLM_def"><p class="first last">Alzheimer’s disease</p></td></tr><tr><td class="NLM_term">AUC</td><td class="NLM_def"><p class="first last">area under the curve</p></td></tr><tr><td class="NLM_term">BCRP</td><td class="NLM_def"><p class="first last">breast cancer resistance protein</p></td></tr><tr><td class="NLM_term">BID</td><td class="NLM_def"><p class="first last">twice a day</p></td></tr><tr><td class="NLM_term">CCR2</td><td class="NLM_def"><p class="first last">C–C chemokine receptor type 2</p></td></tr><tr><td class="NLM_term">CF</td><td class="NLM_def"><p class="first last">cystic fibrosis</p></td></tr><tr><td class="NLM_term">CNS</td><td class="NLM_def"><p class="first last">central nervous system</p></td></tr><tr><td class="NLM_term">COPD</td><td class="NLM_def"><p class="first last">chronic obstructive pulmonary disease</p></td></tr><tr><td class="NLM_term">CXCL1</td><td class="NLM_def"><p class="first last">C–X–C motif ligand 1</p></td></tr><tr><td class="NLM_term">CXCL8</td><td class="NLM_def"><p class="first last">C–X–C motif ligand 8</p></td></tr><tr><td class="NLM_term">CXCR2</td><td class="NLM_def"><p class="first last">C–X–C chemokine receptor type 2</p></td></tr><tr><td class="NLM_term">DNAUC</td><td class="NLM_def"><p class="first last">dose normalized area under curve</p></td></tr><tr><td class="NLM_term"><i>ee</i></td><td class="NLM_def"><p class="first last">enantiomeric excess</p></td></tr><tr><td class="NLM_term">EWG</td><td class="NLM_def"><p class="first last">electron withdrawing group</p></td></tr><tr><td class="NLM_term">FaSSIF</td><td class="NLM_def"><p class="first last">fasted state simulated intestinal fluids</p></td></tr><tr><td class="NLM_term">GPCR</td><td class="NLM_def"><p class="first last">G-protein-coupled receptor</p></td></tr><tr><td class="NLM_term">Gro-α</td><td class="NLM_def"><p class="first last">growth-related oncogene-alpha</p></td></tr><tr><td class="NLM_term">HWB</td><td class="NLM_def"><p class="first last">human whole blood</p></td></tr><tr><td class="NLM_term">ICB</td><td class="NLM_def"><p class="first last">immune checkpoint blockage</p></td></tr><tr><td class="NLM_term">IL-8</td><td class="NLM_def"><p class="first last">interleukin 8</p></td></tr><tr><td class="NLM_term">IV</td><td class="NLM_def"><p class="first last">intravenous</p></td></tr><tr><td class="NLM_term">LHS</td><td class="NLM_def"><p class="first last">left-hand side</p></td></tr><tr><td class="NLM_term">LTP</td><td class="NLM_def"><p class="first last">long-term potentiation</p></td></tr><tr><td class="NLM_term">MS</td><td class="NLM_def"><p class="first last">multiple sclerosis</p></td></tr><tr><td class="NLM_term">MW</td><td class="NLM_def"><p class="first last">molecular weight</p></td></tr><tr><td class="NLM_term">NK cells</td><td class="NLM_def"><p class="first last">natural killer cells</p></td></tr><tr><td class="NLM_term">PFI</td><td class="NLM_def"><p class="first last">property forecast index</p></td></tr><tr><td class="NLM_term">P-gp</td><td class="NLM_def"><p class="first last">P-glycoprotein</p></td></tr><tr><td class="NLM_term">PK</td><td class="NLM_def"><p class="first last">pharmacokinetics</p></td></tr><tr><td class="NLM_term">PMN</td><td class="NLM_def"><p class="first last">polymorphonuclear leukocyte</p></td></tr><tr><td class="NLM_term">RA</td><td class="NLM_def"><p class="first last">rheumatoid arthritis</p></td></tr><tr><td class="NLM_term">RHS</td><td class="NLM_def"><p class="first last">right-hand side</p></td></tr><tr><td class="NLM_term">SAR</td><td class="NLM_def"><p class="first last">structure–activity relationship</p></td></tr><tr><td class="NLM_term">SFC</td><td class="NLM_def"><p class="first last">supercritical fluid chromatography</p></td></tr><tr><td class="NLM_term">SOA</td><td class="NLM_def"><p class="first last">short oral absorption</p></td></tr><tr><td class="NLM_term"><i>T</i><sub>1/2</sub></td><td class="NLM_def"><p class="first last">half-life</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i55">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_31531" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_31531" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 37 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stadtmann, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zarbock, A.</span></span> <span> </span><span class="NLM_article-title">CXCR2: From bench to bedside</span>. <i>Front. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">263</span>, <span class="refDoi"> DOI: 10.3389/fimmu.2012.00263</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01854&amp;key=10.3389%2Ffimmu.2012.00263" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01854&amp;key=22936934" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01854&amp;key=1%3ACAS%3A280%3ADC%252BC38bivFKqtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2012&pages=263&author=A.+Stadtmannauthor=A.+Zarbock&title=CXCR2%3A+From+bench+to+bedside&doi=10.3389%2Ffimmu.2012.00263"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">CXCR2: From Bench to Bedside</span></div><div class="casAuthors">Stadtmann Anika; Zarbock Alexander</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in immunology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">263</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Leukocyte recruitment to sites of infection or tissue damage plays a crucial role for the innate immune response.  Chemokine-dependent signaling in immune cells is a very important mechanism leading to integrin activation and leukocyte recruitment.  CXC chemokine receptor 2 (CXCR2) is a prominent chemokine receptor on neutrophils.  During the last years, several studies were performed investigating the role of CXCR2 in different diseases.  Until now, many CXCR2 inhibitors are tested in animal models and clinical trials and promising results were obtained.  This review gives an overview of the structure of CXCR2 and the signaling pathways that are activated following CXCR2 stimulation.  We discuss in detail the role of this chemokine receptor in different disease models including acute lung injury, COPD, sepsis, and ischemia-reperfusion-injury.  Furthermore, this review summarizes the results of clinical trials which used CXCR2 inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRipfUTvwjJVINpW7w2tapOfW6udTcc2eZqT08hJTFG2Lntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC38bivFKqtA%253D%253D&md5=f6b8fbe259f1d85097de0434ce2f97b9</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.3389%2Ffimmu.2012.00263&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffimmu.2012.00263%26sid%3Dliteratum%253Aachs%26aulast%3DStadtmann%26aufirst%3DA.%26aulast%3DZarbock%26aufirst%3DA.%26atitle%3DCXCR2%253A%2520From%2520bench%2520to%2520bedside%26jtitle%3DFront.%2520Immunol.%26date%3D2012%26volume%3D3%26spage%3D263%26doi%3D10.3389%2Ffimmu.2012.00263" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Holz, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khalilieh, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ludwig-Sengpiel, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watz, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stryszak, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soni, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsai, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sadeh, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Magnussen, H.</span></span> <span> </span><span class="NLM_article-title">SCH527123, a novel CXCR2 antagonist, inhibits ozone-induced neutrophilia in healthy subjects</span>. <i>Eur. Respir. J.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>35</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">564</span>– <span class="NLM_lpage">570</span>, <span class="refDoi"> DOI: 10.1183/09031936.00048509</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01854&amp;key=10.1183%2F09031936.00048509" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01854&amp;key=19643947" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01854&amp;key=1%3ACAS%3A528%3ADC%252BC3cXksVGnsbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2010&pages=564-570&issue=3&author=O.+Holzauthor=S.+Khaliliehauthor=A.+Ludwig-Sengpielauthor=H.+Watzauthor=P.+Stryszakauthor=P.+Soniauthor=M.+Tsaiauthor=J.+Sadehauthor=H.+Magnussen&title=SCH527123%2C+a+novel+CXCR2+antagonist%2C+inhibits+ozone-induced+neutrophilia+in+healthy+subjects&doi=10.1183%2F09031936.00048509"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">SCH527123, a novel CXCR2 antagonist, inhibits ozone-induced neutrophilia in healthy subjects</span></div><div class="casAuthors">Holz, O.; Khalilieh, S.; Ludwig-Sengpiel, A.; Watz, H.; Stryszak, P.; Soni, P.; Tsai, M.; Sadeh, J.; Magnussen, H.</div><div class="citationInfo"><span class="NLM_cas:title">European Respiratory Journal</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">564-570</span>CODEN:
                <span class="NLM_cas:coden">ERJOEI</span>;
        ISSN:<span class="NLM_cas:issn">0903-1936</span>.
    
            (<span class="NLM_cas:orgname">European Respiratory Society</span>)
        </div><div class="casAbstract">SCH527123 is a novel, selective CXC chemokine receptor 2 antagonist that inhibits neutrophil activation and modulates neutrophil trafficking in animal models, characteristics that may be beneficial in the treatment of conditions with unbalanced pulmonary neutrophilia, such as chronic obstructive pulmonary disease.  The purpose of this proof-of-principle study was to det. whether SCH527123 inhibits ozone-induced neutrophil recruitment in healthy humans.  In a randomized, double-blind, placebo-controlled, three-way crossover study, oral SCH527123 (50 mg once daily, 4 days), prednisolone (50 mg once), or placebo was alternated with 2-wk washouts.  18 Healthy ozone responders (>20% increase in sputum neutrophils) underwent ozone challenge tests (250 ppb, 3 h intermittent exercise) 1 h after the last treatment dose.  Sputum was induced at 3 h post-challenge.  After SCH527123 treatment, the ozone challenge resulted in significantly lower sputum neutrophil counts (0.13 × 106 mL-1) compared with prednisolone (0.84 × 106/mL-1; p < 0.001) or placebo (2.98 × 106 mL-1; p < 0.001).  Comparable results were obtained for total cell count, percentage of sputum neutrophils, and for interleukin-8 and myeloperoxidase in sputum supernatant.  Post-challenge, SCH527123 inhibited neutrophilia in peripheral blood but significantly less than in sputum.  All treatments were safe and well tolerated.  SCH527123 causes significant attenuation of ozone-induced airway neutrophilia in healthy subjects.  Further evaluation in a large trial of patients with pulmonary disorders is warranted.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqJwysQ82AncbVg90H21EOLACvtfcHk0li7Fr4ISvNCGA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXksVGnsbs%253D&md5=ae0702b5eb1122d2c919a4130b3f471e</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1183%2F09031936.00048509&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1183%252F09031936.00048509%26sid%3Dliteratum%253Aachs%26aulast%3DHolz%26aufirst%3DO.%26aulast%3DKhalilieh%26aufirst%3DS.%26aulast%3DLudwig-Sengpiel%26aufirst%3DA.%26aulast%3DWatz%26aufirst%3DH.%26aulast%3DStryszak%26aufirst%3DP.%26aulast%3DSoni%26aufirst%3DP.%26aulast%3DTsai%26aufirst%3DM.%26aulast%3DSadeh%26aufirst%3DJ.%26aulast%3DMagnussen%26aufirst%3DH.%26atitle%3DSCH527123%252C%2520a%2520novel%2520CXCR2%2520antagonist%252C%2520inhibits%2520ozone-induced%2520neutrophilia%2520in%2520healthy%2520subjects%26jtitle%3DEur.%2520Respir.%2520J.%26date%3D2010%26volume%3D35%26issue%3D3%26spage%3D564%26epage%3D570%26doi%3D10.1183%2F09031936.00048509" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Aul, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Summerhill, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kilty, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plumb, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, D.</span></span> <span> </span><span class="NLM_article-title">LPS challenge in healthy subjects: an investigation of neutrophil chemotaxis mechanisms involving CXCR1 and CXCR2</span>. <i>Int. Immunopharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>13</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">225</span>– <span class="NLM_lpage">231</span>, <span class="refDoi"> DOI: 10.1016/j.intimp.2012.04.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01854&amp;key=10.1016%2Fj.intimp.2012.04.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01854&amp;key=22561413" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01854&amp;key=1%3ACAS%3A528%3ADC%252BC38Xot12nu7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2012&pages=225-231&issue=3&author=R.+Aulauthor=S.+Patelauthor=S.+Summerhillauthor=I.+Kiltyauthor=J.+Plumbauthor=D.+Singh&title=LPS+challenge+in+healthy+subjects%3A+an+investigation+of+neutrophil+chemotaxis+mechanisms+involving+CXCR1+and+CXCR2&doi=10.1016%2Fj.intimp.2012.04.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">LPS challenge in healthy subjects: An investigation of neutrophil chemotaxis mechanisms involving CXCR1 and CXCR2</span></div><div class="casAuthors">Aul, Raminder; Patel, Sheena; Summerhill, Susan; Kilty, Iain; Plumb, Jonathan; Singh, Dave</div><div class="citationInfo"><span class="NLM_cas:title">International Immunopharmacology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">225-231</span>CODEN:
                <span class="NLM_cas:coden">IINMBA</span>;
        ISSN:<span class="NLM_cas:issn">1567-5769</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">LPS inhalation was used to investigate whether sputum supernatant post-LPS challenge increases neutrophil chemotactic activity and to elucidate the role of CXCR1/CXCR2 signalling in this process.14 healthy non-smoking subjects inhaled 30 μg of LPS.  Sputum was induced at baseline, 6 and 24 h post-LPS challenge.  Differential cell counts were detd. and supernatants CXCL8, CXCL1, IL-6 and CCL2 levels measured.  Peripheral blood neutrophils obtained from healthy volunteers were used for chemotaxis expts. using sputum supernatant.  To delineate signalling mechanisms, the effects of a CXCR2/CXCR1 (dual) antagonist (Sch527123) and a CXCR2 specific antagonist (SB656933) were tested.  LPS inhalation significantly increased sputum neutrophil counts from 45.3% to 76.7% and 69.3% at 6 and 24 h resp.  LPS increased CXCL8, IL-6 and CCL2 levels but not CXCL1.  Neutrophil chemotaxis significantly increased (2.7 fold) at 24 h compared to baseline.  Chemotaxis was inhibited by 79.0% with Sch527123 and 52.0% with SB656933.  We conclude that LPS challenge increases sputum supernatant CXCL8 levels, which is assocd. with increased chemotactic activity which is dependent on both CXCR1 and CXCR2.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpeBzkQc4_KA7Vg90H21EOLACvtfcHk0li7Fr4ISvNCGA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xot12nu7s%253D&md5=c196cbe3264f545d5e2d90b1b95a6c05</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1016%2Fj.intimp.2012.04.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.intimp.2012.04.008%26sid%3Dliteratum%253Aachs%26aulast%3DAul%26aufirst%3DR.%26aulast%3DPatel%26aufirst%3DS.%26aulast%3DSummerhill%26aufirst%3DS.%26aulast%3DKilty%26aufirst%3DI.%26aulast%3DPlumb%26aufirst%3DJ.%26aulast%3DSingh%26aufirst%3DD.%26atitle%3DLPS%2520challenge%2520in%2520healthy%2520subjects%253A%2520an%2520investigation%2520of%2520neutrophil%2520chemotaxis%2520mechanisms%2520involving%2520CXCR1%2520and%2520CXCR2%26jtitle%3DInt.%2520Immunopharmacol.%26date%3D2012%26volume%3D13%26issue%3D3%26spage%3D225%26epage%3D231%26doi%3D10.1016%2Fj.intimp.2012.04.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Breland, U. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Halvorsen, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hol, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Øie, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paulsson-Berne, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yndestad, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Otterdal, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hedin, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wæhre, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sandberg, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frøland, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haraldsen, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gullestad, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Damås, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hansson, G. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aukrust, P.</span></span> <span> </span><span class="NLM_article-title">A potential role of the CXC chemokine GRO[alpha] in atherosclerosis and plaque destabilization: downregulatory effects of statins</span>. <i>Arterioscler., Thromb., Vasc. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>28</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">1005</span>– <span class="NLM_lpage">1011</span>, <span class="refDoi"> DOI: 10.1161/ATVBAHA.108.162305</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01854&amp;key=10.1161%2FATVBAHA.108.162305" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01854&amp;key=18276907" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01854&amp;key=1%3ACAS%3A528%3ADC%252BD1cXktlymu7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2008&pages=1005-1011&issue=5&author=U.+M.+Brelandauthor=B.+Halvorsenauthor=J.+Holauthor=E.+%C3%98ieauthor=G.+Paulsson-Berneauthor=A.+Yndestadauthor=C.+Smithauthor=K.+Otterdalauthor=U.+Hedinauthor=T.+W%C3%A6hreauthor=W.+J.+Sandbergauthor=S.+S.+Fr%C3%B8landauthor=G.+Haraldsenauthor=L.+Gullestadauthor=J.+K.+Dam%C3%A5sauthor=G.+K.+Hanssonauthor=P.+Aukrust&title=A+potential+role+of+the+CXC+chemokine+GRO%5Balpha%5D+in+atherosclerosis+and+plaque+destabilization%3A+downregulatory+effects+of+statins&doi=10.1161%2FATVBAHA.108.162305"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">A Potential Role of the CXC Chemokine GROα in Atherosclerosis and Plaque Destabilization</span></div><div class="casAuthors">Breland, Unni M.; Halvorsen, Bente; Hol, Johanna; Oeie, Erik; Paulsson-Berne, Gabrielle; Yndestad, Arne; Smith, Camilla; Otterdal, Kari; Hedin, Ulf; Waehre, Torgun; Sandberg, Wiggo J.; Froeland, Stig S.; Haraldsen, Guttorm; Gullestad, Lars; Damaas, Jan K.; Hansson, Goeran K.; Aukrust, Paal</div><div class="citationInfo"><span class="NLM_cas:title">Arteriosclerosis, Thrombosis, and Vascular Biology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1005-1011</span>CODEN:
                <span class="NLM_cas:coden">ATVBFA</span>;
        ISSN:<span class="NLM_cas:issn">1079-5642</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Objective: the authors examd. the role of the CXCR2 ligand growth-related oncogene (GRO) α in human atherosclerosis.  Methods and Results: GROα levels were examd. by enzyme immunoassay, real-time quant. RT-PCR, and cDNA microarrays.  The in vitro effect of statins on GROα was examd. in endothelial cells and THP-1 macrophages.  The main findings were: (1) GROα was among the 10 most differentially expressed transcripts comparing peripheral blood mononuclear cells (PBMCs) from patients with coronary artery disease (CAD) and healthy controls; (2) both patients with stable and particularly those with unstable angina had increased plasma levels of GROα comparing controls; (3) increased expression of GROα within symptomatic carotid plaques, located to macrophages and endothelial cells; (4) GROα enhanced the release of matrix metalloproteinases in vascular smooth muscle cells, and increased the binding of acetylated LDL in macrophages; (5) atorvastatin down-regulated GROα levels as shown both in vitro in endothelial cells and macrophages and in vivo in PBMCs from CAD patients, and (6) the effect on GROα in endothelial cells involved increased storage and reduced secretion of GROα.  Conclusions: GROα could be involved in atherogenesis and plaque destabilization, potentially contributing to inflammation, matrix degrdn., and lipid accumulation within the atherosclerotic lesion.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoDh3s7N_2sDbVg90H21EOLACvtfcHk0ljRn03fhevBYQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXktlymu7s%253D&md5=b115b0a96f8fd9294fde1fc8ad4ab61c</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1161%2FATVBAHA.108.162305&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1161%252FATVBAHA.108.162305%26sid%3Dliteratum%253Aachs%26aulast%3DBreland%26aufirst%3DU.%2BM.%26aulast%3DHalvorsen%26aufirst%3DB.%26aulast%3DHol%26aufirst%3DJ.%26aulast%3D%25C3%2598ie%26aufirst%3DE.%26aulast%3DPaulsson-Berne%26aufirst%3DG.%26aulast%3DYndestad%26aufirst%3DA.%26aulast%3DSmith%26aufirst%3DC.%26aulast%3DOtterdal%26aufirst%3DK.%26aulast%3DHedin%26aufirst%3DU.%26aulast%3DW%25C3%25A6hre%26aufirst%3DT.%26aulast%3DSandberg%26aufirst%3DW.%2BJ.%26aulast%3DFr%25C3%25B8land%26aufirst%3DS.%2BS.%26aulast%3DHaraldsen%26aufirst%3DG.%26aulast%3DGullestad%26aufirst%3DL.%26aulast%3DDam%25C3%25A5s%26aufirst%3DJ.%2BK.%26aulast%3DHansson%26aufirst%3DG.%2BK.%26aulast%3DAukrust%26aufirst%3DP.%26atitle%3DA%2520potential%2520role%2520of%2520the%2520CXC%2520chemokine%2520GRO%255Balpha%255D%2520in%2520atherosclerosis%2520and%2520plaque%2520destabilization%253A%2520downregulatory%2520effects%2520of%2520statins%26jtitle%3DArterioscler.%252C%2520Thromb.%252C%2520Vasc.%2520Biol.%26date%3D2008%26volume%3D28%26issue%3D5%26spage%3D1005%26epage%3D1011%26doi%3D10.1161%2FATVBAHA.108.162305" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Boppana, N. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Devarajan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gopal, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barathan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bakar, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shankar, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ebrahim, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Farooq, S. M.</span></span> <span> </span><span class="NLM_article-title">Blockade of CXCR2 signalling: a potential therapeutic target for preventing neutrophil-mediated inflammatory diseases</span>. <i>Exp. Biol. Med.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>239</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">509</span>– <span class="NLM_lpage">518</span>, <span class="refDoi"> DOI: 10.1177/1535370213520110</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01854&amp;key=10.1177%2F1535370213520110" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01854&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhslWju73K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=239&publication_year=2014&pages=509-518&issue=5&author=N.+B.+Boppanaauthor=A.+Devarajanauthor=K.+Gopalauthor=M.+Barathanauthor=S.+A.+Bakarauthor=E.+M.+Shankarauthor=A.+S.+Ebrahimauthor=S.+M.+Farooq&title=Blockade+of+CXCR2+signalling%3A+a+potential+therapeutic+target+for+preventing+neutrophil-mediated+inflammatory+diseases&doi=10.1177%2F1535370213520110"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Blockade of CXCR2 signalling: a potential therapeutic target for preventing neutrophil-mediated inflammatory diseases</span></div><div class="casAuthors">Boppana, Nithin B.; Devarajan, Asokan; Gopal, Kaliappan; Barathan, Muttiah; Bakar, Sazaly A.; Shankar, Esaki M.; Ebrahim, Abdul S.; Farooq, Shukkur M.</div><div class="citationInfo"><span class="NLM_cas:title">Experimental Biology and Medicine (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">239</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">509-518, 10 pp.</span>CODEN:
                <span class="NLM_cas:coden">EBMMBE</span>;
        ISSN:<span class="NLM_cas:issn">1535-3699</span>.
    
            (<span class="NLM_cas:orgname">Sage Publications Ltd.</span>)
        </div><div class="casAbstract">A review.  Polymorphonuclear neutrophils (PMN) play a key role in host innate immune responses by migrating to the sites of inflammation.  Furthermore, PMN recruitment also plays a significant role in the pathophysiol. of a plethora of inflammatory disorders such as chronic obstructive pulmonary disease (COPD), gram neg. sepsis, inflammatory bowel disease (IBD), lung injury, and arthritis.  Of note, chemokine-dependent signalling is implicated in the amplification of immune responses by virtue of its role in PMN chemotaxis in most of the inflammatory diseases.  It has been clin. established that impediment of PMN recruitment ameliorates disease severity and provides relief in majority of other immune-assocd. disorders.  This review focuses on different novel approaches clin. proven to be effective in blocking chemokine signalling assocd. with PMN recruitment that includes CXCR2 antagonists, chemokine analogs, anti-CXCR2 monoclonal antibodies, and CXCR2 knock-out models.  It also highlights the significance of the utility of nanoparticles in drugs used for blocking migration of PMN to the sites of inflammation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGriOOI311CiRrVg90H21EOLACvtfcHk0ljRn03fhevBYQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhslWju73K&md5=e4d6596fc62f02a4baa0dbc17771707c</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1177%2F1535370213520110&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F1535370213520110%26sid%3Dliteratum%253Aachs%26aulast%3DBoppana%26aufirst%3DN.%2BB.%26aulast%3DDevarajan%26aufirst%3DA.%26aulast%3DGopal%26aufirst%3DK.%26aulast%3DBarathan%26aufirst%3DM.%26aulast%3DBakar%26aufirst%3DS.%2BA.%26aulast%3DShankar%26aufirst%3DE.%2BM.%26aulast%3DEbrahim%26aufirst%3DA.%2BS.%26aulast%3DFarooq%26aufirst%3DS.%2BM.%26atitle%3DBlockade%2520of%2520CXCR2%2520signalling%253A%2520a%2520potential%2520therapeutic%2520target%2520for%2520preventing%2520neutrophil-mediated%2520inflammatory%2520diseases%26jtitle%3DExp.%2520Biol.%2520Med.%26date%3D2014%26volume%3D239%26issue%3D5%26spage%3D509%26epage%3D518%26doi%3D10.1177%2F1535370213520110" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, B. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mistry, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smart, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Connolly, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carpenter, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cooray, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bloomer, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tal-Singer, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lazaar, A. L.</span></span> <span> </span><span class="NLM_article-title">The pharmacokinetics and pharmacodynamics of Danirixin (GSK1325756) – a selective CXCR2 antagonist – in healthy adult subjects</span>. <i>BMC Pharmacol. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">18</span>, <span class="refDoi"> DOI: 10.1186/s40360-015-0017-x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01854&amp;key=10.1186%2Fs40360-015-0017-x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01854&amp;key=26092545" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01854&amp;key=1%3ACAS%3A280%3ADC%252BC2MblslersQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2015&pages=18&author=B.+E.+Millerauthor=S.+Mistryauthor=K.+Smartauthor=P.+Connollyauthor=D.+C.+Carpenterauthor=H.+Coorayauthor=J.+C.+Bloomerauthor=R.+Tal-Singerauthor=A.+L.+Lazaar&title=The+pharmacokinetics+and+pharmacodynamics+of+Danirixin+%28GSK1325756%29+%E2%80%93+a+selective+CXCR2+antagonist+%E2%80%93+in+healthy+adult+subjects&doi=10.1186%2Fs40360-015-0017-x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6aR"><div class="casContent"><span class="casTitleNuber">6a</span><div class="casTitle"><span class="NLM_cas:atitle">The pharmacokinetics and pharmacodynamics of danirixin (GSK1325756)--a selective CXCR2 antagonist --in healthy adult subjects</span></div><div class="casAuthors">Miller Bruce E; Tal-Singer Ruth; Mistry Sunil; Smart Kevin; Smart Kevin; Connolly Paul; Carpenter Donald C; Cooray Hiran; Cooray Hiran; Bloomer Jackie C; Lazaar Aili L</div><div class="citationInfo"><span class="NLM_cas:title">BMC pharmacology & toxicology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">18</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Excessive neutrophil presence and activation is important in a number of acute and chronic inflammatory diseases.  The CXCR2 chemokine receptor is important in controlling the extravasation and activation of neutrophils.  Selective antagonism of the CXCR2 receptor is a potential approach to reducing neutrophil migration and activation.  Danirixin, is a small molecule, CXCR2 antagonist being evaluated as a potential anti-inflammatory medicine.  METHODS:  (1) First time in human (FTIH) double-blind, placebo-controlled study to evaluate the safety, pharmacokinetics, and pharmacodynamics of single ascending and repeat oral doses of danirixin in healthy male subjects; (2) single-dose study of age, gender, food, and proton-pump inhibitor effects on the pharmacokinetics of danirixin in healthy adult subjects; and placebo-controlled study of the pharmacokinetics of danirixin in healthy elderly subjects.  RESULTS:  There were no serious adverse events and no adverse events considered to be of clinical relevance.  There were no withdrawals due to adverse events.  Systemic exposure following single doses of danirixin 10 mg, 25 mg, 50 mg, 100 mg, and 200 mg increased with increasing dose.  Engagement of pharmacology was demonstrated as inhibition of ex-vivo CXCL1-induced CD11b expression on peripheral blood neutrophils when compared to placebo (approximately 50% for 50 mg and 100 mg danirixin, and 72% at 200 mg).  There was a 37% decrease in Cmax and a 16% decrease in AUC (0-∞) following administration of danirixin in the presence of food.  Cmax also decreased by 65% when danirixin 100 mg was administered following omeprazole 40 mg once daily for 5 days.  The AUC (0-∞) and Cmax were 50% lower in elderly subjects compared with younger subjects.  CONCLUSION:  The dose-dependent inhibition of agonist-induced neutrophil activation following single and repeated once daily oral administration of danirixin suggests that this CXCR2 antagonist may have benefit in neutrophil-predominant inflammatory diseases.  Co-administration with food, gastric acid reducing agents, and variable exposure in the elderly have important clinical implications that need to be taken into consideration in subsequent clinical evaluations.  TRIAL REGISTRATION:  ClinicalTrials.gov identifiers: NCT01209052 and NCT01209104.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRAKy_l8uoE8MrRqEXsZufAfW6udTcc2eYNcXZZ4edmPbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2MblslersQ%253D%253D&md5=031af976bb431023281306bde2964584</span></div><a href="/servlet/linkout?suffix=cit6a&amp;dbid=16384&amp;doi=10.1186%2Fs40360-015-0017-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs40360-015-0017-x%26sid%3Dliteratum%253Aachs%26aulast%3DMiller%26aufirst%3DB.%2BE.%26aulast%3DMistry%26aufirst%3DS.%26aulast%3DSmart%26aufirst%3DK.%26aulast%3DConnolly%26aufirst%3DP.%26aulast%3DCarpenter%26aufirst%3DD.%2BC.%26aulast%3DCooray%26aufirst%3DH.%26aulast%3DBloomer%26aufirst%3DJ.%2BC.%26aulast%3DTal-Singer%26aufirst%3DR.%26aulast%3DLazaar%26aufirst%3DA.%2BL.%26atitle%3DThe%2520pharmacokinetics%2520and%2520pharmacodynamics%2520of%2520Danirixin%2520%2528GSK1325756%2529%2520%25E2%2580%2593%2520a%2520selective%2520CXCR2%2520antagonist%2520%25E2%2580%2593%2520in%2520healthy%2520adult%2520subjects%26jtitle%3DBMC%2520Pharmacol.%2520Toxicol.%26date%3D2015%26volume%3D16%26spage%3D18%26doi%3D10.1186%2Fs40360-015-0017-x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit6b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Rennard, S. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dale, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Donohue, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kanniess, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Magnussen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sutherland, E. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watz, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stryszak, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosenberg, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Staudinger, H.</span></span> <span> </span><span class="NLM_article-title">CXCR2 antagonist MK-7123. a phase 2 proof-of-concept trial for chronic obstructive pulmonary disease</span>. <i>Am. J. Respir. Crit. Care Med.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>191</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">1001</span>– <span class="NLM_lpage">1011</span>, <span class="refDoi"> DOI: 10.1164/rccm.201405-0992OC</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01854&amp;key=10.1164%2Frccm.201405-0992OC" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01854&amp;key=25695403" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01854&amp;key=1%3ACAS%3A528%3ADC%252BC2MXptlKmt7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=191&publication_year=2015&pages=1001-1011&issue=9&author=S.+I.+Rennardauthor=D.+C.+Daleauthor=J.+F.+Donohueauthor=F.+Kanniessauthor=H.+Magnussenauthor=E.+R.+Sutherlandauthor=H.+Watzauthor=S.+Luauthor=P.+Stryszakauthor=E.+Rosenbergauthor=H.+Staudinger&title=CXCR2+antagonist+MK-7123.+a+phase+2+proof-of-concept+trial+for+chronic+obstructive+pulmonary+disease&doi=10.1164%2Frccm.201405-0992OC"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6bR"><div class="casContent"><span class="casTitleNuber">6b</span><div class="casTitle"><span class="NLM_cas:atitle">CXCR2 antagonist MK-7123: a phase 2 proof-of-concept trial for chronic obstructive pulmonary disease</span></div><div class="casAuthors">Rennard, Stephen I.; Dale, David C.; Donohue, James F.; Kanniess, Frank; Magnussen, Helgo; Sutherland, E. Rand; Watz, Henrik; Lu, Susan; Stryszak, Paul; Rosenberg, Elizabeth; Staudinger, Heribert</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Respiratory and Critical Care Medicine</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">191</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1001-1011</span>CODEN:
                <span class="NLM_cas:coden">AJCMED</span>;
        ISSN:<span class="NLM_cas:issn">1073-449X</span>.
    
            (<span class="NLM_cas:orgname">American Thoracic Society</span>)
        </div><div class="casAbstract">Rationale: An antagonist (MK-7123) of the cytokine receptor CXCR2 reduces neutrophil chemotaxis and thus may alleviate airway inflammation in chronic obstructive pulmonary disease (COPD).  Objectives: To assess the efficacy, safety, and tolerability of three dose levels of MK-7123, compared with placebo, in patients with moderate to severe COPD.  Methods: This 6-mo, double-blind study randomized patients with moderate to severe COPD (already on std. therapy) to daily MK-7123 at 10, 30, or 50 mg or placebo.  The primary endpoint was change from baseline in post-bronchodilator FEV1.  Measurements and Main Results: A total of 616 patients (71% male; mean age, 63 yr; 45% current smokers; baseline FEV1 [SD], 1.43 L [0.45]; mean FEV1 percent predicted, 43.9%) were randomized.  Only MK-7123 50 mg led to significant improvement in FEV1 over placebo (mean difference [SE], 67 mL [32]).  Reduced sputum neutrophil count was obsd. among the 122 patients examd.; P = 0.003 (3 mo) and P = 0.092 (6 mo) (MK-7123 50 mg vs. placebo).  The stratum of current smokers, but not that of nonsmokers, showed significant improvement vs. placebo in FEV1 (168 mL) and time-to-first exacerbation, and showed numerical improvement in St.  George's Respiratory Questionnaire for COPD score.  MK-7123 caused a dose-dependent decrease in abs. neutrophil count (ANC) and reduced inflammatory biomarkers matrix metallopeptidase-9 and myeloperoxidase in plasma and sputum; ANC lower than 1.5 × 109/L led to discontinuations with higher doses of MK-7123 (18% in the MK-7123 50-mg group vs. 1% in placebo).  Plasma C-reactive protein and fibrinogen increased with MK-7123 treatment.  Rates of infections at 6 mo were similar in all groups.  Conclusions: Treatment with MK-7123 50 mg vs. placebo led to significant improvement in FEV1 in patients with COPD, suggesting clin. important antiinflammatory effects with CXCR2 antagonism, although dose-related discontinuations were obsd. because of ANC decreases with MK-7123.  Greater response was obsd. in smokers vs. ex-smokers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqoAKNB3Km0H7Vg90H21EOLACvtfcHk0li-AOe5Ir-E8A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXptlKmt7k%253D&md5=ff8ee6fb8a25a5e158de81c1344079c5</span></div><a href="/servlet/linkout?suffix=cit6b&amp;dbid=16384&amp;doi=10.1164%2Frccm.201405-0992OC&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1164%252Frccm.201405-0992OC%26sid%3Dliteratum%253Aachs%26aulast%3DRennard%26aufirst%3DS.%2BI.%26aulast%3DDale%26aufirst%3DD.%2BC.%26aulast%3DDonohue%26aufirst%3DJ.%2BF.%26aulast%3DKanniess%26aufirst%3DF.%26aulast%3DMagnussen%26aufirst%3DH.%26aulast%3DSutherland%26aufirst%3DE.%2BR.%26aulast%3DWatz%26aufirst%3DH.%26aulast%3DLu%26aufirst%3DS.%26aulast%3DStryszak%26aufirst%3DP.%26aulast%3DRosenberg%26aufirst%3DE.%26aulast%3DStaudinger%26aufirst%3DH.%26atitle%3DCXCR2%2520antagonist%2520MK-7123.%2520a%2520phase%25202%2520proof-of-concept%2520trial%2520for%2520chronic%2520obstructive%2520pulmonary%2520disease%26jtitle%3DAm.%2520J.%2520Respir.%2520Crit.%2520Care%2520Med.%26date%3D2015%26volume%3D191%26issue%3D9%26spage%3D1001%26epage%3D1011%26doi%3D10.1164%2Frccm.201405-0992OC" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Koch, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kunkel, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shah, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hosaka, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Halloran, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haines, G. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burdick, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pope, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strieter, R. M.</span></span> <span> </span><span class="NLM_article-title">Growth-related gene product alpha. A chemotactic cytokine for neutrophils in rheumatoid arthritis</span>. <i>J. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">1995</span>,  <span class="NLM_volume"><i>155</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">3660</span>– <span class="NLM_lpage">3666</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=155&publication_year=1995&pages=3660-3666&issue=7&author=A.+E.+Kochauthor=S.+L.+Kunkelauthor=M.+R.+Shahauthor=S.+Hosakaauthor=M.+M.+Halloranauthor=G.+K.+Hainesauthor=M.+D.+Burdickauthor=R.+M.+Popeauthor=R.+M.+Strieter&title=Growth-related+gene+product+alpha.+A+chemotactic+cytokine+for+neutrophils+in+rheumatoid+arthritis"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKoch%26aufirst%3DA.%2BE.%26aulast%3DKunkel%26aufirst%3DS.%2BL.%26aulast%3DShah%26aufirst%3DM.%2BR.%26aulast%3DHosaka%26aufirst%3DS.%26aulast%3DHalloran%26aufirst%3DM.%2BM.%26aulast%3DHaines%26aufirst%3DG.%2BK.%26aulast%3DBurdick%26aufirst%3DM.%2BD.%26aulast%3DPope%26aufirst%3DR.%2BM.%26aulast%3DStrieter%26aufirst%3DR.%2BM.%26atitle%3DGrowth-related%2520gene%2520product%2520alpha.%2520A%2520chemotactic%2520cytokine%2520for%2520neutrophils%2520in%2520rheumatoid%2520arthritis%26jtitle%3DJ.%2520Immunol.%26date%3D1995%26volume%3D155%26issue%3D7%26spage%3D3660%26epage%3D3666" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Steele, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karim, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leach, J. D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bailey, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Upstill-Goddard, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rishi, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Foth, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bryson, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McDaid, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eberlein, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Candido, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clarke, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nixon, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Connelly, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jamieson, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carter, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balkwill, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Evans, T. R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strathdee, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Biankin, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nibbs, R. J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barry, S. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sansom, O. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morton, J. P.</span></span> <span> </span><span class="NLM_article-title">CXCR2 inhibition profoundly suppresses metastases and augments immunotherapy in pancreatic ductal adenocarcinoma</span>. <i>Cancer Cell</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">832</span>– <span class="NLM_lpage">845</span>, <span class="refDoi"> DOI: 10.1016/j.ccell.2016.04.014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01854&amp;key=10.1016%2Fj.ccell.2016.04.014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01854&amp;key=27265504" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01854&amp;key=1%3ACAS%3A528%3ADC%252BC28Xpt1enurs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2016&pages=832-845&author=C.+W.+Steeleauthor=S.+A.+Karimauthor=J.+D.+G.+Leachauthor=P.+Baileyauthor=R.+Upstill-Goddardauthor=L.+Rishiauthor=M.+Fothauthor=S.+Brysonauthor=K.+McDaidauthor=Z.+Wilsonauthor=C.+Eberleinauthor=J.+B.+Candidoauthor=M.+Clarkeauthor=C.+Nixonauthor=J.+Connellyauthor=N.+Jamiesonauthor=C.+R.+Carterauthor=F.+Balkwillauthor=D.+K.+Changauthor=T.+R.+J.+Evansauthor=D.+Strathdeeauthor=A.+V.+Biankinauthor=R.+J.+B.+Nibbsauthor=S.+T.+Barryauthor=O.+J.+Sansomauthor=J.+P.+Morton&title=CXCR2+inhibition+profoundly+suppresses+metastases+and+augments+immunotherapy+in+pancreatic+ductal+adenocarcinoma&doi=10.1016%2Fj.ccell.2016.04.014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">CXCR2 Inhibition Profoundly Suppresses Metastases and Augments Immunotherapy in Pancreatic Ductal Adenocarcinoma</span></div><div class="casAuthors">Steele, Colin W.; Karim, Saadia A.; Leach, Joshua D. G.; Bailey, Peter; Upstill-Goddard, Rosanna; Rishi, Loveena; Foth, Mona; Bryson, Sheila; McDaid, Karen; Wilson, Zena; Eberlein, Catherine; Candido, Juliana B.; Clarke, Mairi; Nixon, Colin; Connelly, John; Jamieson, Nigel; Carter, C. Ross; Balkwill, Frances; Chang, David K.; Evans, T. R. Jeffry; Strathdee, Douglas; Biankin, Andrew V.; Nibbs, Robert J. B.; Barry, Simon T.; Sansom, Owen J.; Morton, Jennifer P.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">832-845</span>CODEN:
                <span class="NLM_cas:coden">CCAECI</span>;
        ISSN:<span class="NLM_cas:issn">1535-6108</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">CXCR2 has been suggested to have both tumor-promoting and tumor-suppressive properties.  Here we show that CXCR2 signaling is upregulated in human pancreatic cancer, predominantly in neutrophil/myeloid-derived suppressor cells, but rarely in tumor cells.  Genetic ablation or inhibition of CXCR2 abrogated metastasis, but only inhibition slowed tumorigenesis.  Depletion of neutrophils/myeloid-derived suppressor cells also suppressed metastasis suggesting a key role for CXCR2 in establishing and maintaining the metastatic niche.  Importantly, loss or inhibition of CXCR2 improved T cell entry, and combined inhibition of CXCR2 and PD1 in mice with established disease significantly extended survival.  We show that CXCR2 signaling in the myeloid compartment can promote pancreatic tumorigenesis and is required for pancreatic cancer metastasis, making it an excellent therapeutic target.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGowCJXXdB8AXLVg90H21EOLACvtfcHk0liLu8vKFolRgA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xpt1enurs%253D&md5=1dcdaeae6b2ddf2d486de8a7abbf106d</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1016%2Fj.ccell.2016.04.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccell.2016.04.014%26sid%3Dliteratum%253Aachs%26aulast%3DSteele%26aufirst%3DC.%2BW.%26aulast%3DKarim%26aufirst%3DS.%2BA.%26aulast%3DLeach%26aufirst%3DJ.%2BD.%2BG.%26aulast%3DBailey%26aufirst%3DP.%26aulast%3DUpstill-Goddard%26aufirst%3DR.%26aulast%3DRishi%26aufirst%3DL.%26aulast%3DFoth%26aufirst%3DM.%26aulast%3DBryson%26aufirst%3DS.%26aulast%3DMcDaid%26aufirst%3DK.%26aulast%3DWilson%26aufirst%3DZ.%26aulast%3DEberlein%26aufirst%3DC.%26aulast%3DCandido%26aufirst%3DJ.%2BB.%26aulast%3DClarke%26aufirst%3DM.%26aulast%3DNixon%26aufirst%3DC.%26aulast%3DConnelly%26aufirst%3DJ.%26aulast%3DJamieson%26aufirst%3DN.%26aulast%3DCarter%26aufirst%3DC.%2BR.%26aulast%3DBalkwill%26aufirst%3DF.%26aulast%3DChang%26aufirst%3DD.%2BK.%26aulast%3DEvans%26aufirst%3DT.%2BR.%2BJ.%26aulast%3DStrathdee%26aufirst%3DD.%26aulast%3DBiankin%26aufirst%3DA.%2BV.%26aulast%3DNibbs%26aufirst%3DR.%2BJ.%2BB.%26aulast%3DBarry%26aufirst%3DS.%2BT.%26aulast%3DSansom%26aufirst%3DO.%2BJ.%26aulast%3DMorton%26aufirst%3DJ.%2BP.%26atitle%3DCXCR2%2520inhibition%2520profoundly%2520suppresses%2520metastases%2520and%2520augments%2520immunotherapy%2520in%2520pancreatic%2520ductal%2520adenocarcinoma%26jtitle%3DCancer%2520Cell%26date%3D2016%26volume%3D29%26spage%3D832%26epage%3D845%26doi%3D10.1016%2Fj.ccell.2016.04.014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horner, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paul, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Troncoso, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deng, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spring, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zebala, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maeda, D. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DePinho, R. A.</span></span> <span> </span><span class="NLM_article-title">Effective combinatorial immunotherapy for castration-resistant prostate cancer</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>543</i></span>,  <span class="NLM_fpage">728</span>– <span class="NLM_lpage">732</span>, <span class="refDoi"> DOI: 10.1038/nature21676</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01854&amp;key=10.1038%2Fnature21676" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01854&amp;key=28321130" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01854&amp;key=1%3ACAS%3A528%3ADC%252BC2sXltVWntbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=543&publication_year=2017&pages=728-732&author=X.+Luauthor=J.+W.+Hornerauthor=E.+Paulauthor=X.+Shangauthor=P.+Troncosoauthor=P.+Dengauthor=S.+Jiangauthor=Q.+Changauthor=D.+J.+Springauthor=P.+Sharmaauthor=J.+A.+Zebalaauthor=D.+Y.+Maedaauthor=Y.+A.+Wangauthor=R.+A.+DePinho&title=Effective+combinatorial+immunotherapy+for+castration-resistant+prostate+cancer&doi=10.1038%2Fnature21676"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Effective combinatorial immunotherapy for castration-resistant prostate cancer</span></div><div class="casAuthors">Lu, Xin; Horner, James W.; Paul, Erin; Shang, Xiaoying; Troncoso, Patricia; Deng, Pingna; Jiang, Shan; Chang, Qing; Spring, Denise J.; Sharma, Padmanee; Zebala, John A.; Maeda, Dean Y.; Wang, Y. Alan; DePinho, Ronald A.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">543</span>
        (<span class="NLM_cas:issue">7647</span>),
    <span class="NLM_cas:pages">728-732</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A significant fraction of patients with advanced prostate cancer treated with androgen deprivation therapy experience relapse with relentless progression to lethal metastatic castration-resistant prostate cancer (mCRPC).  Immune checkpoint blockade using antibodies against cytotoxic-T-lymphocyte-assocd. protein 4 (CTLA4) or programmed cell death 1/programmed cell death 1 ligand 1 (PD1/PD-L1) generates durable therapeutic responses in a significant subset of patients across a variety of cancer types.  However, mCRPC showed overwhelming de novo resistance to immune checkpoint blockade, motivating a search for targeted therapies that overcome this resistance.  Myeloid-derived suppressor cells (MDSCs) are known to play important roles in tumor immune evasion.  The abundance of circulating MDSCs correlates with prostate-specific antigen levels and metastasis in patients with prostate cancer.  Mouse models of prostate cancer show that MDSCs (CD11b+Gr1+) promote tumor initiation and progression.  These observations prompted the authors to hypothesize that robust immunotherapy responses in mCRPC may be elicited by the combined actions of immune checkpoint blockade agents together with targeted agents that neutralize MDSCs yet preserve T-cell function.  Here the authors develop a novel chimeric mouse model of mCRPC to efficiently test combination therapies in an autochthonous setting.  Combination of anti-CTLA4 and anti-PD1 engendered only modest efficacy.  Targeted therapy against mCRPC-infiltrating MDSCs, using multi-kinase inhibitors such as cabozantinib and BEZ235, also showed minimal anti-tumor activities.  Strikingly, primary and metastatic CRPC showed robust synergistic responses when immune checkpoint blockade was combined with MDSC-targeted therapy.  Mechanistically, combination therapy efficacy stemmed from the up-regulation of interleukin-1 receptor antagonist and suppression of MDSC-promoting cytokines secreted by prostate cancer cells.  These observations illuminate a clin. path hypothesis for combining immune checkpoint blockade with MDSC-targeted therapies in the treatment of mCRPC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrh7-q_yEgcWrVg90H21EOLACvtfcHk0liLu8vKFolRgA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXltVWntbg%253D&md5=66daee4919d9beaeb083b73a7e686fe7</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1038%2Fnature21676&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature21676%26sid%3Dliteratum%253Aachs%26aulast%3DLu%26aufirst%3DX.%26aulast%3DHorner%26aufirst%3DJ.%2BW.%26aulast%3DPaul%26aufirst%3DE.%26aulast%3DShang%26aufirst%3DX.%26aulast%3DTroncoso%26aufirst%3DP.%26aulast%3DDeng%26aufirst%3DP.%26aulast%3DJiang%26aufirst%3DS.%26aulast%3DChang%26aufirst%3DQ.%26aulast%3DSpring%26aufirst%3DD.%2BJ.%26aulast%3DSharma%26aufirst%3DP.%26aulast%3DZebala%26aufirst%3DJ.%2BA.%26aulast%3DMaeda%26aufirst%3DD.%2BY.%26aulast%3DWang%26aufirst%3DY.%2BA.%26aulast%3DDePinho%26aufirst%3DR.%2BA.%26atitle%3DEffective%2520combinatorial%2520immunotherapy%2520for%2520castration-resistant%2520prostate%2520cancer%26jtitle%3DNature%26date%3D2017%26volume%3D543%26spage%3D728%26epage%3D732%26doi%3D10.1038%2Fnature21676" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, M.</span></span> <span> </span><span class="NLM_article-title">Correlation of C-X-C chemokine receptor 2 upregulation with poor prognosis and recurrence in human glioma</span>. <i>OncoTargets Ther.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">3203</span>– <span class="NLM_lpage">3209</span>, <span class="refDoi"> DOI: 10.2147/OTT.S91626</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01854&amp;key=10.2147%2FOTT.S91626" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01854&amp;key=26586954" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01854&amp;key=1%3ACAS%3A280%3ADC%252BC28rgsVSrsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2015&pages=3203-3209&author=L.+Yangauthor=Z.+Liuauthor=R.+Wuauthor=Q.+Yaoauthor=Z.+Guauthor=M.+Liu&title=Correlation+of+C-X-C+chemokine+receptor+2+upregulation+with+poor+prognosis+and+recurrence+in+human+glioma&doi=10.2147%2FOTT.S91626"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Correlation of C-X-C chemokine receptor 2 upregulation with poor prognosis and recurrence in human glioma</span></div><div class="casAuthors">Yang Liu; Liu Zenghui; Yao Qi; Gu Zhikai; Wu Ronghua; Liu Mei</div><div class="citationInfo"><span class="NLM_cas:title">OncoTargets and therapy</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">3203-9</span>
        ISSN:<span class="NLM_cas:issn">1178-6930</span>.
    </div><div class="casAbstract">C-X-C chemokine receptor 2 (CXCR2), a member of the G-protein-coupled receptor family, is an interleukin-8 receptor and results in the activation of neutrophils.  To date, CXCR2 has been identified with many cell events, including inflammation, neovascularization, metastasis, and cell carcinogenesis.  This study aimed to investigate alterations in the expression of CXCR2 in patients with brain gliomas and relationships with pathological grades and clinicopathological characteristics.  Brain tissue specimens from 60 patients with glioma and 15 patients undergoing surgery for epilepsy (controls) were detected using streptavidin-perosidase immunohistochemistry.  Western blotting was used to evaluate CXCR2 protein levels with fresh tissues derived from glioma cases or controls.  Correlations between CXCR2 expression and clinicopathological characteristics were analyzed using SPSS software.  The results showed high-grade gliomas with high CXCR2 expression as compared with normal tissues.  The expression of CXCR2 was significantly related to high grades and recurrence of tumor but not to age or sex.  During an in vitro wound healing assay, U251 migration was reduced when the CXCR2-specific inhibitor SB225002 was applied.  Our results suggested that the high expression of CXCR2 in gliomas was closely correlated to the degree of malignancy and recurrence and that CXCR2 inhibition decreased the migration of glioma cells.  Therefore, CXCR2 may serve as a potential therapeutic target for the recurrence and migration of gliomas.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSaWQI_kNsvcAHqQV89nF-2fW6udTcc2eYiM5I2DM2MArntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28rgsVSrsg%253D%253D&md5=7a6b8b247214f25d5348ca7dd018deff</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.2147%2FOTT.S91626&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252FOTT.S91626%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DL.%26aulast%3DLiu%26aufirst%3DZ.%26aulast%3DWu%26aufirst%3DR.%26aulast%3DYao%26aufirst%3DQ.%26aulast%3DGu%26aufirst%3DZ.%26aulast%3DLiu%26aufirst%3DM.%26atitle%3DCorrelation%2520of%2520C-X-C%2520chemokine%2520receptor%25202%2520upregulation%2520with%2520poor%2520prognosis%2520and%2520recurrence%2520in%2520human%2520glioma%26jtitle%3DOncoTargets%2520Ther.%26date%3D2015%26volume%3D8%26spage%3D3203%26epage%3D3209%26doi%3D10.2147%2FOTT.S91626" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Veenstra, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ransohoff, R. M.</span></span> <span> </span><span class="NLM_article-title">Chemokine receptor CXCR2: physiology regulator and neuroinflammation controller?</span>. <i>J. Neuroimmunol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>246</i></span> (<span class="NLM_issue">1–2</span>),  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">9</span>, <span class="refDoi"> DOI: 10.1016/j.jneuroim.2012.02.016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01854&amp;key=10.1016%2Fj.jneuroim.2012.02.016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01854&amp;key=22445294" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01854&amp;key=1%3ACAS%3A528%3ADC%252BC38XktlGrtLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=246&publication_year=2012&pages=1-9&issue=1%E2%80%932&author=M.+Veenstraauthor=R.+M.+Ransohoff&title=Chemokine+receptor+CXCR2%3A+physiology+regulator+and+neuroinflammation+controller%3F&doi=10.1016%2Fj.jneuroim.2012.02.016"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11aR"><div class="casContent"><span class="casTitleNuber">11a</span><div class="casTitle"><span class="NLM_cas:atitle">Chemokine receptor CXCR2: Physiology regulator and neuroinflammation controller?</span></div><div class="casAuthors">Veenstra, Mike; Ransohoff, Richard M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neuroimmunology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">246</span>
        (<span class="NLM_cas:issue">1-2</span>),
    <span class="NLM_cas:pages">1-9</span>CODEN:
                <span class="NLM_cas:coden">JNRIDW</span>;
        ISSN:<span class="NLM_cas:issn">0165-5728</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  The innate immune system is a crucial component of inflammatory reactions, while the central nervous system (CNS) is the most vulnerable site of the body to inflammatory tissue injury.  Neuroinflammatory brain pathologies are disorders in which the CNS is threatened by its own immune system.  Chemokine receptor CXCR2 and its ligands have been implicated in several neuroinflammatory brain pathologies, as well as in neutrophil recruitment and in the developmental positioning of neural cells.  This review focuses on the basics of CXCR2, its regulating role in bone marrow neutrophil recruitment, oligodendrocyte progenitor cell positioning and neural repair mechanisms, as well as its diverse roles in neuroinflammatory brain pathologies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqymMsAIWT3DbVg90H21EOLACvtfcHk0lhvJqczreyjAA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XktlGrtLY%253D&md5=b2bae645562bb600d1af93a45d247d8c</span></div><a href="/servlet/linkout?suffix=cit11a&amp;dbid=16384&amp;doi=10.1016%2Fj.jneuroim.2012.02.016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jneuroim.2012.02.016%26sid%3Dliteratum%253Aachs%26aulast%3DVeenstra%26aufirst%3DM.%26aulast%3DRansohoff%26aufirst%3DR.%2BM.%26atitle%3DChemokine%2520receptor%2520CXCR2%253A%2520physiology%2520regulator%2520and%2520neuroinflammation%2520controller%253F%26jtitle%3DJ.%2520Neuroimmunol.%26date%3D2012%26volume%3D246%26issue%3D1%25E2%2580%25932%26spage%3D1%26epage%3D9%26doi%3D10.1016%2Fj.jneuroim.2012.02.016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit11b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Semple, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kossmann, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morganti-Kossmann, M. C.</span></span> <span> </span><span class="NLM_article-title">Role of chemokines in CNS health and pathology: a focus on the CCL2/CCR2 and CXCL8/CXCR2 networks</span>. <i>J. Cereb. Blood Flow Metab.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>30</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">459</span>– <span class="NLM_lpage">473</span>, <span class="refDoi"> DOI: 10.1038/jcbfm.2009.240</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01854&amp;key=10.1038%2Fjcbfm.2009.240" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01854&amp;key=19904283" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01854&amp;key=1%3ACAS%3A528%3ADC%252BC3cXisF2htbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2010&pages=459-473&issue=3&author=B.+D.+Sempleauthor=T.+Kossmannauthor=M.+C.+Morganti-Kossmann&title=Role+of+chemokines+in+CNS+health+and+pathology%3A+a+focus+on+the+CCL2%2FCCR2+and+CXCL8%2FCXCR2+networks&doi=10.1038%2Fjcbfm.2009.240"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11bR"><div class="casContent"><span class="casTitleNuber">11b</span><div class="casTitle"><span class="NLM_cas:atitle">Role of chemokines in CNS health and pathology: a focus on the CCL2/CCR2 and CXCL8/CXCR2 networks</span></div><div class="casAuthors">Semple, Bridgette D.; Kossmann, Thomas; Morganti-Kossmann, Maria Cristina</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cerebral Blood Flow & Metabolism</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">459-473</span>CODEN:
                <span class="NLM_cas:coden">JCBMDN</span>;
        ISSN:<span class="NLM_cas:issn">0271-678X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Chemokines and their receptors have crucial roles in the trafficking of leukocytes, and are of particular interest in the context of the unique immune responses elicited in the central nervous system (CNS).  The chemokine system CC ligand 2 (CCL2) with its receptor CC receptor 2 (CCR2), as well as the receptor CXCR2 and its multiple ligands CXCL1, CXCL2 and CXCL8, have been implicated in a wide range of neuropathologies, including trauma, ischemic injury and multiple sclerosis.  This review aims to overview the current understanding of chemokines as mediators of leukocyte migration into the CNS under neuroinflammatory conditions.  We will specifically focus on the involvement of two chemokine networks, namely CCL2/CCR2 and CXCL8/CXCR2, in promoting macrophage and neutrophil infiltration, resp., into the lesioned parenchyma after focal traumatic brain injury.  The constitutive brain expression of these chemokines and their receptors, including their recently identified roles in the modulation of neuroprotection, neurogenesis, and neurotransmission, will be discussed.  In conclusion, the value of evidence obtained from the use of Ccl2- and Cxcr2-deficient mice will be reported, in the context of potential therapeutics inhibiting chemokine activity which are currently in clin. trial for various inflammatory diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqeX4Qux2JPI7Vg90H21EOLACvtfcHk0lgNEQ1VjjqXAg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXisF2htbY%253D&md5=7150522e070aa6564823e514221bbbf7</span></div><a href="/servlet/linkout?suffix=cit11b&amp;dbid=16384&amp;doi=10.1038%2Fjcbfm.2009.240&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fjcbfm.2009.240%26sid%3Dliteratum%253Aachs%26aulast%3DSemple%26aufirst%3DB.%2BD.%26aulast%3DKossmann%26aufirst%3DT.%26aulast%3DMorganti-Kossmann%26aufirst%3DM.%2BC.%26atitle%3DRole%2520of%2520chemokines%2520in%2520CNS%2520health%2520and%2520pathology%253A%2520a%2520focus%2520on%2520the%2520CCL2%252FCCR2%2520and%2520CXCL8%252FCXCR2%2520networks%26jtitle%3DJ.%2520Cereb.%2520Blood%2520Flow%2520Metab.%26date%3D2010%26volume%3D30%26issue%3D3%26spage%3D459%26epage%3D473%26doi%3D10.1038%2Fjcbfm.2009.240" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit11c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Melik-Parsadaniantz, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rostene, W.</span></span> <span> </span><span class="NLM_article-title">Chemokines and neuromodulation</span>. <i>J. Neuroimmunol.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>198</i></span> (<span class="NLM_issue">1–2</span>),  <span class="NLM_fpage">62</span>– <span class="NLM_lpage">68</span>, <span class="refDoi"> DOI: 10.1016/j.jneuroim.2008.04.022</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01854&amp;key=10.1016%2Fj.jneuroim.2008.04.022" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01854&amp;key=18538863" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01854&amp;key=1%3ACAS%3A528%3ADC%252BD1cXoslGgsbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=198&publication_year=2008&pages=62-68&issue=1%E2%80%932&author=S.+Melik-Parsadaniantzauthor=W.+Rostene&title=Chemokines+and+neuromodulation&doi=10.1016%2Fj.jneuroim.2008.04.022"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11cR"><div class="casContent"><span class="casTitleNuber">11c</span><div class="casTitle"><span class="NLM_cas:atitle">Chemokines and neuromodulation</span></div><div class="casAuthors">Melik-Parsadaniantz, Stephane; Rostene, William</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neuroimmunology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">198</span>
        (<span class="NLM_cas:issue">1-2</span>),
    <span class="NLM_cas:pages">62-68</span>CODEN:
                <span class="NLM_cas:coden">JNRIDW</span>;
        ISSN:<span class="NLM_cas:issn">0165-5728</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Chemokines are not only mediators of the immune system and expressed in inflammatory situations.  They are also constitutively expressed in the brain in both glial cells and neurons.  Several recent evidence suggest that they can have a neurotransmitter/neuromodulatory role on brain functions similar to several neuropeptides reported so far.  The aim of this short review is to illustrate that point using two chemokine systems, SDF-1/CXCL12 and its receptor CXCR4 and MCP-1/CCL2 and its receptor CCR2.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrTVjsIs1WaTbVg90H21EOLACvtfcHk0lgNEQ1VjjqXAg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXoslGgsbY%253D&md5=a5b4862f735d6dcf35990defa51d83c9</span></div><a href="/servlet/linkout?suffix=cit11c&amp;dbid=16384&amp;doi=10.1016%2Fj.jneuroim.2008.04.022&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jneuroim.2008.04.022%26sid%3Dliteratum%253Aachs%26aulast%3DMelik-Parsadaniantz%26aufirst%3DS.%26aulast%3DRostene%26aufirst%3DW.%26atitle%3DChemokines%2520and%2520neuromodulation%26jtitle%3DJ.%2520Neuroimmunol.%26date%3D2008%26volume%3D198%26issue%3D1%25E2%2580%25932%26spage%3D62%26epage%3D68%26doi%3D10.1016%2Fj.jneuroim.2008.04.022" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Du, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, X. G.</span></span> <span> </span><span class="NLM_article-title">protein-coupled receptors as therapeutic targets for multiple sclerosis</span>. <i>Cell Res.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>22</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">1108</span>– <span class="NLM_lpage">1128</span>, <span class="refDoi"> DOI: 10.1038/cr.2012.87</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01854&amp;key=10.1038%2Fcr.2012.87" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01854&amp;key=22664908" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01854&amp;key=1%3ACAS%3A528%3ADC%252BC38Xpsl2isbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2012&pages=1108-1128&issue=7&author=C.+S.+Duauthor=X.+G.+Xie&title=protein-coupled+receptors+as+therapeutic+targets+for+multiple+sclerosis&doi=10.1038%2Fcr.2012.87"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">G protein-coupled receptors as therapeutic targets for multiple sclerosis</span></div><div class="casAuthors">Du, Changsheng; Xie, Xin</div><div class="citationInfo"><span class="NLM_cas:title">Cell Research</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1108-1128</span>CODEN:
                <span class="NLM_cas:coden">CREEB6</span>;
        ISSN:<span class="NLM_cas:issn">1001-0602</span>.
    
            (<span class="NLM_cas:orgname">NPG Nature Asia-Pacific</span>)
        </div><div class="casAbstract">A review.  G protein-coupled receptors (GPCRs) mediate most of our physiol. responses to hormones, neurotransmitters and environmental stimulants.  They are considered as the most successful therapeutic targets for a broad spectrum of diseases.  Multiple sclerosis (MS) is an inflammatory disease that is characterized by immune-mediated demyelination and degeneration of the central nervous system (CNS).  It is the leading cause of non-traumatic disability in young adults.  Great progress has been made over the past few decades in understanding the pathogenesis of MS.  Numerous data from animal and clin. studies indicate that many GPCRs are critically involved in various aspects of MS pathogenesis, including antigen presentation, cytokine prodn., T-cell differentiation, T-cell proliferation, T-cell invasion, etc.  In this review, we summarize the recent findings regarding the expression or functional changes of GPCRs in MS patients or animal models, and the influences of GPCRs on disease severity upon genetic or pharmacol. manipulations.  Hopefully some of these findings will lead to the development of novel therapies for MS in the near future.  Cell Research (2012) 22:1108-1128. doi:10.1038/cr.2012.87; published online 5 June 2012.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrpXXysrXy5SbVg90H21EOLACvtfcHk0lgNEQ1VjjqXAg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xpsl2isbs%253D&md5=843512eaf86556f5eaaad867ac134adc</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1038%2Fcr.2012.87&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fcr.2012.87%26sid%3Dliteratum%253Aachs%26aulast%3DDu%26aufirst%3DC.%2BS.%26aulast%3DXie%26aufirst%3DX.%2BG.%26atitle%3Dprotein-coupled%2520receptors%2520as%2520therapeutic%2520targets%2520for%2520multiple%2520sclerosis%26jtitle%3DCell%2520Res.%26date%3D2012%26volume%3D22%26issue%3D7%26spage%3D1108%26epage%3D1128%26doi%3D10.1038%2Fcr.2012.87" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.-F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Y.-F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, S.-W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, W.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Q.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ge, L.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, R.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.-F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, Z.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, G.-H.</span></span> <span> </span><span class="NLM_article-title">CXCL1 triggers caspase-3 dependent tau cleavage in long-term neuronal cultures and in the hippocampus of aged mice: implications in Alzheimer’s disease</span>. <i>J. Alzheimer's Dis.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>48</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">89</span>– <span class="NLM_lpage">104</span>, <span class="refDoi"> DOI: 10.3233/JAD-150041</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01854&amp;key=10.3233%2FJAD-150041" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01854&amp;key=26401931" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01854&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsFyit7%252FO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2015&pages=89-104&issue=1&author=X.-F.+Zhangauthor=Y.-F.+Zhaoauthor=S.-W.+Zhuauthor=W.-J.+Huangauthor=Y.+Luoauthor=Q.-Y.+Chenauthor=L.-J.+Geauthor=R.-S.+Liauthor=J.-F.+Wangauthor=M.+Sunauthor=Z.-C.+Xiaoauthor=G.-H.+Fan&title=CXCL1+triggers+caspase-3+dependent+tau+cleavage+in+long-term+neuronal+cultures+and+in+the+hippocampus+of+aged+mice%3A+implications+in+Alzheimer%E2%80%99s+disease&doi=10.3233%2FJAD-150041"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">CXCL1 Triggers Caspase-3 Dependent Tau Cleavage in Long-Term Neuronal Cultures and in the Hippocampus of Aged Mice: Implications in Alzheimer's Disease</span></div><div class="casAuthors">Zhang, Xiao-Fang; Zhao, Yan-Feng; Zhu, Shun-Wei; Huang, Wei-Jie; Luo, Yan; Chen, Qing-Ying; Ge, Li-Jun; Li, Run-Sheng; Wang, Jian-Fei; Sun, Mu; Xiao, Zhi-Cheng; Fan, Guo-Huang</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Alzheimer's Disease</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">89-104</span>CODEN:
                <span class="NLM_cas:coden">JADIF9</span>;
        ISSN:<span class="NLM_cas:issn">1387-2877</span>.
    
            (<span class="NLM_cas:orgname">IOS Press</span>)
        </div><div class="casAbstract">Truncation of tau protein is considered an early event in Alzheimer's disease (AD) and is believed to play a major pathogenic role in sporadic AD.  However, causative factors that trigger tau truncation in AD remain poorly understood.  In the present study, we demonstrate that CXCL1 (C-X-C motif ligand 1), a specific ligand for the chemokine receptor CXCR2, induced cleavage of tau at ASP421 in a caspase-3-dependent manner in long-term but not short-term cultured neurons.  The cleaved tau formed varicosities or bead-like structures along the neurites, an abnormal distribution of tau induced by CXCL1 that has not been obsd. previously.  CXCL1-induced activation of GSK3β and the subsequent phosphorylation of tau preceded and were required for caspase-3 activation and tau cleavage.  Moreover, intrahippocampal microinjection of lentiviral CXCL1 induced tau cleavage in hippocampal neurons in aged (15-18 mo of age) but not adult mice (5-10 mo of age).  Our data highlight a new role of CXCR2 in tau cleavage and suggest that targeting CXCR2 may offer therapeutic benefits to patients with AD and potentially other tauopathies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoeGiYjnZjJUrVg90H21EOLACvtfcHk0lhW9qHS25GUgg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsFyit7%252FO&md5=b8fa7c85dea78585af77d0cd738a4aea</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.3233%2FJAD-150041&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3233%252FJAD-150041%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DX.-F.%26aulast%3DZhao%26aufirst%3DY.-F.%26aulast%3DZhu%26aufirst%3DS.-W.%26aulast%3DHuang%26aufirst%3DW.-J.%26aulast%3DLuo%26aufirst%3DY.%26aulast%3DChen%26aufirst%3DQ.-Y.%26aulast%3DGe%26aufirst%3DL.-J.%26aulast%3DLi%26aufirst%3DR.-S.%26aulast%3DWang%26aufirst%3DJ.-F.%26aulast%3DSun%26aufirst%3DM.%26aulast%3DXiao%26aufirst%3DZ.-C.%26aulast%3DFan%26aufirst%3DG.-H.%26atitle%3DCXCL1%2520triggers%2520caspase-3%2520dependent%2520tau%2520cleavage%2520in%2520long-term%2520neuronal%2520cultures%2520and%2520in%2520the%2520hippocampus%2520of%2520aged%2520mice%253A%2520implications%2520in%2520Alzheimer%25E2%2580%2599s%2520disease%26jtitle%3DJ.%2520Alzheimer%2527s%2520Dis.%26date%3D2015%26volume%3D48%26issue%3D1%26spage%3D89%26epage%3D104%26doi%3D10.3233%2FJAD-150041" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Z.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, D.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ji, R.-R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, Y.-J.</span></span> <span> </span><span class="NLM_article-title">Chemokine contribution to neuropathic pain: respective induction of CXCL1 and CXCR2 in spinal cord astrocytes and neurons</span>. <i>Pain</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>154</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">2185</span>– <span class="NLM_lpage">2197</span>, <span class="refDoi"> DOI: 10.1016/j.pain.2013.07.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01854&amp;key=10.1016%2Fj.pain.2013.07.002" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=154&publication_year=2013&pages=2185-2197&issue=10&author=Z.-J.+Zhangauthor=D.-L.+Caoauthor=X.+Zhangauthor=R.-R.+Jiauthor=Y.-J.+Gao&title=Chemokine+contribution+to+neuropathic+pain%3A+respective+induction+of+CXCL1+and+CXCR2+in+spinal+cord+astrocytes+and+neurons&doi=10.1016%2Fj.pain.2013.07.002"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1016%2Fj.pain.2013.07.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pain.2013.07.002%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DZ.-J.%26aulast%3DCao%26aufirst%3DD.-L.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DJi%26aufirst%3DR.-R.%26aulast%3DGao%26aufirst%3DY.-J.%26atitle%3DChemokine%2520contribution%2520to%2520neuropathic%2520pain%253A%2520respective%2520induction%2520of%2520CXCL1%2520and%2520CXCR2%2520in%2520spinal%2520cord%2520astrocytes%2520and%2520neurons%26jtitle%3DPain%26date%3D2013%26volume%3D154%26issue%3D10%26spage%3D2185%26epage%3D2197%26doi%3D10.1016%2Fj.pain.2013.07.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">White, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hertzberg, R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jurewicz, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chaikin, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Widdowson, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Foley, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, L. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griswold, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sarau, H. M.</span></span> <span> </span><span class="NLM_article-title">Identification of a potent, selective non-peptide CXCR2 antagonist that inhibits interleukin-8-induced neutrophil migration</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>273</i></span> (<span class="NLM_issue">17</span>),  <span class="NLM_fpage">10095</span>– <span class="NLM_lpage">10098</span>, <span class="refDoi"> DOI: 10.1074/jbc.273.17.10095</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01854&amp;key=10.1074%2Fjbc.273.17.10095" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=273&publication_year=1998&pages=10095-10098&issue=17&author=J.+R.+Whiteauthor=J.+M.+Leeauthor=P.+R.+Youngauthor=R.+P.+Hertzbergauthor=A.+J.+Jurewiczauthor=M.+A.+Chaikinauthor=K.+Widdowsonauthor=J.+J.+Foleyauthor=L.+D.+Martinauthor=D.+E.+Griswoldauthor=H.+M.+Sarau&title=Identification+of+a+potent%2C+selective+non-peptide+CXCR2+antagonist+that+inhibits+interleukin-8-induced+neutrophil+migration&doi=10.1074%2Fjbc.273.17.10095"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1074%2Fjbc.273.17.10095&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.273.17.10095%26sid%3Dliteratum%253Aachs%26aulast%3DWhite%26aufirst%3DJ.%2BR.%26aulast%3DLee%26aufirst%3DJ.%2BM.%26aulast%3DYoung%26aufirst%3DP.%2BR.%26aulast%3DHertzberg%26aufirst%3DR.%2BP.%26aulast%3DJurewicz%26aufirst%3DA.%2BJ.%26aulast%3DChaikin%26aufirst%3DM.%2BA.%26aulast%3DWiddowson%26aufirst%3DK.%26aulast%3DFoley%26aufirst%3DJ.%2BJ.%26aulast%3DMartin%26aufirst%3DL.%2BD.%26aulast%3DGriswold%26aufirst%3DD.%2BE.%26aulast%3DSarau%26aufirst%3DH.%2BM.%26atitle%3DIdentification%2520of%2520a%2520potent%252C%2520selective%2520non-peptide%2520CXCR2%2520antagonist%2520that%2520inhibits%2520interleukin-8-induced%2520neutrophil%2520migration%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1998%26volume%3D273%26issue%3D17%26spage%3D10095%26epage%3D10098%26doi%3D10.1074%2Fjbc.273.17.10095" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Bertini, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allegretti, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bizzarri, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moriconi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Locati, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zampella, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cervellera, M. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">di Cioccio, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cesta, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galliera, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martinez, F. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Bitondo, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Troiani, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sabbatini, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">D’Anniballe, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anacardio, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cutrin, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cavalieri, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mainiero, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strippoli, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Villa, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Girolamo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gentile, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Santoni, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corda, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poli, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mantovani, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghezzi, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colotta, F.</span></span> <span> </span><span class="NLM_article-title">Noncompetitive allosteric inhibitors of the inflammatory chemokine receptors CXCR1 and CXCR2: Prevention of reperfusion injury</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>101</i></span> (<span class="NLM_issue">32</span>),  <span class="NLM_fpage">11791</span>– <span class="NLM_lpage">11796</span>, <span class="refDoi"> DOI: 10.1073/pnas.0402090101</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01854&amp;key=10.1073%2Fpnas.0402090101" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=101&publication_year=2004&pages=11791-11796&issue=32&author=R.+Bertiniauthor=M.+Allegrettiauthor=C.+Bizzarriauthor=A.+Moriconiauthor=M.+Locatiauthor=G.+Zampellaauthor=M.+N.+Cervelleraauthor=V.+di+Cioccioauthor=M.+C.+Cestaauthor=E.+Gallieraauthor=F.+O.+Martinezauthor=R.+Di+Bitondoauthor=G.+Troianiauthor=V.+Sabbatiniauthor=G.+D%E2%80%99Anniballeauthor=R.+Anacardioauthor=J.+C.+Cutrinauthor=B.+Cavalieriauthor=F.+Mainieroauthor=R.+Strippoliauthor=P.+Villaauthor=M.+Di+Girolamoauthor=F.+Martinauthor=M.+Gentileauthor=A.+Santoniauthor=D.+Cordaauthor=G.+Poliauthor=A.+Mantovaniauthor=P.+Ghezziauthor=F.+Colotta&title=Noncompetitive+allosteric+inhibitors+of+the+inflammatory+chemokine+receptors+CXCR1+and+CXCR2%3A+Prevention+of+reperfusion+injury&doi=10.1073%2Fpnas.0402090101"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16a&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0402090101&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0402090101%26sid%3Dliteratum%253Aachs%26aulast%3DBertini%26aufirst%3DR.%26aulast%3DAllegretti%26aufirst%3DM.%26aulast%3DBizzarri%26aufirst%3DC.%26aulast%3DMoriconi%26aufirst%3DA.%26aulast%3DLocati%26aufirst%3DM.%26aulast%3DZampella%26aufirst%3DG.%26aulast%3DCervellera%26aufirst%3DM.%2BN.%26aulast%3Ddi%2BCioccio%26aufirst%3DV.%26aulast%3DCesta%26aufirst%3DM.%2BC.%26aulast%3DGalliera%26aufirst%3DE.%26aulast%3DMartinez%26aufirst%3DF.%2BO.%26aulast%3DDi%2BBitondo%26aufirst%3DR.%26aulast%3DTroiani%26aufirst%3DG.%26aulast%3DSabbatini%26aufirst%3DV.%26aulast%3DD%25E2%2580%2599Anniballe%26aufirst%3DG.%26aulast%3DAnacardio%26aufirst%3DR.%26aulast%3DCutrin%26aufirst%3DJ.%2BC.%26aulast%3DCavalieri%26aufirst%3DB.%26aulast%3DMainiero%26aufirst%3DF.%26aulast%3DStrippoli%26aufirst%3DR.%26aulast%3DVilla%26aufirst%3DP.%26aulast%3DDi%2BGirolamo%26aufirst%3DM.%26aulast%3DMartin%26aufirst%3DF.%26aulast%3DGentile%26aufirst%3DM.%26aulast%3DSantoni%26aufirst%3DA.%26aulast%3DCorda%26aufirst%3DD.%26aulast%3DPoli%26aufirst%3DG.%26aulast%3DMantovani%26aufirst%3DA.%26aulast%3DGhezzi%26aufirst%3DP.%26aulast%3DColotta%26aufirst%3DF.%26atitle%3DNoncompetitive%2520allosteric%2520inhibitors%2520of%2520the%2520inflammatory%2520chemokine%2520receptors%2520CXCR1%2520and%2520CXCR2%253A%2520Prevention%2520of%2520reperfusion%2520injury%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2004%26volume%3D101%26issue%3D32%26spage%3D11791%26epage%3D11796%26doi%3D10.1073%2Fpnas.0402090101" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit16b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Chapman, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phillips, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hipkin, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Curran, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lundell, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fine, J. S.</span></span> <span> </span><span class="NLM_article-title">CXCR2 antagonists for the treatment of pulmonary disease</span>. <i>Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>121</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">55</span>– <span class="NLM_lpage">68</span>, <span class="refDoi"> DOI: 10.1016/j.pharmthera.2008.10.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01854&amp;key=10.1016%2Fj.pharmthera.2008.10.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01854&amp;key=19026683" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01854&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhsFagtrrJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=121&publication_year=2009&pages=55-68&issue=1&author=R.+W.+Chapmanauthor=J.+E.+Phillipsauthor=R.+W.+Hipkinauthor=A.+K.+Curranauthor=D.+Lundellauthor=J.+S.+Fine&title=CXCR2+antagonists+for+the+treatment+of+pulmonary+disease&doi=10.1016%2Fj.pharmthera.2008.10.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16bR"><div class="casContent"><span class="casTitleNuber">16b</span><div class="casTitle"><span class="NLM_cas:atitle">CXCR2 antagonists for the treatment of pulmonary disease</span></div><div class="casAuthors">Chapman, R. W.; Phillips, J. E.; Hipkin, R. W.; Curran, A. K.; Lundell, D.; Fine, J. S.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacology & Therapeutics</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">121</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">55-68</span>CODEN:
                <span class="NLM_cas:coden">PHTHDT</span>;
        ISSN:<span class="NLM_cas:issn">0163-7258</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  Chemokines have long been implicated in the initiation and amplification of inflammatory responses by virtue of their role in leukocyte chemotaxis.  The expression of one of the receptors for these chemokines, CXCR2, on a variety of cell types and tissues suggests that these receptors may have a broad functional role under both constitutive conditions and in the pathophysiol. of a no. of acute and chronic diseases.  With the development of several pharmacol., immunol. and genetic tools to study CXCR2 function, an important role for this CXC chemokine receptor subtype has been identified in chronic obstructive pulmonary disease (COPD), asthma and fibrotic pulmonary disorders.  Interference with CXCR2 receptor function has demonstrated different effects in the lungs including inhibition of pulmonary damage induced by neutrophils (PMNs), antigen or irritant-induced goblet cell hyperplasia and angiogenesis/collagen deposition caused by lung injury.  Many of these features are common to inflammatory and fibrotic disorders of the lung.  Clin. trials evaluating small mol. CXCR2 antagonists in COPD, asthma and cystic fibrosis are currently underway.  These studies hold considerable promise for identifying novel and efficacious treatments of pulmonary disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpPf1-c-1ciWrVg90H21EOLACvtfcHk0li7BwnUOeJOsw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhsFagtrrJ&md5=37a5047ab1b8a37739311d273dd7d854</span></div><a href="/servlet/linkout?suffix=cit16b&amp;dbid=16384&amp;doi=10.1016%2Fj.pharmthera.2008.10.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pharmthera.2008.10.005%26sid%3Dliteratum%253Aachs%26aulast%3DChapman%26aufirst%3DR.%2BW.%26aulast%3DPhillips%26aufirst%3DJ.%2BE.%26aulast%3DHipkin%26aufirst%3DR.%2BW.%26aulast%3DCurran%26aufirst%3DA.%2BK.%26aulast%3DLundell%26aufirst%3DD.%26aulast%3DFine%26aufirst%3DJ.%2BS.%26atitle%3DCXCR2%2520antagonists%2520for%2520the%2520treatment%2520of%2520pulmonary%2520disease%26jtitle%3DPharmacol.%2520Ther.%26date%3D2009%26volume%3D121%26issue%3D1%26spage%3D55%26epage%3D68%26doi%3D10.1016%2Fj.pharmthera.2008.10.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit16c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Opfermann, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Derhaschnig, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Felli, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wenisch, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Santer, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zuckermann, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dworschak, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jilma, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steinlechner, B.</span></span> <span> </span><span class="NLM_article-title">A pilot study on reparixin, a CXCR1/2 antagonist, to assess safety and efficacy in attenuating ischaemia-reperfusion injury and inflammation after on-pump coronary artery bypass graft surgery</span>. <i>Clin. Exp. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>180</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">131</span>– <span class="NLM_lpage">142</span>, <span class="refDoi"> DOI: 10.1111/cei.12488</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01854&amp;key=10.1111%2Fcei.12488" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01854&amp;key=25402332" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01854&amp;key=1%3ACAS%3A528%3ADC%252BC2MXjvFyktr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=180&publication_year=2015&pages=131-142&issue=1&author=P.+Opfermannauthor=U.+Derhaschnigauthor=A.+Felliauthor=J.+Wenischauthor=D.+Santerauthor=A.+Zuckermannauthor=M.+Dworschakauthor=B.+Jilmaauthor=B.+Steinlechner&title=A+pilot+study+on+reparixin%2C+a+CXCR1%2F2+antagonist%2C+to+assess+safety+and+efficacy+in+attenuating+ischaemia-reperfusion+injury+and+inflammation+after+on-pump+coronary+artery+bypass+graft+surgery&doi=10.1111%2Fcei.12488"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16cR"><div class="casContent"><span class="casTitleNuber">16c</span><div class="casTitle"><span class="NLM_cas:atitle">A pilot study on reparixin, a CXCR1/2 antagonist, to assess safety and efficacy in attenuating ischaemia-reperfusion injury and inflammation after on-pump coronary artery bypass graft surgery</span></div><div class="casAuthors">Opfermann, P.; Derhaschnig, U.; Felli, A.; Wenisch, J.; Santer, D.; Zuckermann, A.; Dworschak, M.; Jilma, B.; Steinlechner, B.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical & Experimental Immunology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">180</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">131-142</span>CODEN:
                <span class="NLM_cas:coden">CEXIAL</span>;
        ISSN:<span class="NLM_cas:issn">0009-9104</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Summary : Reparixin, a CXCR 1/2 antagonist, has been shown to mitigate ischemia-reperfusion injury (IRI) in various organ systems in animals, but data in humans are scarce.  The aim of this double-blinded, placebo-controlled pilot study was to evaluate the safety and efficacy of reparixin to suppress IRI and inflammation in patients undergoing on-pump coronary artery bypass grafting (CABG).  Patients received either reparixin or placebo (n = 16 in each group) after induction of anesthesia until 8 h after cardiopulmonary bypass (CPB).  We compared markers of systemic and pulmonary inflammation, surrogates of myocardial IRI and clin. outcomes using Mann-Whitney U- and Fisher's exact tests.  Thirty- and 90-day mortality was 0% in both groups.  No side effects were obsd. in the treatment group.  Surgical revision, pleural and pericardial effusion, infection and atrial fibrillation rates were not different between groups.  Reparixin significantly reduced the proportion of neutrophil granulocytes in blood at the beginning [49%, interquartile range (IQR) = 45-57 vs. 58%, IQR = 53-66, P = 0·035], end (71%, IQR = 67-76 vs. 79%, IQR = 71-83, P = 0·023) and 1 h after CPB (73%, IQR = 71-75 vs. 77%, IQR = 72-80, P = 0·035).  Reparixin patients required a lesser pos. fluid balance during surgery (2575 mL, IQR = 2027-3080 vs. 3200 mL, IQR = 2928-3778, P = 0·029) and during ICU stay (2603 mL, IQR = 1023-4288 vs. 4200 mL, IQR = 2313-8160, P = 0·021).  Numerically, more control patients required noradrenaline ≥ 0·11 μg/kg/min (50 vs. 19%, P = 0·063) and dobutamine (50 vs. 25%, P = 0·14).  Therefore, administration of reparixin in CABG patients appears to be feasible and safe.  It concurrently attenuated postoperative granulocytosis in peripheral blood.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGob_XhfQP58LbVg90H21EOLACvtfcHk0li7BwnUOeJOsw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXjvFyktr0%253D&md5=8300dc5f57fd2abb79a3984f95d79efc</span></div><a href="/servlet/linkout?suffix=cit16c&amp;dbid=16384&amp;doi=10.1111%2Fcei.12488&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fcei.12488%26sid%3Dliteratum%253Aachs%26aulast%3DOpfermann%26aufirst%3DP.%26aulast%3DDerhaschnig%26aufirst%3DU.%26aulast%3DFelli%26aufirst%3DA.%26aulast%3DWenisch%26aufirst%3DJ.%26aulast%3DSanter%26aufirst%3DD.%26aulast%3DZuckermann%26aufirst%3DA.%26aulast%3DDworschak%26aufirst%3DM.%26aulast%3DJilma%26aufirst%3DB.%26aulast%3DSteinlechner%26aufirst%3DB.%26atitle%3DA%2520pilot%2520study%2520on%2520reparixin%252C%2520a%2520CXCR1%252F2%2520antagonist%252C%2520to%2520assess%2520safety%2520and%2520efficacy%2520in%2520attenuating%2520ischaemia-reperfusion%2520injury%2520and%2520inflammation%2520after%2520on-pump%2520coronary%2520artery%2520bypass%2520graft%2520surgery%26jtitle%3DClin.%2520Exp.%2520Immunol.%26date%3D2015%26volume%3D180%26issue%3D1%26spage%3D131%26epage%3D142%26doi%3D10.1111%2Fcei.12488" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nicholls, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiley, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dainty, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">MacIntosh, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phillips, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gaw, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mårdh, C. K.</span></span> <span> </span><span class="NLM_article-title">Pharmacological characterization of AZD5069, a slowly reversible CXC chemokine receptor 2 antagonist</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>353</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">340</span>– <span class="NLM_lpage">350</span>, <span class="refDoi"> DOI: 10.1124/jpet.114.221358</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01854&amp;key=10.1124%2Fjpet.114.221358" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01854&amp;key=25736418" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01854&amp;key=1%3ACAS%3A528%3ADC%252BC2MXlvVWnu7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=353&publication_year=2015&pages=340-350&issue=2&author=D.+J.+Nichollsauthor=K.+Wileyauthor=I.+Daintyauthor=F.+MacIntoshauthor=C.+Phillipsauthor=A.+Gawauthor=C.+K.+M%C3%A5rdh&title=Pharmacological+characterization+of+AZD5069%2C+a+slowly+reversible+CXC+chemokine+receptor+2+antagonist&doi=10.1124%2Fjpet.114.221358"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacological characterization of AZD5069, a slowly reversible CXC chemokine receptor 2 antagonist</span></div><div class="casAuthors">Nicholls, David J.; Wiley, Katherine; Dainty, Ian; MacIntosh, Fraser; Phillips, Caroline; Gaw, Alasdair; Mardh, Carina Karrman</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">353</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">340-350</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">1521-0103</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">In normal physiol. responses to injury and infection, inflammatory cells enter tissue and sites of inflammation through a chemotactic process regulated by several families of proteins, including inflammatory chemokines, a family of small inducible cytokines.  In neutrophils, chemokines chemokine (CXC motif) ligand 1 (CXCL1) and CXCL8 are potent chemoattractants and activate G protein-coupled receptors CXC chemokine receptor 1 (CXCR1) and CXCR2.  Several small-mol. antagonists of CXCR2 have been developed to inhibit the inflammatory responses mediated by this receptor.  Here, we present the data describing the pharmacol. of AZD5069 [N-(2-(2,3-difluorobenzylthio)-6-((2R,3S)-3,4-dihydroxybutan-2-yloxy)[2,4,5,6-13C4, 1,3-15N-2]pyrimidin-4-yl)azetidine-1-sulfonamide,[15N2,13C4]N-(2-(2,3-difluoro-6-[3H]-benzylthio)-6-((2R,3S)-3,4-dihydroxybutan-2-yloxy)pyrimidin-4-yl)azetidine-1-sulfonamide], a novel antagonist of CXCR2.  AZD5069 was shown to inhibit binding of radio-labeled CXCL8 to human CXCR2 with a pIC50 value of 9.1.  Furthermore, AZD5069 inhibited neutrophil chemotaxis, with a pA2 of approx. 9.6, and adhesion mol. expression, with a pA2 of 6.9, in response to CXCL1.  AZD5069 was a slowly reversible antagonist of CXCR2 with effects of time and temp. evident on the pharmacol. and binding kinetics.  With short incubation times, AZD5069 appeared to have an antagonist profile with insurmountable antagonism of calcium response curves.  This behavior was also obsd. in vivo in an acute lipopolysaccharide-induced lung inflammation model.  Altogether, the data presented here show that AZD5069 represents a novel, potent, and selective CXCR2 antagonist with potential as a therapeutic agent in inflammatory conditions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoj1gxnHr4vbbVg90H21EOLACvtfcHk0ljsClI0RNO5TQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXlvVWnu7g%253D&md5=1ffebbdc9c02dbd015d985062ac820f2</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1124%2Fjpet.114.221358&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.114.221358%26sid%3Dliteratum%253Aachs%26aulast%3DNicholls%26aufirst%3DD.%2BJ.%26aulast%3DWiley%26aufirst%3DK.%26aulast%3DDainty%26aufirst%3DI.%26aulast%3DMacIntosh%26aufirst%3DF.%26aulast%3DPhillips%26aufirst%3DC.%26aulast%3DGaw%26aufirst%3DA.%26aulast%3DM%25C3%25A5rdh%26aufirst%3DC.%2BK.%26atitle%3DPharmacological%2520characterization%2520of%2520AZD5069%252C%2520a%2520slowly%2520reversible%2520CXC%2520chemokine%2520receptor%25202%2520antagonist%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2015%26volume%3D353%26issue%3D2%26spage%3D340%26epage%3D350%26doi%3D10.1124%2Fjpet.114.221358" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Walters, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Austin, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Austin, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonnert, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cage, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christie, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ebden, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">gardiner, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grahames, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hill, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hunt, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jewell, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewis, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nicholls, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robinson, D.</span></span> <span> </span><span class="NLM_article-title">Evaluation of a series of bicyclic CXCR2 antagonists</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>18</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">798</span>– <span class="NLM_lpage">803</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2007.11.039</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01854&amp;key=10.1016%2Fj.bmcl.2007.11.039" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2008&pages=798-803&issue=2&author=I.+Waltersauthor=C.+Austinauthor=A.+Austinauthor=R.+Bonnertauthor=P.+Cageauthor=M.+Christieauthor=M.+Ebdenauthor=S.+gardinerauthor=C.+Grahamesauthor=S.+Hillauthor=F.+Huntauthor=R.+Jewellauthor=S.+Lewisauthor=I.+Martinauthor=D.+Nichollsauthor=D.+Robinson&title=Evaluation+of+a+series+of+bicyclic+CXCR2+antagonists&doi=10.1016%2Fj.bmcl.2007.11.039"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2007.11.039&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2007.11.039%26sid%3Dliteratum%253Aachs%26aulast%3DWalters%26aufirst%3DI.%26aulast%3DAustin%26aufirst%3DC.%26aulast%3DAustin%26aufirst%3DA.%26aulast%3DBonnert%26aufirst%3DR.%26aulast%3DCage%26aufirst%3DP.%26aulast%3DChristie%26aufirst%3DM.%26aulast%3DEbden%26aufirst%3DM.%26aulast%3Dgardiner%26aufirst%3DS.%26aulast%3DGrahames%26aufirst%3DC.%26aulast%3DHill%26aufirst%3DS.%26aulast%3DHunt%26aufirst%3DF.%26aulast%3DJewell%26aufirst%3DR.%26aulast%3DLewis%26aufirst%3DS.%26aulast%3DMartin%26aufirst%3DI.%26aulast%3DNicholls%26aufirst%3DD.%26aulast%3DRobinson%26aufirst%3DD.%26atitle%3DEvaluation%2520of%2520a%2520series%2520of%2520bicyclic%2520CXCR2%2520antagonists%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2008%26volume%3D18%26issue%3D2%26spage%3D798%26epage%3D803%26doi%3D10.1016%2Fj.bmcl.2007.11.039" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gonsiorek, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hesk, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fossetta, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qiu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jakway, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Billah, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dwyer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deno, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taveras, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lundell, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hipkin, R. W.</span></span> <span> </span><span class="NLM_article-title">Pharmacological characterization of Sch527123, a potent allosteric CXCR1/CXCR2 antagonist</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>322</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">477</span>– <span class="NLM_lpage">485</span>, <span class="refDoi"> DOI: 10.1124/jpet.106.118927</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01854&amp;key=10.1124%2Fjpet.106.118927" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01854&amp;key=17496166" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01854&amp;key=1%3ACAS%3A528%3ADC%252BD2sXoslSjt7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=322&publication_year=2007&pages=477-485&issue=2&author=W.+Gonsiorekauthor=X.+Fanauthor=D.+Heskauthor=J.+Fossettaauthor=H.+Qiuauthor=J.+Jakwayauthor=M.+Billahauthor=M.+Dwyerauthor=J.+Chaoauthor=G.+Denoauthor=A.+Taverasauthor=D.+J.+Lundellauthor=R.+W.+Hipkin&title=Pharmacological+characterization+of+Sch527123%2C+a+potent+allosteric+CXCR1%2FCXCR2+antagonist&doi=10.1124%2Fjpet.106.118927"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacological characterization of Sch527123, a potent allosteric CXCR1/CXCR2 antagonist</span></div><div class="casAuthors">Gonsiorek, Waldemar; Fan, Xuedong; Hesk, David; Fossetta, James; Qiu, Hongchen; Jakway, James; Billah, Motasim; Dwyer, Michael; Chao, Jianhua; Deno, Gregory; Taveras, Art; Lundell, Daniel J.; Hipkin, R. William</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">322</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">477-485</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">In neutrophils, growth-related protein-α (CXCL1) and interleukin-8 (CXCL8), are potent chemoattractants and can stimulate myeloperoxidase release via activation of the G protein-coupled receptors CXCR1 and CXCR2.  The role of CXCR1 and CXCR2 in the pathogenesis of inflammatory responses has encouraged the development of small mol. antagonists for these receptors.  The data presented herein describe the pharmacol. of 2-hydroxy-N,N-dimethyl-3-{2-[[(R)-1-(5-methyl-furan-2-yl)-propyl]amino]-3,4-dioxo-cyclobut-1-enylamino}benzamide (Sch527123), a novel antagonist of both CXCR1 and CXCR2.  Sch527123 inhibited chemokine binding to (and activation of) these receptors in an insurmountable manner and, as such, is categorized as an allosteric antagonist.  Sch527123 inhibited neutrophil chemotaxis and myeloperoxidase release in response to CXCL1 and CXCL8 but had no effect on the response of these cells to C5a or formyl-methionyl-leucyl-phenylalanine.  The pharmacol. specificity of Sch527123 was confirmed by testing in a diversity profile against a panel of enzymes, channels, and receptors.  To measure compd. affinity, we characterized [3H]Sch527123 in both equil. and nonequil. binding analyses.  Sch527123 binding to CXCR1 and CXCR2 was both saturable and reversible.  Although Sch527123 bound to CXCR1 with good affinity (Kd = 3.9±0.3 nM), the compd. is CXCR2-selective (Kd = 0.049±0.004 nM).  Taken together, our data show that Sch527123 represents a novel, potent, and specific CXCR2 antagonist with potential therapeutic utility in a variety of inflammatory conditions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqb79iH3wA1yrVg90H21EOLACvtfcHk0liFOEw6OGAHaw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXoslSjt7s%253D&md5=37691994ca29fa4dfe33d094d0cd9b93</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1124%2Fjpet.106.118927&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.106.118927%26sid%3Dliteratum%253Aachs%26aulast%3DGonsiorek%26aufirst%3DW.%26aulast%3DFan%26aufirst%3DX.%26aulast%3DHesk%26aufirst%3DD.%26aulast%3DFossetta%26aufirst%3DJ.%26aulast%3DQiu%26aufirst%3DH.%26aulast%3DJakway%26aufirst%3DJ.%26aulast%3DBillah%26aufirst%3DM.%26aulast%3DDwyer%26aufirst%3DM.%26aulast%3DChao%26aufirst%3DJ.%26aulast%3DDeno%26aufirst%3DG.%26aulast%3DTaveras%26aufirst%3DA.%26aulast%3DLundell%26aufirst%3DD.%2BJ.%26aulast%3DHipkin%26aufirst%3DR.%2BW.%26atitle%3DPharmacological%2520characterization%2520of%2520Sch527123%252C%2520a%2520potent%2520allosteric%2520CXCR1%252FCXCR2%2520antagonist%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2007%26volume%3D322%26issue%3D2%26spage%3D477%26epage%3D485%26doi%3D10.1124%2Fjpet.106.118927" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rennard, S. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dale, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Donohue, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kanniess, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Magnussen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sutherland, E. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watz, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stryszak, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosenberg, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Staudinger, H.</span></span> <span> </span><span class="NLM_article-title">CXCR2 antagonist MK-7123: a phase 2 proof-of-concept trial for chronic obstructive pulmonary disease</span>. <i>Am. J. Respir. Crit. Care Med.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>191</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">1001</span>– <span class="NLM_lpage">1011</span>, <span class="refDoi"> DOI: 10.1164/rccm.201405-0992OC</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01854&amp;key=10.1164%2Frccm.201405-0992OC" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01854&amp;key=25695403" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01854&amp;key=1%3ACAS%3A528%3ADC%252BC2MXptlKmt7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=191&publication_year=2015&pages=1001-1011&issue=9&author=S.+I.+Rennardauthor=D.+C.+Daleauthor=J.+F.+Donohueauthor=F.+Kanniessauthor=H.+Magnussenauthor=E.+R.+Sutherlandauthor=H.+Watzauthor=S.+Luauthor=P.+Stryszakauthor=E.+Rosenbergauthor=H.+Staudinger&title=CXCR2+antagonist+MK-7123%3A+a+phase+2+proof-of-concept+trial+for+chronic+obstructive+pulmonary+disease&doi=10.1164%2Frccm.201405-0992OC"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">CXCR2 antagonist MK-7123: a phase 2 proof-of-concept trial for chronic obstructive pulmonary disease</span></div><div class="casAuthors">Rennard, Stephen I.; Dale, David C.; Donohue, James F.; Kanniess, Frank; Magnussen, Helgo; Sutherland, E. Rand; Watz, Henrik; Lu, Susan; Stryszak, Paul; Rosenberg, Elizabeth; Staudinger, Heribert</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Respiratory and Critical Care Medicine</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">191</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1001-1011</span>CODEN:
                <span class="NLM_cas:coden">AJCMED</span>;
        ISSN:<span class="NLM_cas:issn">1073-449X</span>.
    
            (<span class="NLM_cas:orgname">American Thoracic Society</span>)
        </div><div class="casAbstract">Rationale: An antagonist (MK-7123) of the cytokine receptor CXCR2 reduces neutrophil chemotaxis and thus may alleviate airway inflammation in chronic obstructive pulmonary disease (COPD).  Objectives: To assess the efficacy, safety, and tolerability of three dose levels of MK-7123, compared with placebo, in patients with moderate to severe COPD.  Methods: This 6-mo, double-blind study randomized patients with moderate to severe COPD (already on std. therapy) to daily MK-7123 at 10, 30, or 50 mg or placebo.  The primary endpoint was change from baseline in post-bronchodilator FEV1.  Measurements and Main Results: A total of 616 patients (71% male; mean age, 63 yr; 45% current smokers; baseline FEV1 [SD], 1.43 L [0.45]; mean FEV1 percent predicted, 43.9%) were randomized.  Only MK-7123 50 mg led to significant improvement in FEV1 over placebo (mean difference [SE], 67 mL [32]).  Reduced sputum neutrophil count was obsd. among the 122 patients examd.; P = 0.003 (3 mo) and P = 0.092 (6 mo) (MK-7123 50 mg vs. placebo).  The stratum of current smokers, but not that of nonsmokers, showed significant improvement vs. placebo in FEV1 (168 mL) and time-to-first exacerbation, and showed numerical improvement in St.  George's Respiratory Questionnaire for COPD score.  MK-7123 caused a dose-dependent decrease in abs. neutrophil count (ANC) and reduced inflammatory biomarkers matrix metallopeptidase-9 and myeloperoxidase in plasma and sputum; ANC lower than 1.5 × 109/L led to discontinuations with higher doses of MK-7123 (18% in the MK-7123 50-mg group vs. 1% in placebo).  Plasma C-reactive protein and fibrinogen increased with MK-7123 treatment.  Rates of infections at 6 mo were similar in all groups.  Conclusions: Treatment with MK-7123 50 mg vs. placebo led to significant improvement in FEV1 in patients with COPD, suggesting clin. important antiinflammatory effects with CXCR2 antagonism, although dose-related discontinuations were obsd. because of ANC decreases with MK-7123.  Greater response was obsd. in smokers vs. ex-smokers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqoAKNB3Km0H7Vg90H21EOLACvtfcHk0liFOEw6OGAHaw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXptlKmt7k%253D&md5=ff8ee6fb8a25a5e158de81c1344079c5</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1164%2Frccm.201405-0992OC&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1164%252Frccm.201405-0992OC%26sid%3Dliteratum%253Aachs%26aulast%3DRennard%26aufirst%3DS.%2BI.%26aulast%3DDale%26aufirst%3DD.%2BC.%26aulast%3DDonohue%26aufirst%3DJ.%2BF.%26aulast%3DKanniess%26aufirst%3DF.%26aulast%3DMagnussen%26aufirst%3DH.%26aulast%3DSutherland%26aufirst%3DE.%2BR.%26aulast%3DWatz%26aufirst%3DH.%26aulast%3DLu%26aufirst%3DS.%26aulast%3DStryszak%26aufirst%3DP.%26aulast%3DRosenberg%26aufirst%3DE.%26aulast%3DStaudinger%26aufirst%3DH.%26atitle%3DCXCR2%2520antagonist%2520MK-7123%253A%2520a%2520phase%25202%2520proof-of-concept%2520trial%2520for%2520chronic%2520obstructive%2520pulmonary%2520disease%26jtitle%3DAm.%2520J.%2520Respir.%2520Crit.%2520Care%2520Med.%26date%3D2015%26volume%3D191%26issue%3D9%26spage%3D1001%26epage%3D1011%26doi%3D10.1164%2Frccm.201405-0992OC" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ning, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Labonte, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bohanes, P. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gerger, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benhaim, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paez, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosenberg, D. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagulapalli Venkata, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Louie, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petasis, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ladner, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lenz, H.-J.</span></span> <span> </span><span class="NLM_article-title">The CXCR2 antagonist, SCH-527123, shows antitumor activity and sensitizes cells to oxaliplatin in preclinical colon cancer models</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>11</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">1353</span>– <span class="NLM_lpage">1364</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-11-0915</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01854&amp;key=10.1158%2F1535-7163.MCT-11-0915" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01854&amp;key=22391039" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01854&amp;key=1%3ACAS%3A528%3ADC%252BC38XotlCitr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2012&pages=1353-1364&issue=6&author=Y.+Ningauthor=M.+J.+Labonteauthor=W.+Zhangauthor=P.+O.+Bohanesauthor=A.+Gergerauthor=D.+Yangauthor=L.+Benhaimauthor=D.+Paezauthor=D.+O.+Rosenbergauthor=K.+C.+Nagulapalli+Venkataauthor=S.+G.+Louieauthor=N.+A.+Petasisauthor=R.+D.+Ladnerauthor=H.-J.+Lenz&title=The+CXCR2+antagonist%2C+SCH-527123%2C+shows+antitumor+activity+and+sensitizes+cells+to+oxaliplatin+in+preclinical+colon+cancer+models&doi=10.1158%2F1535-7163.MCT-11-0915"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">The CXCR2 Antagonist, SCH-527123, Shows Antitumor Activity and Sensitizes Cells to Oxaliplatin in Preclinical Colon Cancer Models</span></div><div class="casAuthors">Ning, Yan; Labonte, Melissa J.; Zhang, Wu; Bohanes, Pierre O.; Gerger, Armin; Yang, Dongyun; Benhaim, Leonor; Paez, David; Rosenberg, David O.; Nagulapalli Venkata, Kalyan C.; Louie, Stan G.; Petasis, Nicos A.; Ladner, Robert D.; Lenz, Heinz-Josef</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1353-1364</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Colorectal cancer is the second most common cause of cancer-related death in the United States.  Recent studies showed that interleukin-8 (IL-8) and its receptors (CXCR1 and CXCR2) are significantly upregulated in both the tumor and its microenvironment, and act as key regulators of proliferation, angiogenesis, and metastasis.  Our previous study showed that IL-8 overexpression in colorectal cancer cells triggers the upregulation of the CXCR2-mediated proliferative pathway.  The aim of this study was to investigate whether the CXCR2 antagonist, SCH-527123, inhibits colorectal cancer proliferation and if it can sensitize colorectal cancer cells to oxaliplatin both in vitro and in vivo.  SCH-527123 showed concn.-dependent antiproliferative effects in HCT116, Caco2, and their resp. IL-8-overexpressing variants colorectal cancer cell lines.  Moreover, SCH-527123 was able to suppress CXCR2-mediated signal transduction as shown through decreased phosphorylation of the NF-κB/mitogen-activated protein kinase (MAPK)/AKT pathway.  These findings corresponded with decreased cell migration and invasion, while increased apoptosis in colorectal cancer cell lines.  In vivo results verified that SCH-527123 treatment decreased tumor growth and microvessel d. when compared with vehicle-treated tumors.  Importantly, these preclin. studies showed that the combination of SCH-527123 and oxaliplatin resulted in a greater decrease in cell proliferation, tumor growth, apoptosis, and angiogenesis that was superior to single-agent treatment.  Taken together, these findings suggest that targeting CXCR2 may block tumor proliferation, migration, invasion, and angiogenesis.  In addn., CXCR2 blockade may further sensitize colorectal cancer to oxaliplatin treatment.  Mol Cancer Ther; 11(6); 1353-64. ©2012 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpAJ_al2gEJlrVg90H21EOLACvtfcHk0lgAFFDIQnkAIA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XotlCitr0%253D&md5=81a34537214fdbeabd53a5e8c443f83d</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-11-0915&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-11-0915%26sid%3Dliteratum%253Aachs%26aulast%3DNing%26aufirst%3DY.%26aulast%3DLabonte%26aufirst%3DM.%2BJ.%26aulast%3DZhang%26aufirst%3DW.%26aulast%3DBohanes%26aufirst%3DP.%2BO.%26aulast%3DGerger%26aufirst%3DA.%26aulast%3DYang%26aufirst%3DD.%26aulast%3DBenhaim%26aufirst%3DL.%26aulast%3DPaez%26aufirst%3DD.%26aulast%3DRosenberg%26aufirst%3DD.%2BO.%26aulast%3DNagulapalli%2BVenkata%26aufirst%3DK.%2BC.%26aulast%3DLouie%26aufirst%3DS.%2BG.%26aulast%3DPetasis%26aufirst%3DN.%2BA.%26aulast%3DLadner%26aufirst%3DR.%2BD.%26aulast%3DLenz%26aufirst%3DH.-J.%26atitle%3DThe%2520CXCR2%2520antagonist%252C%2520SCH-527123%252C%2520shows%2520antitumor%2520activity%2520and%2520sensitizes%2520cells%2520to%2520oxaliplatin%2520in%2520preclinical%2520colon%2520cancer%2520models%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2012%26volume%3D11%26issue%3D6%26spage%3D1353%26epage%3D1364%26doi%3D10.1158%2F1535-7163.MCT-11-0915" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Porter, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bradley, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Charlton, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cox, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hunt, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janus, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewis, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oakley, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Connor, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reilly, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Press, N. J.</span></span> <span> </span><span class="NLM_article-title">The discovery of potent, orally bioavailable pyrimidine-5-carbonitrile-6-alkyl CXCR2 receptor antagonists</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>24</i></span> (<span class="NLM_issue">15</span>),  <span class="NLM_fpage">3285</span>– <span class="NLM_lpage">3290</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2014.06.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01854&amp;key=10.1016%2Fj.bmcl.2014.06.011" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2014&pages=3285-3290&issue=15&author=D.+W.+Porterauthor=M.+Bradleyauthor=Z.+Brownauthor=S.+J.+Charltonauthor=B.+Coxauthor=P.+Huntauthor=D.+Janusauthor=S.+Lewisauthor=P.+Oakleyauthor=D.+O%E2%80%99Connorauthor=J.+Reillyauthor=N.+Smithauthor=N.+J.+Press&title=The+discovery+of+potent%2C+orally+bioavailable+pyrimidine-5-carbonitrile-6-alkyl+CXCR2+receptor+antagonists&doi=10.1016%2Fj.bmcl.2014.06.011"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2014.06.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2014.06.011%26sid%3Dliteratum%253Aachs%26aulast%3DPorter%26aufirst%3DD.%2BW.%26aulast%3DBradley%26aufirst%3DM.%26aulast%3DBrown%26aufirst%3DZ.%26aulast%3DCharlton%26aufirst%3DS.%2BJ.%26aulast%3DCox%26aufirst%3DB.%26aulast%3DHunt%26aufirst%3DP.%26aulast%3DJanus%26aufirst%3DD.%26aulast%3DLewis%26aufirst%3DS.%26aulast%3DOakley%26aufirst%3DP.%26aulast%3DO%25E2%2580%2599Connor%26aufirst%3DD.%26aulast%3DReilly%26aufirst%3DJ.%26aulast%3DSmith%26aufirst%3DN.%26aulast%3DPress%26aufirst%3DN.%2BJ.%26atitle%3DThe%2520discovery%2520of%2520potent%252C%2520orally%2520bioavailable%2520pyrimidine-5-carbonitrile-6-alkyl%2520CXCR2%2520receptor%2520antagonists%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2014%26volume%3D24%26issue%3D15%26spage%3D3285%26epage%3D3290%26doi%3D10.1016%2Fj.bmcl.2014.06.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carson, K. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trivedi, B. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yue, W. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ye, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glynn, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Connor, D. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roth, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luly, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Low, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heilig, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hunt, S.</span></span> <span> </span><span class="NLM_article-title">Synthesis and structure-activity relationship of 2-amino-3-heteroaryl-quinoxalines as non-peptide, small-molecule antagonists for interleukin-8 receptor</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>11</i></span> (<span class="NLM_issue">17</span>),  <span class="NLM_fpage">3777</span>– <span class="NLM_lpage">3790</span>, <span class="refDoi"> DOI: 10.1016/S0968-0896(03)00399-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01854&amp;key=10.1016%2FS0968-0896%2803%2900399-7" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2003&pages=3777-3790&issue=17&author=J.+J.+Liauthor=K.+G.+Carsonauthor=B.+K.+Trivediauthor=W.+S.+Yueauthor=Q.+Yeauthor=R.+A.+Glynnauthor=S.+R.+Millerauthor=D.+T.+Connorauthor=B.+D.+Rothauthor=J.+R.+Lulyauthor=J.+E.+Lowauthor=D.+J.+Heiligauthor=W.+Yangauthor=S.+Qinauthor=S.+Hunt&title=Synthesis+and+structure-activity+relationship+of+2-amino-3-heteroaryl-quinoxalines+as+non-peptide%2C+small-molecule+antagonists+for+interleukin-8+receptor&doi=10.1016%2FS0968-0896%2803%2900399-7"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1016%2FS0968-0896%2803%2900399-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0968-0896%252803%252900399-7%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DJ.%2BJ.%26aulast%3DCarson%26aufirst%3DK.%2BG.%26aulast%3DTrivedi%26aufirst%3DB.%2BK.%26aulast%3DYue%26aufirst%3DW.%2BS.%26aulast%3DYe%26aufirst%3DQ.%26aulast%3DGlynn%26aufirst%3DR.%2BA.%26aulast%3DMiller%26aufirst%3DS.%2BR.%26aulast%3DConnor%26aufirst%3DD.%2BT.%26aulast%3DRoth%26aufirst%3DB.%2BD.%26aulast%3DLuly%26aufirst%3DJ.%2BR.%26aulast%3DLow%26aufirst%3DJ.%2BE.%26aulast%3DHeilig%26aufirst%3DD.%2BJ.%26aulast%3DYang%26aufirst%3DW.%26aulast%3DQin%26aufirst%3DS.%26aulast%3DHunt%26aufirst%3DS.%26atitle%3DSynthesis%2520and%2520structure-activity%2520relationship%2520of%25202-amino-3-heteroaryl-quinoxalines%2520as%2520non-peptide%252C%2520small-molecule%2520antagonists%2520for%2520interleukin-8%2520receptor%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2003%26volume%3D11%26issue%3D17%26spage%3D3777%26epage%3D3790%26doi%3D10.1016%2FS0968-0896%2803%2900399-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schuler, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Engles, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maeda, D. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quinn, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirpotina, L. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wicomb, W. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mason, S. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Auten, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zebala, J. A.</span></span> <span> </span><span class="NLM_article-title">Boronic acid-containing aminopyridine- and aminopyrimidinecarboxamide CXCR1/2 antagonists: Optimization of aqueous solubility and oral bioavailability</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>25</i></span> (<span class="NLM_issue">18</span>),  <span class="NLM_fpage">3793</span>– <span class="NLM_lpage">3797</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2015.07.090</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01854&amp;key=10.1016%2Fj.bmcl.2015.07.090" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2015&pages=3793-3797&issue=18&author=A.+D.+Schulerauthor=C.+A.+Englesauthor=D.+Y.+Maedaauthor=M.+T.+Quinnauthor=L.+N.+Kirpotinaauthor=W.+N.+Wicombauthor=S.+N.+Masonauthor=R.+L.+Autenauthor=J.+A.+Zebala&title=Boronic+acid-containing+aminopyridine-+and+aminopyrimidinecarboxamide+CXCR1%2F2+antagonists%3A+Optimization+of+aqueous+solubility+and+oral+bioavailability&doi=10.1016%2Fj.bmcl.2015.07.090"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2015.07.090&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2015.07.090%26sid%3Dliteratum%253Aachs%26aulast%3DSchuler%26aufirst%3DA.%2BD.%26aulast%3DEngles%26aufirst%3DC.%2BA.%26aulast%3DMaeda%26aufirst%3DD.%2BY.%26aulast%3DQuinn%26aufirst%3DM.%2BT.%26aulast%3DKirpotina%26aufirst%3DL.%2BN.%26aulast%3DWicomb%26aufirst%3DW.%2BN.%26aulast%3DMason%26aufirst%3DS.%2BN.%26aulast%3DAuten%26aufirst%3DR.%2BL.%26aulast%3DZebala%26aufirst%3DJ.%2BA.%26atitle%3DBoronic%2520acid-containing%2520aminopyridine-%2520and%2520aminopyrimidinecarboxamide%2520CXCR1%252F2%2520antagonists%253A%2520Optimization%2520of%2520aqueous%2520solubility%2520and%2520oral%2520bioavailability%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2015%26volume%3D25%26issue%3D18%26spage%3D3793%26epage%3D3797%26doi%3D10.1016%2Fj.bmcl.2015.07.090" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Traves, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">barnes, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Donnelly, L. E.</span></span> <span> </span><span class="NLM_article-title">Specific CXC but not CC chemokines cause elevated monocyte migration in COPD: a role for CXCR2</span>. <i>J. Leukocyte Biol.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>76</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">441</span>– <span class="NLM_lpage">450</span>, <span class="refDoi"> DOI: 10.1189/jlb.1003495</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01854&amp;key=10.1189%2Fjlb.1003495" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01854&amp;key=15155777" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01854&amp;key=1%3ACAS%3A528%3ADC%252BD2cXmtlKrsLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=76&publication_year=2004&pages=441-450&issue=2&author=S.+L.+Travesauthor=S.+J.+Smithauthor=P.+J.+barnesauthor=L.+E.+Donnelly&title=Specific+CXC+but+not+CC+chemokines+cause+elevated+monocyte+migration+in+COPD%3A+a+role+for+CXCR2&doi=10.1189%2Fjlb.1003495"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25aR"><div class="casContent"><span class="casTitleNuber">25a</span><div class="casTitle"><span class="NLM_cas:atitle">Specific CXC but not CC chemokines cause elevated monocyte migration in COPD: A role for CXCR2</span></div><div class="casAuthors">Traves, Suzanne L.; Smith, Susan J.; Barnes, Peter J.; Donnelly, Louise E.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Leukocyte Biology</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">76</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">441-450</span>CODEN:
                <span class="NLM_cas:coden">JLBIE7</span>;
        ISSN:<span class="NLM_cas:issn">0741-5400</span>.
    
            (<span class="NLM_cas:orgname">Federation of American Societies for Experimental Biology</span>)
        </div><div class="casAbstract">Leukocyte migration is crit. to maintaining host defense, but uncontrolled cellular infiltration into tissues can lead to chronic inflammation.  In the lung, such diseases include chronic obstructive pulmonary disease (COPD), a debilitating, respiratory condition characterized by progressive and largely irreversible airflow limitation for which cigarette smoking is the major risk factor.  COPD is assocd. with an increased inflammatory cell influx including increased macrophage nos. in the airways and tissue.  Alveolar macrophages develop from immigrating blood monocytes and have the capacity to cause the pathol. changes assocd. with COPD.  This study addressed the hypothesis that increased macrophage nos. in COPD are a result of increased recruitment of monocytes from the circulation.  Chemotaxis assays of peripheral blood mononuclear cells (PBMC)/monocytes from nonsmokers, smokers, and COPD patients demonstrated increased chemotactic responses for cells from COPD patients when compared with controls toward growth-related oncogene (GRO)α and neutrophil-activating peptide (NAP)-2 but not toward monocyte chemoattractant protein, interleukin-8, or epithelial-derived NAP(ENA)-78.  The enhanced chemotactic response toward GROα and NAP-2 was not mediated by differences in expression of their cellular receptors, CXCR1 or CXCR2.  Receptor expression studies using flow cytometry indicated that in COPD, monocyte expression of CXCR2 is regulated differently from nonsmokers and smokers, which may account for the enhanced migration toward GROα and NAP-2.  The results highlight the potential of CXCR2 antagonists as therapy for COPD and demonstrate that an enhanced PBMC/monocyte response to specific CXC chemokines in these patients may contribute to increased recruitment and activation of macrophages in the lungs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr99e2ZPsnEhrVg90H21EOLACvtfcHk0lgRQkKm1Q3wFw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXmtlKrsLY%253D&md5=96ff850e7ae1ffaa342c196b785380ac</span></div><a href="/servlet/linkout?suffix=cit25a&amp;dbid=16384&amp;doi=10.1189%2Fjlb.1003495&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1189%252Fjlb.1003495%26sid%3Dliteratum%253Aachs%26aulast%3DTraves%26aufirst%3DS.%2BL.%26aulast%3DSmith%26aufirst%3DS.%2BJ.%26aulast%3Dbarnes%26aufirst%3DP.%2BJ.%26aulast%3DDonnelly%26aufirst%3DL.%2BE.%26atitle%3DSpecific%2520CXC%2520but%2520not%2520CC%2520chemokines%2520cause%2520elevated%2520monocyte%2520migration%2520in%2520COPD%253A%2520a%2520role%2520for%2520CXCR2%26jtitle%3DJ.%2520Leukocyte%2520Biol.%26date%3D2004%26volume%3D76%26issue%3D2%26spage%3D441%26epage%3D450%26doi%3D10.1189%2Fjlb.1003495" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit25b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Ryu, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cho, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choi, H. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jantaratnotai, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McLarnon, J. G.</span></span> <span> </span><span class="NLM_article-title">Pharmacological antagonism of interleukin-8 receptor CXCR2 inhibits inflammatory reactivity and is neuroprotective in an animal of Alzeimer’s disease</span>. <i>J. Neuroinflammation</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">144</span>, <span class="refDoi"> DOI: 10.1186/s12974-015-0339-z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01854&amp;key=10.1186%2Fs12974-015-0339-z" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01854&amp;key=26255110" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01854&amp;key=1%3ACAS%3A280%3ADC%252BC287htlGqsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2015&pages=144&author=J.+K.+Ryuauthor=T.+Choauthor=H.+B.+Choiauthor=N.+Jantaratnotaiauthor=J.+G.+McLarnon&title=Pharmacological+antagonism+of+interleukin-8+receptor+CXCR2+inhibits+inflammatory+reactivity+and+is+neuroprotective+in+an+animal+of+Alzeimer%E2%80%99s+disease&doi=10.1186%2Fs12974-015-0339-z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25bR"><div class="casContent"><span class="casTitleNuber">25b</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacological antagonism of interleukin-8 receptor CXCR2 inhibits inflammatory reactivity and is neuroprotective in an animal model of Alzheimer's disease</span></div><div class="casAuthors">Ryu Jae K; McLarnon James G; Cho T; Choi Hyun B; Jantaratnotai N</div><div class="citationInfo"><span class="NLM_cas:title">Journal of neuroinflammation</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">144</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  The chemokine interleukin-8 (IL-8) and its receptor CXCR2 contribute to chemotactic responses in Alzheimer's disease (AD); however, properties of the ligand and receptor have not been characterized in animal models of disease.  The primary aim of our study was to examine effects of pharmacological antagonism of CXCR2 as a strategy to inhibit receptor-mediated inflammatory reactivity and enhance neuronal viability in animals receiving intrahippocampal injection of amyloid-beta (Aβ1-42).  METHODS:  In vivo studies used an animal model of Alzheimer's disease incorporating injection of full-length Aβ1-42 into rat hippocampus.  Immunohistochemical staining of rat brain was used to measure microgliosis, astrogliosis, neuronal viability, and oxidative stress.  Western blot and Reverse Transcription PCR (RT-PCR) were used to determine levels of CXCR2 in animal tissue with the latter also used to determine expression of pro-inflammatory mediators.  Immunostaining of human AD and non-demented (ND) tissue was also undertaken.  RESULTS:  We initially determined that in the human brain, AD relative to ND tissue exhibited marked increases in expression of CXCR2 with cell-specific receptor expression prominent in microglia.  In Aβ1-42-injected rat brain, CXCR2 and IL-8 showed time-dependent increases in expression, concomitant with enhanced gliosis, relative to controls phosphate-buffered saline (PBS) or reverse peptide Aβ42-1 injection.  Administration of the competitive CXCR2 antagonist SB332235 to peptide-injected rats significantly reduced expression of CXCR2 and microgliosis, with astrogliosis unchanged.  Double staining studies demonstrated localization of CXCR2 and microglial immunoreactivity nearby deposits of Aβ1-42 with SB332235 effective in inhibiting receptor expression and microgliosis.  The numbers of neurons in granule cell layer (GCL) were reduced in rats receiving Aβ1-42, compared with PBS, with administration of SB332235 to peptide-injected animals conferring neuroprotection.  Oxidative stress was indicated in the animal model since both 4-hydroxynonenal (4-HNE) and hydroethidine (HEt) were markedly elevated in Aβ1-42 vs.  PBS-injected rat brain and diminished with SB332235 treatment.  CONCLUSION:  Overall, the findings suggest critical roles for CXCR2-dependent inflammatory responses in an AD animal model with pharmacological modulation of the receptor effective in inhibiting inflammatory reactivity and conferring neuroprotection against oxidative damage.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTlVb_4YHQbkJHZzFRCXxVKfW6udTcc2eZcqE6DAEwuzLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC287htlGqsA%253D%253D&md5=a4a56be1719e802cc9dd8e746aef4183</span></div><a href="/servlet/linkout?suffix=cit25b&amp;dbid=16384&amp;doi=10.1186%2Fs12974-015-0339-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs12974-015-0339-z%26sid%3Dliteratum%253Aachs%26aulast%3DRyu%26aufirst%3DJ.%2BK.%26aulast%3DCho%26aufirst%3DT.%26aulast%3DChoi%26aufirst%3DH.%2BB.%26aulast%3DJantaratnotai%26aufirst%3DN.%26aulast%3DMcLarnon%26aufirst%3DJ.%2BG.%26atitle%3DPharmacological%2520antagonism%2520of%2520interleukin-8%2520receptor%2520CXCR2%2520inhibits%2520inflammatory%2520reactivity%2520and%2520is%2520neuroprotective%2520in%2520an%2520animal%2520of%2520Alzeimer%25E2%2580%2599s%2520disease%26jtitle%3DJ.%2520Neuroinflammation%26date%3D2015%26volume%3D12%26spage%3D144%26doi%3D10.1186%2Fs12974-015-0339-z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit25c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Busch-Petersen, J.</span></span> <span> </span><span class="NLM_article-title">Small molecule antagonists of the CXCR2 and CXCR1 chemokine receptors as therapeutic agents for the treatment of inflammatory diseases</span>. <i>Curr. Top. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">1345</span>– <span class="NLM_lpage">1352</span>, <span class="refDoi"> DOI: 10.2174/15680266106061345</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01854&amp;key=10.2174%2F15680266106061345" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01854&amp;key=16918453" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01854&amp;key=1%3ACAS%3A528%3ADC%252BD28Xps1Sltr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2006&pages=1345-1352&author=J.+Busch-Petersen&title=Small+molecule+antagonists+of+the+CXCR2+and+CXCR1+chemokine+receptors+as+therapeutic+agents+for+the+treatment+of+inflammatory+diseases&doi=10.2174%2F15680266106061345"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25cR"><div class="casContent"><span class="casTitleNuber">25c</span><div class="casTitle"><span class="NLM_cas:atitle">Small molecule antagonists of the CXCR2 and CXCR1 chemokine receptors as therapeutic agents for the treatment of inflammatory diseases</span></div><div class="casAuthors">Busch-Petersen, Jakob</div><div class="citationInfo"><span class="NLM_cas:title">Current Topics in Medicinal Chemistry (Sharjah, United Arab Emirates)</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">1345-1352</span>CODEN:
                <span class="NLM_cas:coden">CTMCCL</span>;
        ISSN:<span class="NLM_cas:issn">1568-0266</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  In the past eight years, numerous series of small mol. CXCR2 and CXCR1 antagonists have been disclosed.  These compds. have proved to be effective inhibitors of ELR+ chemokine-induced chemotaxis of neutrophils and other immune cells in vitro and have also been efficacious in several animal models of inflammatory disease.  Although some of these compds. have been reported to be in clin. development, no data on clin. studies in patients with inflammatory disease has been revealed to date.  This review details the medicinal chem. and pharmacol. of the aforementioned antagonist series.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqCATg8ZJMoxLVg90H21EOLACvtfcHk0lhvcN3HftdleQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xps1Sltr0%253D&md5=0054b0053f9a9a45adeac60677960085</span></div><a href="/servlet/linkout?suffix=cit25c&amp;dbid=16384&amp;doi=10.2174%2F15680266106061345&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F15680266106061345%26sid%3Dliteratum%253Aachs%26aulast%3DBusch-Petersen%26aufirst%3DJ.%26atitle%3DSmall%2520molecule%2520antagonists%2520of%2520the%2520CXCR2%2520and%2520CXCR1%2520chemokine%2520receptors%2520as%2520therapeutic%2520agents%2520for%2520the%2520treatment%2520of%2520inflammatory%2520diseases%26jtitle%3DCurr.%2520Top.%2520Med.%2520Chem.%26date%3D2006%26volume%3D6%26spage%3D1345%26epage%3D1352%26doi%3D10.2174%2F15680266106061345" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lazaar, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sweeney, L. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">MacDonald, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alexis, N. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tal-Singer, R.</span></span> <span> </span><span class="NLM_article-title">SB-656933, a novel CXCR2 selective antagonist, inhibits ex vivo neutrophil activation and ozone-induced airway inflammation in humans</span>. <i>Br. J. Clin. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>72</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">282</span>– <span class="NLM_lpage">293</span>, <span class="refDoi"> DOI: 10.1111/j.1365-2125.2011.03968.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01854&amp;key=10.1111%2Fj.1365-2125.2011.03968.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01854&amp;key=21426372" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01854&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtV2qtrvO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=72&publication_year=2011&pages=282-293&issue=2&author=A.+L.+Lazaarauthor=L.+E.+Sweeneyauthor=A.+J.+MacDonaldauthor=N.+E.+Alexisauthor=C.+Chenauthor=R.+Tal-Singer&title=SB-656933%2C+a+novel+CXCR2+selective+antagonist%2C+inhibits+ex+vivo+neutrophil+activation+and+ozone-induced+airway+inflammation+in+humans&doi=10.1111%2Fj.1365-2125.2011.03968.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">SB-656933, a novel CXCR2 selective antagonist, inhibits ex vivo neutrophil activation and ozone-induced airway inflammation in humans</span></div><div class="casAuthors">Lazaar, Aili L.; Sweeney, Lisa E.; MacDonald, Alexander J.; Alexis, Neil E.; Chen, Chao; Tal-Singer, Ruth</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Clinical Pharmacology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">72</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">282-293</span>CODEN:
                <span class="NLM_cas:coden">BCPHBM</span>;
        ISSN:<span class="NLM_cas:issn">0306-5251</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">AIMS To det. the safety and tolerability of a novel selective CXCR2 antagonist and assess its pharmacodynamic effects using measures of neutrophil activation and function, including CD11b expression in whole blood and ozone-induced airway inflammation in healthy subjects.  METHODS Flow cytometric detn. of ex vivo CXCL1-induced CD11b expression on peripheral blood neutrophils was performed following single dose oral administration of SB-656933 (dose range 2-1100 mg).  A subsequent randomized study (placebo, 50 mg and 150 mg) was performed to explore the dose-response for ozone-induced airway inflammation, as measured by sputum biomarkers.  RESULTS Oral administration of SB-656933 resulted in significant inhibition of CXCL1-induced CD11b expression on peripheral blood neutrophils at single doses greater than or equal to 50 mg.  Maximum inhibition (70%) relative to placebo was obsd. following administration of SB-656933 400 mg (95% CI 60%, 77%).  This was sustained up to a dose of 1100 mg.  Single doses of SB-656933 reduced ozone-induced airway inflammation in a dose-dependent manner.  Relative to placebo, there were 55% (95% CI 20%, 75%) and 74% (95% CI 55%, 85%) fewer neutrophils in the sputum of subjects after a single dose of 50 mg or 150 mg, resp.  There was a corresponding redn. in myeloperoxidase concns. in the sputum supernatant of 32.8% (95% CI 9.2, 50.3) and 50.5% (95% CI 33.3, 63.3).  SB-656933 was safe and well-tolerated at all doses.  CONCLUSIONS SB-656933 is a CXCR2 antagonist that demonstrates dose-dependent effects on neutrophil activation and recruitment within a well-tolerated dose range.  These data suggest that SB-656933 may be an effective agent in neutrophil-predominant diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqj4fRS8HijE7Vg90H21EOLACvtfcHk0lhvcN3HftdleQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtV2qtrvO&md5=cd2f3253ca0b12435a59634ecb63ceea</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1111%2Fj.1365-2125.2011.03968.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1365-2125.2011.03968.x%26sid%3Dliteratum%253Aachs%26aulast%3DLazaar%26aufirst%3DA.%2BL.%26aulast%3DSweeney%26aufirst%3DL.%2BE.%26aulast%3DMacDonald%26aufirst%3DA.%2BJ.%26aulast%3DAlexis%26aufirst%3DN.%2BE.%26aulast%3DChen%26aufirst%3DC.%26aulast%3DTal-Singer%26aufirst%3DR.%26atitle%3DSB-656933%252C%2520a%2520novel%2520CXCR2%2520selective%2520antagonist%252C%2520inhibits%2520ex%2520vivo%2520neutrophil%2520activation%2520and%2520ozone-induced%2520airway%2520inflammation%2520in%2520humans%26jtitle%3DBr.%2520J.%2520Clin.%2520Pharmacol.%26date%3D2011%26volume%3D72%26issue%3D2%26spage%3D282%26epage%3D293%26doi%3D10.1111%2Fj.1365-2125.2011.03968.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, B. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mistry, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smart, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Connolly, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carpenter, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cooray, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bloomer, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tal-Singer, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lazaar, A. L.</span></span> <span> </span><span class="NLM_article-title">The pharmacokinetics and pharmacodynamics of danirixin (GSK1325756) - a selective CXCR2 antagonist - in healthy adult subjects</span>. <i>BMC Pharmacol. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">18</span>, <span class="refDoi"> DOI: 10.1186/s40360-015-0017-x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01854&amp;key=10.1186%2Fs40360-015-0017-x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01854&amp;key=26092545" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01854&amp;key=1%3ACAS%3A280%3ADC%252BC2MblslersQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2015&pages=18&author=B.+E.+Millerauthor=S.+Mistryauthor=K.+Smartauthor=P.+Connollyauthor=D.+C.+Carpenterauthor=H.+Coorayauthor=J.+C.+Bloomerauthor=R.+Tal-Singerauthor=A.+L.+Lazaar&title=The+pharmacokinetics+and+pharmacodynamics+of+danirixin+%28GSK1325756%29+-+a+selective+CXCR2+antagonist+-+in+healthy+adult+subjects&doi=10.1186%2Fs40360-015-0017-x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27aR"><div class="casContent"><span class="casTitleNuber">27a</span><div class="casTitle"><span class="NLM_cas:atitle">The pharmacokinetics and pharmacodynamics of danirixin (GSK1325756)--a selective CXCR2 antagonist --in healthy adult subjects</span></div><div class="casAuthors">Miller Bruce E; Tal-Singer Ruth; Mistry Sunil; Smart Kevin; Smart Kevin; Connolly Paul; Carpenter Donald C; Cooray Hiran; Cooray Hiran; Bloomer Jackie C; Lazaar Aili L</div><div class="citationInfo"><span class="NLM_cas:title">BMC pharmacology & toxicology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">18</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Excessive neutrophil presence and activation is important in a number of acute and chronic inflammatory diseases.  The CXCR2 chemokine receptor is important in controlling the extravasation and activation of neutrophils.  Selective antagonism of the CXCR2 receptor is a potential approach to reducing neutrophil migration and activation.  Danirixin, is a small molecule, CXCR2 antagonist being evaluated as a potential anti-inflammatory medicine.  METHODS:  (1) First time in human (FTIH) double-blind, placebo-controlled study to evaluate the safety, pharmacokinetics, and pharmacodynamics of single ascending and repeat oral doses of danirixin in healthy male subjects; (2) single-dose study of age, gender, food, and proton-pump inhibitor effects on the pharmacokinetics of danirixin in healthy adult subjects; and placebo-controlled study of the pharmacokinetics of danirixin in healthy elderly subjects.  RESULTS:  There were no serious adverse events and no adverse events considered to be of clinical relevance.  There were no withdrawals due to adverse events.  Systemic exposure following single doses of danirixin 10 mg, 25 mg, 50 mg, 100 mg, and 200 mg increased with increasing dose.  Engagement of pharmacology was demonstrated as inhibition of ex-vivo CXCL1-induced CD11b expression on peripheral blood neutrophils when compared to placebo (approximately 50% for 50 mg and 100 mg danirixin, and 72% at 200 mg).  There was a 37% decrease in Cmax and a 16% decrease in AUC (0-∞) following administration of danirixin in the presence of food.  Cmax also decreased by 65% when danirixin 100 mg was administered following omeprazole 40 mg once daily for 5 days.  The AUC (0-∞) and Cmax were 50% lower in elderly subjects compared with younger subjects.  CONCLUSION:  The dose-dependent inhibition of agonist-induced neutrophil activation following single and repeated once daily oral administration of danirixin suggests that this CXCR2 antagonist may have benefit in neutrophil-predominant inflammatory diseases.  Co-administration with food, gastric acid reducing agents, and variable exposure in the elderly have important clinical implications that need to be taken into consideration in subsequent clinical evaluations.  TRIAL REGISTRATION:  ClinicalTrials.gov identifiers: NCT01209052 and NCT01209104.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRAKy_l8uoE8MrRqEXsZufAfW6udTcc2eaDSmPCsOVcwrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2MblslersQ%253D%253D&md5=031af976bb431023281306bde2964584</span></div><a href="/servlet/linkout?suffix=cit27a&amp;dbid=16384&amp;doi=10.1186%2Fs40360-015-0017-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs40360-015-0017-x%26sid%3Dliteratum%253Aachs%26aulast%3DMiller%26aufirst%3DB.%2BE.%26aulast%3DMistry%26aufirst%3DS.%26aulast%3DSmart%26aufirst%3DK.%26aulast%3DConnolly%26aufirst%3DP.%26aulast%3DCarpenter%26aufirst%3DD.%2BC.%26aulast%3DCooray%26aufirst%3DH.%26aulast%3DBloomer%26aufirst%3DJ.%2BC.%26aulast%3DTal-Singer%26aufirst%3DR.%26aulast%3DLazaar%26aufirst%3DA.%2BL.%26atitle%3DThe%2520pharmacokinetics%2520and%2520pharmacodynamics%2520of%2520danirixin%2520%2528GSK1325756%2529%2520-%2520a%2520selective%2520CXCR2%2520antagonist%2520-%2520in%2520healthy%2520adult%2520subjects%26jtitle%3DBMC%2520Pharmacol.%2520Toxicol.%26date%3D2015%26volume%3D16%26spage%3D18%26doi%3D10.1186%2Fs40360-015-0017-x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit27b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Dwyer, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, Y.</span></span> <span> </span><span class="NLM_article-title">CXCR2 modulators: a patent review (2009 – 2013)</span>. <i>Expert Opin. Ther. Pat.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>24</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">519</span>– <span class="NLM_lpage">534</span>, <span class="refDoi"> DOI: 10.1517/13543776.2014.887682</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01854&amp;key=10.1517%2F13543776.2014.887682" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01854&amp;key=24555661" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01854&amp;key=1%3ACAS%3A528%3ADC%252BC2cXmt1Ghu70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2014&pages=519-534&issue=5&author=M.+P.+Dwyerauthor=Y.+Yu&title=CXCR2+modulators%3A+a+patent+review+%282009+%E2%80%93+2013%29&doi=10.1517%2F13543776.2014.887682"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27bR"><div class="casContent"><span class="casTitleNuber">27b</span><div class="casTitle"><span class="NLM_cas:atitle">CXCR2 modulators: a patent review (2009 - 2013)</span></div><div class="casAuthors">Dwyer, Michael P.; Yu, Younong</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Therapeutic Patents</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">519-534</span>CODEN:
                <span class="NLM_cas:coden">EOTPEG</span>;
        ISSN:<span class="NLM_cas:issn">1354-3776</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Introduction: Small-mol. antagonists of CXC chemokine receptor 2 (CXCR2) have attracted a considerable amt. of attention due to the key central role that this receptor plays in inflammatory conditions.  Recently, several CXCR2 receptor antagonists have demonstrated promising proof of activity in early pulmonary clin. trials, which has stimulated addnl. efforts to identify new CXCR2 receptor antagonists.  Areas covered: During the period 2009 - 2013, there were numerous patent publications from various companies claiming the discovery of novel CXCR2 receptor antagonists.  Herein, an interpretation of these new patent publications combined with emerging disclosures from the peer-reviewed literature during this time frame is given.  This review highlights the preferred or representative compds. from the patent applications along with relevant biol. characterization.  Expert opinion: Many of the new CXCR2 receptor antagonists described in this review represent closely related analogs to previously disclosed clin. candidates.  With the recent discontinuation of several CXCR2 receptor antagonists in the clinic, addnl. clin. trial information for CXCR2 receptor antagonists, both past and present, will det. the long-term therapeutic potential of these compds. for the treatment of a variety of inflammatory disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrrLzyTSdxdHbVg90H21EOLACvtfcHk0lgLsuGX4HpUFw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXmt1Ghu70%253D&md5=c1b5bd8730268cd12851722a3880a118</span></div><a href="/servlet/linkout?suffix=cit27b&amp;dbid=16384&amp;doi=10.1517%2F13543776.2014.887682&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F13543776.2014.887682%26sid%3Dliteratum%253Aachs%26aulast%3DDwyer%26aufirst%3DM.%2BP.%26aulast%3DYu%26aufirst%3DY.%26atitle%3DCXCR2%2520modulators%253A%2520a%2520patent%2520review%2520%25282009%2520%25E2%2580%2593%25202013%2529%26jtitle%3DExpert%2520Opin.%2520Ther.%2520Pat.%26date%3D2014%26volume%3D24%26issue%3D5%26spage%3D519%26epage%3D534%26doi%3D10.1517%2F13543776.2014.887682" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Ha, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Debnath, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neamati, N.</span></span> <span> </span><span class="NLM_article-title">Role of the CXCL8-CXCR1/2 axis in cancer and inflammatory diseases</span>. <i>Theranostics</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>7</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">1543</span>– <span class="NLM_lpage">1587</span>, <span class="refDoi"> DOI: 10.7150/thno.15625</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01854&amp;key=10.7150%2Fthno.15625" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2017&pages=1543-1587&issue=6&author=H.+Haauthor=B.+Debnathauthor=N.+Neamati&title=Role+of+the+CXCL8-CXCR1%2F2+axis+in+cancer+and+inflammatory+diseases&doi=10.7150%2Fthno.15625"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28a&amp;dbid=16384&amp;doi=10.7150%2Fthno.15625&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.7150%252Fthno.15625%26sid%3Dliteratum%253Aachs%26aulast%3DHa%26aufirst%3DH.%26aulast%3DDebnath%26aufirst%3DB.%26aulast%3DNeamati%26aufirst%3DN.%26atitle%3DRole%2520of%2520the%2520CXCL8-CXCR1%252F2%2520axis%2520in%2520cancer%2520and%2520inflammatory%2520diseases%26jtitle%3DTheranostics%26date%3D2017%26volume%3D7%26issue%3D6%26spage%3D1543%26epage%3D1587%26doi%3D10.7150%2Fthno.15625" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="note"><p class="first last">and references therein.</p></div><div class="NLM_citation" id="cit28b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Busch-Petersen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span> <span> </span><span class="NLM_article-title">Phenol-containing antagonists of the CXCR2 receptor</span>. <i>Expert Opin. Ther. Pat.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>18</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">629</span>– <span class="NLM_lpage">637</span>, <span class="refDoi"> DOI: 10.1517/13543776.18.6.629</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01854&amp;key=10.1517%2F13543776.18.6.629" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01854&amp;key=1%3ACAS%3A528%3ADC%252BD1cXmt1Okt78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2008&pages=629-637&issue=6&author=J.+Busch-Petersenauthor=Y.+Wang&title=Phenol-containing+antagonists+of+the+CXCR2+receptor&doi=10.1517%2F13543776.18.6.629"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28bR"><div class="casContent"><span class="casTitleNuber">28b</span><div class="casTitle"><span class="NLM_cas:atitle">Phenol-containing antagonists of the CXCR2 receptor</span></div><div class="casAuthors">Busch-Petersen, Jakob; Wang, Yonghui</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Therapeutic Patents</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">629-637</span>CODEN:
                <span class="NLM_cas:coden">EOTPEG</span>;
        ISSN:<span class="NLM_cas:issn">1354-3776</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Background: ELR+ chemokines interact with the CXCR2 receptor on neutrophils and other immune cells to induce chemotaxis.  This event plays a key role in a large no. of autoimmune diseases and thus antagonists of the CXCR2 receptor have garnered considerable interest in the pharmaceutical industry during the past decade and a half.  Objective: The objective of the article is to review recent developments in the patent literature related to the phenol-contg. antagonists.  Method: Although many other chemotypes have emerged since the first disclosure of phenol-contg. antagonists, this compd. class is by far the most successful, having yielded all but one of the clin. candidates reported so far, and thus the scope of this review is limited just this antagonist type.  Conclusion: During the past few years, phenol-contg. CXCR2 antagonists have evolved from promising leads to clin. candidates, and structural diversity within the class has been expanded.  Lead compds. have now entered patient studies and will be of great importance not just for this compd. class, but also for the therapeutic viability of CXCR2 antagonists in general.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqoVVFcZ1sbF7Vg90H21EOLACvtfcHk0lgLsuGX4HpUFw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXmt1Okt78%253D&md5=0f83eb8215ad9bf8ee2331b2a67edce5</span></div><a href="/servlet/linkout?suffix=cit28b&amp;dbid=16384&amp;doi=10.1517%2F13543776.18.6.629&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F13543776.18.6.629%26sid%3Dliteratum%253Aachs%26aulast%3DBusch-Petersen%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DY.%26atitle%3DPhenol-containing%2520antagonists%2520of%2520the%2520CXCR2%2520receptor%26jtitle%3DExpert%2520Opin.%2520Ther.%2520Pat.%26date%3D2008%26volume%3D18%26issue%3D6%26spage%3D629%26epage%3D637%26doi%3D10.1517%2F13543776.18.6.629" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luan, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gong, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Y.-G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cai, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiang, J.-N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elliott, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, X.</span></span> <span> </span><span class="NLM_article-title">Discovery of CNS penetrant CXCR2 antagonists for the potential treatment of CNS demyelinating disorders</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>7</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">397</span>– <span class="NLM_lpage">402</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.5b00489</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.5b00489" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=397-402&issue=4&author=H.+Xuauthor=H.+Luauthor=Z.+Xuauthor=L.+Luanauthor=C.+Liauthor=Y.+Xuauthor=K.+Dongauthor=J.+Zhangauthor=X.+Liauthor=Y.+Liauthor=G.+Liuauthor=S.+Gongauthor=Y.-G.+Zhaoauthor=A.+Liuauthor=Y.+Zhangauthor=W.+Zhangauthor=X.+Caiauthor=J.-N.+Xiangauthor=J.+D.+Elliottauthor=X.+Lin&title=Discovery+of+CNS+penetrant+CXCR2+antagonists+for+the+potential+treatment+of+CNS+demyelinating+disorders&doi=10.1021%2Facsmedchemlett.5b00489"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.5b00489&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.5b00489%26sid%3Dliteratum%253Aachs%26aulast%3DXu%26aufirst%3DH.%26aulast%3DLu%26aufirst%3DH.%26aulast%3DXu%26aufirst%3DZ.%26aulast%3DLuan%26aufirst%3DL.%26aulast%3DLi%26aufirst%3DC.%26aulast%3DXu%26aufirst%3DY.%26aulast%3DDong%26aufirst%3DK.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DG.%26aulast%3DGong%26aufirst%3DS.%26aulast%3DZhao%26aufirst%3DY.-G.%26aulast%3DLiu%26aufirst%3DA.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DW.%26aulast%3DCai%26aufirst%3DX.%26aulast%3DXiang%26aufirst%3DJ.-N.%26aulast%3DElliott%26aufirst%3DJ.%2BD.%26aulast%3DLin%26aufirst%3DX.%26atitle%3DDiscovery%2520of%2520CNS%2520penetrant%2520CXCR2%2520antagonists%2520for%2520the%2520potential%2520treatment%2520of%2520CNS%2520demyelinating%2520disorders%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2016%26volume%3D7%26issue%3D4%26spage%3D397%26epage%3D402%26doi%3D10.1021%2Facsmedchemlett.5b00489" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Young, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Green, D. V.S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luscombe, C. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hill, A. P.</span></span> <span> </span><span class="NLM_article-title">Getting physical in drug discovery II: the impact of chromatographic hydrophobicity measurements and aromaticity</span>. <i>Drug Discovery Today</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">822</span>– <span class="NLM_lpage">830</span>, <span class="refDoi"> DOI: 10.1016/j.drudis.2011.06.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01854&amp;key=10.1016%2Fj.drudis.2011.06.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01854&amp;key=21704184" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01854&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtFCru7vF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2011&pages=822-830&author=R.+J.+Youngauthor=D.+V.S.+Greenauthor=C.+N.+Luscombeauthor=A.+P.+Hill&title=Getting+physical+in+drug+discovery+II%3A+the+impact+of+chromatographic+hydrophobicity+measurements+and+aromaticity&doi=10.1016%2Fj.drudis.2011.06.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Getting physical in drug discovery II: the impact of chromatographic hydrophobicity measurements and aromaticity</span></div><div class="casAuthors">Young, Robert J.; Green, Darren V. S.; Luscombe, Christopher N.; Hill, Alan P.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">17/18</span>),
    <span class="NLM_cas:pages">822-830</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Here, we review the performance of chromatog. hydrophobicity measurements in a data set of 100 000 GlaxoSmithKline compds., demonstrating the advantages of the method over octanol-water partitioning and highlighting new insights for drug discovery.  The value of chromatog. measurements, vs. other hydrophobicity ests., was supported by improved relationships with soly., permeation, cytochrome P450s, intrinsic clearance, hERG binding and promiscuity.  We also obsd. marked differentiation of the relative influence of intrinsic and effective hydrophobicity.  The summing of hydrophobicity values plus arom. ring count [log D pH7.4 (or log P) + #Ar], indicated a wide relevance for simplistic property forecast indexes' in developability assays, clearly enhanced by chromatog. values; therefore establishing new foundations for enriching property-based drug design.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqmIJyWi-DBW7Vg90H21EOLACvtfcHk0liLTzfPy8R3Eg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtFCru7vF&md5=22788603a45aa77537e8666433473d14</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2011.06.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2011.06.001%26sid%3Dliteratum%253Aachs%26aulast%3DYoung%26aufirst%3DR.%2BJ.%26aulast%3DGreen%26aufirst%3DD.%2BV.S.%26aulast%3DLuscombe%26aufirst%3DC.%2BN.%26aulast%3DHill%26aufirst%3DA.%2BP.%26atitle%3DGetting%2520physical%2520in%2520drug%2520discovery%2520II%253A%2520the%2520impact%2520of%2520chromatographic%2520hydrophobicity%2520measurements%2520and%2520aromaticity%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2011%26volume%3D16%26spage%3D822%26epage%3D830%26doi%3D10.1016%2Fj.drudis.2011.06.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span>Unpublished result.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Unpublished+result."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dunpublished%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Busch-Petersen, J.</span></span> <span> </span><span class="NLM_article-title">IL-8 Receptor Antagonists</span>. <span class="NLM_patent">US20070249672A1</span>, Oct 25, <span class="NLM_year">2007</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2007&author=J.+Busch-Petersen&title=IL-8+Receptor+Antagonists"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DBusch-Petersen%26aufirst%3DJ.%26atitle%3DIL-8%2520Receptor%2520Antagonists%26date%3D2007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ito, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prasad, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">An, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Unadkat, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kusuhara, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sugiyama, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sahi, J.</span></span> <span> </span><span class="NLM_article-title">Solute carrier family of the organic anion-transporting polypeptides 1A2-Madin-Darby Canine Kidney II: a promising in vitro system to understand the role of organic anion-transporting polypeptide 1A2 in blood-brain barrier drug penetration</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>43</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">1008</span>– <span class="NLM_lpage">1018</span>, <span class="refDoi"> DOI: 10.1124/dmd.115.064170</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01854&amp;key=10.1124%2Fdmd.115.064170" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2015&pages=1008-1018&issue=7&author=H.+Liuauthor=N.+Yuauthor=S.+Luauthor=S.+Itoauthor=X.+Zhangauthor=B.+Prasadauthor=E.+Heauthor=X.+Luauthor=Y.+Liauthor=F.+Wangauthor=H.+Xuauthor=G.+Anauthor=J.+D.+Unadkatauthor=H.+Kusuharaauthor=Y.+Sugiyamaauthor=J.+Sahi&title=Solute+carrier+family+of+the+organic+anion-transporting+polypeptides+1A2-Madin-Darby+Canine+Kidney+II%3A+a+promising+in+vitro+system+to+understand+the+role+of+organic+anion-transporting+polypeptide+1A2+in+blood-brain+barrier+drug+penetration&doi=10.1124%2Fdmd.115.064170"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit33a&amp;dbid=16384&amp;doi=10.1124%2Fdmd.115.064170&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.115.064170%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DH.%26aulast%3DYu%26aufirst%3DN.%26aulast%3DLu%26aufirst%3DS.%26aulast%3DIto%26aufirst%3DS.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DPrasad%26aufirst%3DB.%26aulast%3DHe%26aufirst%3DE.%26aulast%3DLu%26aufirst%3DX.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DF.%26aulast%3DXu%26aufirst%3DH.%26aulast%3DAn%26aufirst%3DG.%26aulast%3DUnadkat%26aufirst%3DJ.%2BD.%26aulast%3DKusuhara%26aufirst%3DH.%26aulast%3DSugiyama%26aufirst%3DY.%26aulast%3DSahi%26aufirst%3DJ.%26atitle%3DSolute%2520carrier%2520family%2520of%2520the%2520organic%2520anion-transporting%2520polypeptides%25201A2-Madin-Darby%2520Canine%2520Kidney%2520II%253A%2520a%2520promising%2520in%2520vitro%2520system%2520to%2520understand%2520the%2520role%2520of%2520organic%2520anion-transporting%2520polypeptide%25201A2%2520in%2520blood-brain%2520barrier%2520drug%2520penetration%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2015%26volume%3D43%26issue%3D7%26spage%3D1008%26epage%3D1018%26doi%3D10.1124%2Fdmd.115.064170" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit33b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sahi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Summerfield, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, K.</span></span> <span> </span><span class="NLM_article-title">Correlation between membrane protein expression levels and transcellular transport activity for breast cancer resistance protein</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>45</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">449</span>– <span class="NLM_lpage">456</span>, <span class="refDoi"> DOI: 10.1124/dmd.116.074245</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01854&amp;key=10.1124%2Fdmd.116.074245" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2017&pages=449-456&issue=5&author=H.+Liuauthor=L.+Huangauthor=Y.+Liauthor=T.+Fuauthor=X.+Sunauthor=Y.+Y.+Zhangauthor=R.+Gaoauthor=Q.+Chenauthor=W.+Zhangauthor=J.+Sahiauthor=S.+Summerfieldauthor=K.+Dong&title=Correlation+between+membrane+protein+expression+levels+and+transcellular+transport+activity+for+breast+cancer+resistance+protein&doi=10.1124%2Fdmd.116.074245"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit33b&amp;dbid=16384&amp;doi=10.1124%2Fdmd.116.074245&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.116.074245%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DH.%26aulast%3DHuang%26aufirst%3DL.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DFu%26aufirst%3DT.%26aulast%3DSun%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DY.%2BY.%26aulast%3DGao%26aufirst%3DR.%26aulast%3DChen%26aufirst%3DQ.%26aulast%3DZhang%26aufirst%3DW.%26aulast%3DSahi%26aufirst%3DJ.%26aulast%3DSummerfield%26aufirst%3DS.%26aulast%3DDong%26aufirst%3DK.%26atitle%3DCorrelation%2520between%2520membrane%2520protein%2520expression%2520levels%2520and%2520transcellular%2520transport%2520activity%2520for%2520breast%2520cancer%2520resistance%2520protein%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2017%26volume%3D45%26issue%3D5%26spage%3D449%26epage%3D456%26doi%3D10.1124%2Fdmd.116.074245" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Clarysse, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brouwers, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tack, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Annaert, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Augustijns, P.</span></span> <span> </span><span class="NLM_article-title">Intestinal drug solubility estimation based on simulated intestinal fluids: comparison with solubility in human intestinal fluids</span>. <i>Eur. J. Pharm. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>43</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">260</span>– <span class="NLM_lpage">269</span>, <span class="refDoi"> DOI: 10.1016/j.ejps.2011.04.016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01854&amp;key=10.1016%2Fj.ejps.2011.04.016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01854&amp;key=21570465" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01854&amp;key=1%3ACAS%3A528%3ADC%252BC3MXotVejs7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2011&pages=260-269&issue=4&author=S.+Clarysseauthor=J.+Brouwersauthor=J.+Tackauthor=P.+Annaertauthor=P.+Augustijns&title=Intestinal+drug+solubility+estimation+based+on+simulated+intestinal+fluids%3A+comparison+with+solubility+in+human+intestinal+fluids&doi=10.1016%2Fj.ejps.2011.04.016"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Intestinal drug solubility estimation based on simulated intestinal fluids: Comparison with solubility in human intestinal fluids</span></div><div class="casAuthors">Clarysse, Sarah; Brouwers, Joachim; Tack, Jan; Annaert, Pieter; Augustijns, Patrick</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmaceutical Sciences</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">43</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">260-269</span>CODEN:
                <span class="NLM_cas:coden">EPSCED</span>;
        ISSN:<span class="NLM_cas:issn">0928-0987</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The purpose of this study was to validate both existing fasted and fed state simulated intestinal fluids (FaSSIF and FeSSIF), and simpler, alternative media for predicting intraluminal drug soly. during drug discovery and early drug development.  For 17 model drugs, the solubilizing capacity of FaSSIFc and FeSSIFc (subscript indicates the use of crude taurocholate) and different concns. of D-α-tocopheryl polyethylene glycol 1000 succinate (TPGS) in phosphate buffer were correlated with the solubilizing capacity of human intestinal fluids (HIF) in the fasted and the early postprandial state.  A good correlation between soly. in fasted HIF and FaSSIFc and between soly. in fed HIF and FeSSIFc was obtained, indicated by R 2 values of 0.91 and 0.86, resp.  Comparable values were obtained for 0.1% TPGS for the fasted state (R 2 = 0.84) and 2% TPGS for the fed state (R 2 = 0.84).  Direct estn. of intestinal drug soly. by the measured solubilities in FaSSIFc and FeSSIFc was acceptable.  However, better ests. were obtained by calcg. solubilities based on the equations describing the relationship between solubilities in FaSSIFc and FeSSIFc as function of obsd. solubilities in HIF.  Using this approach, the predictive value of the TPGS-based solvent system was also acceptable and comparable to that of FaSSIFc and FeSSIFc.  In conclusion, FaSSIFc and FeSSIFc can be considered biorelevant media for intestinal soly. estn.  A simpler TPGS-based system may be a valuable alternative with improved stability and lower cost.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGorRrkPlVCvR7Vg90H21EOLACvtfcHk0lg4956o7fZpZQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXotVejs7Y%253D&md5=dea97977f90d6859c47d6d8c41037d94</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1016%2Fj.ejps.2011.04.016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejps.2011.04.016%26sid%3Dliteratum%253Aachs%26aulast%3DClarysse%26aufirst%3DS.%26aulast%3DBrouwers%26aufirst%3DJ.%26aulast%3DTack%26aufirst%3DJ.%26aulast%3DAnnaert%26aufirst%3DP.%26aulast%3DAugustijns%26aufirst%3DP.%26atitle%3DIntestinal%2520drug%2520solubility%2520estimation%2520based%2520on%2520simulated%2520intestinal%2520fluids%253A%2520comparison%2520with%2520solubility%2520in%2520human%2520intestinal%2520fluids%26jtitle%3DEur.%2520J.%2520Pharm.%2520Sci.%26date%3D2011%26volume%3D43%26issue%3D4%26spage%3D260%26epage%3D269%26doi%3D10.1016%2Fj.ejps.2011.04.016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hammarlund-Udenaes, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fridén, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Syvänen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gupta, A.</span></span> <span> </span><span class="NLM_article-title">On the rate and extent of drug delivery to the brain</span>. <i>Pharm. Res.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>25</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">1737</span>– <span class="NLM_lpage">1750</span>, <span class="refDoi"> DOI: 10.1007/s11095-007-9502-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01854&amp;key=10.1007%2Fs11095-007-9502-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01854&amp;key=18058202" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01854&amp;key=1%3ACAS%3A528%3ADC%252BD1cXot1Whsb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2008&pages=1737-1750&issue=8&author=M.+Hammarlund-Udenaesauthor=M.+Frid%C3%A9nauthor=S.+Syv%C3%A4nenauthor=A.+Gupta&title=On+the+rate+and+extent+of+drug+delivery+to+the+brain&doi=10.1007%2Fs11095-007-9502-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">On The Rate and Extent of Drug Delivery to the Brain</span></div><div class="casAuthors">Hammarlund-Udenaes, Margareta; Friden, Markus; Syvaenen, Stina; Gupta, Anubha</div><div class="citationInfo"><span class="NLM_cas:title">Pharmaceutical Research</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1737-1750</span>CODEN:
                <span class="NLM_cas:coden">PHREEB</span>;
        ISSN:<span class="NLM_cas:issn">0724-8741</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">A review.  To define and differentiate relevant aspects of blood-brain barrier transport and distribution in order to aid research methodol. in brain drug delivery.  Pharmacokinetic parameters relative to the rate and extent of brain drug delivery are described and illustrated with relevant data, with special emphasis on the unbound, pharmacol. active drug mol.  Drug delivery to the brain can be comprehensively described using three parameters: K p,uu (concn. ratio of unbound drug in brain to blood), CLin (permeability clearance into the brain), and V u,brain (intra-brain distribution).  The permeability of the blood-brain barrier is less relevant to drug action within the CNS than the extent of drug delivery, as most drugs are administered on a continuous (repeated) basis.  K p,uu can differ between CNS-active drugs by a factor of up to 150-fold.  This range is much smaller than that for log BB ratios (K p), which can differ by up to at least 2000-fold, or for BBB permeabilities, which span an even larger range (up to at least 20,000-fold difference).  Methods that measure the three parameters K p,uu, CLin, and V u,brain can give clin. valuable ests. of brain drug delivery in early drug discovery programs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrkysWU99T_hbVg90H21EOLACvtfcHk0ljRF72IZPTLTA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXot1Whsb8%253D&md5=20f106a980c4949b78ead8c00cb5db41</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1007%2Fs11095-007-9502-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11095-007-9502-2%26sid%3Dliteratum%253Aachs%26aulast%3DHammarlund-Udenaes%26aufirst%3DM.%26aulast%3DFrid%25C3%25A9n%26aufirst%3DM.%26aulast%3DSyv%25C3%25A4nen%26aufirst%3DS.%26aulast%3DGupta%26aufirst%3DA.%26atitle%3DOn%2520the%2520rate%2520and%2520extent%2520of%2520drug%2520delivery%2520to%2520the%2520brain%26jtitle%3DPharm.%2520Res.%26date%3D2008%26volume%3D25%26issue%3D8%26spage%3D1737%26epage%3D1750%26doi%3D10.1007%2Fs11095-007-9502-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Sin, Y. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sedgwick, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chea, E. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Willoughby, D. A.</span></span> <span> </span><span class="NLM_article-title">Mast cells in newly formed lining tissue during acute inflammation: a six-day air pouch model in the mouse</span>. <i>Ann. Rheum. Dis.</i> <span class="NLM_year" style="font-weight: bold;">1986</span>,  <span class="NLM_volume"><i>45</i></span>,  <span class="NLM_fpage">873</span>– <span class="NLM_lpage">877</span>, <span class="refDoi"> DOI: 10.1136/ard.45.10.873</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01854&amp;key=10.1136%2Fard.45.10.873" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01854&amp;key=3789822" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01854&amp;key=1%3ACAS%3A280%3ADyaL2s%252FnsFSksQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=1986&pages=873-877&author=Y.+M.+Sinauthor=A.+D.+Sedgwickauthor=E.+P.+Cheaauthor=D.+A.+Willoughby&title=Mast+cells+in+newly+formed+lining+tissue+during+acute+inflammation%3A+a+six-day+air+pouch+model+in+the+mouse&doi=10.1136%2Fard.45.10.873"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit36aR"><div class="casContent"><span class="casTitleNuber">36a</span><div class="casTitle"><span class="NLM_cas:atitle">Mast cells in newly formed lining tissue during acute inflammation: a six day air pouch model in the mouse</span></div><div class="casAuthors">Sin Y M; Sedgwick A D; Chea E P; Willoughby D A</div><div class="citationInfo"><span class="NLM_cas:title">Annals of the rheumatic diseases</span>
        (<span class="NLM_cas:date">1986</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">873-7</span>
        ISSN:<span class="NLM_cas:issn">0003-4967</span>.
    </div><div class="casAbstract">Connective tissue mast cells were topographically and quantitatively studied in the newly formed lining tissue of six day old air pouches induced in the dorsal surface of mice.  The results showed that the number of mast cells in the cavities innermost lining increased after injection of carrageenan into the cavity.  Degranulation of mast cells was also observed.  Variations in mast cell numbers in the lining seemed to correlate with the histamine content.  These findings suggest that mast cells not only participate in the initiation of the early phase of acute inflammation but also appear to play an important part in regulating and prolonging more chronic inflammatory reactions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQzNq5BkzaFXYIRAdBLKY41fW6udTcc2eYAkF85HM6Ttrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaL2s%252FnsFSksQ%253D%253D&md5=02bad9998244afe20593f79bb73f94f1</span></div><a href="/servlet/linkout?suffix=cit36a&amp;dbid=16384&amp;doi=10.1136%2Fard.45.10.873&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1136%252Fard.45.10.873%26sid%3Dliteratum%253Aachs%26aulast%3DSin%26aufirst%3DY.%2BM.%26aulast%3DSedgwick%26aufirst%3DA.%2BD.%26aulast%3DChea%26aufirst%3DE.%2BP.%26aulast%3DWilloughby%26aufirst%3DD.%2BA.%26atitle%3DMast%2520cells%2520in%2520newly%2520formed%2520lining%2520tissue%2520during%2520acute%2520inflammation%253A%2520a%2520six-day%2520air%2520pouch%2520model%2520in%2520the%2520mouse%26jtitle%3DAnn.%2520Rheum.%2520Dis.%26date%3D1986%26volume%3D45%26spage%3D873%26epage%3D877%26doi%3D10.1136%2Fard.45.10.873" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit36b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Romano, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Faggioni, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sironi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sacco, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Echtenacher, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Santo, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salmona, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghezzi, P.</span></span> <span> </span><span class="NLM_article-title">Carrageenan-induced acute inflammation in the mouse air pouch synovial model. Role of tumor necrosis factor</span>. <i>Mediators Inflammation</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">32</span>– <span class="NLM_lpage">38</span>, <span class="refDoi"> DOI: 10.1080/09629359791901</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01854&amp;key=10.1080%2F09629359791901" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01854&amp;key=18472831" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01854&amp;key=1%3ACAS%3A528%3ADyaK2sXitFSnurk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=1997&pages=32-38&author=M.+Romanoauthor=R.+Faggioniauthor=M.+Sironiauthor=S.+Saccoauthor=B.+Echtenacherauthor=E.+Di+Santoauthor=M.+Salmonaauthor=P.+Ghezzi&title=Carrageenan-induced+acute+inflammation+in+the+mouse+air+pouch+synovial+model.+Role+of+tumor+necrosis+factor&doi=10.1080%2F09629359791901"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit36bR"><div class="casContent"><span class="casTitleNuber">36b</span><div class="casTitle"><span class="NLM_cas:atitle">Carrageenan-induced acute inflammation in the mouse air pouch synovial model. Role of tumor necrosis factor</span></div><div class="casAuthors">Romano, M.; Faggioni, R.; Sironi, M.; Sacco, S.; Echtenacher, B.; Di Santo, E.; Salmona, M.; Ghezzi, P.</div><div class="citationInfo"><span class="NLM_cas:title">Mediators of Inflammation</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">32-38</span>CODEN:
                <span class="NLM_cas:coden">MNFLEF</span>;
        ISSN:<span class="NLM_cas:issn">0962-9351</span>.
    
            (<span class="NLM_cas:orgname">Rapid Science Publishers</span>)
        </div><div class="casAbstract">The mouse air pouch model of inflammation was used to study the interaction between cytokines, prostaglandin E2 (PGE2) and cell migration during the various phases of acute local inflammation induced by carrageenan.  In serum, the levels of interleukin 1 (IL-1), interleukin 6 (IL-6), tumor necrosis factor (TNF), serum amyloid-A (SAA) and Fe++ were never different from controls, indicating that no systemic inflammatory changes were induced.  Locally the exudate vol. and the no. of leukocytes recruited into the pouch increased progressively until 7 days after carrageenan.  The same was true for PGE2 prodn.  The authors could not measure IL-1 but the prodn. of IL-6 and TNF reached a max. after 5-24 h then quickly decreased.  Anti-TNF antibodies inhibited cell migration by 50% 24 h after treatment.  Pretreatment with interleukin 10 (IL-10) inhibited TNF prodn. almost completely and cell migration by 60%.  Carrageenan-induced inflammation was modulated by anti-inflammatory drugs.  Pretreatment with dexamethasone (DEX) or indomethacin (INDO) inhibited cell migration and reduced the concn. of TNF in the exudate.  Prodn. of PGE2 or vascular permeability did not correlate with the no. of cells in the pouch.  Local TNF seems to play an important role in this model, particularly for leukocyte migration in the first phase of the inflammatory process.  In conclusion, the air pouch seems to be a good model for studying the regulation of the early events of local inflammation, particularly the role of cytokines and cell migration.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrHKWtVeBJh-rVg90H21EOLACvtfcHk0ljRF72IZPTLTA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXitFSnurk%253D&md5=2961e25118b643663940ff9ba7243e79</span></div><a href="/servlet/linkout?suffix=cit36b&amp;dbid=16384&amp;doi=10.1080%2F09629359791901&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F09629359791901%26sid%3Dliteratum%253Aachs%26aulast%3DRomano%26aufirst%3DM.%26aulast%3DFaggioni%26aufirst%3DR.%26aulast%3DSironi%26aufirst%3DM.%26aulast%3DSacco%26aufirst%3DS.%26aulast%3DEchtenacher%26aufirst%3DB.%26aulast%3DDi%2BSanto%26aufirst%3DE.%26aulast%3DSalmona%26aufirst%3DM.%26aulast%3DGhezzi%26aufirst%3DP.%26atitle%3DCarrageenan-induced%2520acute%2520inflammation%2520in%2520the%2520mouse%2520air%2520pouch%2520synovial%2520model.%2520Role%2520of%2520tumor%2520necrosis%2520factor%26jtitle%3DMediators%2520Inflammation%26date%3D1997%26volume%3D6%26spage%3D32%26epage%3D38%26doi%3D10.1080%2F09629359791901" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit36c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stevens, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brennan, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davies, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rowland, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Houston, J. B.</span></span> <span> </span><span class="NLM_article-title">The six-day-old rat air pouch model of inflammation: characterization of the inflammatory response to carrageenan</span>. <i>J. Pharmacol. Toxicol. Methods</i> <span class="NLM_year" style="font-weight: bold;">1994</span>,  <span class="NLM_volume"><i>32</i></span>,  <span class="NLM_fpage">139</span>– <span class="NLM_lpage">147</span>, <span class="refDoi"> DOI: 10.1016/1056-8719(94)90067-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01854&amp;key=10.1016%2F1056-8719%2894%2990067-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01854&amp;key=7858307" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01854&amp;key=1%3ACAS%3A528%3ADyaK2MXit1KgtL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=1994&pages=139-147&author=S.+W.+Martinauthor=A.+J.+Stevensauthor=B.+S.+Brennanauthor=D.+Daviesauthor=M.+Rowlandauthor=J.+B.+Houston&title=The+six-day-old+rat+air+pouch+model+of+inflammation%3A+characterization+of+the+inflammatory+response+to+carrageenan&doi=10.1016%2F1056-8719%2894%2990067-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit36cR"><div class="casContent"><span class="casTitleNuber">36c</span><div class="casTitle"><span class="NLM_cas:atitle">The six-day-old rat air pouch model of inflammation: characterization of the inflammatory response to carrageenan</span></div><div class="casAuthors">Martin, S. W.; Stevens, A. J.; Brennan, B. S.; Davies, D.; Rowland, M.; Houston, J. B.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacological and Toxicological Methods</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">139-47</span>CODEN:
                <span class="NLM_cas:coden">JPTMEZ</span>;
        ISSN:<span class="NLM_cas:issn">1056-8719</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Inflammation was induced in the 6-day-old rat air pouch by injection of carrageenan.  The model was characterized in terms of exudate vol., leukocyte influx, cell free protein, prostaglandin E2 levels, and granuloma formation.  The time course of all these inflammatory markers, except prostaglandin E2, showed a 3-h lag followed by a rapid increase to 8 h.  Thereafter, the rate of increase was much slower to 48 h.  Differential cell counts indicated a predominantly polymorphonuclear cell response (75%) during the first 48 h.  Prostaglandin E2 levels increased rapidly after a 3-h lag, to a max. of 440 ng/mL at 15 h and thereafter quickly declined to 140+60 ng/mL at 21 h.  Prostaglandin E2 levels were the most sensitive inflammatory marker to (S+)-ibuprofen and were reduced dose dependently in the range 0.05 to 1 mg/kg.  The authors have demonstrated the time course for duration of NSAID-induced redn. of prostaglandin E2 levels during inflammation in an individual animal.  Rac-ibuprofen (0.1-1 mg/kg) reduced leukocyte influx at 3 and 5 h, after which drug effects gradually diminished by 24 h.  Rac-ibuprofen at 1 mg/kg significantly reduced the vol. of air pouch exudate recovered at 24 h but had no effect on protein levels.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrf91INg9ULjbVg90H21EOLACvtfcHk0lje-cvW-oGxSA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXit1KgtL8%253D&md5=e5d37f9b9d7cc1227e76bc67d17c601b</span></div><a href="/servlet/linkout?suffix=cit36c&amp;dbid=16384&amp;doi=10.1016%2F1056-8719%2894%2990067-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F1056-8719%252894%252990067-1%26sid%3Dliteratum%253Aachs%26aulast%3DMartin%26aufirst%3DS.%2BW.%26aulast%3DStevens%26aufirst%3DA.%2BJ.%26aulast%3DBrennan%26aufirst%3DB.%2BS.%26aulast%3DDavies%26aufirst%3DD.%26aulast%3DRowland%26aufirst%3DM.%26aulast%3DHouston%26aufirst%3DJ.%2BB.%26atitle%3DThe%2520six-day-old%2520rat%2520air%2520pouch%2520model%2520of%2520inflammation%253A%2520characterization%2520of%2520the%2520inflammatory%2520response%2520to%2520carrageenan%26jtitle%3DJ.%2520Pharmacol.%2520Toxicol.%2520Methods%26date%3D1994%26volume%3D32%26spage%3D139%26epage%3D147%26doi%3D10.1016%2F1056-8719%2894%2990067-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit36d"><span><span class="NLM_label">(d) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Hambelton, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, P.</span></span> <span> </span><span class="NLM_article-title">Studies on carrageenan air pouch inflammation in the rat</span>. <i>Br. J. Exp. Pathol.</i> <span class="NLM_year" style="font-weight: bold;">1989</span>,  <span class="NLM_volume"><i>70</i></span>,  <span class="NLM_fpage">425</span>– <span class="NLM_lpage">433</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=70&publication_year=1989&pages=425-433&author=P.+Hambeltonauthor=P.+Miller&title=Studies+on+carrageenan+air+pouch+inflammation+in+the+rat"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit36d&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHambelton%26aufirst%3DP.%26aulast%3DMiller%26aufirst%3DP.%26atitle%3DStudies%2520on%2520carrageenan%2520air%2520pouch%2520inflammation%2520in%2520the%2520rat%26jtitle%3DBr.%2520J.%2520Exp.%2520Pathol.%26date%3D1989%26volume%3D70%26spage%3D425%26epage%3D433" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Corey, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bakshi, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shibata, S.</span></span> <span> </span><span class="NLM_article-title">Highly enantioselective borane reduction of ketones catalyzed by chiral oxazaborolidines. Mechanism and synthetic implications</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">1987</span>,  <span class="NLM_volume"><i>109</i></span>,  <span class="NLM_fpage">5551</span>– <span class="NLM_lpage">5553</span>, <span class="refDoi"> DOI: 10.1021/ja00252a056</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja00252a056" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref37/cit37a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01854&amp;key=1%3ACAS%3A528%3ADyaL2sXlslGlsrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=109&publication_year=1987&pages=5551-5553&author=E.+J.+Coreyauthor=R.+K.+Bakshiauthor=S.+Shibata&title=Highly+enantioselective+borane+reduction+of+ketones+catalyzed+by+chiral+oxazaborolidines.+Mechanism+and+synthetic+implications&doi=10.1021%2Fja00252a056"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit37aR"><div class="casContent"><span class="casTitleNuber">37a</span><div class="casTitle"><span class="NLM_cas:atitle">Highly enantioselective borane reduction of ketones catalyzed by chiral oxazaborolidines.  Mechanism and synthetic implications</span></div><div class="casAuthors">Corey, E. J.; Bakshi, Raman K.; Shibata, Saizo</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">1987</span>),
    <span class="NLM_cas:volume">109</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">5551-3</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    </div><div class="casAbstract">An enantioselective redn. of ketones to secondary alcs.,e.g., PhCOMe to (R)-PhMeCHOH, by vic-amino alcs. and BH3-THF is reported.  Two key reaction intermediates involved in a catalytic redn. with BH3.THF as the stoichiometric reductant.  (S)-Diphenylprolinol reacts with BH3.THF upon heating to form oxazaborolidine I, which is a catalyst for these redns.  I forms a complex II.  Amino alc. III similarly effects enantioselective redn. of ketones.  I and II are the most effective reducing agents found to date.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpr0FOvqDo-BLVg90H21EOLACvtfcHk0lje-cvW-oGxSA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL2sXlslGlsrs%253D&md5=e52d09fe788534f0f5d8168d2ad93e4f</span></div><a href="/servlet/linkout?suffix=cit37a&amp;dbid=16384&amp;doi=10.1021%2Fja00252a056&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja00252a056%26sid%3Dliteratum%253Aachs%26aulast%3DCorey%26aufirst%3DE.%2BJ.%26aulast%3DBakshi%26aufirst%3DR.%2BK.%26aulast%3DShibata%26aufirst%3DS.%26atitle%3DHighly%2520enantioselective%2520borane%2520reduction%2520of%2520ketones%2520catalyzed%2520by%2520chiral%2520oxazaborolidines.%2520Mechanism%2520and%2520synthetic%2520implications%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D1987%26volume%3D109%26spage%3D5551%26epage%3D5553%26doi%3D10.1021%2Fja00252a056" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit37b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Corey, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bakshi, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shibata, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, V. K.</span></span> <span> </span><span class="NLM_article-title">A stable and easily prepared catalyst for the enantioselective reduction of ketones. Applications to multistep syntheses</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">1987</span>,  <span class="NLM_volume"><i>109</i></span>,  <span class="NLM_fpage">7925</span>– <span class="NLM_lpage">7926</span>, <span class="refDoi"> DOI: 10.1021/ja00259a075</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja00259a075" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref37/cit37b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01854&amp;key=1%3ACAS%3A528%3ADyaL1cXnsFShtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=109&publication_year=1987&pages=7925-7926&author=E.+J.+Coreyauthor=R.+K.+Bakshiauthor=S.+Shibataauthor=C.+P.+Chenauthor=V.+K.+Singh&title=A+stable+and+easily+prepared+catalyst+for+the+enantioselective+reduction+of+ketones.+Applications+to+multistep+syntheses&doi=10.1021%2Fja00259a075"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit37bR"><div class="casContent"><span class="casTitleNuber">37b</span><div class="casTitle"><span class="NLM_cas:atitle">A stable and easily prepared catalyst for the enantioselective reduction of ketones.  Applications to multistep syntheses</span></div><div class="casAuthors">Corey, E. J.; Bakshi, Raman K.; Shibata, Saizo; Chen, Chung Pin; Singh, Vinod K.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">1987</span>),
    <span class="NLM_cas:volume">109</span>
        (<span class="NLM_cas:issue">25</span>),
    <span class="NLM_cas:pages">7925-6</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    </div><div class="casAbstract">The readily available and stable oxazaborolidine I is an excellent catalyst for the enantioselective redn. of a wide range of ketones.  The stereochem. course of the redn. is predictable and the secondary alcs. formed are generally produced with high enantioselectivity.  Use of I or its enantiomer provides outstanding control of stereochem. at C(15) in prostaglandin synthesis.  A general and highly enantioselective synthesis of trans-2,5-diarylfurans, potent antagonists of platelet activating factor, also illustrates the value of this enantioselective redn.  Both I and its enantiomer can be obtained from (±)-pyroglutamic acid.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrJ6p262xrQBrVg90H21EOLACvtfcHk0lje-cvW-oGxSA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL1cXnsFShtA%253D%253D&md5=4deaae8502b4e75f0744e46a9e774dec</span></div><a href="/servlet/linkout?suffix=cit37b&amp;dbid=16384&amp;doi=10.1021%2Fja00259a075&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja00259a075%26sid%3Dliteratum%253Aachs%26aulast%3DCorey%26aufirst%3DE.%2BJ.%26aulast%3DBakshi%26aufirst%3DR.%2BK.%26aulast%3DShibata%26aufirst%3DS.%26aulast%3DChen%26aufirst%3DC.%2BP.%26aulast%3DSingh%26aufirst%3DV.%2BK.%26atitle%3DA%2520stable%2520and%2520easily%2520prepared%2520catalyst%2520for%2520the%2520enantioselective%2520reduction%2520of%2520ketones.%2520Applications%2520to%2520multistep%2520syntheses%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D1987%26volume%3D109%26spage%3D7925%26epage%3D7926%26doi%3D10.1021%2Fja00259a075" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6a','cit6b'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11a','cit11b','cit11c'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16a','cit16b','cit16c'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25a','cit25b','cit25c'],'ref26':['cit26'],'ref27':['cit27a','cit27b'],'ref28':['cit28a','cit28b'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33a','cit33b'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36a','cit36b','cit36c','cit36d'],'ref37':['cit37a','cit37b']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 9 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Francesca Toselli, Marlene Fredenwall, Peder Svensson, Xue-Qing Li, Anders Johansson, Lars Weidolf, <span class="NLM_string-name hlFld-ContribAuthor">Martin A. Hayes</span>. </span><span class="cited-content_cbyCitation_article-title">Hip To Be Square: Oxetanes as Design Elements To Alter Metabolic Pathways. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>62 </em>
                                    (16)
                                     , 7383-7399. <a href="https://doi.org/10.1021/acs.jmedchem.9b00030" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b00030</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b00030&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.9b00030%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DHip%252BTo%252BBe%252BSquare%25253A%252BOxetanes%252Bas%252BDesign%252BElements%252BTo%252BAlter%252BMetabolic%252BPathways%26aulast%3DToselli%26aufirst%3DFrancesca%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D06012019%26date%3D02082019%26date%3D16072019%26volume%3D62%26issue%3D16%26spage%3D7383%26epage%3D7399" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Huihui Ti, Yang Zhou, Xue Liang, Runfeng Li, Ke Ding, <span class="NLM_string-name hlFld-ContribAuthor">Xin Zhao</span>. </span><span class="cited-content_cbyCitation_article-title">Targeted Treatments for Chronic Obstructive Pulmonary Disease (COPD) Using Low-Molecular-Weight Drugs (LMWDs). </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>62 </em>
                                    (13)
                                     , 5944-5978. <a href="https://doi.org/10.1021/acs.jmedchem.8b01520" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.8b01520</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.8b01520&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.8b01520%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DTargeted%252BTreatments%252Bfor%252BChronic%252BObstructive%252BPulmonary%252BDisease%252B%252528COPD%252529%252BUsing%252BLow-Molecular-Weight%252BDrugs%252B%252528LMWDs%252529%26aulast%3DTi%26aufirst%3DHuihui%26date%3D2019%26date%3D2019%26date%3D2018%26date%3D30092018%26date%3D12022019%26date%3D25012019%26volume%3D62%26issue%3D13%26spage%3D5944%26epage%3D5978" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Maxim Epifanov, Paul J. Foth, Frances Gu, Charlotte Barrillon, Sahil S. Kanani, Carolyn S. Higman, Jason E. Hein, <span class="NLM_string-name hlFld-ContribAuthor">Glenn M. Sammis</span>. </span><span class="cited-content_cbyCitation_article-title">One-Pot 1,1-Dihydrofluoroalkylation of Amines Using Sulfuryl Fluoride. </span><span class="cited-content_cbyCitation_journal-name">Journal of the American Chemical Society</span><span> <strong>2018,</strong> <em>140 </em>
                                    (48)
                                     , 16464-16468. <a href="https://doi.org/10.1021/jacs.8b11309" title="DOI URL">https://doi.org/10.1021/jacs.8b11309</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/jacs.8b11309&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fjacs.8b11309%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520the%2520American%2520Chemical%2520Society%26atitle%3DOne-Pot%252B1%25252C1-Dihydrofluoroalkylation%252Bof%252BAmines%252BUsing%252BSulfuryl%252BFluoride%26aulast%3DEpifanov%26aufirst%3DMaxim%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D19102018%26date%3D19112018%26date%3D15112018%26volume%3D140%26issue%3D48%26spage%3D16464%26epage%3D16468" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Bei  Zhang</span>, <span class="hlFld-ContribAuthor ">Yue  Huang</span>, <span class="hlFld-ContribAuthor ">Si-Rui  Zhang</span>, <span class="hlFld-ContribAuthor ">Meng-Xing  Huang</span>, <span class="hlFld-ContribAuthor ">Chen  Zhang</span>, <span class="hlFld-ContribAuthor ">Hai-Bin  Luo</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis and biological evaluation of novel pyrazolopyrimidone derivatives as potent PDE1 inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic Chemistry</span><span> <strong>2021,</strong> <em>114 </em>, 105104. <a href="https://doi.org/10.1016/j.bioorg.2021.105104" title="DOI URL">https://doi.org/10.1016/j.bioorg.2021.105104</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bioorg.2021.105104&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bioorg.2021.105104%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520Chemistry%26atitle%3DDesign%25252C%252Bsynthesis%252Band%252Bbiological%252Bevaluation%252Bof%252Bnovel%252Bpyrazolopyrimidone%252Bderivatives%252Bas%252Bpotent%252BPDE1%252Binhibitors%26aulast%3DZhang%26aufirst%3DBei%26date%3D2021%26volume%3D114%26spage%3D105104" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ding  Xue</span>, <span class="hlFld-ContribAuthor ">Wenmin  Chen</span>, <span class="hlFld-ContribAuthor ">Nouri  Neamati</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery, structure-activity relationship study and biological evaluation of 2-thioureidothiophene-3-carboxylates as a novel class of C-X-C chemokine receptor 2 (CXCR2) antagonists. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>204 </em>, 112387. <a href="https://doi.org/10.1016/j.ejmech.2020.112387" title="DOI URL">https://doi.org/10.1016/j.ejmech.2020.112387</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2020.112387&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2020.112387%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%25252C%252Bstructure-activity%252Brelationship%252Bstudy%252Band%252Bbiological%252Bevaluation%252Bof%252B2-thioureidothiophene-3-carboxylates%252Bas%252Ba%252Bnovel%252Bclass%252Bof%252BC-X-C%252Bchemokine%252Breceptor%252B2%252B%252528CXCR2%252529%252Bantagonists%26aulast%3DXue%26aufirst%3DDing%26date%3D2020%26volume%3D204%26spage%3D112387" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Thierry  Milcent</span>, <span class="hlFld-ContribAuthor ">Benoit  Crousse</span>. </span><span class="cited-content_cbyCitation_article-title">Construction of
              N
              ‐
              
                CF
                2
                H
              
              ,
              N
              ‐
              
                CF
                3
              
              , and
              N
              ‐
              
                CH
                2
                CF
                3
              
              Motifs. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2020,</strong>,, 723-761. <a href="https://doi.org/10.1002/9783527824342.ch24" title="DOI URL">https://doi.org/10.1002/9783527824342.ch24</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/9783527824342.ch24&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2F9783527824342.ch24%26sid%3Dliteratum%253Aachs%26atitle%3DConstruction%252Bof%252BN%252B%2525E2%252580%252590%252BCF%252B2%252BH%252B%25252C%252BN%252B%2525E2%252580%252590%252BCF%252B3%252B%25252C%252Band%252BN%252B%2525E2%252580%252590%252BCH%252B2%252BCF%252B3%252BMotifs%26aulast%3DMilcent%26aufirst%3DThierry%26date%3D2020%26date%3D2020%26spage%3D723%26epage%3D761%26pub%3DWiley%26atitle%3DEmerging%252BFluorinated%252BMotifs%26aulast%3DCahard%26aufirst%3DDominique%26date%3D2020%26date%3D2020%26volume%3D29" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Lu  Wang</span>, <span class="hlFld-ContribAuthor ">Hanyu  Yang</span>, <span class="hlFld-ContribAuthor ">Caixia  Zang</span>, <span class="hlFld-ContribAuthor ">Yi  Dong</span>, <span class="hlFld-ContribAuthor ">Junmei  Shang</span>, <span class="hlFld-ContribAuthor ">Jiajing  Chen</span>, <span class="hlFld-ContribAuthor ">Yue  Wang</span>, <span class="hlFld-ContribAuthor ">Hui  Liu</span>, <span class="hlFld-ContribAuthor ">Zihong  Zhang</span>, <span class="hlFld-ContribAuthor ">Heng  Xu</span>, <span class="hlFld-ContribAuthor ">Xiuqi  Bao</span>, <span class="hlFld-ContribAuthor ">Dan  Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">CXCR2 antagonism promotes oligodendrocyte precursor cell differentiation and enhances remyelination in a mouse model of multiple sclerosis. </span><span class="cited-content_cbyCitation_journal-name">Neurobiology of Disease</span><span> <strong>2020,</strong> <em>134 </em>, 104630. <a href="https://doi.org/10.1016/j.nbd.2019.104630" title="DOI URL">https://doi.org/10.1016/j.nbd.2019.104630</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.nbd.2019.104630&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.nbd.2019.104630%26sid%3Dliteratum%253Aachs%26jtitle%3DNeurobiology%2520of%2520Disease%26atitle%3DCXCR2%252Bantagonism%252Bpromotes%252Boligodendrocyte%252Bprecursor%252Bcell%252Bdifferentiation%252Band%252Benhances%252Bremyelination%252Bin%252Ba%252Bmouse%252Bmodel%252Bof%252Bmultiple%252Bsclerosis%26aulast%3DWang%26aufirst%3DLu%26date%3D2020%26volume%3D134%26spage%3D104630" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Hanqing.  Tong</span>, <span class="hlFld-ContribAuthor ">Cui  Chen</span>, <span class="hlFld-ContribAuthor ">Weibing.  Liu</span>, <span class="hlFld-ContribAuthor ">Yupeng.  Pan</span>, <span class="hlFld-ContribAuthor ">Linhai.  Duan</span>. </span><span class="cited-content_cbyCitation_article-title">Chlorothiomethylation of Alkynes with HCl and Dimethyl Sulfoxide: An Efficient Approach to (E)‐α‐chloro‐β‐(methylthio)alkenes. </span><span class="cited-content_cbyCitation_journal-name">Asian Journal of Organic Chemistry</span><span> <strong>2019,</strong> <em>8 </em>
                                    (4)
                                     , 479-481. <a href="https://doi.org/10.1002/ajoc.201900108" title="DOI URL">https://doi.org/10.1002/ajoc.201900108</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/ajoc.201900108&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fajoc.201900108%26sid%3Dliteratum%253Aachs%26jtitle%3DAsian%2520Journal%2520of%2520Organic%2520Chemistry%26atitle%3DChlorothiomethylation%252Bof%252BAlkynes%252Bwith%252BHCl%252Band%252BDimethyl%252BSulfoxide%25253A%252BAn%252BEfficient%252BApproach%252Bto%252B%252528E%252529%2525E2%252580%252590%2525CE%2525B1%2525E2%252580%252590chloro%2525E2%252580%252590%2525CE%2525B2%2525E2%252580%252590%252528methylthio%252529alkenes%26aulast%3DTong%26aufirst%3DHanqing.%26date%3D2019%26date%3D2019%26volume%3D8%26issue%3D4%26spage%3D479%26epage%3D481" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yujie  Ma</span>, <span class="hlFld-ContribAuthor ">Jing  Li</span>, <span class="hlFld-ContribAuthor ">Jianxun  Ye</span>, <span class="hlFld-ContribAuthor ">Delong  Liu</span>, <span class="hlFld-ContribAuthor ">Wanbin  Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis of chiral chromanols
              via
              a RuPHOX–Ru catalyzed asymmetric hydrogenation of chromones. </span><span class="cited-content_cbyCitation_journal-name">Chemical Communications</span><span> <strong>2018,</strong> <em>54 </em>
                                    (96)
                                     , 13571-13574. <a href="https://doi.org/10.1039/C8CC07787H" title="DOI URL">https://doi.org/10.1039/C8CC07787H</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C8CC07787H&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC8CC07787H%26sid%3Dliteratum%253Aachs%26jtitle%3DChemical%2520Communications%26atitle%3DSynthesis%252Bof%252Bchiral%252Bchromanols%252Bvia%252Ba%252BRuPHOX%2525E2%252580%252593Ru%252Bcatalyzed%252Basymmetric%252Bhydrogenation%252Bof%252Bchromones%26aulast%3DMa%26aufirst%3DYujie%26date%3D2018%26date%3D2018%26volume%3D54%26issue%3D96%26spage%3D13571%26epage%3D13574" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.7b01854/20180315/images/medium/jm-2017-01854x_0015.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.7b01854/20180315/images/large/jm-2017-01854x_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01854&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.7b01854/20180315/images/medium/jm-2017-01854x_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.7b01854/20180315/images/large/jm-2017-01854x_0001.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Structures of representative small molecule CXCR2 antagonists.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.7b01854/20180315/images/large/jm-2017-01854x_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01854&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2a" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.7b01854/20180315/images/medium/jm-2017-01854x_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.7b01854/20180315/images/large/jm-2017-01854x_0002.jpeg" id="rightTab-GRAPHIC-d128e2287-autogenerated" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. (a) Mouse whole blood CD11b assay of compound <b>68</b>. (b) Human whole blood CD11b assay of compound <b>68</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.7b01854/20180315/images/large/jm-2017-01854x_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01854&amp;id=fig2a"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3a" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.7b01854/20180315/images/medium/jm-2017-01854x_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.7b01854/20180315/images/large/jm-2017-01854x_0003.jpeg" id="rightTab-GRAPHIC-d128e2519-autogenerated" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. (a) Compound <b>68</b> inhibited neutrophil migration to the air pouch in mouse. The neutrophil cell number in the lavage were counted after 4 h carageenan induction, and the percentage was calculated compared to vehicle group. * <i>p</i> < 0.05, ** <i>p</i> < 0.01, compared with the vehicle group. One-Way ANOVA, followed by Bonferroni multiple comparison test. (b) Compound <b>68</b> inhibited neutrophil migration to air pouch in rat. The neutrophil cell number in the lavage were counted after 4 h carageenan induction, and the percentage was calculated compared to vehicle group. *** <i>p</i> < 0.001 indicates significantly decreasing compared with the vehicle group. One-way ANOVA, followed by Dunnett’s multiple comparison test.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.7b01854/20180315/images/large/jm-2017-01854x_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01854&amp;id=fig3a"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.7b01854/20180315/images/medium/jm-2017-01854x_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.7b01854/20180315/images/large/jm-2017-01854x_0005.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Retrosynthetic Analysis and Synthesis of RHS Intermediate <b>75</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.7b01854/20180315/images/large/jm-2017-01854x_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01854&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) (<i>R</i>)-CBS, BH<sub>3</sub>·THF, THF, −60 °C; (b) phthalimide, PPh<sub>3</sub>, DIAD, THF, 0 °C, 28% over two steps; (c) hydrazine, EtOH, reflux, 100%.</p></p></figure><figure data-id="sch2" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.7b01854/20180315/images/medium/jm-2017-01854x_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.7b01854/20180315/images/large/jm-2017-01854x_0006.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of Lead Compound <b>40</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.7b01854/20180315/images/large/jm-2017-01854x_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01854&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) ethyl 2-bromo-2-methylpropanoate, K<sub>2</sub>CO<sub>3</sub>, DMF, 60 °C; (b) <i>m</i>-CPBA, DCM, rt, 64% over two steps; (c) DIBAL-H, THF, −50 °C → rt; (d) triflic anhydride, pyridine, DCM, rt; (e) TBAF, THF, −15 °C → 30 °C, 46% over three steps;( f) 37% HCl, dioxane, reflux, 98%; (g) (i) <b>75</b>, triphosgene, NaHCO<sub>3</sub>, DCM, 0 °C → rt, (ii) pyridine, rt, 58%.</p></p></figure><figure data-id="sch3" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.7b01854/20180315/images/medium/jm-2017-01854x_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.7b01854/20180315/images/large/jm-2017-01854x_0007.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthesis of Lead Compound <b>68</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.7b01854/20180315/images/large/jm-2017-01854x_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01854&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) LiHMDS, MeI, THF, −70 °C → rt; (b) 37% HCl, dioxane, reflux, 66% over two steps; c) (i) <b>75</b>, triphosgene, NaHCO<sub>3</sub>, DCM, 0 °C → rt, (ii) pyridine, 40 °C, 96%; (d) chiral SFC separation, 22%.</p></p></figure><figure data-id="fig4" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.7b01854/20180315/images/medium/jm-2017-01854x_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.7b01854/20180315/images/large/jm-2017-01854x_0004.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. A view of one of the independent molecules from the crystal structure of <b>68</b>, showing the numbering scheme employed (the second molecule is numbered in an analogous fashion, from N31 to C57). Anisotropic atomic displacement ellipsoids for the non-hydrogen atoms are shown at the 50% probability level. For clarity, only one of the two disorder components for the 3-methyltetrahydrofuran-3-yl group is shown. Hydrogen atoms are displayed with an arbitrarily small radius.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.7b01854/20180315/images/large/jm-2017-01854x_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01854&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i55">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_55502" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_55502" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 37 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stadtmann, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zarbock, A.</span></span> <span> </span><span class="NLM_article-title">CXCR2: From bench to bedside</span>. <i>Front. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">263</span>, <span class="refDoi"> DOI: 10.3389/fimmu.2012.00263</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01854&amp;key=10.3389%2Ffimmu.2012.00263" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01854&amp;key=22936934" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01854&amp;key=1%3ACAS%3A280%3ADC%252BC38bivFKqtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2012&pages=263&author=A.+Stadtmannauthor=A.+Zarbock&title=CXCR2%3A+From+bench+to+bedside&doi=10.3389%2Ffimmu.2012.00263"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">CXCR2: From Bench to Bedside</span></div><div class="casAuthors">Stadtmann Anika; Zarbock Alexander</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in immunology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">263</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Leukocyte recruitment to sites of infection or tissue damage plays a crucial role for the innate immune response.  Chemokine-dependent signaling in immune cells is a very important mechanism leading to integrin activation and leukocyte recruitment.  CXC chemokine receptor 2 (CXCR2) is a prominent chemokine receptor on neutrophils.  During the last years, several studies were performed investigating the role of CXCR2 in different diseases.  Until now, many CXCR2 inhibitors are tested in animal models and clinical trials and promising results were obtained.  This review gives an overview of the structure of CXCR2 and the signaling pathways that are activated following CXCR2 stimulation.  We discuss in detail the role of this chemokine receptor in different disease models including acute lung injury, COPD, sepsis, and ischemia-reperfusion-injury.  Furthermore, this review summarizes the results of clinical trials which used CXCR2 inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRipfUTvwjJVINpW7w2tapOfW6udTcc2eZdEmtS6GSDiLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC38bivFKqtA%253D%253D&md5=f6b8fbe259f1d85097de0434ce2f97b9</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.3389%2Ffimmu.2012.00263&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffimmu.2012.00263%26sid%3Dliteratum%253Aachs%26aulast%3DStadtmann%26aufirst%3DA.%26aulast%3DZarbock%26aufirst%3DA.%26atitle%3DCXCR2%253A%2520From%2520bench%2520to%2520bedside%26jtitle%3DFront.%2520Immunol.%26date%3D2012%26volume%3D3%26spage%3D263%26doi%3D10.3389%2Ffimmu.2012.00263" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Holz, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khalilieh, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ludwig-Sengpiel, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watz, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stryszak, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soni, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsai, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sadeh, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Magnussen, H.</span></span> <span> </span><span class="NLM_article-title">SCH527123, a novel CXCR2 antagonist, inhibits ozone-induced neutrophilia in healthy subjects</span>. <i>Eur. Respir. J.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>35</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">564</span>– <span class="NLM_lpage">570</span>, <span class="refDoi"> DOI: 10.1183/09031936.00048509</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01854&amp;key=10.1183%2F09031936.00048509" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01854&amp;key=19643947" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01854&amp;key=1%3ACAS%3A528%3ADC%252BC3cXksVGnsbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2010&pages=564-570&issue=3&author=O.+Holzauthor=S.+Khaliliehauthor=A.+Ludwig-Sengpielauthor=H.+Watzauthor=P.+Stryszakauthor=P.+Soniauthor=M.+Tsaiauthor=J.+Sadehauthor=H.+Magnussen&title=SCH527123%2C+a+novel+CXCR2+antagonist%2C+inhibits+ozone-induced+neutrophilia+in+healthy+subjects&doi=10.1183%2F09031936.00048509"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">SCH527123, a novel CXCR2 antagonist, inhibits ozone-induced neutrophilia in healthy subjects</span></div><div class="casAuthors">Holz, O.; Khalilieh, S.; Ludwig-Sengpiel, A.; Watz, H.; Stryszak, P.; Soni, P.; Tsai, M.; Sadeh, J.; Magnussen, H.</div><div class="citationInfo"><span class="NLM_cas:title">European Respiratory Journal</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">564-570</span>CODEN:
                <span class="NLM_cas:coden">ERJOEI</span>;
        ISSN:<span class="NLM_cas:issn">0903-1936</span>.
    
            (<span class="NLM_cas:orgname">European Respiratory Society</span>)
        </div><div class="casAbstract">SCH527123 is a novel, selective CXC chemokine receptor 2 antagonist that inhibits neutrophil activation and modulates neutrophil trafficking in animal models, characteristics that may be beneficial in the treatment of conditions with unbalanced pulmonary neutrophilia, such as chronic obstructive pulmonary disease.  The purpose of this proof-of-principle study was to det. whether SCH527123 inhibits ozone-induced neutrophil recruitment in healthy humans.  In a randomized, double-blind, placebo-controlled, three-way crossover study, oral SCH527123 (50 mg once daily, 4 days), prednisolone (50 mg once), or placebo was alternated with 2-wk washouts.  18 Healthy ozone responders (>20% increase in sputum neutrophils) underwent ozone challenge tests (250 ppb, 3 h intermittent exercise) 1 h after the last treatment dose.  Sputum was induced at 3 h post-challenge.  After SCH527123 treatment, the ozone challenge resulted in significantly lower sputum neutrophil counts (0.13 × 106 mL-1) compared with prednisolone (0.84 × 106/mL-1; p < 0.001) or placebo (2.98 × 106 mL-1; p < 0.001).  Comparable results were obtained for total cell count, percentage of sputum neutrophils, and for interleukin-8 and myeloperoxidase in sputum supernatant.  Post-challenge, SCH527123 inhibited neutrophilia in peripheral blood but significantly less than in sputum.  All treatments were safe and well tolerated.  SCH527123 causes significant attenuation of ozone-induced airway neutrophilia in healthy subjects.  Further evaluation in a large trial of patients with pulmonary disorders is warranted.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqJwysQ82AncbVg90H21EOLACvtfcHk0lia-PPxAbRPqw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXksVGnsbs%253D&md5=ae0702b5eb1122d2c919a4130b3f471e</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1183%2F09031936.00048509&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1183%252F09031936.00048509%26sid%3Dliteratum%253Aachs%26aulast%3DHolz%26aufirst%3DO.%26aulast%3DKhalilieh%26aufirst%3DS.%26aulast%3DLudwig-Sengpiel%26aufirst%3DA.%26aulast%3DWatz%26aufirst%3DH.%26aulast%3DStryszak%26aufirst%3DP.%26aulast%3DSoni%26aufirst%3DP.%26aulast%3DTsai%26aufirst%3DM.%26aulast%3DSadeh%26aufirst%3DJ.%26aulast%3DMagnussen%26aufirst%3DH.%26atitle%3DSCH527123%252C%2520a%2520novel%2520CXCR2%2520antagonist%252C%2520inhibits%2520ozone-induced%2520neutrophilia%2520in%2520healthy%2520subjects%26jtitle%3DEur.%2520Respir.%2520J.%26date%3D2010%26volume%3D35%26issue%3D3%26spage%3D564%26epage%3D570%26doi%3D10.1183%2F09031936.00048509" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Aul, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Summerhill, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kilty, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plumb, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, D.</span></span> <span> </span><span class="NLM_article-title">LPS challenge in healthy subjects: an investigation of neutrophil chemotaxis mechanisms involving CXCR1 and CXCR2</span>. <i>Int. Immunopharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>13</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">225</span>– <span class="NLM_lpage">231</span>, <span class="refDoi"> DOI: 10.1016/j.intimp.2012.04.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01854&amp;key=10.1016%2Fj.intimp.2012.04.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01854&amp;key=22561413" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01854&amp;key=1%3ACAS%3A528%3ADC%252BC38Xot12nu7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2012&pages=225-231&issue=3&author=R.+Aulauthor=S.+Patelauthor=S.+Summerhillauthor=I.+Kiltyauthor=J.+Plumbauthor=D.+Singh&title=LPS+challenge+in+healthy+subjects%3A+an+investigation+of+neutrophil+chemotaxis+mechanisms+involving+CXCR1+and+CXCR2&doi=10.1016%2Fj.intimp.2012.04.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">LPS challenge in healthy subjects: An investigation of neutrophil chemotaxis mechanisms involving CXCR1 and CXCR2</span></div><div class="casAuthors">Aul, Raminder; Patel, Sheena; Summerhill, Susan; Kilty, Iain; Plumb, Jonathan; Singh, Dave</div><div class="citationInfo"><span class="NLM_cas:title">International Immunopharmacology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">225-231</span>CODEN:
                <span class="NLM_cas:coden">IINMBA</span>;
        ISSN:<span class="NLM_cas:issn">1567-5769</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">LPS inhalation was used to investigate whether sputum supernatant post-LPS challenge increases neutrophil chemotactic activity and to elucidate the role of CXCR1/CXCR2 signalling in this process.14 healthy non-smoking subjects inhaled 30 μg of LPS.  Sputum was induced at baseline, 6 and 24 h post-LPS challenge.  Differential cell counts were detd. and supernatants CXCL8, CXCL1, IL-6 and CCL2 levels measured.  Peripheral blood neutrophils obtained from healthy volunteers were used for chemotaxis expts. using sputum supernatant.  To delineate signalling mechanisms, the effects of a CXCR2/CXCR1 (dual) antagonist (Sch527123) and a CXCR2 specific antagonist (SB656933) were tested.  LPS inhalation significantly increased sputum neutrophil counts from 45.3% to 76.7% and 69.3% at 6 and 24 h resp.  LPS increased CXCL8, IL-6 and CCL2 levels but not CXCL1.  Neutrophil chemotaxis significantly increased (2.7 fold) at 24 h compared to baseline.  Chemotaxis was inhibited by 79.0% with Sch527123 and 52.0% with SB656933.  We conclude that LPS challenge increases sputum supernatant CXCL8 levels, which is assocd. with increased chemotactic activity which is dependent on both CXCR1 and CXCR2.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpeBzkQc4_KA7Vg90H21EOLACvtfcHk0lia-PPxAbRPqw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xot12nu7s%253D&md5=c196cbe3264f545d5e2d90b1b95a6c05</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1016%2Fj.intimp.2012.04.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.intimp.2012.04.008%26sid%3Dliteratum%253Aachs%26aulast%3DAul%26aufirst%3DR.%26aulast%3DPatel%26aufirst%3DS.%26aulast%3DSummerhill%26aufirst%3DS.%26aulast%3DKilty%26aufirst%3DI.%26aulast%3DPlumb%26aufirst%3DJ.%26aulast%3DSingh%26aufirst%3DD.%26atitle%3DLPS%2520challenge%2520in%2520healthy%2520subjects%253A%2520an%2520investigation%2520of%2520neutrophil%2520chemotaxis%2520mechanisms%2520involving%2520CXCR1%2520and%2520CXCR2%26jtitle%3DInt.%2520Immunopharmacol.%26date%3D2012%26volume%3D13%26issue%3D3%26spage%3D225%26epage%3D231%26doi%3D10.1016%2Fj.intimp.2012.04.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Breland, U. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Halvorsen, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hol, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Øie, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paulsson-Berne, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yndestad, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Otterdal, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hedin, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wæhre, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sandberg, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frøland, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haraldsen, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gullestad, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Damås, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hansson, G. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aukrust, P.</span></span> <span> </span><span class="NLM_article-title">A potential role of the CXC chemokine GRO[alpha] in atherosclerosis and plaque destabilization: downregulatory effects of statins</span>. <i>Arterioscler., Thromb., Vasc. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>28</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">1005</span>– <span class="NLM_lpage">1011</span>, <span class="refDoi"> DOI: 10.1161/ATVBAHA.108.162305</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01854&amp;key=10.1161%2FATVBAHA.108.162305" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01854&amp;key=18276907" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01854&amp;key=1%3ACAS%3A528%3ADC%252BD1cXktlymu7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2008&pages=1005-1011&issue=5&author=U.+M.+Brelandauthor=B.+Halvorsenauthor=J.+Holauthor=E.+%C3%98ieauthor=G.+Paulsson-Berneauthor=A.+Yndestadauthor=C.+Smithauthor=K.+Otterdalauthor=U.+Hedinauthor=T.+W%C3%A6hreauthor=W.+J.+Sandbergauthor=S.+S.+Fr%C3%B8landauthor=G.+Haraldsenauthor=L.+Gullestadauthor=J.+K.+Dam%C3%A5sauthor=G.+K.+Hanssonauthor=P.+Aukrust&title=A+potential+role+of+the+CXC+chemokine+GRO%5Balpha%5D+in+atherosclerosis+and+plaque+destabilization%3A+downregulatory+effects+of+statins&doi=10.1161%2FATVBAHA.108.162305"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">A Potential Role of the CXC Chemokine GROα in Atherosclerosis and Plaque Destabilization</span></div><div class="casAuthors">Breland, Unni M.; Halvorsen, Bente; Hol, Johanna; Oeie, Erik; Paulsson-Berne, Gabrielle; Yndestad, Arne; Smith, Camilla; Otterdal, Kari; Hedin, Ulf; Waehre, Torgun; Sandberg, Wiggo J.; Froeland, Stig S.; Haraldsen, Guttorm; Gullestad, Lars; Damaas, Jan K.; Hansson, Goeran K.; Aukrust, Paal</div><div class="citationInfo"><span class="NLM_cas:title">Arteriosclerosis, Thrombosis, and Vascular Biology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1005-1011</span>CODEN:
                <span class="NLM_cas:coden">ATVBFA</span>;
        ISSN:<span class="NLM_cas:issn">1079-5642</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Objective: the authors examd. the role of the CXCR2 ligand growth-related oncogene (GRO) α in human atherosclerosis.  Methods and Results: GROα levels were examd. by enzyme immunoassay, real-time quant. RT-PCR, and cDNA microarrays.  The in vitro effect of statins on GROα was examd. in endothelial cells and THP-1 macrophages.  The main findings were: (1) GROα was among the 10 most differentially expressed transcripts comparing peripheral blood mononuclear cells (PBMCs) from patients with coronary artery disease (CAD) and healthy controls; (2) both patients with stable and particularly those with unstable angina had increased plasma levels of GROα comparing controls; (3) increased expression of GROα within symptomatic carotid plaques, located to macrophages and endothelial cells; (4) GROα enhanced the release of matrix metalloproteinases in vascular smooth muscle cells, and increased the binding of acetylated LDL in macrophages; (5) atorvastatin down-regulated GROα levels as shown both in vitro in endothelial cells and macrophages and in vivo in PBMCs from CAD patients, and (6) the effect on GROα in endothelial cells involved increased storage and reduced secretion of GROα.  Conclusions: GROα could be involved in atherogenesis and plaque destabilization, potentially contributing to inflammation, matrix degrdn., and lipid accumulation within the atherosclerotic lesion.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoDh3s7N_2sDbVg90H21EOLACvtfcHk0lia-PPxAbRPqw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXktlymu7s%253D&md5=b115b0a96f8fd9294fde1fc8ad4ab61c</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1161%2FATVBAHA.108.162305&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1161%252FATVBAHA.108.162305%26sid%3Dliteratum%253Aachs%26aulast%3DBreland%26aufirst%3DU.%2BM.%26aulast%3DHalvorsen%26aufirst%3DB.%26aulast%3DHol%26aufirst%3DJ.%26aulast%3D%25C3%2598ie%26aufirst%3DE.%26aulast%3DPaulsson-Berne%26aufirst%3DG.%26aulast%3DYndestad%26aufirst%3DA.%26aulast%3DSmith%26aufirst%3DC.%26aulast%3DOtterdal%26aufirst%3DK.%26aulast%3DHedin%26aufirst%3DU.%26aulast%3DW%25C3%25A6hre%26aufirst%3DT.%26aulast%3DSandberg%26aufirst%3DW.%2BJ.%26aulast%3DFr%25C3%25B8land%26aufirst%3DS.%2BS.%26aulast%3DHaraldsen%26aufirst%3DG.%26aulast%3DGullestad%26aufirst%3DL.%26aulast%3DDam%25C3%25A5s%26aufirst%3DJ.%2BK.%26aulast%3DHansson%26aufirst%3DG.%2BK.%26aulast%3DAukrust%26aufirst%3DP.%26atitle%3DA%2520potential%2520role%2520of%2520the%2520CXC%2520chemokine%2520GRO%255Balpha%255D%2520in%2520atherosclerosis%2520and%2520plaque%2520destabilization%253A%2520downregulatory%2520effects%2520of%2520statins%26jtitle%3DArterioscler.%252C%2520Thromb.%252C%2520Vasc.%2520Biol.%26date%3D2008%26volume%3D28%26issue%3D5%26spage%3D1005%26epage%3D1011%26doi%3D10.1161%2FATVBAHA.108.162305" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Boppana, N. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Devarajan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gopal, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barathan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bakar, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shankar, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ebrahim, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Farooq, S. M.</span></span> <span> </span><span class="NLM_article-title">Blockade of CXCR2 signalling: a potential therapeutic target for preventing neutrophil-mediated inflammatory diseases</span>. <i>Exp. Biol. Med.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>239</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">509</span>– <span class="NLM_lpage">518</span>, <span class="refDoi"> DOI: 10.1177/1535370213520110</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01854&amp;key=10.1177%2F1535370213520110" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01854&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhslWju73K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=239&publication_year=2014&pages=509-518&issue=5&author=N.+B.+Boppanaauthor=A.+Devarajanauthor=K.+Gopalauthor=M.+Barathanauthor=S.+A.+Bakarauthor=E.+M.+Shankarauthor=A.+S.+Ebrahimauthor=S.+M.+Farooq&title=Blockade+of+CXCR2+signalling%3A+a+potential+therapeutic+target+for+preventing+neutrophil-mediated+inflammatory+diseases&doi=10.1177%2F1535370213520110"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Blockade of CXCR2 signalling: a potential therapeutic target for preventing neutrophil-mediated inflammatory diseases</span></div><div class="casAuthors">Boppana, Nithin B.; Devarajan, Asokan; Gopal, Kaliappan; Barathan, Muttiah; Bakar, Sazaly A.; Shankar, Esaki M.; Ebrahim, Abdul S.; Farooq, Shukkur M.</div><div class="citationInfo"><span class="NLM_cas:title">Experimental Biology and Medicine (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">239</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">509-518, 10 pp.</span>CODEN:
                <span class="NLM_cas:coden">EBMMBE</span>;
        ISSN:<span class="NLM_cas:issn">1535-3699</span>.
    
            (<span class="NLM_cas:orgname">Sage Publications Ltd.</span>)
        </div><div class="casAbstract">A review.  Polymorphonuclear neutrophils (PMN) play a key role in host innate immune responses by migrating to the sites of inflammation.  Furthermore, PMN recruitment also plays a significant role in the pathophysiol. of a plethora of inflammatory disorders such as chronic obstructive pulmonary disease (COPD), gram neg. sepsis, inflammatory bowel disease (IBD), lung injury, and arthritis.  Of note, chemokine-dependent signalling is implicated in the amplification of immune responses by virtue of its role in PMN chemotaxis in most of the inflammatory diseases.  It has been clin. established that impediment of PMN recruitment ameliorates disease severity and provides relief in majority of other immune-assocd. disorders.  This review focuses on different novel approaches clin. proven to be effective in blocking chemokine signalling assocd. with PMN recruitment that includes CXCR2 antagonists, chemokine analogs, anti-CXCR2 monoclonal antibodies, and CXCR2 knock-out models.  It also highlights the significance of the utility of nanoparticles in drugs used for blocking migration of PMN to the sites of inflammation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGriOOI311CiRrVg90H21EOLACvtfcHk0lg4saep-818mQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhslWju73K&md5=e4d6596fc62f02a4baa0dbc17771707c</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1177%2F1535370213520110&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F1535370213520110%26sid%3Dliteratum%253Aachs%26aulast%3DBoppana%26aufirst%3DN.%2BB.%26aulast%3DDevarajan%26aufirst%3DA.%26aulast%3DGopal%26aufirst%3DK.%26aulast%3DBarathan%26aufirst%3DM.%26aulast%3DBakar%26aufirst%3DS.%2BA.%26aulast%3DShankar%26aufirst%3DE.%2BM.%26aulast%3DEbrahim%26aufirst%3DA.%2BS.%26aulast%3DFarooq%26aufirst%3DS.%2BM.%26atitle%3DBlockade%2520of%2520CXCR2%2520signalling%253A%2520a%2520potential%2520therapeutic%2520target%2520for%2520preventing%2520neutrophil-mediated%2520inflammatory%2520diseases%26jtitle%3DExp.%2520Biol.%2520Med.%26date%3D2014%26volume%3D239%26issue%3D5%26spage%3D509%26epage%3D518%26doi%3D10.1177%2F1535370213520110" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, B. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mistry, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smart, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Connolly, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carpenter, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cooray, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bloomer, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tal-Singer, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lazaar, A. L.</span></span> <span> </span><span class="NLM_article-title">The pharmacokinetics and pharmacodynamics of Danirixin (GSK1325756) – a selective CXCR2 antagonist – in healthy adult subjects</span>. <i>BMC Pharmacol. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">18</span>, <span class="refDoi"> DOI: 10.1186/s40360-015-0017-x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01854&amp;key=10.1186%2Fs40360-015-0017-x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01854&amp;key=26092545" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01854&amp;key=1%3ACAS%3A280%3ADC%252BC2MblslersQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2015&pages=18&author=B.+E.+Millerauthor=S.+Mistryauthor=K.+Smartauthor=P.+Connollyauthor=D.+C.+Carpenterauthor=H.+Coorayauthor=J.+C.+Bloomerauthor=R.+Tal-Singerauthor=A.+L.+Lazaar&title=The+pharmacokinetics+and+pharmacodynamics+of+Danirixin+%28GSK1325756%29+%E2%80%93+a+selective+CXCR2+antagonist+%E2%80%93+in+healthy+adult+subjects&doi=10.1186%2Fs40360-015-0017-x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6aR"><div class="casContent"><span class="casTitleNuber">6a</span><div class="casTitle"><span class="NLM_cas:atitle">The pharmacokinetics and pharmacodynamics of danirixin (GSK1325756)--a selective CXCR2 antagonist --in healthy adult subjects</span></div><div class="casAuthors">Miller Bruce E; Tal-Singer Ruth; Mistry Sunil; Smart Kevin; Smart Kevin; Connolly Paul; Carpenter Donald C; Cooray Hiran; Cooray Hiran; Bloomer Jackie C; Lazaar Aili L</div><div class="citationInfo"><span class="NLM_cas:title">BMC pharmacology & toxicology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">18</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Excessive neutrophil presence and activation is important in a number of acute and chronic inflammatory diseases.  The CXCR2 chemokine receptor is important in controlling the extravasation and activation of neutrophils.  Selective antagonism of the CXCR2 receptor is a potential approach to reducing neutrophil migration and activation.  Danirixin, is a small molecule, CXCR2 antagonist being evaluated as a potential anti-inflammatory medicine.  METHODS:  (1) First time in human (FTIH) double-blind, placebo-controlled study to evaluate the safety, pharmacokinetics, and pharmacodynamics of single ascending and repeat oral doses of danirixin in healthy male subjects; (2) single-dose study of age, gender, food, and proton-pump inhibitor effects on the pharmacokinetics of danirixin in healthy adult subjects; and placebo-controlled study of the pharmacokinetics of danirixin in healthy elderly subjects.  RESULTS:  There were no serious adverse events and no adverse events considered to be of clinical relevance.  There were no withdrawals due to adverse events.  Systemic exposure following single doses of danirixin 10 mg, 25 mg, 50 mg, 100 mg, and 200 mg increased with increasing dose.  Engagement of pharmacology was demonstrated as inhibition of ex-vivo CXCL1-induced CD11b expression on peripheral blood neutrophils when compared to placebo (approximately 50% for 50 mg and 100 mg danirixin, and 72% at 200 mg).  There was a 37% decrease in Cmax and a 16% decrease in AUC (0-∞) following administration of danirixin in the presence of food.  Cmax also decreased by 65% when danirixin 100 mg was administered following omeprazole 40 mg once daily for 5 days.  The AUC (0-∞) and Cmax were 50% lower in elderly subjects compared with younger subjects.  CONCLUSION:  The dose-dependent inhibition of agonist-induced neutrophil activation following single and repeated once daily oral administration of danirixin suggests that this CXCR2 antagonist may have benefit in neutrophil-predominant inflammatory diseases.  Co-administration with food, gastric acid reducing agents, and variable exposure in the elderly have important clinical implications that need to be taken into consideration in subsequent clinical evaluations.  TRIAL REGISTRATION:  ClinicalTrials.gov identifiers: NCT01209052 and NCT01209104.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRAKy_l8uoE8MrRqEXsZufAfW6udTcc2ebZoUe6SpI-Obntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2MblslersQ%253D%253D&md5=031af976bb431023281306bde2964584</span></div><a href="/servlet/linkout?suffix=cit6a&amp;dbid=16384&amp;doi=10.1186%2Fs40360-015-0017-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs40360-015-0017-x%26sid%3Dliteratum%253Aachs%26aulast%3DMiller%26aufirst%3DB.%2BE.%26aulast%3DMistry%26aufirst%3DS.%26aulast%3DSmart%26aufirst%3DK.%26aulast%3DConnolly%26aufirst%3DP.%26aulast%3DCarpenter%26aufirst%3DD.%2BC.%26aulast%3DCooray%26aufirst%3DH.%26aulast%3DBloomer%26aufirst%3DJ.%2BC.%26aulast%3DTal-Singer%26aufirst%3DR.%26aulast%3DLazaar%26aufirst%3DA.%2BL.%26atitle%3DThe%2520pharmacokinetics%2520and%2520pharmacodynamics%2520of%2520Danirixin%2520%2528GSK1325756%2529%2520%25E2%2580%2593%2520a%2520selective%2520CXCR2%2520antagonist%2520%25E2%2580%2593%2520in%2520healthy%2520adult%2520subjects%26jtitle%3DBMC%2520Pharmacol.%2520Toxicol.%26date%3D2015%26volume%3D16%26spage%3D18%26doi%3D10.1186%2Fs40360-015-0017-x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit6b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Rennard, S. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dale, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Donohue, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kanniess, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Magnussen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sutherland, E. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watz, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stryszak, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosenberg, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Staudinger, H.</span></span> <span> </span><span class="NLM_article-title">CXCR2 antagonist MK-7123. a phase 2 proof-of-concept trial for chronic obstructive pulmonary disease</span>. <i>Am. J. Respir. Crit. Care Med.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>191</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">1001</span>– <span class="NLM_lpage">1011</span>, <span class="refDoi"> DOI: 10.1164/rccm.201405-0992OC</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01854&amp;key=10.1164%2Frccm.201405-0992OC" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01854&amp;key=25695403" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01854&amp;key=1%3ACAS%3A528%3ADC%252BC2MXptlKmt7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=191&publication_year=2015&pages=1001-1011&issue=9&author=S.+I.+Rennardauthor=D.+C.+Daleauthor=J.+F.+Donohueauthor=F.+Kanniessauthor=H.+Magnussenauthor=E.+R.+Sutherlandauthor=H.+Watzauthor=S.+Luauthor=P.+Stryszakauthor=E.+Rosenbergauthor=H.+Staudinger&title=CXCR2+antagonist+MK-7123.+a+phase+2+proof-of-concept+trial+for+chronic+obstructive+pulmonary+disease&doi=10.1164%2Frccm.201405-0992OC"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6bR"><div class="casContent"><span class="casTitleNuber">6b</span><div class="casTitle"><span class="NLM_cas:atitle">CXCR2 antagonist MK-7123: a phase 2 proof-of-concept trial for chronic obstructive pulmonary disease</span></div><div class="casAuthors">Rennard, Stephen I.; Dale, David C.; Donohue, James F.; Kanniess, Frank; Magnussen, Helgo; Sutherland, E. Rand; Watz, Henrik; Lu, Susan; Stryszak, Paul; Rosenberg, Elizabeth; Staudinger, Heribert</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Respiratory and Critical Care Medicine</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">191</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1001-1011</span>CODEN:
                <span class="NLM_cas:coden">AJCMED</span>;
        ISSN:<span class="NLM_cas:issn">1073-449X</span>.
    
            (<span class="NLM_cas:orgname">American Thoracic Society</span>)
        </div><div class="casAbstract">Rationale: An antagonist (MK-7123) of the cytokine receptor CXCR2 reduces neutrophil chemotaxis and thus may alleviate airway inflammation in chronic obstructive pulmonary disease (COPD).  Objectives: To assess the efficacy, safety, and tolerability of three dose levels of MK-7123, compared with placebo, in patients with moderate to severe COPD.  Methods: This 6-mo, double-blind study randomized patients with moderate to severe COPD (already on std. therapy) to daily MK-7123 at 10, 30, or 50 mg or placebo.  The primary endpoint was change from baseline in post-bronchodilator FEV1.  Measurements and Main Results: A total of 616 patients (71% male; mean age, 63 yr; 45% current smokers; baseline FEV1 [SD], 1.43 L [0.45]; mean FEV1 percent predicted, 43.9%) were randomized.  Only MK-7123 50 mg led to significant improvement in FEV1 over placebo (mean difference [SE], 67 mL [32]).  Reduced sputum neutrophil count was obsd. among the 122 patients examd.; P = 0.003 (3 mo) and P = 0.092 (6 mo) (MK-7123 50 mg vs. placebo).  The stratum of current smokers, but not that of nonsmokers, showed significant improvement vs. placebo in FEV1 (168 mL) and time-to-first exacerbation, and showed numerical improvement in St.  George's Respiratory Questionnaire for COPD score.  MK-7123 caused a dose-dependent decrease in abs. neutrophil count (ANC) and reduced inflammatory biomarkers matrix metallopeptidase-9 and myeloperoxidase in plasma and sputum; ANC lower than 1.5 × 109/L led to discontinuations with higher doses of MK-7123 (18% in the MK-7123 50-mg group vs. 1% in placebo).  Plasma C-reactive protein and fibrinogen increased with MK-7123 treatment.  Rates of infections at 6 mo were similar in all groups.  Conclusions: Treatment with MK-7123 50 mg vs. placebo led to significant improvement in FEV1 in patients with COPD, suggesting clin. important antiinflammatory effects with CXCR2 antagonism, although dose-related discontinuations were obsd. because of ANC decreases with MK-7123.  Greater response was obsd. in smokers vs. ex-smokers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqoAKNB3Km0H7Vg90H21EOLACvtfcHk0lg4saep-818mQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXptlKmt7k%253D&md5=ff8ee6fb8a25a5e158de81c1344079c5</span></div><a href="/servlet/linkout?suffix=cit6b&amp;dbid=16384&amp;doi=10.1164%2Frccm.201405-0992OC&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1164%252Frccm.201405-0992OC%26sid%3Dliteratum%253Aachs%26aulast%3DRennard%26aufirst%3DS.%2BI.%26aulast%3DDale%26aufirst%3DD.%2BC.%26aulast%3DDonohue%26aufirst%3DJ.%2BF.%26aulast%3DKanniess%26aufirst%3DF.%26aulast%3DMagnussen%26aufirst%3DH.%26aulast%3DSutherland%26aufirst%3DE.%2BR.%26aulast%3DWatz%26aufirst%3DH.%26aulast%3DLu%26aufirst%3DS.%26aulast%3DStryszak%26aufirst%3DP.%26aulast%3DRosenberg%26aufirst%3DE.%26aulast%3DStaudinger%26aufirst%3DH.%26atitle%3DCXCR2%2520antagonist%2520MK-7123.%2520a%2520phase%25202%2520proof-of-concept%2520trial%2520for%2520chronic%2520obstructive%2520pulmonary%2520disease%26jtitle%3DAm.%2520J.%2520Respir.%2520Crit.%2520Care%2520Med.%26date%3D2015%26volume%3D191%26issue%3D9%26spage%3D1001%26epage%3D1011%26doi%3D10.1164%2Frccm.201405-0992OC" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Koch, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kunkel, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shah, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hosaka, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Halloran, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haines, G. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burdick, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pope, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strieter, R. M.</span></span> <span> </span><span class="NLM_article-title">Growth-related gene product alpha. A chemotactic cytokine for neutrophils in rheumatoid arthritis</span>. <i>J. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">1995</span>,  <span class="NLM_volume"><i>155</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">3660</span>– <span class="NLM_lpage">3666</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=155&publication_year=1995&pages=3660-3666&issue=7&author=A.+E.+Kochauthor=S.+L.+Kunkelauthor=M.+R.+Shahauthor=S.+Hosakaauthor=M.+M.+Halloranauthor=G.+K.+Hainesauthor=M.+D.+Burdickauthor=R.+M.+Popeauthor=R.+M.+Strieter&title=Growth-related+gene+product+alpha.+A+chemotactic+cytokine+for+neutrophils+in+rheumatoid+arthritis"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKoch%26aufirst%3DA.%2BE.%26aulast%3DKunkel%26aufirst%3DS.%2BL.%26aulast%3DShah%26aufirst%3DM.%2BR.%26aulast%3DHosaka%26aufirst%3DS.%26aulast%3DHalloran%26aufirst%3DM.%2BM.%26aulast%3DHaines%26aufirst%3DG.%2BK.%26aulast%3DBurdick%26aufirst%3DM.%2BD.%26aulast%3DPope%26aufirst%3DR.%2BM.%26aulast%3DStrieter%26aufirst%3DR.%2BM.%26atitle%3DGrowth-related%2520gene%2520product%2520alpha.%2520A%2520chemotactic%2520cytokine%2520for%2520neutrophils%2520in%2520rheumatoid%2520arthritis%26jtitle%3DJ.%2520Immunol.%26date%3D1995%26volume%3D155%26issue%3D7%26spage%3D3660%26epage%3D3666" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Steele, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karim, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leach, J. D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bailey, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Upstill-Goddard, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rishi, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Foth, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bryson, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McDaid, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eberlein, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Candido, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clarke, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nixon, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Connelly, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jamieson, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carter, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balkwill, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Evans, T. R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strathdee, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Biankin, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nibbs, R. J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barry, S. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sansom, O. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morton, J. P.</span></span> <span> </span><span class="NLM_article-title">CXCR2 inhibition profoundly suppresses metastases and augments immunotherapy in pancreatic ductal adenocarcinoma</span>. <i>Cancer Cell</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">832</span>– <span class="NLM_lpage">845</span>, <span class="refDoi"> DOI: 10.1016/j.ccell.2016.04.014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01854&amp;key=10.1016%2Fj.ccell.2016.04.014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01854&amp;key=27265504" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01854&amp;key=1%3ACAS%3A528%3ADC%252BC28Xpt1enurs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2016&pages=832-845&author=C.+W.+Steeleauthor=S.+A.+Karimauthor=J.+D.+G.+Leachauthor=P.+Baileyauthor=R.+Upstill-Goddardauthor=L.+Rishiauthor=M.+Fothauthor=S.+Brysonauthor=K.+McDaidauthor=Z.+Wilsonauthor=C.+Eberleinauthor=J.+B.+Candidoauthor=M.+Clarkeauthor=C.+Nixonauthor=J.+Connellyauthor=N.+Jamiesonauthor=C.+R.+Carterauthor=F.+Balkwillauthor=D.+K.+Changauthor=T.+R.+J.+Evansauthor=D.+Strathdeeauthor=A.+V.+Biankinauthor=R.+J.+B.+Nibbsauthor=S.+T.+Barryauthor=O.+J.+Sansomauthor=J.+P.+Morton&title=CXCR2+inhibition+profoundly+suppresses+metastases+and+augments+immunotherapy+in+pancreatic+ductal+adenocarcinoma&doi=10.1016%2Fj.ccell.2016.04.014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">CXCR2 Inhibition Profoundly Suppresses Metastases and Augments Immunotherapy in Pancreatic Ductal Adenocarcinoma</span></div><div class="casAuthors">Steele, Colin W.; Karim, Saadia A.; Leach, Joshua D. G.; Bailey, Peter; Upstill-Goddard, Rosanna; Rishi, Loveena; Foth, Mona; Bryson, Sheila; McDaid, Karen; Wilson, Zena; Eberlein, Catherine; Candido, Juliana B.; Clarke, Mairi; Nixon, Colin; Connelly, John; Jamieson, Nigel; Carter, C. Ross; Balkwill, Frances; Chang, David K.; Evans, T. R. Jeffry; Strathdee, Douglas; Biankin, Andrew V.; Nibbs, Robert J. B.; Barry, Simon T.; Sansom, Owen J.; Morton, Jennifer P.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">832-845</span>CODEN:
                <span class="NLM_cas:coden">CCAECI</span>;
        ISSN:<span class="NLM_cas:issn">1535-6108</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">CXCR2 has been suggested to have both tumor-promoting and tumor-suppressive properties.  Here we show that CXCR2 signaling is upregulated in human pancreatic cancer, predominantly in neutrophil/myeloid-derived suppressor cells, but rarely in tumor cells.  Genetic ablation or inhibition of CXCR2 abrogated metastasis, but only inhibition slowed tumorigenesis.  Depletion of neutrophils/myeloid-derived suppressor cells also suppressed metastasis suggesting a key role for CXCR2 in establishing and maintaining the metastatic niche.  Importantly, loss or inhibition of CXCR2 improved T cell entry, and combined inhibition of CXCR2 and PD1 in mice with established disease significantly extended survival.  We show that CXCR2 signaling in the myeloid compartment can promote pancreatic tumorigenesis and is required for pancreatic cancer metastasis, making it an excellent therapeutic target.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGowCJXXdB8AXLVg90H21EOLACvtfcHk0lhV_baECBzGRg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xpt1enurs%253D&md5=1dcdaeae6b2ddf2d486de8a7abbf106d</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1016%2Fj.ccell.2016.04.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccell.2016.04.014%26sid%3Dliteratum%253Aachs%26aulast%3DSteele%26aufirst%3DC.%2BW.%26aulast%3DKarim%26aufirst%3DS.%2BA.%26aulast%3DLeach%26aufirst%3DJ.%2BD.%2BG.%26aulast%3DBailey%26aufirst%3DP.%26aulast%3DUpstill-Goddard%26aufirst%3DR.%26aulast%3DRishi%26aufirst%3DL.%26aulast%3DFoth%26aufirst%3DM.%26aulast%3DBryson%26aufirst%3DS.%26aulast%3DMcDaid%26aufirst%3DK.%26aulast%3DWilson%26aufirst%3DZ.%26aulast%3DEberlein%26aufirst%3DC.%26aulast%3DCandido%26aufirst%3DJ.%2BB.%26aulast%3DClarke%26aufirst%3DM.%26aulast%3DNixon%26aufirst%3DC.%26aulast%3DConnelly%26aufirst%3DJ.%26aulast%3DJamieson%26aufirst%3DN.%26aulast%3DCarter%26aufirst%3DC.%2BR.%26aulast%3DBalkwill%26aufirst%3DF.%26aulast%3DChang%26aufirst%3DD.%2BK.%26aulast%3DEvans%26aufirst%3DT.%2BR.%2BJ.%26aulast%3DStrathdee%26aufirst%3DD.%26aulast%3DBiankin%26aufirst%3DA.%2BV.%26aulast%3DNibbs%26aufirst%3DR.%2BJ.%2BB.%26aulast%3DBarry%26aufirst%3DS.%2BT.%26aulast%3DSansom%26aufirst%3DO.%2BJ.%26aulast%3DMorton%26aufirst%3DJ.%2BP.%26atitle%3DCXCR2%2520inhibition%2520profoundly%2520suppresses%2520metastases%2520and%2520augments%2520immunotherapy%2520in%2520pancreatic%2520ductal%2520adenocarcinoma%26jtitle%3DCancer%2520Cell%26date%3D2016%26volume%3D29%26spage%3D832%26epage%3D845%26doi%3D10.1016%2Fj.ccell.2016.04.014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horner, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paul, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Troncoso, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deng, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spring, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zebala, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maeda, D. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DePinho, R. A.</span></span> <span> </span><span class="NLM_article-title">Effective combinatorial immunotherapy for castration-resistant prostate cancer</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>543</i></span>,  <span class="NLM_fpage">728</span>– <span class="NLM_lpage">732</span>, <span class="refDoi"> DOI: 10.1038/nature21676</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01854&amp;key=10.1038%2Fnature21676" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01854&amp;key=28321130" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01854&amp;key=1%3ACAS%3A528%3ADC%252BC2sXltVWntbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=543&publication_year=2017&pages=728-732&author=X.+Luauthor=J.+W.+Hornerauthor=E.+Paulauthor=X.+Shangauthor=P.+Troncosoauthor=P.+Dengauthor=S.+Jiangauthor=Q.+Changauthor=D.+J.+Springauthor=P.+Sharmaauthor=J.+A.+Zebalaauthor=D.+Y.+Maedaauthor=Y.+A.+Wangauthor=R.+A.+DePinho&title=Effective+combinatorial+immunotherapy+for+castration-resistant+prostate+cancer&doi=10.1038%2Fnature21676"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Effective combinatorial immunotherapy for castration-resistant prostate cancer</span></div><div class="casAuthors">Lu, Xin; Horner, James W.; Paul, Erin; Shang, Xiaoying; Troncoso, Patricia; Deng, Pingna; Jiang, Shan; Chang, Qing; Spring, Denise J.; Sharma, Padmanee; Zebala, John A.; Maeda, Dean Y.; Wang, Y. Alan; DePinho, Ronald A.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">543</span>
        (<span class="NLM_cas:issue">7647</span>),
    <span class="NLM_cas:pages">728-732</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A significant fraction of patients with advanced prostate cancer treated with androgen deprivation therapy experience relapse with relentless progression to lethal metastatic castration-resistant prostate cancer (mCRPC).  Immune checkpoint blockade using antibodies against cytotoxic-T-lymphocyte-assocd. protein 4 (CTLA4) or programmed cell death 1/programmed cell death 1 ligand 1 (PD1/PD-L1) generates durable therapeutic responses in a significant subset of patients across a variety of cancer types.  However, mCRPC showed overwhelming de novo resistance to immune checkpoint blockade, motivating a search for targeted therapies that overcome this resistance.  Myeloid-derived suppressor cells (MDSCs) are known to play important roles in tumor immune evasion.  The abundance of circulating MDSCs correlates with prostate-specific antigen levels and metastasis in patients with prostate cancer.  Mouse models of prostate cancer show that MDSCs (CD11b+Gr1+) promote tumor initiation and progression.  These observations prompted the authors to hypothesize that robust immunotherapy responses in mCRPC may be elicited by the combined actions of immune checkpoint blockade agents together with targeted agents that neutralize MDSCs yet preserve T-cell function.  Here the authors develop a novel chimeric mouse model of mCRPC to efficiently test combination therapies in an autochthonous setting.  Combination of anti-CTLA4 and anti-PD1 engendered only modest efficacy.  Targeted therapy against mCRPC-infiltrating MDSCs, using multi-kinase inhibitors such as cabozantinib and BEZ235, also showed minimal anti-tumor activities.  Strikingly, primary and metastatic CRPC showed robust synergistic responses when immune checkpoint blockade was combined with MDSC-targeted therapy.  Mechanistically, combination therapy efficacy stemmed from the up-regulation of interleukin-1 receptor antagonist and suppression of MDSC-promoting cytokines secreted by prostate cancer cells.  These observations illuminate a clin. path hypothesis for combining immune checkpoint blockade with MDSC-targeted therapies in the treatment of mCRPC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrh7-q_yEgcWrVg90H21EOLACvtfcHk0lhV_baECBzGRg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXltVWntbg%253D&md5=66daee4919d9beaeb083b73a7e686fe7</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1038%2Fnature21676&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature21676%26sid%3Dliteratum%253Aachs%26aulast%3DLu%26aufirst%3DX.%26aulast%3DHorner%26aufirst%3DJ.%2BW.%26aulast%3DPaul%26aufirst%3DE.%26aulast%3DShang%26aufirst%3DX.%26aulast%3DTroncoso%26aufirst%3DP.%26aulast%3DDeng%26aufirst%3DP.%26aulast%3DJiang%26aufirst%3DS.%26aulast%3DChang%26aufirst%3DQ.%26aulast%3DSpring%26aufirst%3DD.%2BJ.%26aulast%3DSharma%26aufirst%3DP.%26aulast%3DZebala%26aufirst%3DJ.%2BA.%26aulast%3DMaeda%26aufirst%3DD.%2BY.%26aulast%3DWang%26aufirst%3DY.%2BA.%26aulast%3DDePinho%26aufirst%3DR.%2BA.%26atitle%3DEffective%2520combinatorial%2520immunotherapy%2520for%2520castration-resistant%2520prostate%2520cancer%26jtitle%3DNature%26date%3D2017%26volume%3D543%26spage%3D728%26epage%3D732%26doi%3D10.1038%2Fnature21676" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, M.</span></span> <span> </span><span class="NLM_article-title">Correlation of C-X-C chemokine receptor 2 upregulation with poor prognosis and recurrence in human glioma</span>. <i>OncoTargets Ther.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">3203</span>– <span class="NLM_lpage">3209</span>, <span class="refDoi"> DOI: 10.2147/OTT.S91626</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01854&amp;key=10.2147%2FOTT.S91626" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01854&amp;key=26586954" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01854&amp;key=1%3ACAS%3A280%3ADC%252BC28rgsVSrsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2015&pages=3203-3209&author=L.+Yangauthor=Z.+Liuauthor=R.+Wuauthor=Q.+Yaoauthor=Z.+Guauthor=M.+Liu&title=Correlation+of+C-X-C+chemokine+receptor+2+upregulation+with+poor+prognosis+and+recurrence+in+human+glioma&doi=10.2147%2FOTT.S91626"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Correlation of C-X-C chemokine receptor 2 upregulation with poor prognosis and recurrence in human glioma</span></div><div class="casAuthors">Yang Liu; Liu Zenghui; Yao Qi; Gu Zhikai; Wu Ronghua; Liu Mei</div><div class="citationInfo"><span class="NLM_cas:title">OncoTargets and therapy</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">3203-9</span>
        ISSN:<span class="NLM_cas:issn">1178-6930</span>.
    </div><div class="casAbstract">C-X-C chemokine receptor 2 (CXCR2), a member of the G-protein-coupled receptor family, is an interleukin-8 receptor and results in the activation of neutrophils.  To date, CXCR2 has been identified with many cell events, including inflammation, neovascularization, metastasis, and cell carcinogenesis.  This study aimed to investigate alterations in the expression of CXCR2 in patients with brain gliomas and relationships with pathological grades and clinicopathological characteristics.  Brain tissue specimens from 60 patients with glioma and 15 patients undergoing surgery for epilepsy (controls) were detected using streptavidin-perosidase immunohistochemistry.  Western blotting was used to evaluate CXCR2 protein levels with fresh tissues derived from glioma cases or controls.  Correlations between CXCR2 expression and clinicopathological characteristics were analyzed using SPSS software.  The results showed high-grade gliomas with high CXCR2 expression as compared with normal tissues.  The expression of CXCR2 was significantly related to high grades and recurrence of tumor but not to age or sex.  During an in vitro wound healing assay, U251 migration was reduced when the CXCR2-specific inhibitor SB225002 was applied.  Our results suggested that the high expression of CXCR2 in gliomas was closely correlated to the degree of malignancy and recurrence and that CXCR2 inhibition decreased the migration of glioma cells.  Therefore, CXCR2 may serve as a potential therapeutic target for the recurrence and migration of gliomas.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSaWQI_kNsvcAHqQV89nF-2fW6udTcc2eYrmg9VnrsINrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28rgsVSrsg%253D%253D&md5=7a6b8b247214f25d5348ca7dd018deff</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.2147%2FOTT.S91626&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252FOTT.S91626%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DL.%26aulast%3DLiu%26aufirst%3DZ.%26aulast%3DWu%26aufirst%3DR.%26aulast%3DYao%26aufirst%3DQ.%26aulast%3DGu%26aufirst%3DZ.%26aulast%3DLiu%26aufirst%3DM.%26atitle%3DCorrelation%2520of%2520C-X-C%2520chemokine%2520receptor%25202%2520upregulation%2520with%2520poor%2520prognosis%2520and%2520recurrence%2520in%2520human%2520glioma%26jtitle%3DOncoTargets%2520Ther.%26date%3D2015%26volume%3D8%26spage%3D3203%26epage%3D3209%26doi%3D10.2147%2FOTT.S91626" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Veenstra, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ransohoff, R. M.</span></span> <span> </span><span class="NLM_article-title">Chemokine receptor CXCR2: physiology regulator and neuroinflammation controller?</span>. <i>J. Neuroimmunol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>246</i></span> (<span class="NLM_issue">1–2</span>),  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">9</span>, <span class="refDoi"> DOI: 10.1016/j.jneuroim.2012.02.016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01854&amp;key=10.1016%2Fj.jneuroim.2012.02.016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01854&amp;key=22445294" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01854&amp;key=1%3ACAS%3A528%3ADC%252BC38XktlGrtLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=246&publication_year=2012&pages=1-9&issue=1%E2%80%932&author=M.+Veenstraauthor=R.+M.+Ransohoff&title=Chemokine+receptor+CXCR2%3A+physiology+regulator+and+neuroinflammation+controller%3F&doi=10.1016%2Fj.jneuroim.2012.02.016"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11aR"><div class="casContent"><span class="casTitleNuber">11a</span><div class="casTitle"><span class="NLM_cas:atitle">Chemokine receptor CXCR2: Physiology regulator and neuroinflammation controller?</span></div><div class="casAuthors">Veenstra, Mike; Ransohoff, Richard M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neuroimmunology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">246</span>
        (<span class="NLM_cas:issue">1-2</span>),
    <span class="NLM_cas:pages">1-9</span>CODEN:
                <span class="NLM_cas:coden">JNRIDW</span>;
        ISSN:<span class="NLM_cas:issn">0165-5728</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  The innate immune system is a crucial component of inflammatory reactions, while the central nervous system (CNS) is the most vulnerable site of the body to inflammatory tissue injury.  Neuroinflammatory brain pathologies are disorders in which the CNS is threatened by its own immune system.  Chemokine receptor CXCR2 and its ligands have been implicated in several neuroinflammatory brain pathologies, as well as in neutrophil recruitment and in the developmental positioning of neural cells.  This review focuses on the basics of CXCR2, its regulating role in bone marrow neutrophil recruitment, oligodendrocyte progenitor cell positioning and neural repair mechanisms, as well as its diverse roles in neuroinflammatory brain pathologies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqymMsAIWT3DbVg90H21EOLACvtfcHk0lgW39drXfGVnw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XktlGrtLY%253D&md5=b2bae645562bb600d1af93a45d247d8c</span></div><a href="/servlet/linkout?suffix=cit11a&amp;dbid=16384&amp;doi=10.1016%2Fj.jneuroim.2012.02.016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jneuroim.2012.02.016%26sid%3Dliteratum%253Aachs%26aulast%3DVeenstra%26aufirst%3DM.%26aulast%3DRansohoff%26aufirst%3DR.%2BM.%26atitle%3DChemokine%2520receptor%2520CXCR2%253A%2520physiology%2520regulator%2520and%2520neuroinflammation%2520controller%253F%26jtitle%3DJ.%2520Neuroimmunol.%26date%3D2012%26volume%3D246%26issue%3D1%25E2%2580%25932%26spage%3D1%26epage%3D9%26doi%3D10.1016%2Fj.jneuroim.2012.02.016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit11b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Semple, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kossmann, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morganti-Kossmann, M. C.</span></span> <span> </span><span class="NLM_article-title">Role of chemokines in CNS health and pathology: a focus on the CCL2/CCR2 and CXCL8/CXCR2 networks</span>. <i>J. Cereb. Blood Flow Metab.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>30</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">459</span>– <span class="NLM_lpage">473</span>, <span class="refDoi"> DOI: 10.1038/jcbfm.2009.240</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01854&amp;key=10.1038%2Fjcbfm.2009.240" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01854&amp;key=19904283" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01854&amp;key=1%3ACAS%3A528%3ADC%252BC3cXisF2htbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2010&pages=459-473&issue=3&author=B.+D.+Sempleauthor=T.+Kossmannauthor=M.+C.+Morganti-Kossmann&title=Role+of+chemokines+in+CNS+health+and+pathology%3A+a+focus+on+the+CCL2%2FCCR2+and+CXCL8%2FCXCR2+networks&doi=10.1038%2Fjcbfm.2009.240"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11bR"><div class="casContent"><span class="casTitleNuber">11b</span><div class="casTitle"><span class="NLM_cas:atitle">Role of chemokines in CNS health and pathology: a focus on the CCL2/CCR2 and CXCL8/CXCR2 networks</span></div><div class="casAuthors">Semple, Bridgette D.; Kossmann, Thomas; Morganti-Kossmann, Maria Cristina</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cerebral Blood Flow & Metabolism</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">459-473</span>CODEN:
                <span class="NLM_cas:coden">JCBMDN</span>;
        ISSN:<span class="NLM_cas:issn">0271-678X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Chemokines and their receptors have crucial roles in the trafficking of leukocytes, and are of particular interest in the context of the unique immune responses elicited in the central nervous system (CNS).  The chemokine system CC ligand 2 (CCL2) with its receptor CC receptor 2 (CCR2), as well as the receptor CXCR2 and its multiple ligands CXCL1, CXCL2 and CXCL8, have been implicated in a wide range of neuropathologies, including trauma, ischemic injury and multiple sclerosis.  This review aims to overview the current understanding of chemokines as mediators of leukocyte migration into the CNS under neuroinflammatory conditions.  We will specifically focus on the involvement of two chemokine networks, namely CCL2/CCR2 and CXCL8/CXCR2, in promoting macrophage and neutrophil infiltration, resp., into the lesioned parenchyma after focal traumatic brain injury.  The constitutive brain expression of these chemokines and their receptors, including their recently identified roles in the modulation of neuroprotection, neurogenesis, and neurotransmission, will be discussed.  In conclusion, the value of evidence obtained from the use of Ccl2- and Cxcr2-deficient mice will be reported, in the context of potential therapeutics inhibiting chemokine activity which are currently in clin. trial for various inflammatory diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqeX4Qux2JPI7Vg90H21EOLACvtfcHk0lgW39drXfGVnw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXisF2htbY%253D&md5=7150522e070aa6564823e514221bbbf7</span></div><a href="/servlet/linkout?suffix=cit11b&amp;dbid=16384&amp;doi=10.1038%2Fjcbfm.2009.240&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fjcbfm.2009.240%26sid%3Dliteratum%253Aachs%26aulast%3DSemple%26aufirst%3DB.%2BD.%26aulast%3DKossmann%26aufirst%3DT.%26aulast%3DMorganti-Kossmann%26aufirst%3DM.%2BC.%26atitle%3DRole%2520of%2520chemokines%2520in%2520CNS%2520health%2520and%2520pathology%253A%2520a%2520focus%2520on%2520the%2520CCL2%252FCCR2%2520and%2520CXCL8%252FCXCR2%2520networks%26jtitle%3DJ.%2520Cereb.%2520Blood%2520Flow%2520Metab.%26date%3D2010%26volume%3D30%26issue%3D3%26spage%3D459%26epage%3D473%26doi%3D10.1038%2Fjcbfm.2009.240" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit11c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Melik-Parsadaniantz, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rostene, W.</span></span> <span> </span><span class="NLM_article-title">Chemokines and neuromodulation</span>. <i>J. Neuroimmunol.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>198</i></span> (<span class="NLM_issue">1–2</span>),  <span class="NLM_fpage">62</span>– <span class="NLM_lpage">68</span>, <span class="refDoi"> DOI: 10.1016/j.jneuroim.2008.04.022</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01854&amp;key=10.1016%2Fj.jneuroim.2008.04.022" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01854&amp;key=18538863" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01854&amp;key=1%3ACAS%3A528%3ADC%252BD1cXoslGgsbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=198&publication_year=2008&pages=62-68&issue=1%E2%80%932&author=S.+Melik-Parsadaniantzauthor=W.+Rostene&title=Chemokines+and+neuromodulation&doi=10.1016%2Fj.jneuroim.2008.04.022"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11cR"><div class="casContent"><span class="casTitleNuber">11c</span><div class="casTitle"><span class="NLM_cas:atitle">Chemokines and neuromodulation</span></div><div class="casAuthors">Melik-Parsadaniantz, Stephane; Rostene, William</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neuroimmunology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">198</span>
        (<span class="NLM_cas:issue">1-2</span>),
    <span class="NLM_cas:pages">62-68</span>CODEN:
                <span class="NLM_cas:coden">JNRIDW</span>;
        ISSN:<span class="NLM_cas:issn">0165-5728</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Chemokines are not only mediators of the immune system and expressed in inflammatory situations.  They are also constitutively expressed in the brain in both glial cells and neurons.  Several recent evidence suggest that they can have a neurotransmitter/neuromodulatory role on brain functions similar to several neuropeptides reported so far.  The aim of this short review is to illustrate that point using two chemokine systems, SDF-1/CXCL12 and its receptor CXCR4 and MCP-1/CCL2 and its receptor CCR2.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrTVjsIs1WaTbVg90H21EOLACvtfcHk0li5eNIJXcX91w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXoslGgsbY%253D&md5=a5b4862f735d6dcf35990defa51d83c9</span></div><a href="/servlet/linkout?suffix=cit11c&amp;dbid=16384&amp;doi=10.1016%2Fj.jneuroim.2008.04.022&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jneuroim.2008.04.022%26sid%3Dliteratum%253Aachs%26aulast%3DMelik-Parsadaniantz%26aufirst%3DS.%26aulast%3DRostene%26aufirst%3DW.%26atitle%3DChemokines%2520and%2520neuromodulation%26jtitle%3DJ.%2520Neuroimmunol.%26date%3D2008%26volume%3D198%26issue%3D1%25E2%2580%25932%26spage%3D62%26epage%3D68%26doi%3D10.1016%2Fj.jneuroim.2008.04.022" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Du, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, X. G.</span></span> <span> </span><span class="NLM_article-title">protein-coupled receptors as therapeutic targets for multiple sclerosis</span>. <i>Cell Res.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>22</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">1108</span>– <span class="NLM_lpage">1128</span>, <span class="refDoi"> DOI: 10.1038/cr.2012.87</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01854&amp;key=10.1038%2Fcr.2012.87" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01854&amp;key=22664908" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01854&amp;key=1%3ACAS%3A528%3ADC%252BC38Xpsl2isbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2012&pages=1108-1128&issue=7&author=C.+S.+Duauthor=X.+G.+Xie&title=protein-coupled+receptors+as+therapeutic+targets+for+multiple+sclerosis&doi=10.1038%2Fcr.2012.87"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">G protein-coupled receptors as therapeutic targets for multiple sclerosis</span></div><div class="casAuthors">Du, Changsheng; Xie, Xin</div><div class="citationInfo"><span class="NLM_cas:title">Cell Research</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1108-1128</span>CODEN:
                <span class="NLM_cas:coden">CREEB6</span>;
        ISSN:<span class="NLM_cas:issn">1001-0602</span>.
    
            (<span class="NLM_cas:orgname">NPG Nature Asia-Pacific</span>)
        </div><div class="casAbstract">A review.  G protein-coupled receptors (GPCRs) mediate most of our physiol. responses to hormones, neurotransmitters and environmental stimulants.  They are considered as the most successful therapeutic targets for a broad spectrum of diseases.  Multiple sclerosis (MS) is an inflammatory disease that is characterized by immune-mediated demyelination and degeneration of the central nervous system (CNS).  It is the leading cause of non-traumatic disability in young adults.  Great progress has been made over the past few decades in understanding the pathogenesis of MS.  Numerous data from animal and clin. studies indicate that many GPCRs are critically involved in various aspects of MS pathogenesis, including antigen presentation, cytokine prodn., T-cell differentiation, T-cell proliferation, T-cell invasion, etc.  In this review, we summarize the recent findings regarding the expression or functional changes of GPCRs in MS patients or animal models, and the influences of GPCRs on disease severity upon genetic or pharmacol. manipulations.  Hopefully some of these findings will lead to the development of novel therapies for MS in the near future.  Cell Research (2012) 22:1108-1128. doi:10.1038/cr.2012.87; published online 5 June 2012.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrpXXysrXy5SbVg90H21EOLACvtfcHk0li5eNIJXcX91w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xpsl2isbs%253D&md5=843512eaf86556f5eaaad867ac134adc</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1038%2Fcr.2012.87&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fcr.2012.87%26sid%3Dliteratum%253Aachs%26aulast%3DDu%26aufirst%3DC.%2BS.%26aulast%3DXie%26aufirst%3DX.%2BG.%26atitle%3Dprotein-coupled%2520receptors%2520as%2520therapeutic%2520targets%2520for%2520multiple%2520sclerosis%26jtitle%3DCell%2520Res.%26date%3D2012%26volume%3D22%26issue%3D7%26spage%3D1108%26epage%3D1128%26doi%3D10.1038%2Fcr.2012.87" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.-F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Y.-F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, S.-W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, W.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Q.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ge, L.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, R.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.-F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, Z.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, G.-H.</span></span> <span> </span><span class="NLM_article-title">CXCL1 triggers caspase-3 dependent tau cleavage in long-term neuronal cultures and in the hippocampus of aged mice: implications in Alzheimer’s disease</span>. <i>J. Alzheimer's Dis.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>48</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">89</span>– <span class="NLM_lpage">104</span>, <span class="refDoi"> DOI: 10.3233/JAD-150041</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01854&amp;key=10.3233%2FJAD-150041" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01854&amp;key=26401931" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01854&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsFyit7%252FO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2015&pages=89-104&issue=1&author=X.-F.+Zhangauthor=Y.-F.+Zhaoauthor=S.-W.+Zhuauthor=W.-J.+Huangauthor=Y.+Luoauthor=Q.-Y.+Chenauthor=L.-J.+Geauthor=R.-S.+Liauthor=J.-F.+Wangauthor=M.+Sunauthor=Z.-C.+Xiaoauthor=G.-H.+Fan&title=CXCL1+triggers+caspase-3+dependent+tau+cleavage+in+long-term+neuronal+cultures+and+in+the+hippocampus+of+aged+mice%3A+implications+in+Alzheimer%E2%80%99s+disease&doi=10.3233%2FJAD-150041"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">CXCL1 Triggers Caspase-3 Dependent Tau Cleavage in Long-Term Neuronal Cultures and in the Hippocampus of Aged Mice: Implications in Alzheimer's Disease</span></div><div class="casAuthors">Zhang, Xiao-Fang; Zhao, Yan-Feng; Zhu, Shun-Wei; Huang, Wei-Jie; Luo, Yan; Chen, Qing-Ying; Ge, Li-Jun; Li, Run-Sheng; Wang, Jian-Fei; Sun, Mu; Xiao, Zhi-Cheng; Fan, Guo-Huang</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Alzheimer's Disease</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">89-104</span>CODEN:
                <span class="NLM_cas:coden">JADIF9</span>;
        ISSN:<span class="NLM_cas:issn">1387-2877</span>.
    
            (<span class="NLM_cas:orgname">IOS Press</span>)
        </div><div class="casAbstract">Truncation of tau protein is considered an early event in Alzheimer's disease (AD) and is believed to play a major pathogenic role in sporadic AD.  However, causative factors that trigger tau truncation in AD remain poorly understood.  In the present study, we demonstrate that CXCL1 (C-X-C motif ligand 1), a specific ligand for the chemokine receptor CXCR2, induced cleavage of tau at ASP421 in a caspase-3-dependent manner in long-term but not short-term cultured neurons.  The cleaved tau formed varicosities or bead-like structures along the neurites, an abnormal distribution of tau induced by CXCL1 that has not been obsd. previously.  CXCL1-induced activation of GSK3β and the subsequent phosphorylation of tau preceded and were required for caspase-3 activation and tau cleavage.  Moreover, intrahippocampal microinjection of lentiviral CXCL1 induced tau cleavage in hippocampal neurons in aged (15-18 mo of age) but not adult mice (5-10 mo of age).  Our data highlight a new role of CXCR2 in tau cleavage and suggest that targeting CXCR2 may offer therapeutic benefits to patients with AD and potentially other tauopathies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoeGiYjnZjJUrVg90H21EOLACvtfcHk0li5eNIJXcX91w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsFyit7%252FO&md5=b8fa7c85dea78585af77d0cd738a4aea</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.3233%2FJAD-150041&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3233%252FJAD-150041%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DX.-F.%26aulast%3DZhao%26aufirst%3DY.-F.%26aulast%3DZhu%26aufirst%3DS.-W.%26aulast%3DHuang%26aufirst%3DW.-J.%26aulast%3DLuo%26aufirst%3DY.%26aulast%3DChen%26aufirst%3DQ.-Y.%26aulast%3DGe%26aufirst%3DL.-J.%26aulast%3DLi%26aufirst%3DR.-S.%26aulast%3DWang%26aufirst%3DJ.-F.%26aulast%3DSun%26aufirst%3DM.%26aulast%3DXiao%26aufirst%3DZ.-C.%26aulast%3DFan%26aufirst%3DG.-H.%26atitle%3DCXCL1%2520triggers%2520caspase-3%2520dependent%2520tau%2520cleavage%2520in%2520long-term%2520neuronal%2520cultures%2520and%2520in%2520the%2520hippocampus%2520of%2520aged%2520mice%253A%2520implications%2520in%2520Alzheimer%25E2%2580%2599s%2520disease%26jtitle%3DJ.%2520Alzheimer%2527s%2520Dis.%26date%3D2015%26volume%3D48%26issue%3D1%26spage%3D89%26epage%3D104%26doi%3D10.3233%2FJAD-150041" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Z.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, D.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ji, R.-R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, Y.-J.</span></span> <span> </span><span class="NLM_article-title">Chemokine contribution to neuropathic pain: respective induction of CXCL1 and CXCR2 in spinal cord astrocytes and neurons</span>. <i>Pain</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>154</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">2185</span>– <span class="NLM_lpage">2197</span>, <span class="refDoi"> DOI: 10.1016/j.pain.2013.07.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01854&amp;key=10.1016%2Fj.pain.2013.07.002" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=154&publication_year=2013&pages=2185-2197&issue=10&author=Z.-J.+Zhangauthor=D.-L.+Caoauthor=X.+Zhangauthor=R.-R.+Jiauthor=Y.-J.+Gao&title=Chemokine+contribution+to+neuropathic+pain%3A+respective+induction+of+CXCL1+and+CXCR2+in+spinal+cord+astrocytes+and+neurons&doi=10.1016%2Fj.pain.2013.07.002"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1016%2Fj.pain.2013.07.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pain.2013.07.002%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DZ.-J.%26aulast%3DCao%26aufirst%3DD.-L.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DJi%26aufirst%3DR.-R.%26aulast%3DGao%26aufirst%3DY.-J.%26atitle%3DChemokine%2520contribution%2520to%2520neuropathic%2520pain%253A%2520respective%2520induction%2520of%2520CXCL1%2520and%2520CXCR2%2520in%2520spinal%2520cord%2520astrocytes%2520and%2520neurons%26jtitle%3DPain%26date%3D2013%26volume%3D154%26issue%3D10%26spage%3D2185%26epage%3D2197%26doi%3D10.1016%2Fj.pain.2013.07.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">White, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hertzberg, R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jurewicz, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chaikin, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Widdowson, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Foley, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, L. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griswold, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sarau, H. M.</span></span> <span> </span><span class="NLM_article-title">Identification of a potent, selective non-peptide CXCR2 antagonist that inhibits interleukin-8-induced neutrophil migration</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>273</i></span> (<span class="NLM_issue">17</span>),  <span class="NLM_fpage">10095</span>– <span class="NLM_lpage">10098</span>, <span class="refDoi"> DOI: 10.1074/jbc.273.17.10095</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01854&amp;key=10.1074%2Fjbc.273.17.10095" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=273&publication_year=1998&pages=10095-10098&issue=17&author=J.+R.+Whiteauthor=J.+M.+Leeauthor=P.+R.+Youngauthor=R.+P.+Hertzbergauthor=A.+J.+Jurewiczauthor=M.+A.+Chaikinauthor=K.+Widdowsonauthor=J.+J.+Foleyauthor=L.+D.+Martinauthor=D.+E.+Griswoldauthor=H.+M.+Sarau&title=Identification+of+a+potent%2C+selective+non-peptide+CXCR2+antagonist+that+inhibits+interleukin-8-induced+neutrophil+migration&doi=10.1074%2Fjbc.273.17.10095"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1074%2Fjbc.273.17.10095&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.273.17.10095%26sid%3Dliteratum%253Aachs%26aulast%3DWhite%26aufirst%3DJ.%2BR.%26aulast%3DLee%26aufirst%3DJ.%2BM.%26aulast%3DYoung%26aufirst%3DP.%2BR.%26aulast%3DHertzberg%26aufirst%3DR.%2BP.%26aulast%3DJurewicz%26aufirst%3DA.%2BJ.%26aulast%3DChaikin%26aufirst%3DM.%2BA.%26aulast%3DWiddowson%26aufirst%3DK.%26aulast%3DFoley%26aufirst%3DJ.%2BJ.%26aulast%3DMartin%26aufirst%3DL.%2BD.%26aulast%3DGriswold%26aufirst%3DD.%2BE.%26aulast%3DSarau%26aufirst%3DH.%2BM.%26atitle%3DIdentification%2520of%2520a%2520potent%252C%2520selective%2520non-peptide%2520CXCR2%2520antagonist%2520that%2520inhibits%2520interleukin-8-induced%2520neutrophil%2520migration%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1998%26volume%3D273%26issue%3D17%26spage%3D10095%26epage%3D10098%26doi%3D10.1074%2Fjbc.273.17.10095" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Bertini, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allegretti, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bizzarri, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moriconi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Locati, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zampella, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cervellera, M. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">di Cioccio, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cesta, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galliera, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martinez, F. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Bitondo, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Troiani, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sabbatini, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">D’Anniballe, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anacardio, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cutrin, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cavalieri, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mainiero, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strippoli, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Villa, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Girolamo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gentile, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Santoni, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corda, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poli, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mantovani, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghezzi, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colotta, F.</span></span> <span> </span><span class="NLM_article-title">Noncompetitive allosteric inhibitors of the inflammatory chemokine receptors CXCR1 and CXCR2: Prevention of reperfusion injury</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>101</i></span> (<span class="NLM_issue">32</span>),  <span class="NLM_fpage">11791</span>– <span class="NLM_lpage">11796</span>, <span class="refDoi"> DOI: 10.1073/pnas.0402090101</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01854&amp;key=10.1073%2Fpnas.0402090101" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=101&publication_year=2004&pages=11791-11796&issue=32&author=R.+Bertiniauthor=M.+Allegrettiauthor=C.+Bizzarriauthor=A.+Moriconiauthor=M.+Locatiauthor=G.+Zampellaauthor=M.+N.+Cervelleraauthor=V.+di+Cioccioauthor=M.+C.+Cestaauthor=E.+Gallieraauthor=F.+O.+Martinezauthor=R.+Di+Bitondoauthor=G.+Troianiauthor=V.+Sabbatiniauthor=G.+D%E2%80%99Anniballeauthor=R.+Anacardioauthor=J.+C.+Cutrinauthor=B.+Cavalieriauthor=F.+Mainieroauthor=R.+Strippoliauthor=P.+Villaauthor=M.+Di+Girolamoauthor=F.+Martinauthor=M.+Gentileauthor=A.+Santoniauthor=D.+Cordaauthor=G.+Poliauthor=A.+Mantovaniauthor=P.+Ghezziauthor=F.+Colotta&title=Noncompetitive+allosteric+inhibitors+of+the+inflammatory+chemokine+receptors+CXCR1+and+CXCR2%3A+Prevention+of+reperfusion+injury&doi=10.1073%2Fpnas.0402090101"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16a&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0402090101&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0402090101%26sid%3Dliteratum%253Aachs%26aulast%3DBertini%26aufirst%3DR.%26aulast%3DAllegretti%26aufirst%3DM.%26aulast%3DBizzarri%26aufirst%3DC.%26aulast%3DMoriconi%26aufirst%3DA.%26aulast%3DLocati%26aufirst%3DM.%26aulast%3DZampella%26aufirst%3DG.%26aulast%3DCervellera%26aufirst%3DM.%2BN.%26aulast%3Ddi%2BCioccio%26aufirst%3DV.%26aulast%3DCesta%26aufirst%3DM.%2BC.%26aulast%3DGalliera%26aufirst%3DE.%26aulast%3DMartinez%26aufirst%3DF.%2BO.%26aulast%3DDi%2BBitondo%26aufirst%3DR.%26aulast%3DTroiani%26aufirst%3DG.%26aulast%3DSabbatini%26aufirst%3DV.%26aulast%3DD%25E2%2580%2599Anniballe%26aufirst%3DG.%26aulast%3DAnacardio%26aufirst%3DR.%26aulast%3DCutrin%26aufirst%3DJ.%2BC.%26aulast%3DCavalieri%26aufirst%3DB.%26aulast%3DMainiero%26aufirst%3DF.%26aulast%3DStrippoli%26aufirst%3DR.%26aulast%3DVilla%26aufirst%3DP.%26aulast%3DDi%2BGirolamo%26aufirst%3DM.%26aulast%3DMartin%26aufirst%3DF.%26aulast%3DGentile%26aufirst%3DM.%26aulast%3DSantoni%26aufirst%3DA.%26aulast%3DCorda%26aufirst%3DD.%26aulast%3DPoli%26aufirst%3DG.%26aulast%3DMantovani%26aufirst%3DA.%26aulast%3DGhezzi%26aufirst%3DP.%26aulast%3DColotta%26aufirst%3DF.%26atitle%3DNoncompetitive%2520allosteric%2520inhibitors%2520of%2520the%2520inflammatory%2520chemokine%2520receptors%2520CXCR1%2520and%2520CXCR2%253A%2520Prevention%2520of%2520reperfusion%2520injury%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2004%26volume%3D101%26issue%3D32%26spage%3D11791%26epage%3D11796%26doi%3D10.1073%2Fpnas.0402090101" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit16b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Chapman, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phillips, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hipkin, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Curran, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lundell, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fine, J. S.</span></span> <span> </span><span class="NLM_article-title">CXCR2 antagonists for the treatment of pulmonary disease</span>. <i>Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>121</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">55</span>– <span class="NLM_lpage">68</span>, <span class="refDoi"> DOI: 10.1016/j.pharmthera.2008.10.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01854&amp;key=10.1016%2Fj.pharmthera.2008.10.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01854&amp;key=19026683" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01854&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhsFagtrrJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=121&publication_year=2009&pages=55-68&issue=1&author=R.+W.+Chapmanauthor=J.+E.+Phillipsauthor=R.+W.+Hipkinauthor=A.+K.+Curranauthor=D.+Lundellauthor=J.+S.+Fine&title=CXCR2+antagonists+for+the+treatment+of+pulmonary+disease&doi=10.1016%2Fj.pharmthera.2008.10.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16bR"><div class="casContent"><span class="casTitleNuber">16b</span><div class="casTitle"><span class="NLM_cas:atitle">CXCR2 antagonists for the treatment of pulmonary disease</span></div><div class="casAuthors">Chapman, R. W.; Phillips, J. E.; Hipkin, R. W.; Curran, A. K.; Lundell, D.; Fine, J. S.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacology & Therapeutics</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">121</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">55-68</span>CODEN:
                <span class="NLM_cas:coden">PHTHDT</span>;
        ISSN:<span class="NLM_cas:issn">0163-7258</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  Chemokines have long been implicated in the initiation and amplification of inflammatory responses by virtue of their role in leukocyte chemotaxis.  The expression of one of the receptors for these chemokines, CXCR2, on a variety of cell types and tissues suggests that these receptors may have a broad functional role under both constitutive conditions and in the pathophysiol. of a no. of acute and chronic diseases.  With the development of several pharmacol., immunol. and genetic tools to study CXCR2 function, an important role for this CXC chemokine receptor subtype has been identified in chronic obstructive pulmonary disease (COPD), asthma and fibrotic pulmonary disorders.  Interference with CXCR2 receptor function has demonstrated different effects in the lungs including inhibition of pulmonary damage induced by neutrophils (PMNs), antigen or irritant-induced goblet cell hyperplasia and angiogenesis/collagen deposition caused by lung injury.  Many of these features are common to inflammatory and fibrotic disorders of the lung.  Clin. trials evaluating small mol. CXCR2 antagonists in COPD, asthma and cystic fibrosis are currently underway.  These studies hold considerable promise for identifying novel and efficacious treatments of pulmonary disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpPf1-c-1ciWrVg90H21EOLACvtfcHk0lib4jxPEEjecA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhsFagtrrJ&md5=37a5047ab1b8a37739311d273dd7d854</span></div><a href="/servlet/linkout?suffix=cit16b&amp;dbid=16384&amp;doi=10.1016%2Fj.pharmthera.2008.10.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pharmthera.2008.10.005%26sid%3Dliteratum%253Aachs%26aulast%3DChapman%26aufirst%3DR.%2BW.%26aulast%3DPhillips%26aufirst%3DJ.%2BE.%26aulast%3DHipkin%26aufirst%3DR.%2BW.%26aulast%3DCurran%26aufirst%3DA.%2BK.%26aulast%3DLundell%26aufirst%3DD.%26aulast%3DFine%26aufirst%3DJ.%2BS.%26atitle%3DCXCR2%2520antagonists%2520for%2520the%2520treatment%2520of%2520pulmonary%2520disease%26jtitle%3DPharmacol.%2520Ther.%26date%3D2009%26volume%3D121%26issue%3D1%26spage%3D55%26epage%3D68%26doi%3D10.1016%2Fj.pharmthera.2008.10.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit16c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Opfermann, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Derhaschnig, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Felli, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wenisch, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Santer, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zuckermann, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dworschak, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jilma, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steinlechner, B.</span></span> <span> </span><span class="NLM_article-title">A pilot study on reparixin, a CXCR1/2 antagonist, to assess safety and efficacy in attenuating ischaemia-reperfusion injury and inflammation after on-pump coronary artery bypass graft surgery</span>. <i>Clin. Exp. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>180</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">131</span>– <span class="NLM_lpage">142</span>, <span class="refDoi"> DOI: 10.1111/cei.12488</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01854&amp;key=10.1111%2Fcei.12488" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01854&amp;key=25402332" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01854&amp;key=1%3ACAS%3A528%3ADC%252BC2MXjvFyktr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=180&publication_year=2015&pages=131-142&issue=1&author=P.+Opfermannauthor=U.+Derhaschnigauthor=A.+Felliauthor=J.+Wenischauthor=D.+Santerauthor=A.+Zuckermannauthor=M.+Dworschakauthor=B.+Jilmaauthor=B.+Steinlechner&title=A+pilot+study+on+reparixin%2C+a+CXCR1%2F2+antagonist%2C+to+assess+safety+and+efficacy+in+attenuating+ischaemia-reperfusion+injury+and+inflammation+after+on-pump+coronary+artery+bypass+graft+surgery&doi=10.1111%2Fcei.12488"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16cR"><div class="casContent"><span class="casTitleNuber">16c</span><div class="casTitle"><span class="NLM_cas:atitle">A pilot study on reparixin, a CXCR1/2 antagonist, to assess safety and efficacy in attenuating ischaemia-reperfusion injury and inflammation after on-pump coronary artery bypass graft surgery</span></div><div class="casAuthors">Opfermann, P.; Derhaschnig, U.; Felli, A.; Wenisch, J.; Santer, D.; Zuckermann, A.; Dworschak, M.; Jilma, B.; Steinlechner, B.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical & Experimental Immunology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">180</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">131-142</span>CODEN:
                <span class="NLM_cas:coden">CEXIAL</span>;
        ISSN:<span class="NLM_cas:issn">0009-9104</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Summary : Reparixin, a CXCR 1/2 antagonist, has been shown to mitigate ischemia-reperfusion injury (IRI) in various organ systems in animals, but data in humans are scarce.  The aim of this double-blinded, placebo-controlled pilot study was to evaluate the safety and efficacy of reparixin to suppress IRI and inflammation in patients undergoing on-pump coronary artery bypass grafting (CABG).  Patients received either reparixin or placebo (n = 16 in each group) after induction of anesthesia until 8 h after cardiopulmonary bypass (CPB).  We compared markers of systemic and pulmonary inflammation, surrogates of myocardial IRI and clin. outcomes using Mann-Whitney U- and Fisher's exact tests.  Thirty- and 90-day mortality was 0% in both groups.  No side effects were obsd. in the treatment group.  Surgical revision, pleural and pericardial effusion, infection and atrial fibrillation rates were not different between groups.  Reparixin significantly reduced the proportion of neutrophil granulocytes in blood at the beginning [49%, interquartile range (IQR) = 45-57 vs. 58%, IQR = 53-66, P = 0·035], end (71%, IQR = 67-76 vs. 79%, IQR = 71-83, P = 0·023) and 1 h after CPB (73%, IQR = 71-75 vs. 77%, IQR = 72-80, P = 0·035).  Reparixin patients required a lesser pos. fluid balance during surgery (2575 mL, IQR = 2027-3080 vs. 3200 mL, IQR = 2928-3778, P = 0·029) and during ICU stay (2603 mL, IQR = 1023-4288 vs. 4200 mL, IQR = 2313-8160, P = 0·021).  Numerically, more control patients required noradrenaline ≥ 0·11 μg/kg/min (50 vs. 19%, P = 0·063) and dobutamine (50 vs. 25%, P = 0·14).  Therefore, administration of reparixin in CABG patients appears to be feasible and safe.  It concurrently attenuated postoperative granulocytosis in peripheral blood.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGob_XhfQP58LbVg90H21EOLACvtfcHk0lib4jxPEEjecA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXjvFyktr0%253D&md5=8300dc5f57fd2abb79a3984f95d79efc</span></div><a href="/servlet/linkout?suffix=cit16c&amp;dbid=16384&amp;doi=10.1111%2Fcei.12488&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fcei.12488%26sid%3Dliteratum%253Aachs%26aulast%3DOpfermann%26aufirst%3DP.%26aulast%3DDerhaschnig%26aufirst%3DU.%26aulast%3DFelli%26aufirst%3DA.%26aulast%3DWenisch%26aufirst%3DJ.%26aulast%3DSanter%26aufirst%3DD.%26aulast%3DZuckermann%26aufirst%3DA.%26aulast%3DDworschak%26aufirst%3DM.%26aulast%3DJilma%26aufirst%3DB.%26aulast%3DSteinlechner%26aufirst%3DB.%26atitle%3DA%2520pilot%2520study%2520on%2520reparixin%252C%2520a%2520CXCR1%252F2%2520antagonist%252C%2520to%2520assess%2520safety%2520and%2520efficacy%2520in%2520attenuating%2520ischaemia-reperfusion%2520injury%2520and%2520inflammation%2520after%2520on-pump%2520coronary%2520artery%2520bypass%2520graft%2520surgery%26jtitle%3DClin.%2520Exp.%2520Immunol.%26date%3D2015%26volume%3D180%26issue%3D1%26spage%3D131%26epage%3D142%26doi%3D10.1111%2Fcei.12488" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nicholls, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiley, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dainty, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">MacIntosh, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phillips, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gaw, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mårdh, C. K.</span></span> <span> </span><span class="NLM_article-title">Pharmacological characterization of AZD5069, a slowly reversible CXC chemokine receptor 2 antagonist</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>353</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">340</span>– <span class="NLM_lpage">350</span>, <span class="refDoi"> DOI: 10.1124/jpet.114.221358</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01854&amp;key=10.1124%2Fjpet.114.221358" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01854&amp;key=25736418" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01854&amp;key=1%3ACAS%3A528%3ADC%252BC2MXlvVWnu7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=353&publication_year=2015&pages=340-350&issue=2&author=D.+J.+Nichollsauthor=K.+Wileyauthor=I.+Daintyauthor=F.+MacIntoshauthor=C.+Phillipsauthor=A.+Gawauthor=C.+K.+M%C3%A5rdh&title=Pharmacological+characterization+of+AZD5069%2C+a+slowly+reversible+CXC+chemokine+receptor+2+antagonist&doi=10.1124%2Fjpet.114.221358"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacological characterization of AZD5069, a slowly reversible CXC chemokine receptor 2 antagonist</span></div><div class="casAuthors">Nicholls, David J.; Wiley, Katherine; Dainty, Ian; MacIntosh, Fraser; Phillips, Caroline; Gaw, Alasdair; Mardh, Carina Karrman</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">353</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">340-350</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">1521-0103</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">In normal physiol. responses to injury and infection, inflammatory cells enter tissue and sites of inflammation through a chemotactic process regulated by several families of proteins, including inflammatory chemokines, a family of small inducible cytokines.  In neutrophils, chemokines chemokine (CXC motif) ligand 1 (CXCL1) and CXCL8 are potent chemoattractants and activate G protein-coupled receptors CXC chemokine receptor 1 (CXCR1) and CXCR2.  Several small-mol. antagonists of CXCR2 have been developed to inhibit the inflammatory responses mediated by this receptor.  Here, we present the data describing the pharmacol. of AZD5069 [N-(2-(2,3-difluorobenzylthio)-6-((2R,3S)-3,4-dihydroxybutan-2-yloxy)[2,4,5,6-13C4, 1,3-15N-2]pyrimidin-4-yl)azetidine-1-sulfonamide,[15N2,13C4]N-(2-(2,3-difluoro-6-[3H]-benzylthio)-6-((2R,3S)-3,4-dihydroxybutan-2-yloxy)pyrimidin-4-yl)azetidine-1-sulfonamide], a novel antagonist of CXCR2.  AZD5069 was shown to inhibit binding of radio-labeled CXCL8 to human CXCR2 with a pIC50 value of 9.1.  Furthermore, AZD5069 inhibited neutrophil chemotaxis, with a pA2 of approx. 9.6, and adhesion mol. expression, with a pA2 of 6.9, in response to CXCL1.  AZD5069 was a slowly reversible antagonist of CXCR2 with effects of time and temp. evident on the pharmacol. and binding kinetics.  With short incubation times, AZD5069 appeared to have an antagonist profile with insurmountable antagonism of calcium response curves.  This behavior was also obsd. in vivo in an acute lipopolysaccharide-induced lung inflammation model.  Altogether, the data presented here show that AZD5069 represents a novel, potent, and selective CXCR2 antagonist with potential as a therapeutic agent in inflammatory conditions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoj1gxnHr4vbbVg90H21EOLACvtfcHk0lib4jxPEEjecA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXlvVWnu7g%253D&md5=1ffebbdc9c02dbd015d985062ac820f2</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1124%2Fjpet.114.221358&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.114.221358%26sid%3Dliteratum%253Aachs%26aulast%3DNicholls%26aufirst%3DD.%2BJ.%26aulast%3DWiley%26aufirst%3DK.%26aulast%3DDainty%26aufirst%3DI.%26aulast%3DMacIntosh%26aufirst%3DF.%26aulast%3DPhillips%26aufirst%3DC.%26aulast%3DGaw%26aufirst%3DA.%26aulast%3DM%25C3%25A5rdh%26aufirst%3DC.%2BK.%26atitle%3DPharmacological%2520characterization%2520of%2520AZD5069%252C%2520a%2520slowly%2520reversible%2520CXC%2520chemokine%2520receptor%25202%2520antagonist%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2015%26volume%3D353%26issue%3D2%26spage%3D340%26epage%3D350%26doi%3D10.1124%2Fjpet.114.221358" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Walters, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Austin, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Austin, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonnert, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cage, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christie, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ebden, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">gardiner, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grahames, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hill, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hunt, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jewell, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewis, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nicholls, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robinson, D.</span></span> <span> </span><span class="NLM_article-title">Evaluation of a series of bicyclic CXCR2 antagonists</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>18</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">798</span>– <span class="NLM_lpage">803</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2007.11.039</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01854&amp;key=10.1016%2Fj.bmcl.2007.11.039" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2008&pages=798-803&issue=2&author=I.+Waltersauthor=C.+Austinauthor=A.+Austinauthor=R.+Bonnertauthor=P.+Cageauthor=M.+Christieauthor=M.+Ebdenauthor=S.+gardinerauthor=C.+Grahamesauthor=S.+Hillauthor=F.+Huntauthor=R.+Jewellauthor=S.+Lewisauthor=I.+Martinauthor=D.+Nichollsauthor=D.+Robinson&title=Evaluation+of+a+series+of+bicyclic+CXCR2+antagonists&doi=10.1016%2Fj.bmcl.2007.11.039"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2007.11.039&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2007.11.039%26sid%3Dliteratum%253Aachs%26aulast%3DWalters%26aufirst%3DI.%26aulast%3DAustin%26aufirst%3DC.%26aulast%3DAustin%26aufirst%3DA.%26aulast%3DBonnert%26aufirst%3DR.%26aulast%3DCage%26aufirst%3DP.%26aulast%3DChristie%26aufirst%3DM.%26aulast%3DEbden%26aufirst%3DM.%26aulast%3Dgardiner%26aufirst%3DS.%26aulast%3DGrahames%26aufirst%3DC.%26aulast%3DHill%26aufirst%3DS.%26aulast%3DHunt%26aufirst%3DF.%26aulast%3DJewell%26aufirst%3DR.%26aulast%3DLewis%26aufirst%3DS.%26aulast%3DMartin%26aufirst%3DI.%26aulast%3DNicholls%26aufirst%3DD.%26aulast%3DRobinson%26aufirst%3DD.%26atitle%3DEvaluation%2520of%2520a%2520series%2520of%2520bicyclic%2520CXCR2%2520antagonists%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2008%26volume%3D18%26issue%3D2%26spage%3D798%26epage%3D803%26doi%3D10.1016%2Fj.bmcl.2007.11.039" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gonsiorek, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hesk, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fossetta, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qiu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jakway, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Billah, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dwyer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deno, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taveras, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lundell, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hipkin, R. W.</span></span> <span> </span><span class="NLM_article-title">Pharmacological characterization of Sch527123, a potent allosteric CXCR1/CXCR2 antagonist</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>322</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">477</span>– <span class="NLM_lpage">485</span>, <span class="refDoi"> DOI: 10.1124/jpet.106.118927</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01854&amp;key=10.1124%2Fjpet.106.118927" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01854&amp;key=17496166" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01854&amp;key=1%3ACAS%3A528%3ADC%252BD2sXoslSjt7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=322&publication_year=2007&pages=477-485&issue=2&author=W.+Gonsiorekauthor=X.+Fanauthor=D.+Heskauthor=J.+Fossettaauthor=H.+Qiuauthor=J.+Jakwayauthor=M.+Billahauthor=M.+Dwyerauthor=J.+Chaoauthor=G.+Denoauthor=A.+Taverasauthor=D.+J.+Lundellauthor=R.+W.+Hipkin&title=Pharmacological+characterization+of+Sch527123%2C+a+potent+allosteric+CXCR1%2FCXCR2+antagonist&doi=10.1124%2Fjpet.106.118927"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacological characterization of Sch527123, a potent allosteric CXCR1/CXCR2 antagonist</span></div><div class="casAuthors">Gonsiorek, Waldemar; Fan, Xuedong; Hesk, David; Fossetta, James; Qiu, Hongchen; Jakway, James; Billah, Motasim; Dwyer, Michael; Chao, Jianhua; Deno, Gregory; Taveras, Art; Lundell, Daniel J.; Hipkin, R. William</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">322</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">477-485</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">In neutrophils, growth-related protein-α (CXCL1) and interleukin-8 (CXCL8), are potent chemoattractants and can stimulate myeloperoxidase release via activation of the G protein-coupled receptors CXCR1 and CXCR2.  The role of CXCR1 and CXCR2 in the pathogenesis of inflammatory responses has encouraged the development of small mol. antagonists for these receptors.  The data presented herein describe the pharmacol. of 2-hydroxy-N,N-dimethyl-3-{2-[[(R)-1-(5-methyl-furan-2-yl)-propyl]amino]-3,4-dioxo-cyclobut-1-enylamino}benzamide (Sch527123), a novel antagonist of both CXCR1 and CXCR2.  Sch527123 inhibited chemokine binding to (and activation of) these receptors in an insurmountable manner and, as such, is categorized as an allosteric antagonist.  Sch527123 inhibited neutrophil chemotaxis and myeloperoxidase release in response to CXCL1 and CXCL8 but had no effect on the response of these cells to C5a or formyl-methionyl-leucyl-phenylalanine.  The pharmacol. specificity of Sch527123 was confirmed by testing in a diversity profile against a panel of enzymes, channels, and receptors.  To measure compd. affinity, we characterized [3H]Sch527123 in both equil. and nonequil. binding analyses.  Sch527123 binding to CXCR1 and CXCR2 was both saturable and reversible.  Although Sch527123 bound to CXCR1 with good affinity (Kd = 3.9±0.3 nM), the compd. is CXCR2-selective (Kd = 0.049±0.004 nM).  Taken together, our data show that Sch527123 represents a novel, potent, and specific CXCR2 antagonist with potential therapeutic utility in a variety of inflammatory conditions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqb79iH3wA1yrVg90H21EOLACvtfcHk0lgDI0DyaABebA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXoslSjt7s%253D&md5=37691994ca29fa4dfe33d094d0cd9b93</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1124%2Fjpet.106.118927&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.106.118927%26sid%3Dliteratum%253Aachs%26aulast%3DGonsiorek%26aufirst%3DW.%26aulast%3DFan%26aufirst%3DX.%26aulast%3DHesk%26aufirst%3DD.%26aulast%3DFossetta%26aufirst%3DJ.%26aulast%3DQiu%26aufirst%3DH.%26aulast%3DJakway%26aufirst%3DJ.%26aulast%3DBillah%26aufirst%3DM.%26aulast%3DDwyer%26aufirst%3DM.%26aulast%3DChao%26aufirst%3DJ.%26aulast%3DDeno%26aufirst%3DG.%26aulast%3DTaveras%26aufirst%3DA.%26aulast%3DLundell%26aufirst%3DD.%2BJ.%26aulast%3DHipkin%26aufirst%3DR.%2BW.%26atitle%3DPharmacological%2520characterization%2520of%2520Sch527123%252C%2520a%2520potent%2520allosteric%2520CXCR1%252FCXCR2%2520antagonist%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2007%26volume%3D322%26issue%3D2%26spage%3D477%26epage%3D485%26doi%3D10.1124%2Fjpet.106.118927" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rennard, S. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dale, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Donohue, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kanniess, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Magnussen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sutherland, E. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watz, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stryszak, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosenberg, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Staudinger, H.</span></span> <span> </span><span class="NLM_article-title">CXCR2 antagonist MK-7123: a phase 2 proof-of-concept trial for chronic obstructive pulmonary disease</span>. <i>Am. J. Respir. Crit. Care Med.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>191</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">1001</span>– <span class="NLM_lpage">1011</span>, <span class="refDoi"> DOI: 10.1164/rccm.201405-0992OC</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01854&amp;key=10.1164%2Frccm.201405-0992OC" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01854&amp;key=25695403" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01854&amp;key=1%3ACAS%3A528%3ADC%252BC2MXptlKmt7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=191&publication_year=2015&pages=1001-1011&issue=9&author=S.+I.+Rennardauthor=D.+C.+Daleauthor=J.+F.+Donohueauthor=F.+Kanniessauthor=H.+Magnussenauthor=E.+R.+Sutherlandauthor=H.+Watzauthor=S.+Luauthor=P.+Stryszakauthor=E.+Rosenbergauthor=H.+Staudinger&title=CXCR2+antagonist+MK-7123%3A+a+phase+2+proof-of-concept+trial+for+chronic+obstructive+pulmonary+disease&doi=10.1164%2Frccm.201405-0992OC"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">CXCR2 antagonist MK-7123: a phase 2 proof-of-concept trial for chronic obstructive pulmonary disease</span></div><div class="casAuthors">Rennard, Stephen I.; Dale, David C.; Donohue, James F.; Kanniess, Frank; Magnussen, Helgo; Sutherland, E. Rand; Watz, Henrik; Lu, Susan; Stryszak, Paul; Rosenberg, Elizabeth; Staudinger, Heribert</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Respiratory and Critical Care Medicine</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">191</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1001-1011</span>CODEN:
                <span class="NLM_cas:coden">AJCMED</span>;
        ISSN:<span class="NLM_cas:issn">1073-449X</span>.
    
            (<span class="NLM_cas:orgname">American Thoracic Society</span>)
        </div><div class="casAbstract">Rationale: An antagonist (MK-7123) of the cytokine receptor CXCR2 reduces neutrophil chemotaxis and thus may alleviate airway inflammation in chronic obstructive pulmonary disease (COPD).  Objectives: To assess the efficacy, safety, and tolerability of three dose levels of MK-7123, compared with placebo, in patients with moderate to severe COPD.  Methods: This 6-mo, double-blind study randomized patients with moderate to severe COPD (already on std. therapy) to daily MK-7123 at 10, 30, or 50 mg or placebo.  The primary endpoint was change from baseline in post-bronchodilator FEV1.  Measurements and Main Results: A total of 616 patients (71% male; mean age, 63 yr; 45% current smokers; baseline FEV1 [SD], 1.43 L [0.45]; mean FEV1 percent predicted, 43.9%) were randomized.  Only MK-7123 50 mg led to significant improvement in FEV1 over placebo (mean difference [SE], 67 mL [32]).  Reduced sputum neutrophil count was obsd. among the 122 patients examd.; P = 0.003 (3 mo) and P = 0.092 (6 mo) (MK-7123 50 mg vs. placebo).  The stratum of current smokers, but not that of nonsmokers, showed significant improvement vs. placebo in FEV1 (168 mL) and time-to-first exacerbation, and showed numerical improvement in St.  George's Respiratory Questionnaire for COPD score.  MK-7123 caused a dose-dependent decrease in abs. neutrophil count (ANC) and reduced inflammatory biomarkers matrix metallopeptidase-9 and myeloperoxidase in plasma and sputum; ANC lower than 1.5 × 109/L led to discontinuations with higher doses of MK-7123 (18% in the MK-7123 50-mg group vs. 1% in placebo).  Plasma C-reactive protein and fibrinogen increased with MK-7123 treatment.  Rates of infections at 6 mo were similar in all groups.  Conclusions: Treatment with MK-7123 50 mg vs. placebo led to significant improvement in FEV1 in patients with COPD, suggesting clin. important antiinflammatory effects with CXCR2 antagonism, although dose-related discontinuations were obsd. because of ANC decreases with MK-7123.  Greater response was obsd. in smokers vs. ex-smokers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqoAKNB3Km0H7Vg90H21EOLACvtfcHk0lgDI0DyaABebA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXptlKmt7k%253D&md5=ff8ee6fb8a25a5e158de81c1344079c5</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1164%2Frccm.201405-0992OC&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1164%252Frccm.201405-0992OC%26sid%3Dliteratum%253Aachs%26aulast%3DRennard%26aufirst%3DS.%2BI.%26aulast%3DDale%26aufirst%3DD.%2BC.%26aulast%3DDonohue%26aufirst%3DJ.%2BF.%26aulast%3DKanniess%26aufirst%3DF.%26aulast%3DMagnussen%26aufirst%3DH.%26aulast%3DSutherland%26aufirst%3DE.%2BR.%26aulast%3DWatz%26aufirst%3DH.%26aulast%3DLu%26aufirst%3DS.%26aulast%3DStryszak%26aufirst%3DP.%26aulast%3DRosenberg%26aufirst%3DE.%26aulast%3DStaudinger%26aufirst%3DH.%26atitle%3DCXCR2%2520antagonist%2520MK-7123%253A%2520a%2520phase%25202%2520proof-of-concept%2520trial%2520for%2520chronic%2520obstructive%2520pulmonary%2520disease%26jtitle%3DAm.%2520J.%2520Respir.%2520Crit.%2520Care%2520Med.%26date%3D2015%26volume%3D191%26issue%3D9%26spage%3D1001%26epage%3D1011%26doi%3D10.1164%2Frccm.201405-0992OC" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ning, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Labonte, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bohanes, P. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gerger, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benhaim, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paez, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosenberg, D. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagulapalli Venkata, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Louie, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petasis, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ladner, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lenz, H.-J.</span></span> <span> </span><span class="NLM_article-title">The CXCR2 antagonist, SCH-527123, shows antitumor activity and sensitizes cells to oxaliplatin in preclinical colon cancer models</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>11</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">1353</span>– <span class="NLM_lpage">1364</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-11-0915</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01854&amp;key=10.1158%2F1535-7163.MCT-11-0915" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01854&amp;key=22391039" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01854&amp;key=1%3ACAS%3A528%3ADC%252BC38XotlCitr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2012&pages=1353-1364&issue=6&author=Y.+Ningauthor=M.+J.+Labonteauthor=W.+Zhangauthor=P.+O.+Bohanesauthor=A.+Gergerauthor=D.+Yangauthor=L.+Benhaimauthor=D.+Paezauthor=D.+O.+Rosenbergauthor=K.+C.+Nagulapalli+Venkataauthor=S.+G.+Louieauthor=N.+A.+Petasisauthor=R.+D.+Ladnerauthor=H.-J.+Lenz&title=The+CXCR2+antagonist%2C+SCH-527123%2C+shows+antitumor+activity+and+sensitizes+cells+to+oxaliplatin+in+preclinical+colon+cancer+models&doi=10.1158%2F1535-7163.MCT-11-0915"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">The CXCR2 Antagonist, SCH-527123, Shows Antitumor Activity and Sensitizes Cells to Oxaliplatin in Preclinical Colon Cancer Models</span></div><div class="casAuthors">Ning, Yan; Labonte, Melissa J.; Zhang, Wu; Bohanes, Pierre O.; Gerger, Armin; Yang, Dongyun; Benhaim, Leonor; Paez, David; Rosenberg, David O.; Nagulapalli Venkata, Kalyan C.; Louie, Stan G.; Petasis, Nicos A.; Ladner, Robert D.; Lenz, Heinz-Josef</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1353-1364</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Colorectal cancer is the second most common cause of cancer-related death in the United States.  Recent studies showed that interleukin-8 (IL-8) and its receptors (CXCR1 and CXCR2) are significantly upregulated in both the tumor and its microenvironment, and act as key regulators of proliferation, angiogenesis, and metastasis.  Our previous study showed that IL-8 overexpression in colorectal cancer cells triggers the upregulation of the CXCR2-mediated proliferative pathway.  The aim of this study was to investigate whether the CXCR2 antagonist, SCH-527123, inhibits colorectal cancer proliferation and if it can sensitize colorectal cancer cells to oxaliplatin both in vitro and in vivo.  SCH-527123 showed concn.-dependent antiproliferative effects in HCT116, Caco2, and their resp. IL-8-overexpressing variants colorectal cancer cell lines.  Moreover, SCH-527123 was able to suppress CXCR2-mediated signal transduction as shown through decreased phosphorylation of the NF-κB/mitogen-activated protein kinase (MAPK)/AKT pathway.  These findings corresponded with decreased cell migration and invasion, while increased apoptosis in colorectal cancer cell lines.  In vivo results verified that SCH-527123 treatment decreased tumor growth and microvessel d. when compared with vehicle-treated tumors.  Importantly, these preclin. studies showed that the combination of SCH-527123 and oxaliplatin resulted in a greater decrease in cell proliferation, tumor growth, apoptosis, and angiogenesis that was superior to single-agent treatment.  Taken together, these findings suggest that targeting CXCR2 may block tumor proliferation, migration, invasion, and angiogenesis.  In addn., CXCR2 blockade may further sensitize colorectal cancer to oxaliplatin treatment.  Mol Cancer Ther; 11(6); 1353-64. ©2012 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpAJ_al2gEJlrVg90H21EOLACvtfcHk0lgzt2MH-GI9Tw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XotlCitr0%253D&md5=81a34537214fdbeabd53a5e8c443f83d</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-11-0915&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-11-0915%26sid%3Dliteratum%253Aachs%26aulast%3DNing%26aufirst%3DY.%26aulast%3DLabonte%26aufirst%3DM.%2BJ.%26aulast%3DZhang%26aufirst%3DW.%26aulast%3DBohanes%26aufirst%3DP.%2BO.%26aulast%3DGerger%26aufirst%3DA.%26aulast%3DYang%26aufirst%3DD.%26aulast%3DBenhaim%26aufirst%3DL.%26aulast%3DPaez%26aufirst%3DD.%26aulast%3DRosenberg%26aufirst%3DD.%2BO.%26aulast%3DNagulapalli%2BVenkata%26aufirst%3DK.%2BC.%26aulast%3DLouie%26aufirst%3DS.%2BG.%26aulast%3DPetasis%26aufirst%3DN.%2BA.%26aulast%3DLadner%26aufirst%3DR.%2BD.%26aulast%3DLenz%26aufirst%3DH.-J.%26atitle%3DThe%2520CXCR2%2520antagonist%252C%2520SCH-527123%252C%2520shows%2520antitumor%2520activity%2520and%2520sensitizes%2520cells%2520to%2520oxaliplatin%2520in%2520preclinical%2520colon%2520cancer%2520models%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2012%26volume%3D11%26issue%3D6%26spage%3D1353%26epage%3D1364%26doi%3D10.1158%2F1535-7163.MCT-11-0915" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Porter, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bradley, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Charlton, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cox, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hunt, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janus, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewis, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oakley, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Connor, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reilly, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Press, N. J.</span></span> <span> </span><span class="NLM_article-title">The discovery of potent, orally bioavailable pyrimidine-5-carbonitrile-6-alkyl CXCR2 receptor antagonists</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>24</i></span> (<span class="NLM_issue">15</span>),  <span class="NLM_fpage">3285</span>– <span class="NLM_lpage">3290</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2014.06.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01854&amp;key=10.1016%2Fj.bmcl.2014.06.011" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2014&pages=3285-3290&issue=15&author=D.+W.+Porterauthor=M.+Bradleyauthor=Z.+Brownauthor=S.+J.+Charltonauthor=B.+Coxauthor=P.+Huntauthor=D.+Janusauthor=S.+Lewisauthor=P.+Oakleyauthor=D.+O%E2%80%99Connorauthor=J.+Reillyauthor=N.+Smithauthor=N.+J.+Press&title=The+discovery+of+potent%2C+orally+bioavailable+pyrimidine-5-carbonitrile-6-alkyl+CXCR2+receptor+antagonists&doi=10.1016%2Fj.bmcl.2014.06.011"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2014.06.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2014.06.011%26sid%3Dliteratum%253Aachs%26aulast%3DPorter%26aufirst%3DD.%2BW.%26aulast%3DBradley%26aufirst%3DM.%26aulast%3DBrown%26aufirst%3DZ.%26aulast%3DCharlton%26aufirst%3DS.%2BJ.%26aulast%3DCox%26aufirst%3DB.%26aulast%3DHunt%26aufirst%3DP.%26aulast%3DJanus%26aufirst%3DD.%26aulast%3DLewis%26aufirst%3DS.%26aulast%3DOakley%26aufirst%3DP.%26aulast%3DO%25E2%2580%2599Connor%26aufirst%3DD.%26aulast%3DReilly%26aufirst%3DJ.%26aulast%3DSmith%26aufirst%3DN.%26aulast%3DPress%26aufirst%3DN.%2BJ.%26atitle%3DThe%2520discovery%2520of%2520potent%252C%2520orally%2520bioavailable%2520pyrimidine-5-carbonitrile-6-alkyl%2520CXCR2%2520receptor%2520antagonists%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2014%26volume%3D24%26issue%3D15%26spage%3D3285%26epage%3D3290%26doi%3D10.1016%2Fj.bmcl.2014.06.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carson, K. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trivedi, B. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yue, W. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ye, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glynn, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Connor, D. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roth, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luly, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Low, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heilig, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hunt, S.</span></span> <span> </span><span class="NLM_article-title">Synthesis and structure-activity relationship of 2-amino-3-heteroaryl-quinoxalines as non-peptide, small-molecule antagonists for interleukin-8 receptor</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>11</i></span> (<span class="NLM_issue">17</span>),  <span class="NLM_fpage">3777</span>– <span class="NLM_lpage">3790</span>, <span class="refDoi"> DOI: 10.1016/S0968-0896(03)00399-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01854&amp;key=10.1016%2FS0968-0896%2803%2900399-7" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2003&pages=3777-3790&issue=17&author=J.+J.+Liauthor=K.+G.+Carsonauthor=B.+K.+Trivediauthor=W.+S.+Yueauthor=Q.+Yeauthor=R.+A.+Glynnauthor=S.+R.+Millerauthor=D.+T.+Connorauthor=B.+D.+Rothauthor=J.+R.+Lulyauthor=J.+E.+Lowauthor=D.+J.+Heiligauthor=W.+Yangauthor=S.+Qinauthor=S.+Hunt&title=Synthesis+and+structure-activity+relationship+of+2-amino-3-heteroaryl-quinoxalines+as+non-peptide%2C+small-molecule+antagonists+for+interleukin-8+receptor&doi=10.1016%2FS0968-0896%2803%2900399-7"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1016%2FS0968-0896%2803%2900399-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0968-0896%252803%252900399-7%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DJ.%2BJ.%26aulast%3DCarson%26aufirst%3DK.%2BG.%26aulast%3DTrivedi%26aufirst%3DB.%2BK.%26aulast%3DYue%26aufirst%3DW.%2BS.%26aulast%3DYe%26aufirst%3DQ.%26aulast%3DGlynn%26aufirst%3DR.%2BA.%26aulast%3DMiller%26aufirst%3DS.%2BR.%26aulast%3DConnor%26aufirst%3DD.%2BT.%26aulast%3DRoth%26aufirst%3DB.%2BD.%26aulast%3DLuly%26aufirst%3DJ.%2BR.%26aulast%3DLow%26aufirst%3DJ.%2BE.%26aulast%3DHeilig%26aufirst%3DD.%2BJ.%26aulast%3DYang%26aufirst%3DW.%26aulast%3DQin%26aufirst%3DS.%26aulast%3DHunt%26aufirst%3DS.%26atitle%3DSynthesis%2520and%2520structure-activity%2520relationship%2520of%25202-amino-3-heteroaryl-quinoxalines%2520as%2520non-peptide%252C%2520small-molecule%2520antagonists%2520for%2520interleukin-8%2520receptor%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2003%26volume%3D11%26issue%3D17%26spage%3D3777%26epage%3D3790%26doi%3D10.1016%2FS0968-0896%2803%2900399-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schuler, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Engles, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maeda, D. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quinn, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirpotina, L. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wicomb, W. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mason, S. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Auten, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zebala, J. A.</span></span> <span> </span><span class="NLM_article-title">Boronic acid-containing aminopyridine- and aminopyrimidinecarboxamide CXCR1/2 antagonists: Optimization of aqueous solubility and oral bioavailability</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>25</i></span> (<span class="NLM_issue">18</span>),  <span class="NLM_fpage">3793</span>– <span class="NLM_lpage">3797</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2015.07.090</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01854&amp;key=10.1016%2Fj.bmcl.2015.07.090" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2015&pages=3793-3797&issue=18&author=A.+D.+Schulerauthor=C.+A.+Englesauthor=D.+Y.+Maedaauthor=M.+T.+Quinnauthor=L.+N.+Kirpotinaauthor=W.+N.+Wicombauthor=S.+N.+Masonauthor=R.+L.+Autenauthor=J.+A.+Zebala&title=Boronic+acid-containing+aminopyridine-+and+aminopyrimidinecarboxamide+CXCR1%2F2+antagonists%3A+Optimization+of+aqueous+solubility+and+oral+bioavailability&doi=10.1016%2Fj.bmcl.2015.07.090"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2015.07.090&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2015.07.090%26sid%3Dliteratum%253Aachs%26aulast%3DSchuler%26aufirst%3DA.%2BD.%26aulast%3DEngles%26aufirst%3DC.%2BA.%26aulast%3DMaeda%26aufirst%3DD.%2BY.%26aulast%3DQuinn%26aufirst%3DM.%2BT.%26aulast%3DKirpotina%26aufirst%3DL.%2BN.%26aulast%3DWicomb%26aufirst%3DW.%2BN.%26aulast%3DMason%26aufirst%3DS.%2BN.%26aulast%3DAuten%26aufirst%3DR.%2BL.%26aulast%3DZebala%26aufirst%3DJ.%2BA.%26atitle%3DBoronic%2520acid-containing%2520aminopyridine-%2520and%2520aminopyrimidinecarboxamide%2520CXCR1%252F2%2520antagonists%253A%2520Optimization%2520of%2520aqueous%2520solubility%2520and%2520oral%2520bioavailability%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2015%26volume%3D25%26issue%3D18%26spage%3D3793%26epage%3D3797%26doi%3D10.1016%2Fj.bmcl.2015.07.090" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Traves, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">barnes, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Donnelly, L. E.</span></span> <span> </span><span class="NLM_article-title">Specific CXC but not CC chemokines cause elevated monocyte migration in COPD: a role for CXCR2</span>. <i>J. Leukocyte Biol.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>76</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">441</span>– <span class="NLM_lpage">450</span>, <span class="refDoi"> DOI: 10.1189/jlb.1003495</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01854&amp;key=10.1189%2Fjlb.1003495" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01854&amp;key=15155777" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01854&amp;key=1%3ACAS%3A528%3ADC%252BD2cXmtlKrsLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=76&publication_year=2004&pages=441-450&issue=2&author=S.+L.+Travesauthor=S.+J.+Smithauthor=P.+J.+barnesauthor=L.+E.+Donnelly&title=Specific+CXC+but+not+CC+chemokines+cause+elevated+monocyte+migration+in+COPD%3A+a+role+for+CXCR2&doi=10.1189%2Fjlb.1003495"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25aR"><div class="casContent"><span class="casTitleNuber">25a</span><div class="casTitle"><span class="NLM_cas:atitle">Specific CXC but not CC chemokines cause elevated monocyte migration in COPD: A role for CXCR2</span></div><div class="casAuthors">Traves, Suzanne L.; Smith, Susan J.; Barnes, Peter J.; Donnelly, Louise E.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Leukocyte Biology</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">76</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">441-450</span>CODEN:
                <span class="NLM_cas:coden">JLBIE7</span>;
        ISSN:<span class="NLM_cas:issn">0741-5400</span>.
    
            (<span class="NLM_cas:orgname">Federation of American Societies for Experimental Biology</span>)
        </div><div class="casAbstract">Leukocyte migration is crit. to maintaining host defense, but uncontrolled cellular infiltration into tissues can lead to chronic inflammation.  In the lung, such diseases include chronic obstructive pulmonary disease (COPD), a debilitating, respiratory condition characterized by progressive and largely irreversible airflow limitation for which cigarette smoking is the major risk factor.  COPD is assocd. with an increased inflammatory cell influx including increased macrophage nos. in the airways and tissue.  Alveolar macrophages develop from immigrating blood monocytes and have the capacity to cause the pathol. changes assocd. with COPD.  This study addressed the hypothesis that increased macrophage nos. in COPD are a result of increased recruitment of monocytes from the circulation.  Chemotaxis assays of peripheral blood mononuclear cells (PBMC)/monocytes from nonsmokers, smokers, and COPD patients demonstrated increased chemotactic responses for cells from COPD patients when compared with controls toward growth-related oncogene (GRO)α and neutrophil-activating peptide (NAP)-2 but not toward monocyte chemoattractant protein, interleukin-8, or epithelial-derived NAP(ENA)-78.  The enhanced chemotactic response toward GROα and NAP-2 was not mediated by differences in expression of their cellular receptors, CXCR1 or CXCR2.  Receptor expression studies using flow cytometry indicated that in COPD, monocyte expression of CXCR2 is regulated differently from nonsmokers and smokers, which may account for the enhanced migration toward GROα and NAP-2.  The results highlight the potential of CXCR2 antagonists as therapy for COPD and demonstrate that an enhanced PBMC/monocyte response to specific CXC chemokines in these patients may contribute to increased recruitment and activation of macrophages in the lungs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr99e2ZPsnEhrVg90H21EOLACvtfcHk0lhjtaG9Z3-MAQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXmtlKrsLY%253D&md5=96ff850e7ae1ffaa342c196b785380ac</span></div><a href="/servlet/linkout?suffix=cit25a&amp;dbid=16384&amp;doi=10.1189%2Fjlb.1003495&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1189%252Fjlb.1003495%26sid%3Dliteratum%253Aachs%26aulast%3DTraves%26aufirst%3DS.%2BL.%26aulast%3DSmith%26aufirst%3DS.%2BJ.%26aulast%3Dbarnes%26aufirst%3DP.%2BJ.%26aulast%3DDonnelly%26aufirst%3DL.%2BE.%26atitle%3DSpecific%2520CXC%2520but%2520not%2520CC%2520chemokines%2520cause%2520elevated%2520monocyte%2520migration%2520in%2520COPD%253A%2520a%2520role%2520for%2520CXCR2%26jtitle%3DJ.%2520Leukocyte%2520Biol.%26date%3D2004%26volume%3D76%26issue%3D2%26spage%3D441%26epage%3D450%26doi%3D10.1189%2Fjlb.1003495" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit25b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Ryu, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cho, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choi, H. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jantaratnotai, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McLarnon, J. G.</span></span> <span> </span><span class="NLM_article-title">Pharmacological antagonism of interleukin-8 receptor CXCR2 inhibits inflammatory reactivity and is neuroprotective in an animal of Alzeimer’s disease</span>. <i>J. Neuroinflammation</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">144</span>, <span class="refDoi"> DOI: 10.1186/s12974-015-0339-z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01854&amp;key=10.1186%2Fs12974-015-0339-z" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01854&amp;key=26255110" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01854&amp;key=1%3ACAS%3A280%3ADC%252BC287htlGqsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2015&pages=144&author=J.+K.+Ryuauthor=T.+Choauthor=H.+B.+Choiauthor=N.+Jantaratnotaiauthor=J.+G.+McLarnon&title=Pharmacological+antagonism+of+interleukin-8+receptor+CXCR2+inhibits+inflammatory+reactivity+and+is+neuroprotective+in+an+animal+of+Alzeimer%E2%80%99s+disease&doi=10.1186%2Fs12974-015-0339-z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25bR"><div class="casContent"><span class="casTitleNuber">25b</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacological antagonism of interleukin-8 receptor CXCR2 inhibits inflammatory reactivity and is neuroprotective in an animal model of Alzheimer's disease</span></div><div class="casAuthors">Ryu Jae K; McLarnon James G; Cho T; Choi Hyun B; Jantaratnotai N</div><div class="citationInfo"><span class="NLM_cas:title">Journal of neuroinflammation</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">144</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  The chemokine interleukin-8 (IL-8) and its receptor CXCR2 contribute to chemotactic responses in Alzheimer's disease (AD); however, properties of the ligand and receptor have not been characterized in animal models of disease.  The primary aim of our study was to examine effects of pharmacological antagonism of CXCR2 as a strategy to inhibit receptor-mediated inflammatory reactivity and enhance neuronal viability in animals receiving intrahippocampal injection of amyloid-beta (Aβ1-42).  METHODS:  In vivo studies used an animal model of Alzheimer's disease incorporating injection of full-length Aβ1-42 into rat hippocampus.  Immunohistochemical staining of rat brain was used to measure microgliosis, astrogliosis, neuronal viability, and oxidative stress.  Western blot and Reverse Transcription PCR (RT-PCR) were used to determine levels of CXCR2 in animal tissue with the latter also used to determine expression of pro-inflammatory mediators.  Immunostaining of human AD and non-demented (ND) tissue was also undertaken.  RESULTS:  We initially determined that in the human brain, AD relative to ND tissue exhibited marked increases in expression of CXCR2 with cell-specific receptor expression prominent in microglia.  In Aβ1-42-injected rat brain, CXCR2 and IL-8 showed time-dependent increases in expression, concomitant with enhanced gliosis, relative to controls phosphate-buffered saline (PBS) or reverse peptide Aβ42-1 injection.  Administration of the competitive CXCR2 antagonist SB332235 to peptide-injected rats significantly reduced expression of CXCR2 and microgliosis, with astrogliosis unchanged.  Double staining studies demonstrated localization of CXCR2 and microglial immunoreactivity nearby deposits of Aβ1-42 with SB332235 effective in inhibiting receptor expression and microgliosis.  The numbers of neurons in granule cell layer (GCL) were reduced in rats receiving Aβ1-42, compared with PBS, with administration of SB332235 to peptide-injected animals conferring neuroprotection.  Oxidative stress was indicated in the animal model since both 4-hydroxynonenal (4-HNE) and hydroethidine (HEt) were markedly elevated in Aβ1-42 vs.  PBS-injected rat brain and diminished with SB332235 treatment.  CONCLUSION:  Overall, the findings suggest critical roles for CXCR2-dependent inflammatory responses in an AD animal model with pharmacological modulation of the receptor effective in inhibiting inflammatory reactivity and conferring neuroprotection against oxidative damage.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTlVb_4YHQbkJHZzFRCXxVKfW6udTcc2eY0u8KnaFdVErntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC287htlGqsA%253D%253D&md5=a4a56be1719e802cc9dd8e746aef4183</span></div><a href="/servlet/linkout?suffix=cit25b&amp;dbid=16384&amp;doi=10.1186%2Fs12974-015-0339-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs12974-015-0339-z%26sid%3Dliteratum%253Aachs%26aulast%3DRyu%26aufirst%3DJ.%2BK.%26aulast%3DCho%26aufirst%3DT.%26aulast%3DChoi%26aufirst%3DH.%2BB.%26aulast%3DJantaratnotai%26aufirst%3DN.%26aulast%3DMcLarnon%26aufirst%3DJ.%2BG.%26atitle%3DPharmacological%2520antagonism%2520of%2520interleukin-8%2520receptor%2520CXCR2%2520inhibits%2520inflammatory%2520reactivity%2520and%2520is%2520neuroprotective%2520in%2520an%2520animal%2520of%2520Alzeimer%25E2%2580%2599s%2520disease%26jtitle%3DJ.%2520Neuroinflammation%26date%3D2015%26volume%3D12%26spage%3D144%26doi%3D10.1186%2Fs12974-015-0339-z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit25c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Busch-Petersen, J.</span></span> <span> </span><span class="NLM_article-title">Small molecule antagonists of the CXCR2 and CXCR1 chemokine receptors as therapeutic agents for the treatment of inflammatory diseases</span>. <i>Curr. Top. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">1345</span>– <span class="NLM_lpage">1352</span>, <span class="refDoi"> DOI: 10.2174/15680266106061345</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01854&amp;key=10.2174%2F15680266106061345" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01854&amp;key=16918453" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01854&amp;key=1%3ACAS%3A528%3ADC%252BD28Xps1Sltr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2006&pages=1345-1352&author=J.+Busch-Petersen&title=Small+molecule+antagonists+of+the+CXCR2+and+CXCR1+chemokine+receptors+as+therapeutic+agents+for+the+treatment+of+inflammatory+diseases&doi=10.2174%2F15680266106061345"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25cR"><div class="casContent"><span class="casTitleNuber">25c</span><div class="casTitle"><span class="NLM_cas:atitle">Small molecule antagonists of the CXCR2 and CXCR1 chemokine receptors as therapeutic agents for the treatment of inflammatory diseases</span></div><div class="casAuthors">Busch-Petersen, Jakob</div><div class="citationInfo"><span class="NLM_cas:title">Current Topics in Medicinal Chemistry (Sharjah, United Arab Emirates)</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">1345-1352</span>CODEN:
                <span class="NLM_cas:coden">CTMCCL</span>;
        ISSN:<span class="NLM_cas:issn">1568-0266</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  In the past eight years, numerous series of small mol. CXCR2 and CXCR1 antagonists have been disclosed.  These compds. have proved to be effective inhibitors of ELR+ chemokine-induced chemotaxis of neutrophils and other immune cells in vitro and have also been efficacious in several animal models of inflammatory disease.  Although some of these compds. have been reported to be in clin. development, no data on clin. studies in patients with inflammatory disease has been revealed to date.  This review details the medicinal chem. and pharmacol. of the aforementioned antagonist series.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqCATg8ZJMoxLVg90H21EOLACvtfcHk0lhjtaG9Z3-MAQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xps1Sltr0%253D&md5=0054b0053f9a9a45adeac60677960085</span></div><a href="/servlet/linkout?suffix=cit25c&amp;dbid=16384&amp;doi=10.2174%2F15680266106061345&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F15680266106061345%26sid%3Dliteratum%253Aachs%26aulast%3DBusch-Petersen%26aufirst%3DJ.%26atitle%3DSmall%2520molecule%2520antagonists%2520of%2520the%2520CXCR2%2520and%2520CXCR1%2520chemokine%2520receptors%2520as%2520therapeutic%2520agents%2520for%2520the%2520treatment%2520of%2520inflammatory%2520diseases%26jtitle%3DCurr.%2520Top.%2520Med.%2520Chem.%26date%3D2006%26volume%3D6%26spage%3D1345%26epage%3D1352%26doi%3D10.2174%2F15680266106061345" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lazaar, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sweeney, L. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">MacDonald, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alexis, N. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tal-Singer, R.</span></span> <span> </span><span class="NLM_article-title">SB-656933, a novel CXCR2 selective antagonist, inhibits ex vivo neutrophil activation and ozone-induced airway inflammation in humans</span>. <i>Br. J. Clin. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>72</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">282</span>– <span class="NLM_lpage">293</span>, <span class="refDoi"> DOI: 10.1111/j.1365-2125.2011.03968.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01854&amp;key=10.1111%2Fj.1365-2125.2011.03968.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01854&amp;key=21426372" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01854&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtV2qtrvO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=72&publication_year=2011&pages=282-293&issue=2&author=A.+L.+Lazaarauthor=L.+E.+Sweeneyauthor=A.+J.+MacDonaldauthor=N.+E.+Alexisauthor=C.+Chenauthor=R.+Tal-Singer&title=SB-656933%2C+a+novel+CXCR2+selective+antagonist%2C+inhibits+ex+vivo+neutrophil+activation+and+ozone-induced+airway+inflammation+in+humans&doi=10.1111%2Fj.1365-2125.2011.03968.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">SB-656933, a novel CXCR2 selective antagonist, inhibits ex vivo neutrophil activation and ozone-induced airway inflammation in humans</span></div><div class="casAuthors">Lazaar, Aili L.; Sweeney, Lisa E.; MacDonald, Alexander J.; Alexis, Neil E.; Chen, Chao; Tal-Singer, Ruth</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Clinical Pharmacology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">72</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">282-293</span>CODEN:
                <span class="NLM_cas:coden">BCPHBM</span>;
        ISSN:<span class="NLM_cas:issn">0306-5251</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">AIMS To det. the safety and tolerability of a novel selective CXCR2 antagonist and assess its pharmacodynamic effects using measures of neutrophil activation and function, including CD11b expression in whole blood and ozone-induced airway inflammation in healthy subjects.  METHODS Flow cytometric detn. of ex vivo CXCL1-induced CD11b expression on peripheral blood neutrophils was performed following single dose oral administration of SB-656933 (dose range 2-1100 mg).  A subsequent randomized study (placebo, 50 mg and 150 mg) was performed to explore the dose-response for ozone-induced airway inflammation, as measured by sputum biomarkers.  RESULTS Oral administration of SB-656933 resulted in significant inhibition of CXCL1-induced CD11b expression on peripheral blood neutrophils at single doses greater than or equal to 50 mg.  Maximum inhibition (70%) relative to placebo was obsd. following administration of SB-656933 400 mg (95% CI 60%, 77%).  This was sustained up to a dose of 1100 mg.  Single doses of SB-656933 reduced ozone-induced airway inflammation in a dose-dependent manner.  Relative to placebo, there were 55% (95% CI 20%, 75%) and 74% (95% CI 55%, 85%) fewer neutrophils in the sputum of subjects after a single dose of 50 mg or 150 mg, resp.  There was a corresponding redn. in myeloperoxidase concns. in the sputum supernatant of 32.8% (95% CI 9.2, 50.3) and 50.5% (95% CI 33.3, 63.3).  SB-656933 was safe and well-tolerated at all doses.  CONCLUSIONS SB-656933 is a CXCR2 antagonist that demonstrates dose-dependent effects on neutrophil activation and recruitment within a well-tolerated dose range.  These data suggest that SB-656933 may be an effective agent in neutrophil-predominant diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqj4fRS8HijE7Vg90H21EOLACvtfcHk0lhjtaG9Z3-MAQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtV2qtrvO&md5=cd2f3253ca0b12435a59634ecb63ceea</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1111%2Fj.1365-2125.2011.03968.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1365-2125.2011.03968.x%26sid%3Dliteratum%253Aachs%26aulast%3DLazaar%26aufirst%3DA.%2BL.%26aulast%3DSweeney%26aufirst%3DL.%2BE.%26aulast%3DMacDonald%26aufirst%3DA.%2BJ.%26aulast%3DAlexis%26aufirst%3DN.%2BE.%26aulast%3DChen%26aufirst%3DC.%26aulast%3DTal-Singer%26aufirst%3DR.%26atitle%3DSB-656933%252C%2520a%2520novel%2520CXCR2%2520selective%2520antagonist%252C%2520inhibits%2520ex%2520vivo%2520neutrophil%2520activation%2520and%2520ozone-induced%2520airway%2520inflammation%2520in%2520humans%26jtitle%3DBr.%2520J.%2520Clin.%2520Pharmacol.%26date%3D2011%26volume%3D72%26issue%3D2%26spage%3D282%26epage%3D293%26doi%3D10.1111%2Fj.1365-2125.2011.03968.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, B. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mistry, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smart, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Connolly, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carpenter, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cooray, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bloomer, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tal-Singer, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lazaar, A. L.</span></span> <span> </span><span class="NLM_article-title">The pharmacokinetics and pharmacodynamics of danirixin (GSK1325756) - a selective CXCR2 antagonist - in healthy adult subjects</span>. <i>BMC Pharmacol. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">18</span>, <span class="refDoi"> DOI: 10.1186/s40360-015-0017-x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01854&amp;key=10.1186%2Fs40360-015-0017-x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01854&amp;key=26092545" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01854&amp;key=1%3ACAS%3A280%3ADC%252BC2MblslersQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2015&pages=18&author=B.+E.+Millerauthor=S.+Mistryauthor=K.+Smartauthor=P.+Connollyauthor=D.+C.+Carpenterauthor=H.+Coorayauthor=J.+C.+Bloomerauthor=R.+Tal-Singerauthor=A.+L.+Lazaar&title=The+pharmacokinetics+and+pharmacodynamics+of+danirixin+%28GSK1325756%29+-+a+selective+CXCR2+antagonist+-+in+healthy+adult+subjects&doi=10.1186%2Fs40360-015-0017-x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27aR"><div class="casContent"><span class="casTitleNuber">27a</span><div class="casTitle"><span class="NLM_cas:atitle">The pharmacokinetics and pharmacodynamics of danirixin (GSK1325756)--a selective CXCR2 antagonist --in healthy adult subjects</span></div><div class="casAuthors">Miller Bruce E; Tal-Singer Ruth; Mistry Sunil; Smart Kevin; Smart Kevin; Connolly Paul; Carpenter Donald C; Cooray Hiran; Cooray Hiran; Bloomer Jackie C; Lazaar Aili L</div><div class="citationInfo"><span class="NLM_cas:title">BMC pharmacology & toxicology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">18</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Excessive neutrophil presence and activation is important in a number of acute and chronic inflammatory diseases.  The CXCR2 chemokine receptor is important in controlling the extravasation and activation of neutrophils.  Selective antagonism of the CXCR2 receptor is a potential approach to reducing neutrophil migration and activation.  Danirixin, is a small molecule, CXCR2 antagonist being evaluated as a potential anti-inflammatory medicine.  METHODS:  (1) First time in human (FTIH) double-blind, placebo-controlled study to evaluate the safety, pharmacokinetics, and pharmacodynamics of single ascending and repeat oral doses of danirixin in healthy male subjects; (2) single-dose study of age, gender, food, and proton-pump inhibitor effects on the pharmacokinetics of danirixin in healthy adult subjects; and placebo-controlled study of the pharmacokinetics of danirixin in healthy elderly subjects.  RESULTS:  There were no serious adverse events and no adverse events considered to be of clinical relevance.  There were no withdrawals due to adverse events.  Systemic exposure following single doses of danirixin 10 mg, 25 mg, 50 mg, 100 mg, and 200 mg increased with increasing dose.  Engagement of pharmacology was demonstrated as inhibition of ex-vivo CXCL1-induced CD11b expression on peripheral blood neutrophils when compared to placebo (approximately 50% for 50 mg and 100 mg danirixin, and 72% at 200 mg).  There was a 37% decrease in Cmax and a 16% decrease in AUC (0-∞) following administration of danirixin in the presence of food.  Cmax also decreased by 65% when danirixin 100 mg was administered following omeprazole 40 mg once daily for 5 days.  The AUC (0-∞) and Cmax were 50% lower in elderly subjects compared with younger subjects.  CONCLUSION:  The dose-dependent inhibition of agonist-induced neutrophil activation following single and repeated once daily oral administration of danirixin suggests that this CXCR2 antagonist may have benefit in neutrophil-predominant inflammatory diseases.  Co-administration with food, gastric acid reducing agents, and variable exposure in the elderly have important clinical implications that need to be taken into consideration in subsequent clinical evaluations.  TRIAL REGISTRATION:  ClinicalTrials.gov identifiers: NCT01209052 and NCT01209104.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRAKy_l8uoE8MrRqEXsZufAfW6udTcc2eY_fQfS-bbYW7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2MblslersQ%253D%253D&md5=031af976bb431023281306bde2964584</span></div><a href="/servlet/linkout?suffix=cit27a&amp;dbid=16384&amp;doi=10.1186%2Fs40360-015-0017-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs40360-015-0017-x%26sid%3Dliteratum%253Aachs%26aulast%3DMiller%26aufirst%3DB.%2BE.%26aulast%3DMistry%26aufirst%3DS.%26aulast%3DSmart%26aufirst%3DK.%26aulast%3DConnolly%26aufirst%3DP.%26aulast%3DCarpenter%26aufirst%3DD.%2BC.%26aulast%3DCooray%26aufirst%3DH.%26aulast%3DBloomer%26aufirst%3DJ.%2BC.%26aulast%3DTal-Singer%26aufirst%3DR.%26aulast%3DLazaar%26aufirst%3DA.%2BL.%26atitle%3DThe%2520pharmacokinetics%2520and%2520pharmacodynamics%2520of%2520danirixin%2520%2528GSK1325756%2529%2520-%2520a%2520selective%2520CXCR2%2520antagonist%2520-%2520in%2520healthy%2520adult%2520subjects%26jtitle%3DBMC%2520Pharmacol.%2520Toxicol.%26date%3D2015%26volume%3D16%26spage%3D18%26doi%3D10.1186%2Fs40360-015-0017-x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit27b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Dwyer, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, Y.</span></span> <span> </span><span class="NLM_article-title">CXCR2 modulators: a patent review (2009 – 2013)</span>. <i>Expert Opin. Ther. Pat.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>24</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">519</span>– <span class="NLM_lpage">534</span>, <span class="refDoi"> DOI: 10.1517/13543776.2014.887682</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01854&amp;key=10.1517%2F13543776.2014.887682" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01854&amp;key=24555661" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01854&amp;key=1%3ACAS%3A528%3ADC%252BC2cXmt1Ghu70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2014&pages=519-534&issue=5&author=M.+P.+Dwyerauthor=Y.+Yu&title=CXCR2+modulators%3A+a+patent+review+%282009+%E2%80%93+2013%29&doi=10.1517%2F13543776.2014.887682"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27bR"><div class="casContent"><span class="casTitleNuber">27b</span><div class="casTitle"><span class="NLM_cas:atitle">CXCR2 modulators: a patent review (2009 - 2013)</span></div><div class="casAuthors">Dwyer, Michael P.; Yu, Younong</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Therapeutic Patents</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">519-534</span>CODEN:
                <span class="NLM_cas:coden">EOTPEG</span>;
        ISSN:<span class="NLM_cas:issn">1354-3776</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Introduction: Small-mol. antagonists of CXC chemokine receptor 2 (CXCR2) have attracted a considerable amt. of attention due to the key central role that this receptor plays in inflammatory conditions.  Recently, several CXCR2 receptor antagonists have demonstrated promising proof of activity in early pulmonary clin. trials, which has stimulated addnl. efforts to identify new CXCR2 receptor antagonists.  Areas covered: During the period 2009 - 2013, there were numerous patent publications from various companies claiming the discovery of novel CXCR2 receptor antagonists.  Herein, an interpretation of these new patent publications combined with emerging disclosures from the peer-reviewed literature during this time frame is given.  This review highlights the preferred or representative compds. from the patent applications along with relevant biol. characterization.  Expert opinion: Many of the new CXCR2 receptor antagonists described in this review represent closely related analogs to previously disclosed clin. candidates.  With the recent discontinuation of several CXCR2 receptor antagonists in the clinic, addnl. clin. trial information for CXCR2 receptor antagonists, both past and present, will det. the long-term therapeutic potential of these compds. for the treatment of a variety of inflammatory disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrrLzyTSdxdHbVg90H21EOLACvtfcHk0ljREboTgnTN4w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXmt1Ghu70%253D&md5=c1b5bd8730268cd12851722a3880a118</span></div><a href="/servlet/linkout?suffix=cit27b&amp;dbid=16384&amp;doi=10.1517%2F13543776.2014.887682&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F13543776.2014.887682%26sid%3Dliteratum%253Aachs%26aulast%3DDwyer%26aufirst%3DM.%2BP.%26aulast%3DYu%26aufirst%3DY.%26atitle%3DCXCR2%2520modulators%253A%2520a%2520patent%2520review%2520%25282009%2520%25E2%2580%2593%25202013%2529%26jtitle%3DExpert%2520Opin.%2520Ther.%2520Pat.%26date%3D2014%26volume%3D24%26issue%3D5%26spage%3D519%26epage%3D534%26doi%3D10.1517%2F13543776.2014.887682" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Ha, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Debnath, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neamati, N.</span></span> <span> </span><span class="NLM_article-title">Role of the CXCL8-CXCR1/2 axis in cancer and inflammatory diseases</span>. <i>Theranostics</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>7</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">1543</span>– <span class="NLM_lpage">1587</span>, <span class="refDoi"> DOI: 10.7150/thno.15625</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01854&amp;key=10.7150%2Fthno.15625" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2017&pages=1543-1587&issue=6&author=H.+Haauthor=B.+Debnathauthor=N.+Neamati&title=Role+of+the+CXCL8-CXCR1%2F2+axis+in+cancer+and+inflammatory+diseases&doi=10.7150%2Fthno.15625"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28a&amp;dbid=16384&amp;doi=10.7150%2Fthno.15625&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.7150%252Fthno.15625%26sid%3Dliteratum%253Aachs%26aulast%3DHa%26aufirst%3DH.%26aulast%3DDebnath%26aufirst%3DB.%26aulast%3DNeamati%26aufirst%3DN.%26atitle%3DRole%2520of%2520the%2520CXCL8-CXCR1%252F2%2520axis%2520in%2520cancer%2520and%2520inflammatory%2520diseases%26jtitle%3DTheranostics%26date%3D2017%26volume%3D7%26issue%3D6%26spage%3D1543%26epage%3D1587%26doi%3D10.7150%2Fthno.15625" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="note"><p class="first last">and references therein.</p></div><div class="NLM_citation" id="rightTab-cit28b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Busch-Petersen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span> <span> </span><span class="NLM_article-title">Phenol-containing antagonists of the CXCR2 receptor</span>. <i>Expert Opin. Ther. Pat.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>18</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">629</span>– <span class="NLM_lpage">637</span>, <span class="refDoi"> DOI: 10.1517/13543776.18.6.629</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01854&amp;key=10.1517%2F13543776.18.6.629" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01854&amp;key=1%3ACAS%3A528%3ADC%252BD1cXmt1Okt78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2008&pages=629-637&issue=6&author=J.+Busch-Petersenauthor=Y.+Wang&title=Phenol-containing+antagonists+of+the+CXCR2+receptor&doi=10.1517%2F13543776.18.6.629"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28bR"><div class="casContent"><span class="casTitleNuber">28b</span><div class="casTitle"><span class="NLM_cas:atitle">Phenol-containing antagonists of the CXCR2 receptor</span></div><div class="casAuthors">Busch-Petersen, Jakob; Wang, Yonghui</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Therapeutic Patents</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">629-637</span>CODEN:
                <span class="NLM_cas:coden">EOTPEG</span>;
        ISSN:<span class="NLM_cas:issn">1354-3776</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Background: ELR+ chemokines interact with the CXCR2 receptor on neutrophils and other immune cells to induce chemotaxis.  This event plays a key role in a large no. of autoimmune diseases and thus antagonists of the CXCR2 receptor have garnered considerable interest in the pharmaceutical industry during the past decade and a half.  Objective: The objective of the article is to review recent developments in the patent literature related to the phenol-contg. antagonists.  Method: Although many other chemotypes have emerged since the first disclosure of phenol-contg. antagonists, this compd. class is by far the most successful, having yielded all but one of the clin. candidates reported so far, and thus the scope of this review is limited just this antagonist type.  Conclusion: During the past few years, phenol-contg. CXCR2 antagonists have evolved from promising leads to clin. candidates, and structural diversity within the class has been expanded.  Lead compds. have now entered patient studies and will be of great importance not just for this compd. class, but also for the therapeutic viability of CXCR2 antagonists in general.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqoVVFcZ1sbF7Vg90H21EOLACvtfcHk0ljREboTgnTN4w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXmt1Okt78%253D&md5=0f83eb8215ad9bf8ee2331b2a67edce5</span></div><a href="/servlet/linkout?suffix=cit28b&amp;dbid=16384&amp;doi=10.1517%2F13543776.18.6.629&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F13543776.18.6.629%26sid%3Dliteratum%253Aachs%26aulast%3DBusch-Petersen%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DY.%26atitle%3DPhenol-containing%2520antagonists%2520of%2520the%2520CXCR2%2520receptor%26jtitle%3DExpert%2520Opin.%2520Ther.%2520Pat.%26date%3D2008%26volume%3D18%26issue%3D6%26spage%3D629%26epage%3D637%26doi%3D10.1517%2F13543776.18.6.629" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luan, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gong, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Y.-G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cai, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiang, J.-N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elliott, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, X.</span></span> <span> </span><span class="NLM_article-title">Discovery of CNS penetrant CXCR2 antagonists for the potential treatment of CNS demyelinating disorders</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>7</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">397</span>– <span class="NLM_lpage">402</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.5b00489</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.5b00489" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=397-402&issue=4&author=H.+Xuauthor=H.+Luauthor=Z.+Xuauthor=L.+Luanauthor=C.+Liauthor=Y.+Xuauthor=K.+Dongauthor=J.+Zhangauthor=X.+Liauthor=Y.+Liauthor=G.+Liuauthor=S.+Gongauthor=Y.-G.+Zhaoauthor=A.+Liuauthor=Y.+Zhangauthor=W.+Zhangauthor=X.+Caiauthor=J.-N.+Xiangauthor=J.+D.+Elliottauthor=X.+Lin&title=Discovery+of+CNS+penetrant+CXCR2+antagonists+for+the+potential+treatment+of+CNS+demyelinating+disorders&doi=10.1021%2Facsmedchemlett.5b00489"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.5b00489&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.5b00489%26sid%3Dliteratum%253Aachs%26aulast%3DXu%26aufirst%3DH.%26aulast%3DLu%26aufirst%3DH.%26aulast%3DXu%26aufirst%3DZ.%26aulast%3DLuan%26aufirst%3DL.%26aulast%3DLi%26aufirst%3DC.%26aulast%3DXu%26aufirst%3DY.%26aulast%3DDong%26aufirst%3DK.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DG.%26aulast%3DGong%26aufirst%3DS.%26aulast%3DZhao%26aufirst%3DY.-G.%26aulast%3DLiu%26aufirst%3DA.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DW.%26aulast%3DCai%26aufirst%3DX.%26aulast%3DXiang%26aufirst%3DJ.-N.%26aulast%3DElliott%26aufirst%3DJ.%2BD.%26aulast%3DLin%26aufirst%3DX.%26atitle%3DDiscovery%2520of%2520CNS%2520penetrant%2520CXCR2%2520antagonists%2520for%2520the%2520potential%2520treatment%2520of%2520CNS%2520demyelinating%2520disorders%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2016%26volume%3D7%26issue%3D4%26spage%3D397%26epage%3D402%26doi%3D10.1021%2Facsmedchemlett.5b00489" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Young, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Green, D. V.S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luscombe, C. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hill, A. P.</span></span> <span> </span><span class="NLM_article-title">Getting physical in drug discovery II: the impact of chromatographic hydrophobicity measurements and aromaticity</span>. <i>Drug Discovery Today</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">822</span>– <span class="NLM_lpage">830</span>, <span class="refDoi"> DOI: 10.1016/j.drudis.2011.06.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01854&amp;key=10.1016%2Fj.drudis.2011.06.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01854&amp;key=21704184" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01854&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtFCru7vF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2011&pages=822-830&author=R.+J.+Youngauthor=D.+V.S.+Greenauthor=C.+N.+Luscombeauthor=A.+P.+Hill&title=Getting+physical+in+drug+discovery+II%3A+the+impact+of+chromatographic+hydrophobicity+measurements+and+aromaticity&doi=10.1016%2Fj.drudis.2011.06.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Getting physical in drug discovery II: the impact of chromatographic hydrophobicity measurements and aromaticity</span></div><div class="casAuthors">Young, Robert J.; Green, Darren V. S.; Luscombe, Christopher N.; Hill, Alan P.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">17/18</span>),
    <span class="NLM_cas:pages">822-830</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Here, we review the performance of chromatog. hydrophobicity measurements in a data set of 100 000 GlaxoSmithKline compds., demonstrating the advantages of the method over octanol-water partitioning and highlighting new insights for drug discovery.  The value of chromatog. measurements, vs. other hydrophobicity ests., was supported by improved relationships with soly., permeation, cytochrome P450s, intrinsic clearance, hERG binding and promiscuity.  We also obsd. marked differentiation of the relative influence of intrinsic and effective hydrophobicity.  The summing of hydrophobicity values plus arom. ring count [log D pH7.4 (or log P) + #Ar], indicated a wide relevance for simplistic property forecast indexes' in developability assays, clearly enhanced by chromatog. values; therefore establishing new foundations for enriching property-based drug design.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqmIJyWi-DBW7Vg90H21EOLACvtfcHk0lhoEdbZ8Hllgg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtFCru7vF&md5=22788603a45aa77537e8666433473d14</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2011.06.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2011.06.001%26sid%3Dliteratum%253Aachs%26aulast%3DYoung%26aufirst%3DR.%2BJ.%26aulast%3DGreen%26aufirst%3DD.%2BV.S.%26aulast%3DLuscombe%26aufirst%3DC.%2BN.%26aulast%3DHill%26aufirst%3DA.%2BP.%26atitle%3DGetting%2520physical%2520in%2520drug%2520discovery%2520II%253A%2520the%2520impact%2520of%2520chromatographic%2520hydrophobicity%2520measurements%2520and%2520aromaticity%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2011%26volume%3D16%26spage%3D822%26epage%3D830%26doi%3D10.1016%2Fj.drudis.2011.06.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span>Unpublished result.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Unpublished+result."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dunpublished%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Busch-Petersen, J.</span></span> <span> </span><span class="NLM_article-title">IL-8 Receptor Antagonists</span>. <span class="NLM_patent">US20070249672A1</span>, Oct 25, <span class="NLM_year">2007</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2007&author=J.+Busch-Petersen&title=IL-8+Receptor+Antagonists"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DBusch-Petersen%26aufirst%3DJ.%26atitle%3DIL-8%2520Receptor%2520Antagonists%26date%3D2007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ito, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prasad, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">An, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Unadkat, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kusuhara, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sugiyama, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sahi, J.</span></span> <span> </span><span class="NLM_article-title">Solute carrier family of the organic anion-transporting polypeptides 1A2-Madin-Darby Canine Kidney II: a promising in vitro system to understand the role of organic anion-transporting polypeptide 1A2 in blood-brain barrier drug penetration</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>43</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">1008</span>– <span class="NLM_lpage">1018</span>, <span class="refDoi"> DOI: 10.1124/dmd.115.064170</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01854&amp;key=10.1124%2Fdmd.115.064170" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2015&pages=1008-1018&issue=7&author=H.+Liuauthor=N.+Yuauthor=S.+Luauthor=S.+Itoauthor=X.+Zhangauthor=B.+Prasadauthor=E.+Heauthor=X.+Luauthor=Y.+Liauthor=F.+Wangauthor=H.+Xuauthor=G.+Anauthor=J.+D.+Unadkatauthor=H.+Kusuharaauthor=Y.+Sugiyamaauthor=J.+Sahi&title=Solute+carrier+family+of+the+organic+anion-transporting+polypeptides+1A2-Madin-Darby+Canine+Kidney+II%3A+a+promising+in+vitro+system+to+understand+the+role+of+organic+anion-transporting+polypeptide+1A2+in+blood-brain+barrier+drug+penetration&doi=10.1124%2Fdmd.115.064170"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit33a&amp;dbid=16384&amp;doi=10.1124%2Fdmd.115.064170&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.115.064170%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DH.%26aulast%3DYu%26aufirst%3DN.%26aulast%3DLu%26aufirst%3DS.%26aulast%3DIto%26aufirst%3DS.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DPrasad%26aufirst%3DB.%26aulast%3DHe%26aufirst%3DE.%26aulast%3DLu%26aufirst%3DX.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DF.%26aulast%3DXu%26aufirst%3DH.%26aulast%3DAn%26aufirst%3DG.%26aulast%3DUnadkat%26aufirst%3DJ.%2BD.%26aulast%3DKusuhara%26aufirst%3DH.%26aulast%3DSugiyama%26aufirst%3DY.%26aulast%3DSahi%26aufirst%3DJ.%26atitle%3DSolute%2520carrier%2520family%2520of%2520the%2520organic%2520anion-transporting%2520polypeptides%25201A2-Madin-Darby%2520Canine%2520Kidney%2520II%253A%2520a%2520promising%2520in%2520vitro%2520system%2520to%2520understand%2520the%2520role%2520of%2520organic%2520anion-transporting%2520polypeptide%25201A2%2520in%2520blood-brain%2520barrier%2520drug%2520penetration%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2015%26volume%3D43%26issue%3D7%26spage%3D1008%26epage%3D1018%26doi%3D10.1124%2Fdmd.115.064170" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit33b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sahi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Summerfield, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, K.</span></span> <span> </span><span class="NLM_article-title">Correlation between membrane protein expression levels and transcellular transport activity for breast cancer resistance protein</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>45</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">449</span>– <span class="NLM_lpage">456</span>, <span class="refDoi"> DOI: 10.1124/dmd.116.074245</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01854&amp;key=10.1124%2Fdmd.116.074245" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2017&pages=449-456&issue=5&author=H.+Liuauthor=L.+Huangauthor=Y.+Liauthor=T.+Fuauthor=X.+Sunauthor=Y.+Y.+Zhangauthor=R.+Gaoauthor=Q.+Chenauthor=W.+Zhangauthor=J.+Sahiauthor=S.+Summerfieldauthor=K.+Dong&title=Correlation+between+membrane+protein+expression+levels+and+transcellular+transport+activity+for+breast+cancer+resistance+protein&doi=10.1124%2Fdmd.116.074245"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit33b&amp;dbid=16384&amp;doi=10.1124%2Fdmd.116.074245&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.116.074245%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DH.%26aulast%3DHuang%26aufirst%3DL.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DFu%26aufirst%3DT.%26aulast%3DSun%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DY.%2BY.%26aulast%3DGao%26aufirst%3DR.%26aulast%3DChen%26aufirst%3DQ.%26aulast%3DZhang%26aufirst%3DW.%26aulast%3DSahi%26aufirst%3DJ.%26aulast%3DSummerfield%26aufirst%3DS.%26aulast%3DDong%26aufirst%3DK.%26atitle%3DCorrelation%2520between%2520membrane%2520protein%2520expression%2520levels%2520and%2520transcellular%2520transport%2520activity%2520for%2520breast%2520cancer%2520resistance%2520protein%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2017%26volume%3D45%26issue%3D5%26spage%3D449%26epage%3D456%26doi%3D10.1124%2Fdmd.116.074245" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Clarysse, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brouwers, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tack, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Annaert, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Augustijns, P.</span></span> <span> </span><span class="NLM_article-title">Intestinal drug solubility estimation based on simulated intestinal fluids: comparison with solubility in human intestinal fluids</span>. <i>Eur. J. Pharm. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>43</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">260</span>– <span class="NLM_lpage">269</span>, <span class="refDoi"> DOI: 10.1016/j.ejps.2011.04.016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01854&amp;key=10.1016%2Fj.ejps.2011.04.016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01854&amp;key=21570465" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01854&amp;key=1%3ACAS%3A528%3ADC%252BC3MXotVejs7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2011&pages=260-269&issue=4&author=S.+Clarysseauthor=J.+Brouwersauthor=J.+Tackauthor=P.+Annaertauthor=P.+Augustijns&title=Intestinal+drug+solubility+estimation+based+on+simulated+intestinal+fluids%3A+comparison+with+solubility+in+human+intestinal+fluids&doi=10.1016%2Fj.ejps.2011.04.016"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Intestinal drug solubility estimation based on simulated intestinal fluids: Comparison with solubility in human intestinal fluids</span></div><div class="casAuthors">Clarysse, Sarah; Brouwers, Joachim; Tack, Jan; Annaert, Pieter; Augustijns, Patrick</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmaceutical Sciences</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">43</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">260-269</span>CODEN:
                <span class="NLM_cas:coden">EPSCED</span>;
        ISSN:<span class="NLM_cas:issn">0928-0987</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The purpose of this study was to validate both existing fasted and fed state simulated intestinal fluids (FaSSIF and FeSSIF), and simpler, alternative media for predicting intraluminal drug soly. during drug discovery and early drug development.  For 17 model drugs, the solubilizing capacity of FaSSIFc and FeSSIFc (subscript indicates the use of crude taurocholate) and different concns. of D-α-tocopheryl polyethylene glycol 1000 succinate (TPGS) in phosphate buffer were correlated with the solubilizing capacity of human intestinal fluids (HIF) in the fasted and the early postprandial state.  A good correlation between soly. in fasted HIF and FaSSIFc and between soly. in fed HIF and FeSSIFc was obtained, indicated by R 2 values of 0.91 and 0.86, resp.  Comparable values were obtained for 0.1% TPGS for the fasted state (R 2 = 0.84) and 2% TPGS for the fed state (R 2 = 0.84).  Direct estn. of intestinal drug soly. by the measured solubilities in FaSSIFc and FeSSIFc was acceptable.  However, better ests. were obtained by calcg. solubilities based on the equations describing the relationship between solubilities in FaSSIFc and FeSSIFc as function of obsd. solubilities in HIF.  Using this approach, the predictive value of the TPGS-based solvent system was also acceptable and comparable to that of FaSSIFc and FeSSIFc.  In conclusion, FaSSIFc and FeSSIFc can be considered biorelevant media for intestinal soly. estn.  A simpler TPGS-based system may be a valuable alternative with improved stability and lower cost.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGorRrkPlVCvR7Vg90H21EOLACvtfcHk0liN_ZKdvnwI3A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXotVejs7Y%253D&md5=dea97977f90d6859c47d6d8c41037d94</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1016%2Fj.ejps.2011.04.016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejps.2011.04.016%26sid%3Dliteratum%253Aachs%26aulast%3DClarysse%26aufirst%3DS.%26aulast%3DBrouwers%26aufirst%3DJ.%26aulast%3DTack%26aufirst%3DJ.%26aulast%3DAnnaert%26aufirst%3DP.%26aulast%3DAugustijns%26aufirst%3DP.%26atitle%3DIntestinal%2520drug%2520solubility%2520estimation%2520based%2520on%2520simulated%2520intestinal%2520fluids%253A%2520comparison%2520with%2520solubility%2520in%2520human%2520intestinal%2520fluids%26jtitle%3DEur.%2520J.%2520Pharm.%2520Sci.%26date%3D2011%26volume%3D43%26issue%3D4%26spage%3D260%26epage%3D269%26doi%3D10.1016%2Fj.ejps.2011.04.016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hammarlund-Udenaes, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fridén, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Syvänen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gupta, A.</span></span> <span> </span><span class="NLM_article-title">On the rate and extent of drug delivery to the brain</span>. <i>Pharm. Res.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>25</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">1737</span>– <span class="NLM_lpage">1750</span>, <span class="refDoi"> DOI: 10.1007/s11095-007-9502-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01854&amp;key=10.1007%2Fs11095-007-9502-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01854&amp;key=18058202" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01854&amp;key=1%3ACAS%3A528%3ADC%252BD1cXot1Whsb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2008&pages=1737-1750&issue=8&author=M.+Hammarlund-Udenaesauthor=M.+Frid%C3%A9nauthor=S.+Syv%C3%A4nenauthor=A.+Gupta&title=On+the+rate+and+extent+of+drug+delivery+to+the+brain&doi=10.1007%2Fs11095-007-9502-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">On The Rate and Extent of Drug Delivery to the Brain</span></div><div class="casAuthors">Hammarlund-Udenaes, Margareta; Friden, Markus; Syvaenen, Stina; Gupta, Anubha</div><div class="citationInfo"><span class="NLM_cas:title">Pharmaceutical Research</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1737-1750</span>CODEN:
                <span class="NLM_cas:coden">PHREEB</span>;
        ISSN:<span class="NLM_cas:issn">0724-8741</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">A review.  To define and differentiate relevant aspects of blood-brain barrier transport and distribution in order to aid research methodol. in brain drug delivery.  Pharmacokinetic parameters relative to the rate and extent of brain drug delivery are described and illustrated with relevant data, with special emphasis on the unbound, pharmacol. active drug mol.  Drug delivery to the brain can be comprehensively described using three parameters: K p,uu (concn. ratio of unbound drug in brain to blood), CLin (permeability clearance into the brain), and V u,brain (intra-brain distribution).  The permeability of the blood-brain barrier is less relevant to drug action within the CNS than the extent of drug delivery, as most drugs are administered on a continuous (repeated) basis.  K p,uu can differ between CNS-active drugs by a factor of up to 150-fold.  This range is much smaller than that for log BB ratios (K p), which can differ by up to at least 2000-fold, or for BBB permeabilities, which span an even larger range (up to at least 20,000-fold difference).  Methods that measure the three parameters K p,uu, CLin, and V u,brain can give clin. valuable ests. of brain drug delivery in early drug discovery programs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrkysWU99T_hbVg90H21EOLACvtfcHk0liN_ZKdvnwI3A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXot1Whsb8%253D&md5=20f106a980c4949b78ead8c00cb5db41</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1007%2Fs11095-007-9502-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11095-007-9502-2%26sid%3Dliteratum%253Aachs%26aulast%3DHammarlund-Udenaes%26aufirst%3DM.%26aulast%3DFrid%25C3%25A9n%26aufirst%3DM.%26aulast%3DSyv%25C3%25A4nen%26aufirst%3DS.%26aulast%3DGupta%26aufirst%3DA.%26atitle%3DOn%2520the%2520rate%2520and%2520extent%2520of%2520drug%2520delivery%2520to%2520the%2520brain%26jtitle%3DPharm.%2520Res.%26date%3D2008%26volume%3D25%26issue%3D8%26spage%3D1737%26epage%3D1750%26doi%3D10.1007%2Fs11095-007-9502-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Sin, Y. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sedgwick, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chea, E. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Willoughby, D. A.</span></span> <span> </span><span class="NLM_article-title">Mast cells in newly formed lining tissue during acute inflammation: a six-day air pouch model in the mouse</span>. <i>Ann. Rheum. Dis.</i> <span class="NLM_year" style="font-weight: bold;">1986</span>,  <span class="NLM_volume"><i>45</i></span>,  <span class="NLM_fpage">873</span>– <span class="NLM_lpage">877</span>, <span class="refDoi"> DOI: 10.1136/ard.45.10.873</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01854&amp;key=10.1136%2Fard.45.10.873" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01854&amp;key=3789822" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01854&amp;key=1%3ACAS%3A280%3ADyaL2s%252FnsFSksQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=1986&pages=873-877&author=Y.+M.+Sinauthor=A.+D.+Sedgwickauthor=E.+P.+Cheaauthor=D.+A.+Willoughby&title=Mast+cells+in+newly+formed+lining+tissue+during+acute+inflammation%3A+a+six-day+air+pouch+model+in+the+mouse&doi=10.1136%2Fard.45.10.873"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit36aR"><div class="casContent"><span class="casTitleNuber">36a</span><div class="casTitle"><span class="NLM_cas:atitle">Mast cells in newly formed lining tissue during acute inflammation: a six day air pouch model in the mouse</span></div><div class="casAuthors">Sin Y M; Sedgwick A D; Chea E P; Willoughby D A</div><div class="citationInfo"><span class="NLM_cas:title">Annals of the rheumatic diseases</span>
        (<span class="NLM_cas:date">1986</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">873-7</span>
        ISSN:<span class="NLM_cas:issn">0003-4967</span>.
    </div><div class="casAbstract">Connective tissue mast cells were topographically and quantitatively studied in the newly formed lining tissue of six day old air pouches induced in the dorsal surface of mice.  The results showed that the number of mast cells in the cavities innermost lining increased after injection of carrageenan into the cavity.  Degranulation of mast cells was also observed.  Variations in mast cell numbers in the lining seemed to correlate with the histamine content.  These findings suggest that mast cells not only participate in the initiation of the early phase of acute inflammation but also appear to play an important part in regulating and prolonging more chronic inflammatory reactions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQzNq5BkzaFXYIRAdBLKY41fW6udTcc2eb7ApvFmXjnorntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaL2s%252FnsFSksQ%253D%253D&md5=02bad9998244afe20593f79bb73f94f1</span></div><a href="/servlet/linkout?suffix=cit36a&amp;dbid=16384&amp;doi=10.1136%2Fard.45.10.873&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1136%252Fard.45.10.873%26sid%3Dliteratum%253Aachs%26aulast%3DSin%26aufirst%3DY.%2BM.%26aulast%3DSedgwick%26aufirst%3DA.%2BD.%26aulast%3DChea%26aufirst%3DE.%2BP.%26aulast%3DWilloughby%26aufirst%3DD.%2BA.%26atitle%3DMast%2520cells%2520in%2520newly%2520formed%2520lining%2520tissue%2520during%2520acute%2520inflammation%253A%2520a%2520six-day%2520air%2520pouch%2520model%2520in%2520the%2520mouse%26jtitle%3DAnn.%2520Rheum.%2520Dis.%26date%3D1986%26volume%3D45%26spage%3D873%26epage%3D877%26doi%3D10.1136%2Fard.45.10.873" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit36b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Romano, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Faggioni, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sironi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sacco, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Echtenacher, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Santo, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salmona, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghezzi, P.</span></span> <span> </span><span class="NLM_article-title">Carrageenan-induced acute inflammation in the mouse air pouch synovial model. Role of tumor necrosis factor</span>. <i>Mediators Inflammation</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">32</span>– <span class="NLM_lpage">38</span>, <span class="refDoi"> DOI: 10.1080/09629359791901</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01854&amp;key=10.1080%2F09629359791901" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01854&amp;key=18472831" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01854&amp;key=1%3ACAS%3A528%3ADyaK2sXitFSnurk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=1997&pages=32-38&author=M.+Romanoauthor=R.+Faggioniauthor=M.+Sironiauthor=S.+Saccoauthor=B.+Echtenacherauthor=E.+Di+Santoauthor=M.+Salmonaauthor=P.+Ghezzi&title=Carrageenan-induced+acute+inflammation+in+the+mouse+air+pouch+synovial+model.+Role+of+tumor+necrosis+factor&doi=10.1080%2F09629359791901"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit36bR"><div class="casContent"><span class="casTitleNuber">36b</span><div class="casTitle"><span class="NLM_cas:atitle">Carrageenan-induced acute inflammation in the mouse air pouch synovial model. Role of tumor necrosis factor</span></div><div class="casAuthors">Romano, M.; Faggioni, R.; Sironi, M.; Sacco, S.; Echtenacher, B.; Di Santo, E.; Salmona, M.; Ghezzi, P.</div><div class="citationInfo"><span class="NLM_cas:title">Mediators of Inflammation</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">32-38</span>CODEN:
                <span class="NLM_cas:coden">MNFLEF</span>;
        ISSN:<span class="NLM_cas:issn">0962-9351</span>.
    
            (<span class="NLM_cas:orgname">Rapid Science Publishers</span>)
        </div><div class="casAbstract">The mouse air pouch model of inflammation was used to study the interaction between cytokines, prostaglandin E2 (PGE2) and cell migration during the various phases of acute local inflammation induced by carrageenan.  In serum, the levels of interleukin 1 (IL-1), interleukin 6 (IL-6), tumor necrosis factor (TNF), serum amyloid-A (SAA) and Fe++ were never different from controls, indicating that no systemic inflammatory changes were induced.  Locally the exudate vol. and the no. of leukocytes recruited into the pouch increased progressively until 7 days after carrageenan.  The same was true for PGE2 prodn.  The authors could not measure IL-1 but the prodn. of IL-6 and TNF reached a max. after 5-24 h then quickly decreased.  Anti-TNF antibodies inhibited cell migration by 50% 24 h after treatment.  Pretreatment with interleukin 10 (IL-10) inhibited TNF prodn. almost completely and cell migration by 60%.  Carrageenan-induced inflammation was modulated by anti-inflammatory drugs.  Pretreatment with dexamethasone (DEX) or indomethacin (INDO) inhibited cell migration and reduced the concn. of TNF in the exudate.  Prodn. of PGE2 or vascular permeability did not correlate with the no. of cells in the pouch.  Local TNF seems to play an important role in this model, particularly for leukocyte migration in the first phase of the inflammatory process.  In conclusion, the air pouch seems to be a good model for studying the regulation of the early events of local inflammation, particularly the role of cytokines and cell migration.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrHKWtVeBJh-rVg90H21EOLACvtfcHk0lhO2pjaaQMuLg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXitFSnurk%253D&md5=2961e25118b643663940ff9ba7243e79</span></div><a href="/servlet/linkout?suffix=cit36b&amp;dbid=16384&amp;doi=10.1080%2F09629359791901&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F09629359791901%26sid%3Dliteratum%253Aachs%26aulast%3DRomano%26aufirst%3DM.%26aulast%3DFaggioni%26aufirst%3DR.%26aulast%3DSironi%26aufirst%3DM.%26aulast%3DSacco%26aufirst%3DS.%26aulast%3DEchtenacher%26aufirst%3DB.%26aulast%3DDi%2BSanto%26aufirst%3DE.%26aulast%3DSalmona%26aufirst%3DM.%26aulast%3DGhezzi%26aufirst%3DP.%26atitle%3DCarrageenan-induced%2520acute%2520inflammation%2520in%2520the%2520mouse%2520air%2520pouch%2520synovial%2520model.%2520Role%2520of%2520tumor%2520necrosis%2520factor%26jtitle%3DMediators%2520Inflammation%26date%3D1997%26volume%3D6%26spage%3D32%26epage%3D38%26doi%3D10.1080%2F09629359791901" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit36c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stevens, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brennan, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davies, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rowland, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Houston, J. B.</span></span> <span> </span><span class="NLM_article-title">The six-day-old rat air pouch model of inflammation: characterization of the inflammatory response to carrageenan</span>. <i>J. Pharmacol. Toxicol. Methods</i> <span class="NLM_year" style="font-weight: bold;">1994</span>,  <span class="NLM_volume"><i>32</i></span>,  <span class="NLM_fpage">139</span>– <span class="NLM_lpage">147</span>, <span class="refDoi"> DOI: 10.1016/1056-8719(94)90067-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01854&amp;key=10.1016%2F1056-8719%2894%2990067-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01854&amp;key=7858307" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01854&amp;key=1%3ACAS%3A528%3ADyaK2MXit1KgtL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=1994&pages=139-147&author=S.+W.+Martinauthor=A.+J.+Stevensauthor=B.+S.+Brennanauthor=D.+Daviesauthor=M.+Rowlandauthor=J.+B.+Houston&title=The+six-day-old+rat+air+pouch+model+of+inflammation%3A+characterization+of+the+inflammatory+response+to+carrageenan&doi=10.1016%2F1056-8719%2894%2990067-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit36cR"><div class="casContent"><span class="casTitleNuber">36c</span><div class="casTitle"><span class="NLM_cas:atitle">The six-day-old rat air pouch model of inflammation: characterization of the inflammatory response to carrageenan</span></div><div class="casAuthors">Martin, S. W.; Stevens, A. J.; Brennan, B. S.; Davies, D.; Rowland, M.; Houston, J. B.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacological and Toxicological Methods</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">139-47</span>CODEN:
                <span class="NLM_cas:coden">JPTMEZ</span>;
        ISSN:<span class="NLM_cas:issn">1056-8719</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Inflammation was induced in the 6-day-old rat air pouch by injection of carrageenan.  The model was characterized in terms of exudate vol., leukocyte influx, cell free protein, prostaglandin E2 levels, and granuloma formation.  The time course of all these inflammatory markers, except prostaglandin E2, showed a 3-h lag followed by a rapid increase to 8 h.  Thereafter, the rate of increase was much slower to 48 h.  Differential cell counts indicated a predominantly polymorphonuclear cell response (75%) during the first 48 h.  Prostaglandin E2 levels increased rapidly after a 3-h lag, to a max. of 440 ng/mL at 15 h and thereafter quickly declined to 140+60 ng/mL at 21 h.  Prostaglandin E2 levels were the most sensitive inflammatory marker to (S+)-ibuprofen and were reduced dose dependently in the range 0.05 to 1 mg/kg.  The authors have demonstrated the time course for duration of NSAID-induced redn. of prostaglandin E2 levels during inflammation in an individual animal.  Rac-ibuprofen (0.1-1 mg/kg) reduced leukocyte influx at 3 and 5 h, after which drug effects gradually diminished by 24 h.  Rac-ibuprofen at 1 mg/kg significantly reduced the vol. of air pouch exudate recovered at 24 h but had no effect on protein levels.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrf91INg9ULjbVg90H21EOLACvtfcHk0lhO2pjaaQMuLg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXit1KgtL8%253D&md5=e5d37f9b9d7cc1227e76bc67d17c601b</span></div><a href="/servlet/linkout?suffix=cit36c&amp;dbid=16384&amp;doi=10.1016%2F1056-8719%2894%2990067-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F1056-8719%252894%252990067-1%26sid%3Dliteratum%253Aachs%26aulast%3DMartin%26aufirst%3DS.%2BW.%26aulast%3DStevens%26aufirst%3DA.%2BJ.%26aulast%3DBrennan%26aufirst%3DB.%2BS.%26aulast%3DDavies%26aufirst%3DD.%26aulast%3DRowland%26aufirst%3DM.%26aulast%3DHouston%26aufirst%3DJ.%2BB.%26atitle%3DThe%2520six-day-old%2520rat%2520air%2520pouch%2520model%2520of%2520inflammation%253A%2520characterization%2520of%2520the%2520inflammatory%2520response%2520to%2520carrageenan%26jtitle%3DJ.%2520Pharmacol.%2520Toxicol.%2520Methods%26date%3D1994%26volume%3D32%26spage%3D139%26epage%3D147%26doi%3D10.1016%2F1056-8719%2894%2990067-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit36d"><span><span class="NLM_label">(d) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Hambelton, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, P.</span></span> <span> </span><span class="NLM_article-title">Studies on carrageenan air pouch inflammation in the rat</span>. <i>Br. J. Exp. Pathol.</i> <span class="NLM_year" style="font-weight: bold;">1989</span>,  <span class="NLM_volume"><i>70</i></span>,  <span class="NLM_fpage">425</span>– <span class="NLM_lpage">433</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=70&publication_year=1989&pages=425-433&author=P.+Hambeltonauthor=P.+Miller&title=Studies+on+carrageenan+air+pouch+inflammation+in+the+rat"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit36d&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHambelton%26aufirst%3DP.%26aulast%3DMiller%26aufirst%3DP.%26atitle%3DStudies%2520on%2520carrageenan%2520air%2520pouch%2520inflammation%2520in%2520the%2520rat%26jtitle%3DBr.%2520J.%2520Exp.%2520Pathol.%26date%3D1989%26volume%3D70%26spage%3D425%26epage%3D433" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Corey, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bakshi, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shibata, S.</span></span> <span> </span><span class="NLM_article-title">Highly enantioselective borane reduction of ketones catalyzed by chiral oxazaborolidines. Mechanism and synthetic implications</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">1987</span>,  <span class="NLM_volume"><i>109</i></span>,  <span class="NLM_fpage">5551</span>– <span class="NLM_lpage">5553</span>, <span class="refDoi"> DOI: 10.1021/ja00252a056</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja00252a056" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref37/cit37a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01854&amp;key=1%3ACAS%3A528%3ADyaL2sXlslGlsrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=109&publication_year=1987&pages=5551-5553&author=E.+J.+Coreyauthor=R.+K.+Bakshiauthor=S.+Shibata&title=Highly+enantioselective+borane+reduction+of+ketones+catalyzed+by+chiral+oxazaborolidines.+Mechanism+and+synthetic+implications&doi=10.1021%2Fja00252a056"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit37aR"><div class="casContent"><span class="casTitleNuber">37a</span><div class="casTitle"><span class="NLM_cas:atitle">Highly enantioselective borane reduction of ketones catalyzed by chiral oxazaborolidines.  Mechanism and synthetic implications</span></div><div class="casAuthors">Corey, E. J.; Bakshi, Raman K.; Shibata, Saizo</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">1987</span>),
    <span class="NLM_cas:volume">109</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">5551-3</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    </div><div class="casAbstract">An enantioselective redn. of ketones to secondary alcs.,e.g., PhCOMe to (R)-PhMeCHOH, by vic-amino alcs. and BH3-THF is reported.  Two key reaction intermediates involved in a catalytic redn. with BH3.THF as the stoichiometric reductant.  (S)-Diphenylprolinol reacts with BH3.THF upon heating to form oxazaborolidine I, which is a catalyst for these redns.  I forms a complex II.  Amino alc. III similarly effects enantioselective redn. of ketones.  I and II are the most effective reducing agents found to date.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpr0FOvqDo-BLVg90H21EOLACvtfcHk0lhO2pjaaQMuLg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL2sXlslGlsrs%253D&md5=e52d09fe788534f0f5d8168d2ad93e4f</span></div><a href="/servlet/linkout?suffix=cit37a&amp;dbid=16384&amp;doi=10.1021%2Fja00252a056&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja00252a056%26sid%3Dliteratum%253Aachs%26aulast%3DCorey%26aufirst%3DE.%2BJ.%26aulast%3DBakshi%26aufirst%3DR.%2BK.%26aulast%3DShibata%26aufirst%3DS.%26atitle%3DHighly%2520enantioselective%2520borane%2520reduction%2520of%2520ketones%2520catalyzed%2520by%2520chiral%2520oxazaborolidines.%2520Mechanism%2520and%2520synthetic%2520implications%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D1987%26volume%3D109%26spage%3D5551%26epage%3D5553%26doi%3D10.1021%2Fja00252a056" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit37b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Corey, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bakshi, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shibata, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, V. K.</span></span> <span> </span><span class="NLM_article-title">A stable and easily prepared catalyst for the enantioselective reduction of ketones. Applications to multistep syntheses</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">1987</span>,  <span class="NLM_volume"><i>109</i></span>,  <span class="NLM_fpage">7925</span>– <span class="NLM_lpage">7926</span>, <span class="refDoi"> DOI: 10.1021/ja00259a075</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja00259a075" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref37/cit37b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01854&amp;key=1%3ACAS%3A528%3ADyaL1cXnsFShtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=109&publication_year=1987&pages=7925-7926&author=E.+J.+Coreyauthor=R.+K.+Bakshiauthor=S.+Shibataauthor=C.+P.+Chenauthor=V.+K.+Singh&title=A+stable+and+easily+prepared+catalyst+for+the+enantioselective+reduction+of+ketones.+Applications+to+multistep+syntheses&doi=10.1021%2Fja00259a075"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit37bR"><div class="casContent"><span class="casTitleNuber">37b</span><div class="casTitle"><span class="NLM_cas:atitle">A stable and easily prepared catalyst for the enantioselective reduction of ketones.  Applications to multistep syntheses</span></div><div class="casAuthors">Corey, E. J.; Bakshi, Raman K.; Shibata, Saizo; Chen, Chung Pin; Singh, Vinod K.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">1987</span>),
    <span class="NLM_cas:volume">109</span>
        (<span class="NLM_cas:issue">25</span>),
    <span class="NLM_cas:pages">7925-6</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    </div><div class="casAbstract">The readily available and stable oxazaborolidine I is an excellent catalyst for the enantioselective redn. of a wide range of ketones.  The stereochem. course of the redn. is predictable and the secondary alcs. formed are generally produced with high enantioselectivity.  Use of I or its enantiomer provides outstanding control of stereochem. at C(15) in prostaglandin synthesis.  A general and highly enantioselective synthesis of trans-2,5-diarylfurans, potent antagonists of platelet activating factor, also illustrates the value of this enantioselective redn.  Both I and its enantiomer can be obtained from (±)-pyroglutamic acid.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrJ6p262xrQBrVg90H21EOLACvtfcHk0ljn4jeuf-lmvg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL1cXnsFShtA%253D%253D&md5=4deaae8502b4e75f0744e46a9e774dec</span></div><a href="/servlet/linkout?suffix=cit37b&amp;dbid=16384&amp;doi=10.1021%2Fja00259a075&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja00259a075%26sid%3Dliteratum%253Aachs%26aulast%3DCorey%26aufirst%3DE.%2BJ.%26aulast%3DBakshi%26aufirst%3DR.%2BK.%26aulast%3DShibata%26aufirst%3DS.%26aulast%3DChen%26aufirst%3DC.%2BP.%26aulast%3DSingh%26aufirst%3DV.%2BK.%26atitle%3DA%2520stable%2520and%2520easily%2520prepared%2520catalyst%2520for%2520the%2520enantioselective%2520reduction%2520of%2520ketones.%2520Applications%2520to%2520multistep%2520syntheses%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D1987%26volume%3D109%26spage%3D7925%26epage%3D7926%26doi%3D10.1021%2Fja00259a075" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i51"><a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.7b01854">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_80682"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a class="ext-link" href="/">ACS Publications website</a> at DOI: <a class="ext-link" href="/doi/abs/10.1021/acs.jmedchem.7b01854">10.1021/acs.jmedchem.7b01854</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">Detailed synthetic procedures for compounds <b>9</b>–<b>39</b>, <b>41</b>–<b>65</b>, <b>67</b>, <b>69</b>–<b>71</b>, and <b>35′</b>–<b>38′</b> and spectral data for the compounds (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.7b01854/suppl_file/jm7b01854_si_001.pdf">PDF</a>)</p></li><li><p class="inline">Molecular formula strings and some in vitro data (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.7b01854/suppl_file/jm7b01854_si_002.csv">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.7b01854/suppl_file/jm7b01854_si_001.pdf">jm7b01854_si_001.pdf (4.01 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.7b01854/suppl_file/jm7b01854_si_002.csv">jm7b01854_si_002.csv (4.2 kb)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.7b01854&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2018.61.issue-6%3Bwgroup%3Astring%3AACHS+website+Group%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.7b01854%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.7b01854" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                3MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"679992156956199f","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
